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ABSTRACT 
A series of 9 hydroxypyridinones (HOPO) metal-based iron chelators (from which 6 of them 
are novel) have been prepared, characterised and derivatized in a manner to exploit an active 
transport mechanism; Large neutral Amino Acid Transporter-1 (LAT-1), which is found to be 
overexpressed in various types of cancer as well as to be presented in the blood-brain barrier 
(BBB) (Figure i).  
 
Figure (i): Structure of HOPO based compounds synthesised. Novel compounds are 
in the dotted frames.  
Additionally, it appears that the involvement of iron into metabolic pathways and/or the 
formation of low levels of reactive oxygen species (ROS) enhances the survival and 
proliferation of various types of cancer including malignant melanoma. The anticancer 
capacity of the series of HOPO based metal chelators, have been evaluated in an in vitro model 
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consisting of human (eg. A375, VVM1, HS-294T) and rodent (eg. B16F-10) melanoma cells 
as well as non-melanoma epidermoid carcinoma (eg. A431) and immortalized, non-malignant 
keratinocyte (eg. HaCaT) cells. The results of this study demonstrated that a single compound 
a methylated analogue of L-mimosine, can exert anticancer capacity as at the administered 
concentration it acts as a pro-oxidant triggering the production of high (toxic) levels of ROS, 
selectively in melanoma cell lines. The accumulation of ROS, drives the cells to apoptosis via 
activation of a well characterised downstream cascade that includes that activation of the 
terminal caspase 3/7 via the action of intrinsic (activation of caspase-9 pathway) and extrinsic 
(activation of caspase-8 pathway) 
Additionally, the excessive production of oxidative cellular stress and iron misregulation may 
be substantially involved in the dopaminergic neuron degeneration seen in the brains of 
Parkinson's disease (PD) patients. Here we evaluated the effectiveness of the synthesised iron 
chelators, based on the hydroxypyridinone core with the ability to cross the BBB and penetrate 
the brain. Immortalised human dopaminergic neuronal precursor cells (LUHMES) were 
treated with the PD-related toxins 6-hydroxydopamine (6-OHDA), which generates 
superoxide radicals, 1-methyl-4-phenylpyridinium (MPP+), a mitochondrial complex I 
inhibitor, and the ferroptosis activator, erastin. Extensive cytotoxicological profiling revealed 
that three (rac-SK-2, rac-SK-3 and L-SK-4) out of the five tested compounds (rac-SK-1, rac-
SK-2, rac-SK-3, L-SK-4 and rac-SK-5) rescue dopaminergic neuronal cells without inducing 
any toxic effects to cells, revealed through multiple cytotoxicological assays.  
In order to validate which structural features were essential for the transportation and the action 
of the compound, a series of control compounds (which they were lacking either the amino 
acid moiety or the coordination unit) have also been designed and screened against both 
melanoma cancer as well as PD cell lines. These control compounds of the associated 
molecules supported the rational design behind them according to which, the HOPO core is 
essential for the metal binding and the amino acid side vector for the transportation across the 
biological membranes via LAT-1.    
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1 Introduction  
1.1 Skin Cancer – Classes of the disease  
Skin cancer is one of the most common types of cancer worldwide with an increasing incidence 
rate over the past decade, and it can be categorised into several classes according to the kind 
of skin cells that it involves (Figure 1).1  
 
Figure 1: Layers from which skin is composed.2  
 
There are three main classes of skin cancer. Basal skin carcinoma (BCC) originates from basal 
cells that are located in the basal layer epidermis or the follicular epithelium and it has the 
highest prevalence amongst skin cancer rates.3 Another class of skin cancer is the squamous 
cell carcinoma (SCC) that derives from the cells that compose the top surface of epidermis.3 
Malignant melanoma is the third class of skin cancer that originates from the melanocytes; 
cells that are responsible for the melanin production and the most aggressive known type of 
skin cancer.3 Both BCC and SCC are subcategorised as non-malignant skin cancers (NMSC) 
and the most common histologic subtypes (~20%) of all malignancies diagnosed across the 
UK per annum, whilst worth wide about 5.5 million patients are diagnosed with NMSC.4,5 
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Most of the BCC cases tend to be curable through surgical excision by erosion of the local 
anatomical structure (mainly on head or neck) and are rarely metastatic.6 On the contrary, the 
prognosis for SCCs is less favourable because it can metastasize with significantly higher rate 
of mortality. SCCs are characterised by the present of atypical keratinocytes, however they 
can also exhibit a broad spectrum of clinical manifestations.3 Barton V. et al. suggested that 
the development of NMSC can also lead to an increased risk of other malignancies.7 
1.1.1 Malignant melanoma  
 
 Malignant melanoma is the most aggressive form of skin cancer and one of the most lethal 
amongst all solid tumour types.8,9 According to international demographic reports, ~250000 
people are diagnosed with malignant melanoma annually, with the overall trend being 
increasing over the last decade.10 In the UK, 1 in 54 people will be diagnosed with melanoma 
during their life, rendering the disease the fifth most common of type of cancer.10 Over that 
last two decades the disease incidence rates have been increased dramatically (134%), while 
it seems that is one of the most common cancers among young (between ages 15-35) and fair-
skinned people.10 The incident rate projections report for 2035 suggest an additional increase 
of 7%.10 The late diagnosis is mainly observed in 1 in 10 cases and 59000 patients diagnosed 
with the disease, were reported for 10 years survival post-diagnosis.10  
 
1.1.2 Origin of the disease 
 
The development of the disease is a result of a combination of genetic and metabolic 
abnormalities at the pigment producing cells (melanocytes) that are located in the neural crest 
and can migrate to the skin (mainly) during embryonic development11. Additionally, 
melanoma can originate from the cutaneous melanocytes or it can be developed in the mucosal 
surfaces (uveal tract of the eye, leptomeninges, gastrointestinal sites, oral cavity, and genital 
mucosa).11 Unfortunately, the exact pathogenesis of melanoma cancer still remains unclear. 
However, skin phototype, hair colour, numerous atypical naevi (pigmented moles), and 
genetic predisposition appear to be the most dominant factors that affect the development of 
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the disease.12 Changes in socio-economic status and in lifestyle habits, such as intense and 
sporadic exposure to sun - mainly during childhood, has been linked to the steadily rising 
numbers of new diagnosed cases.13 However, the main reason for the observed trends still 
remains the prolonged exposure to solar ultraviolet (UV) radiation.14–16 
Interestingly, melanoma genome analysis demonstrated the strong association between the 
frequency of mutational events and UV radiation exposure, suggesting the latter as the leading 
risk factor.17,18  
 
1.1.3 Cancer stem cells in skin cancer progression 
 
During the last few decades, there has been research that aims to investigate the stem cell 
theory of cancer. According to this theory, a small population of cancer cells within a specific 
tumour seems to exhibit stem cell properties.19,20 Thus, this can explain the ability of cancer 
cells to reproduce themselves generating the range of cancer cells that compose the tumour 
and also that promote the development of malignancy.19,20 An important implication of this 
theory is that cancer stem cells can promote metastasis of a tumour type to different sites 
(ability to migrate), whereas in the event of resistance to a treatment, they can potentially cause 
a future relapse.21  
One of the most extensively studied tissue with a well-defined structural hierarchical 
organization is mouse skin, hence it has been widely used for studying skin carcinogenesis. 
Skin carcinogenesis is characterised by multiple steps including hyperplasia, dysplasia and 
benign papilloma to squamous invasive carcinoma and spindle carcinoma.22 In addition to this, 
the elevated levels of DNA alterations of the target cells have been linked with the progression 
of this process.23 Although, it still remains unclear whether the target cancer stem cell pre-
possess the capacity to reproduce indefinitely or the genetic modifications results in the 
immortalisation of more committed cells with limited life span.23 It has been documented from 
different studies that tumours of different malignancies can arise from different target cells.24,25 
More specifically, it was suggested that malignant tumours are developed from cells residing 
in the bulge of the hair follicle and have a high self-renewal potency, while papilloma may 
4 | P a g e  
 
arise from stem cells of the interfollicular epidermis.24,25 These findings suggest that cells with 
mutation on their RAS gene remained on the epidermis for an extended period of time without 
the formation of lesions, hence, those cells belong to a stem cell population.26 Several reports 
have demonstrated the implication of cancer stem cells in the development and progression of 
malignant melanoma as well as their ability to exhibit resistance to current therapies.27 
Melanoma cells can form spheres of non-adherent cells that maintain their renewal properties 
over long periods, thus supporting the presence of cell with stem cells features within the 
melanoma population.28 Furthermore, the development of melanoma tumours is mainly 
characterised by substantial changes in their genome including chromosomal translocations, 
deletions, amplifications or mutations which suggest the extensive heterogeneity in melanoma 
population.29 Moreover, it has been shown by Kaplan R et al. that melanoma cells can secrete 
factors capable of directing the migration of hematopoietic progenitor cells to metastatic 
sites.29 For example, nodal (which is secreted by melanoma cells) acts as a morphogen for 
progenitor cells and it can also contribute to the determination of sites for tumour metastasis.30 
Additionally, important stem cell markers such as CD133, CD166, nestin, NoTCh etc. seem 
to be upregulated in melanoma cancer.22,31,32 On the contrary, others suggest that melanoma 
heterogeneity is mainly based on a clonal variation while the formation of tumours arise from 
different clones induced by other molecular mechanism.32 As a result of this, the unsuccessful 
results of current treatments can be attributed to the potential participation and activation of 
different molecular mechanisms during the progression of the disease.32,33  
1.2 Clinical diagnosis and therapy 
The clinical diagnosis of malignant melanoma is mostly unambiguous and in most cases 
accurate. However, in some instances, the non-pigment malignant melanocytic lesions are 
misinterpreted as NMSC.34 On the other hand, prognosis of the diagnosed metastatic deposits 
remains extremely poor highlighting the need for a more effective eradication of the primary 
tumour deposits.35,36 
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The clinical examination of the neoplasm mainly relies on dermoscopy, computerised 
imagining, whole body digital scanning and confocal laser microscopy.37 In addition to this, 
excisional biopsy is required for the histological evaluation, classification and staging 
according to the protocols of the American Joint Commission of Cancer (AJCC) TNM 
system.38,39 Technological advances in molecular biology allowed the identification of genes 
and key pathogenic events responsible for melanoma tumorigenesis including UV-induced 
DNA damage, reactive oxygen species (ROS) (over)production, the secretion of growth 
factors derived from keratinocytes, as well as the suppression of T-cell mediated immune 
responses.40,41 Early disease can be treated by surgical tumour removal, whereas, upon disease 
progression to metastatic stages, the available treatment options are poor.42 Moreover, current 
therapeutic strategies are not promising.42 Despite the fact that several therapeutic regimens 
based on the combination therapy entered clinical trials, none of them have been proven to 
improving survival sates. Therefore, the establishment of new therapeutic strategies or the 
improvement of the already existencing ones, is pivotal.  
 
1.2.1 Current therapeutic approaches 
 
The development of malignant melanoma is strongly associated with the dysregulation of 
several proteins including, the mitogen-activated protein kinase (MAPK), the micropthalmia 
transcription factor (MITF), the epidermal growth factor (EGFR), the N-Ras sarcoma protein 
(NRAS) protooncogene as well as the B-rapidly accelerated fibrosarcoma (BRAF) 
oncogene.43–47 Therefore, the recent molecular drugs aim to target the MAPK pathway which 
contributes by 90% in the development of the disease.45 In fact, 50% of cases present activating 
mutations in BRAF. Vemurafenib (Figure 2A) and dabrafenib (Figure 2B) shown some 
exceptional inhibitory ability against BRAF activation whereas trametinib (Figure 2C), which 
is a MAPK kinase (MEK) inhibitor was found to be effective in blocking the downstream 
signalling activation of BRAF.48–50 Others suggested that combination treatment with BRAF 
and MEK inhibitors has elicited considerable tumour regression.51,52  
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Figure 2: Structure of (A) vemurafenib, (B) dabrafenib and (C) trametinib 
 
1.2.1.1 Immunotherapeutic approach 
 
Nowadays, molecular immunotherapy is an attractive therapeutic approach that has shown 
promising results towards malignant melanoma treatment.53 Initially, adaptive immunotherapy 
exploiting tumour infiltrating lymphocytes (TIL) or genetically engineered T-cells expressing 
chimeric antigen receptors (CAT-T 5 cells) has been correlated with 50-70% response 
rates.54,55 Afterwards, administration of interleukin-2 (IL-2) or interferon-alpha (IFN-α) as a 
single agent or adjuvant therapy was found to be an effective approach in sustaining disease’s 
control.51,56,57 It has been also demonstrated that patients diagnosed with advanced or even 
intermediate stage of the disease can undergo adjuvant systemic therapy including the 
administration of intermediate doses of IFN-α or adjuvant radiotherapy post-surgical 
clearance.58,59 Most recently, it has been reported that treatment with immune check-point 
regulators has been adopted as a way to oppose the induction of immunological tolerance 
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during melanoma development and formation.60,61 T-Lymphocyte associated protein 4 
(CTLA4) inhibitors including ipilimumab or tremelimumab were found to be effective as 
monotherapy or in combination with the cytotoxic drug dacarbazine (Figure 3).60,61   
 
 
Figure 3: Structure of dacarbazine 
 
Moreover, nivolumab and lambrolizumab (monoclonal antibodies) can target the pro-death 
receptor-1 ligand 1 (PD-L1) which is frequently expressed in melanoma cells suggesting an 
alternative therapeutic approach, towards the treatment of melanoma.62  
 
1.2.1.2 Chemotherapeutic agents and radiotherapy  
 
Single agent chemotherapy involving treatment with dacarbazine (Figure 3), temozolamide 
(Figure 4A) and fotemustine (Figure 4B) is frequently used for the treatment of melanoma 
mainly due to their low toxicity and simplicity of administration.63  
 
 
Figure 4: Structure of (A) temozolamide and (B) fotemustine 
 
However, such a treatment approach is mainly associated with low responses rates (~10%).63 
Bio-chemotherapy, a compbination of all the above mentioned regimens with administration 
of cytokines, is considered as a promising strategy with potentially better response rates.64 Last 
but not least, radiation therapy in combination with the chemotherapeutic agents is widely 
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employed for the treatment of distant metastases including those in the lungs, lymph nodes, 
spleen liver, biliary, bones and gastrointestinal tract.65 
 
1.3 The involvement of metals in cancer development and metastasis 
Several reports noted the importance of metals in human biology. It is well known that the 
human body uses essential metals; iron, zinc, copper manganese, molybdenum, selenium 
magnesium, calcium, potassium and sodium for the maintenance and the proper function of 
the organism.66 Tracer amounts of those metals (apart from iron, copper and zinc) play a 
pivotal role in cellular organisations with most of them being integral for the function of 
enzymes required for the catalysis of biochemical reactions.66,67 For example, ribonucleotide 
reductase, an enzyme that participates in the rate limiting step of the synthesis of DNA, 
contains iron atom as a cofactor, whereas zinc is contained in enzymes that are responsible for 
gene expression e.g. zinc transcription factor. In addition to this, copper is a cofactor in at least 
13 enzymes, which most these have application in the rigidity, mechanical strength and 
competence of the bones, ATP synthesis, as well as the synthesis of myelin in brain.68–70 On 
the contrary, depletion of those metals can be fatal or can associated with the development of 
several diseases, such as anaemia due to iron deficiency or ischaemic heart disease induced by 
copper deficiency.66  Conversely, an excess of these metals can also lead to toxic effects that 
are linked with inflammation.66 It has been also demonstrated in the past, that many metals 
contribute to development, progression and metastasis of several types of cancer by interfering 
on key biological process that mediate the cell motility, invasion and dissemination.66  
 
1.3.1 The role of copper in cancer 
 
It has been shown, that elevated levels of copper have the ability to induce malignancies by 
promoting the tumour growth, the angiogenesis and metastasis of cancer.71,72  The role of 
copper in facilitating angiogenesis has been demonstrated to be crucial for the activity of lysyl 
oxidase (LOX) and lysyl oxidase-like (LOXL); enzymes that are necessary for the cross 
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linking of collagen and elastin fibres.73,74 In addition to this, these two enzymes are 
participating in cell angiogenesis, proliferation and differentiation and upon dysregulation of 
their expression levels they can contribute to the development of metastasis.67 The secretion 
of LOX allows the tumorigenic cell to induce alteration of the extracellular matrix to proffer 
a pre-metastatic phase.67 Furthermore, LOXL2 can interact with E-cadherin gene suppressor; 
SNAIL causing in that way the downregulation of E-cadherin thus facilitating in that way the 
promotion of epithelial to mesenchymal transition.75 Another cell motility protein that plays 
an important role in the development of breast cancer cell is the MEMO protein which required 
a Cu(II) for its oxidase activity.76 It has been shown previously, that MEMO facilitates the 
migrator capacity of breast cancer cells.76 Additionally, it is essential element for the invasion 
and metastasis of these cells. Furthermore, it has also been reported that MEMO protein can 
also induce elevation of ROS as the Cu(II) ion is redox active and it can therefore participate 
in Fenton Chemistry (2.1).66,68,72,76  
1.3.2 The role of zinc in cancer  
 
Matrix Metaloproteases (MMPs) play a crucial role in the invasion and metastasis of cancer 
as they can degrade the surrounding cellular tissue enabling the access of cancerous cells.77 
The catalytic action of most these particular superfamily of enzymes is mediated by zinc, 
which is located in their active centre.77 Not surprisingly, evidence shown that elevation of 
zinc labile pool in cancer led to significant activation of MMP whereas their action was 
abolished upon chelation of zinc.78 Interestingly, the expression levels of MPPs; MMP-1 and 
MPP-3 is mediated by the transcription factor zinc-binding protein-89 (ZBP-89).67,79 
Furthermore, the expression levels of ZBP-89 were significantly higher in cell renal carcinoma 
and it was demonstrated that its overall expression is significantly higher in metastasized cells 
compared to the non-metastasized ones.80–82 Hence, through the involvement of zinc in key 
enzymes and molecules that regulate the cell motility and invasion it can be concluded that 
regulation of zinc can be a major contributor in cancer development and metastasis.66  
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1.3.2.1 The role of iron in cancer 
 
Due to the poor bioavailability of iron, the contribution of different proteins involved in iron 
import storage and export has to be perfectly mediated as there is currently unknown way of 
excreting iron in humans.83 Malignant cancer is mainly associated with dysregulated iron 
haemostasis.84 It has been also demonstrated that cancer cells are not using the surplus of iron 
just for the transformation and proliferation but also during the late stages to promote 
metastasis and angiogenesis.85,86 Moreover, the ability of iron to remodel the extracellular 
matrix was also correlated with cancer invasion.87 The essential role of iron in cancer 
development has been assessed in animal models in the past.83 The outcome of these studies 
was that mice fed with low iron diet prior to tumour implantation showed significantly delayed 
tumour growth.88 The necessity of tumour cells to acquire iron leads to a depletion of the iron 
levels in liver and spleen (post implantation).88 As a result, it was suggested that red blood cell 
recycling and iron storage in the liver and spleen are compromised, hence the erythropoiesis 
was significantly reduced, inducing anaemia.88,89 Not surprisingly patients diagnosed with 
cancer tend to develop anaemia due to the dysregulation of iron metabolism.83 The expression 
of a variety of iron regulated genes including the transferrin receptor1 (TfR1), ferritin light 
chain (FTL) and the iron regulatory protein (IRP-2) in cancerous cells was strongly associated 
with a series of events such as poor prognosis, higher tumour grade and increased 
chemoresistance.90–93 However, the most important aspect of iron that makes it an essential 
component for the development of cancer is its ability to participate in the catalysis of ROS 
production via its redox potency – Fenton Chemistry (2.1.1).90–93 In addition to this, it has been 
previously suggested that the contribution of ROS in cancer depends on its levels.84,94 High 
ROS levels can be cytotoxic and that results in apoptosis, whereas low levels of ROS can 
activate oncogenes and consequently carcinogenesis.94–98 Moreover, low levels of ROS have 
been shown to increase the expression levels of proteins that are associated with the 
angiogenesis and metastasis including; SNAIL, AP-1, VEGF as well as the activation of the 
NF-κB patheway.95,98–101 Overall it has been demonstrated that some malignancies including 
malignant melamoma express significantly elevated amount of ROS in order to proliferate and 
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metastasize.102–104 Excessive ROS accumulation has been associated with cancer development, 
as oxidative stress can induce lipid peroxidation (Figure 5A), protein carbonylation (Figure 
5B) as well as DNA oxidative damage (Figure 5C).83 This effect can lead to genetic instability 
and tumorigenesis.105  
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Figure 5: ROS driven (A) lipid peroxidation (B) protein carbonylation and (C) oxidation of 
DNA- bases (herein the formation of 8-oxo2-deoxyguanisine is shown).  
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1.4 Metal chelation based treatment 
Due to the involvement of metals in cancer development and progression it is not surprising 
that metal chelators are being considered as potential therapeutic targets agents that would aim 
the restore of metal homeostasis by preventing the metal induced cell growth and 
proliferation.106 As it was mentioned above, low levels of ROS are essential for cell 
proliferation whereas the high levels of ROS can be cytotoxic. Therefore, metal chelators 
should act either as anti-oxidants and promote the redox silencing of Fe(III) or Cu(II) or act as 
pro-oxidants (depending at the concentration).107 Pro-oxidant metal chelators can induce toxic 
levels of ROS activating downstream apoptotic cascades.108,109 To this end, according to the 
literature, a variety of metal chelators have been designed as potential anticancer therapeutic 
agents (Table 1).
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Table 1: Selected classes of metal chelators that were used against various type of cancer. 
Class of chelator Structure Metal 
target 
Activity against cancer 
B
is
p
id
o
n
es
 
 
 
- Human Pancreatic cancer; MiaPaCa-2 CFPAC1, BxPC3110 
 
Cu(II) Prostate cancer; PC3111 
H
y
d
ro
x
a
m
ic
 
a
ci
d
s 
 
and derivatives 
Zn(II) 
Human Kidney epithelial; HEK293112 
Neuroblastoma; BE(2)C113 
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Desferoxamine (DFO) 
Fe(III) 
Various cancer types114–117 
 
 
Deferasirox 
 
Fe(III) 
Oesophageal adenocarcinoma; OE16, OE33 
oesophageal; squamous carcinoma; OE21, TE4118 
Hydroxypyridinones 
(HOPOs) 
1-hydroxypyridin-
2(H)-ones 
(1, 2-HOPOs) 
 
Fe(III), 
Zn(II) 
 
Human colon carcinoma; HCT-116119 
B16 malignant melanoma119 
Lymphoid neoplasm; P388D1119 
 
MPPs inhibitor120,121 
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and derivatives 
Glioma stem cells; BT-142122,123 
3-hydroxypyridin-
2(H)-ones 
(3, 2-HOPOs) 
 
Zn(II), 
Fe(III), 
Cu(II) 
CDK-2 inhibitor124 
 
MMPs inhibitor125 
Fibrosarcoma; HT-1080124 
 
and derivatives 
Human malignant melanoma; A375126 
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3-hydroxypyridin-
4(H)-ones 
(3, 4- HOPOs) 
 
Deferiprone  (DFP) and 
derivatives 
Zn(II), 
Fe(III), 
Cu(II), 
Al(III) 
Various types of cancer127–135 
 
 
L-Mimosine 
Various types of cancer136–140 
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Hydroxypyrimidinon
es (HOPYs) 
 
and derivatives 
Fe(III), 
Zn(II) 
Xeroderma pigmentosum G.141,142 
Bladder carcinoma; T4141,142 
DNA-repair complex; ERCG1-XPF141,142 
Thiosemicarbazole 
 
Fe(III)  
Lung carcinoma; M109143 
Ovarian carcinoma; A278143 
Human Nasopharyngeal carcinoma; KB143 
Leukemia; L1210143 
Ribunucleotide reductase inhibitor144 
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Tachpyridines 
 
and derivatives 
Fe(III), 
Zn(II) , 
Cu(II) 
Various cancer types145–153 
 
Quinolines 
 
8-hydroxy quinolones 
and derivatives 
Fe(III), 
Zn(II) , 
Cu(II) 
Various cancer types154–161 
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1.4.1 Toxicity of metal chelators and prodrugs 
 
The development of metal chelators can be associated with the appearance of side effects mainly 
due to the lack of either cellular or metal selectivity. For example, regardless the exceptional 
ability of deferiprone (DFP) to bind Fe(III) over Cu(II) and Zn(II) it was found that it inhibits non 
selectively lipoxygenases and tyrosine hydroxylase.162,163 Additionally, administration of DFP  
also induces agranulocytosis.164 A naturally occurring metal chelator; L-mimosine obtained from 
the plant Mimosa and Leucaena genara endowed with the range of biological functions including 
anti-cancer, anti-inflamatory, anti-viral and anti-fibrotic capacity.106 It was also demonstrated that 
L-mimosine exerted anticancer activity against various melanoma cell lines (with EC50= 100 µM) 
by inducing cell cycle growth arrest and activating apoptotic cascades, however the side effects 
associated with its strong cytotoxicity, discouraged its further development.136–139 In another 
example, thiocarbazone triapine and DFO also show some anticancer activity in clinical 
trials.83,117,165 However, due to the serious side effects such as hearing abnormalities, optic 
neuropathy and growth failure in children, their further administration has been hampered.83 In an 
attempt to limit the side effects associated with the administration of metal chelators the research 
was focused in the design of prodrugs that can undergo in situ action/activation.166 For example, 
exploiting the disulphide bonds for the activation of the iron pro-chelators, show encouraging 
results in vitro mainly because iron coordination achieved via the intracellular reduction of 
disulphide forming high affinity tridentate thiolate chelators (Figure 6).167  
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Figure 6: Intracellular reduction of disulphide bond leads to activation of anti-proliferative 
thiosemicarbazone chelator.167 
Furthermore, cancer cells exhibit a higher reducing environment compared to the surrounding 
tissues, making the reductive activation an alternative strategy to enhance cancer cell specificity, 
owing to significantly higher amounts of reduced glutathione compared to the healthy cells.167,168  
Additionally, Akam A. et al. used a glucose-conjugated thiosemicarbazole pro-chelator against 
colon carcinoma, proving that enhanced pro-chelator was accumulated and acted preferentially in 
cancer cells (Figure 7).169  
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Figure 7: Redox directed glucocongugate pro-chelator based strategy for iron coordination.169 
This approach was based on the fact that malignant cancer cells tend to overexpress the GLUT1 
transporter (more details can be found in 1.12.1.3.1 and 1.12.1.3.1.1).170 Glucose conjugates of 
several chemotherapeutic drugs including paclitaxel and doxorubicin experience significantly 
improved therapeutic efficacy in vivo.171–173 Therefore, these strategies aim in the selective iron 
pool targeting of carcinogenic cells.  
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1.5 Neurodegenerative diseases 
Neurological disorders are a class of disorders - pathological conditions – that affect the nervous 
system. It has been previously documented that neurodegenerative disorders, constitute a major 
burden on modern society as they affect one in four people worldwide.174 Particularly, in Europe, 
neurological disorders cause around 35% of years lost due to ill-health, disability or early death.175 
The primary risk factor for such disorder is mainly the age.176 This will exacerbate the healthcare 
burden of the pathology of this disease as the average age of the global population is expected to 
rise rapidly, especially in countries with a rising life expectancy (i.e. industrialised developed or 
newly industrialised countries).176–178 The common characteristic aspect of all the 
neurodegenerative diseases in the loss of neuronal structural composition and hence the loss of 
their function, with Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease 
being the lead examples of such diseases.179 The underlying cause is poorly understood in the 
majority of neurodegenerative diseases and the progression of the diseases in often unclear. The 
diagnosis relies on empirical clinical criteria but a definitive diagnosis requires post-mortem 
autopsy.180  Interestingly, certain hallmarks and patterns have been identified in the most important 
neurodegenerative diseases including AD, PD, amyotrophic lateral sclerosis, prion diseases and 
Huntington’s disease.176 All the mentioned disorders are characterised by the progressive loss of 
specific localised cell populations and the abnormal accumulation and aggregation of certain 
proteins.176,181–183  
1.6 Parkinson’s disease 
 
1.6.1 Epidemiology 
 
Parkinson’s disease was first characterised by James Parkinson at the beginning of the 19 th century 
and overall is the second most common neurodegenerative disease worldwide after AD.184,185 The 
incidence rate of PD is estimated to be 8-18 cases per 100,000 persons per annum, but it varies 
across different geographical locations, and it is higher in populations with a higher average age.186 
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The prevalence of PD in the UK was estimated to exceed 150,000 cases or 5.1% of the overall 
population according to the last statistical analysis that was performed in 2018.187 The prevalence 
was estimated based on medical records and it therefore likely that a significant undiagnosed cases 
exist in addition to these recorded cases.187 According to the statistical analysis, the biggest risk 
for PD development is age, which is illustrated by the fact that over 90% of PD suffers are aged 
60 or older.187 In addition to this, studies suggested that the disease more often appeared in men 
whereas others found no differences between sexes.177–179,186 Most Western societies have a rapid 
ageing population, which lead to an increasing development of the diseases in future, whereas in 
the UK, studied pointed out that we should expect an approximately 50% increase of PD diagnosed 
cases by 2020.187 Similarly, the number of diagnosed cases for 15 of the world’s most populous 
nations is expected to double by 2030, driven by a pronounced increase of cases in the rapidly 
industrialised and developing countries including China, India, Indonesia, Brazil, Pakistan, 
Bangladesh, Russia, Nigeria, etc.).186,188  
 
1.6.2 Pathology and symptoms 
 
PD as neurodegenerative disease is mainly characterised by the loss of the neuron in nigrostratial 
pathway and the presence of intracellular proteins inclusions, known as Lewy bodies (Figure 
8).182,189,190  
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Figure 8: Formation of Lewy bodies is one of the common parameters that contributes to the 
development of PD.189 
The loss of neuronal cells affects the dopaminergic neurons projecting into the substantia nigra 
of the midbrain striatum (Figure 9).182,189–192  
 
Figure 9: PD arises from the degradation of dopaminergic neuronal cells; Substantia nigra (SNpc) 
locares in the Putamen and Caudate of the midbrain.192 
Additionally, the neurons projecting into the putamen are lost preferentially over the caudate.192 
At the time of death, it has been demonstrated that up to 70-80% of neurons in that area are 
lost.182,191,192 The neuronal loss leads to a significant depletion of the levels of dopamine in the 
striatum, causing perturbation of the signal transduction to the areas responsible for motor 
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control.192–195 In addition to this, depletion of dopamine is also correlated with the most common 
PD symptoms including; resting tremors, stiffness and bradykinesia.191,194,196,197 Non-motor 
symptoms can also exist, however their cause is not clear yet. Interestingly it has been previously 
reported that a large population of dopaminergic neurons is lost prior to the appearance of the 
symptoms. The exact cause of neuronal degradation is still unknown, however the protein 
aggregation (Lewy bodies) and oxidative stress (both developed in PD brains) are known to be 
cytotoxic, hence they might contribute significantly to the development of the disease.198–200 
Moreover, α-synuclein, is the most dominant species of aggregated proteins found in PD brains 
and unfortunately the exact role in both health and disease remains unclear.201 It is thought that 
under healthy conditions it is neuroprotective for non-dopaminergic neurons, however, aggregates 
of the insoluble α-synuclein exhibit toxicity in the presence of dopamine.201 It has been shown 
previously in the literature that multiple mutations on the synuclein genes have been shown to be 
associated with the development of PD or to constitute a risk factor for sporadic PD.191,202 
 
1.6.3 Genetic origin of PD 
 
Other pathological risk factors that are related to the development of the disease include gene 
polymorphism, however just a small amount of cases can be attributed to genetic factors.202 So 
far, ten different loci are known; PARK1 to PARK10, however the exact mutations remained 
unknown.203 The most well studied mutations concern the genes PARK1, -2 and -8.204,205 For 
example, genetic mutation on PARK1 leads to a formation of an autosomal dominant PD family 
which is mainly characterised by an early onset with aggressive progress.206 Furthermore, the 
PARK1 gene (as well as SNCA) encodes α-synuclein.207,208 α-Synuclein plays a fundamental role 
into the supplement of synaptic vesicles in presynaptic terminals.209 Additionally, it was found 
that α-synuclein is responsible for the controlled release of dopamine.210 Therefore, mutation on 
the respective genes leads (mainly) to a significant reduction of the dopamine’s storage.207 Another 
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mutation concerns PARK2, which is responsible for the expression of parkin protein – a 
component of the ubiquitin-proteosome system.211–213 PARK2, participates into the regulation of 
monoamine oxidase (MAO) which is responsible for the regulation of dopamine’s oxidation.212 
Mutation in this gene is known to cause a familiar form of PD known as autosomal recessive 
juvenile PD.204 Finally, another mutation which is widely studied concerns PARK8 which encodes 
leucine-rich repeat kinase- 2 (LRRK2).214 LRRK2 is associated with a variety of cellular functions 
including signal transductions, and apoptotic processes.214 The relationship between the LRRK2 
and neurodegeneration of dopamine endings in striatum has been previously studied and it was 
concluded that mutation in LRRK2 has been identified as risk factor for the development of PD.215–
217 On the contrary, selective inhibition of the mutated form of LRRK2 shown some 
neuroprotective effect and thus it could be used as an alternative therapeutic strategy against the 
disease.214,218,219  
Another important class of genes those mutations can cause PD is the Pantothenic-Induced 
putative kinase-1 (PINK-1).220 The expression of these genes lead to the formation of a 
mitochondrial serine/threonine kinase-1 which is involved in the mitochondrial response against 
cellular and oxidative stress, protecting in that way neurons from mitochondrial dysfunction and 
proteosomal induction of apoptosis.221–223 In the unfortunate event of PARK-1 mutation, the 
defective protein is not able to act properly against the oxidative damage facilitating in that way 
the neuronal degradation and eventually PD development.224,225 Nevertheless, more than 90% of 
the PD diagnosed cases are idiopathic.226,227 Not surprisingly, environmental factors, such as 
smoking, diet, exposure to toxins, heavy metals or herbicides, have been marked as risk factors 
for PD, however their effect remains contested.177,182 
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1.6.4 The contribution of metal-induced oxidative stress into PD development 
 
The elevated levels of redox active metals including Fe(III) and Cu(II) in the substantia nigra of 
the PD diagnosed patients is often correlated with the protein aggregation, while iron and copper 
levels in other part of the brain were not elevated.228–232 As it has been mentioned in the previous 
chapter (1.3 and 1.4) above, Fe(III) and Cu(II) are participating in Fenton reaction to produce free 
radicals from hydrogen peroxide which is mainly produced in mitochondria as a by-product of 
natural metabolism mainly during the metabolic production of DOPAL by the action of 
monoamine oxidase-B (MAO-B).233,234 The toxicity mediated by those metals in cells appears at 
least partly linked to the development of oxidative stress in mitochondrial DNA which leads to 
progressive mitochondrial dysfunction.235 α-Synclein misfolding and aggregation has also been 
shown to be enhanced by the metal-induced oxidative damage.236,237 It has been suggested that the 
dysregulated iron localization in PD exacerbates the stress on dopaminergic neurons caused by 
protein aggregates and oxidative stress on multiple levels.191,198,233,235–237 Therefore, this effect can 
lead into the selective and preferential death of dopaminergic cells, hence, the contribution of iron 
in these process links to PD development and progression. The removal of iron and/or copper from 
PD brains is therefore a novel approach for the treatment of disease.  
1.7 Toxin-induced PD for in vitro and in vivo studies 
Prior to the screening of drugs against PD in either an in vitro or in vivo model it is essential to 
introduce a parkinsonian phenotype. This is because there is not currently an isolated cell line that 
is genetically modified to correspond to PD.  PD pathogenesis can be studied using some 
experimental model been produced after exposure with some neurotoxins that tend to produce 
similar phenotypes to those of the disease.238,239 Although a variety of natural and synthetic 
molecules can exert neurodegradation effect on dopaminergic neurons, only a handful are used in 
animal models to reproduce some of the hallmarks of PD.239  
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1.7.1 6-hydroxydopamine (6-OHDA) 
 
One of the catecholaminergic neurotoxins that is widely used for both in vitro and in vivo study of 
PD is a noradrenergic analogue called 6-hydroxydopamine (6-OHDA) (Figure 10A).240 
 
 
Figure 10: Structural similarities between the neurotoxin; (A) 6-OHDA and the neurotransmitters; 
(B) dopamine and (C) Norepinephrine.   
As it can be observed from (Figure 10), 6-OHDA possess structural similarities with both 
dopamine (Figure 10B) and norepinephrine (Figure 10C) exhibiting in that way high affinity for 
a variety of catecholaminergic plasma membrane transported including dopamine (DAT) and 
norepinephrine transporters (NET).241,242 Therefore, 6-OHDA can enter both dopaminergic and 
norandrenergic neurons inducing damage to the catecholaminergic pathways. The mode of action 
of this neurotoxin it is mainly associated with the induction of ROS.239 Additionally, its auto-
oxidation can lead to the formation of hydrogen peroxide and para-quinone which is known as a 
powerful electrophile which can react further with either side chains of proteins or DNA bases 
(Figure 11).239 
 
 
Figure 11: Oxidation of 6-OHDA into hydrogen peroxide and quinone.  
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Injection of 6-OHDA in mice and dogs directly in the SNpc or the striatum (as it can poorly cross 
the BBB) shown a maximal reduction of striatal dopamine as well as gradual degradation of the 
dopaminergic neuronal cells.239 Another function of 6-OHDA is its ability to inhibit both complex 
I and IV of the mitochondrial respiratory chain preventing in that way the redox cycle of the 
coenzyme NADH and the binding of cytochrome C.243,244 Additionally, the inhibition of these 
complexes can also lead to perturbation in the gradient across the membranes since the proton 
transportation is prevented.243,244 
1.7.2 MPTP/ MPP+ 
 
Despite the variety of neurotoxins that can be used for the understanding of neuronal related 
pathologies that occur in basal ganglia and/or in the SNpc, a single toxin seems to target 
specifically and selectively those neurons that are involved in the development of PD.245 This toxin 
is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Figure 12A). 
 
Figure 12: Structures of (A) MPTP, (B) Meperidine and (C) MPP+ 
 
MPTP is a narcotic synthetic compound that is related to meperidine (Figure 12B).245 This toxin, 
is relatively water insoluble and therefore it can cross the BBB and easily reach easily the brain 
cells.246 Furthermore, MPTP can be captured by organelles with an acidic environment including 
lysosomes and astrocytes.247 Interestingly, MPTP is not toxic itself, however its oxidized form; 1-
methyl-4-phenylpyridinium (MPP+) is toxic (Figure 12C).245,246 The oxidation of MPTP into 
MPP+ is regulated by MAO-B, which is located in astrocytes and serotogenic neurons.246  Once 
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the toxic oxidized product reaches the extracellular fluid, via the DAT, it is taken to the 
dopaminergic neuronal terminals.246 The mode of action of the MPP+ is mainly to inhibit  complex 
I of the mitochondrial respiration chain causing cyto(neuro) toxic effects. Initially, inhibition of 
complex I can cause perturbations in the production of ATP as the blockage prevents  ion 
transportation.247–250 Additionally, such inhibition leads to disruption of calcium hemostasis, as the 
concentration of the extracellular calcium is elevated, promoting in that way the activation of the 
calcium-depended enzymes; protein kinase-1, calpain I and II.251–253 The activation of these 
proteins is associated with the disruption of cell function and cell death.251,252 Eventually, and most 
importantly, MPP+ stimulates the generation of ROS via the faulty maintenance of NADH 
dehydrogenases. On the other hand, experiments on monkeys treated with MPP+ show the 
elevation of the Fe(II) which is incorporated into Fenton chemistry. ROS and Fe(II) have been 
strongly implicated to the development of PD.254–256  
1.7.3 Erastin 
 
There are multiple cell death mechanisms that are associated with the development of PD, with 
ferroptosis being one those.257 Ferroptosis, is an iron-dependent cell death pathway (that differs 
from apoptosis) which involves several molecular events that were previously found to be 
correlated with the pathogenesis of PD.258 More specifically, ferroptosis, is triggered by small 
molecules or conditions that inhibit the biosynthesis of glutathione and/or the glutathione 
dependent antioxidant enzyme; glutathione peroxidase 4 (GPX4).258 As a result of this, the 
intracellular levels of reduced glutathione are depleted and the levels of liable iron pool are 
elevated (as reduced glutathione acts as a natural ligand of iron in the liable iron pool).259 These 
features of ferroptosis are strongly associated with the pathogenesis of PD as the increased 
availability of iron contributes significantly to the induction of the oxidative damage via ROS 
elevation and lipid peroxidation.258,260 Erastin is one of the lead neurotoxins that can induce 
ferroptosis (Figure 13).  
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Figure 13: Structure of erastin. 
 
The mode of action of this toxin is to inhibit the xCT cysteine/glutamate antiporter preventing the 
cystine update into the cells (Figure 14).261 
 
Figure 14: Erastin prevents the entrance of cystine preventing the biosynthesis of glutathione.261 
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Starvation of cystine and hence cysteine can have detrimental effect into the antioxidant defense 
of the cell as both compounds act as precursor of glutathione.261 In addition to this, the lack of 
glutathione prevents the detoxification of the cell and also allows the liable iron being unbound, 
promoting in that way the Fenton reaction with all the cytotoxic events that are associated.  
1.8 Current Treatments  
At the present time, there is no cure for PD and the existing treatment options are only used to 
manage the motor symptoms of the disease and not reverse the cellular loss or prevent further 
neuronal degradation.191,199  
1.8.1 Non-pharmacological therapies 
 
Non-pharmacological methods are used as potential therapeutic approaches against the disease 
and they include deep brain stimulation of the subthalamic nucleus.236,262 This well-established 
technique was found to improve significantly the motor functions of the patients.263 Despite the 
promising results of this therapeutic approach, it is only used for just 5-10% of diagnosed with PD 
patients due to strict patient criteria.264 Another option that offers potential restoration of motor 
symptoms, involves the foetal mesencephalic graft transplantation.265,266 According to this 
treatment option, the nigrostriatal dopaminergic pathway can be restored facilitating the reverse 
of motor function dysregulations.265,266 However, the success of this graft is limited and post-
mortem analysis indicates the presence of Lewy bodies in the dopaminergic neurons of the 
grafts.267 Further development of this technique was hampered due to bioethical and legal 
limitations.268  
Eventually, gene therapy is an alternative approach which has been employed in clinical trials in 
PD patients and due to the promising results, further research projects are in process.269 
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1.8.2 Pharmacological therapies – Existing treatments  
 
Because the main symptoms of PD are associated with the depletion of dopamine, the dopamine’s 
metabolism is the main target of the current treatments (Figure 15).
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Figure 15: Metabolism of L-DOPA and dopamine in peripheral and central nervous system
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1.8.2.1 L-DOPA supplements 
 
Nowadays there is a variety of drugs on the market that are able to target proteins in order to 
increase the available dopamine in the striatum. The initial drug therapy against PD involved the 
administration of (L)-3,4-dihydroxyphenylalanine or levodopa (L-DOPA).191 L-DOPA is the 
hydrophilic precursor of dopamine, which can be transported from the peripheral nervous system 
to the central nervous system by exploiting an active transport mechanism; Large neutral Amino 
Acid Transporter-1 (LAT-1) on the blood brain barrier (BBB).270–272  Upon transportation of L-
DOPA to the CNS, it is picked by the presynaptic dopaminergic endings and it converted to 
dopamine by the action of Amino Acid Decarboxylase (AADC) enzymes.273 Apart from the CNS, 
L-DOPA has the ability to be decarboxylated into dopamine in the PNS.273 The accumulation of 
dopamine into the PNS is often associated with adverse side effects including nausea and 
dyskinesia.274 To bypass the development of the side effects, L-DOPA is co-administered with a 
peripheral L-DOPA decarboxylase inhibitor (DDCI) (not capable to cross the BBB) such as , 
benzerazide (Figure 16A) and carbidopa (Figure 16B).275–277 
 
 
 
Figure 16: Structure of DDC inhibitors that used against PD. 
 
The inhibition of peripheral L-DOPA decarboxylation reduces the development of the site effects 
by decreasing the concentration and accumulation of the systemic dopamine but also it can 
increase the bioavailability of the drug on the CNS.278  However, prolong administration of L-
DOPA seems to loss its activity due to the wearing-off effect according to which L-DOPA’s 
activity is decreased because of a progressive destruction of dopaminergic neurons.279  
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1.8.2.2 Catechol-O-Methyl Transferase Inhibitors (COMT) 
 
COMT inhibitors belongs to a relatively new class of drugs against PD.280 The role of COMT 
enzymes is to introduce a methyl group to the 3-hydroxy group of catecholamine core of both 
dopamine (in the CNS) and L-DOPA (in the PNS) which is denoted by the S-adenosyl methionine 
(SAM) as part of the metabolic decomposition of these molecules (Figure 15).281 The methylation 
leads to the formation of the inactive compounds; 3-O-methoxytyramine and 3-O-methyldopa 
respectively (Figure 15).280  The co-administration of inhibitor of DOPA-decarboxylase and L-
DOPA reduces the production of dopamine but increase the concentration of L-DOPA that can be 
methylated by COMT.282 The main therapeutic action of COMT inhibitor is to prevent the 
methylation of L-DOPA to 3-O-methyldopa in the PNS and increase the bioavailability of the 
drug.282 Additionally, COMT inhibition can also prevent the methylation of dopamine in the 
CNS.282 The two well-known COMT inhibitors are Tolcapone (Figure 17A) and entacapone 
(Figure 17B), opicapone (Figure 17C) and nitecapone (Figure 17D).282,283  
 
Figure 17: Structure of COMT inhibitors used against PD. 
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The advantages of tolcapone over entacapone are the longer duration and inhibition of COMT in 
both the PNS and CNS, whereas entacapone can only inhibit the peripheral COMT .284 However, 
all of them show toxicity that is mainly associated with the nitro group and the catechol core. To 
this end a variety of COMT inhibitors based on HOPO core are known, however they are not used 
for the treatment of PD but against psychiatric disorders.285  
1.8.2.3 Monoamine Oxidase (MAO) Inhibitors 
 
Monoamine oxidases (MAOs) are enzymes that catalyze the oxidation reaction of the monoamine 
(dopamine) to the respective aldehyde; DOPAL (Figure 15).286 In humans there are two types of 
MAO; MAO-A and B with MAO-B being the most dominant form in the striatum responsible for 
the oxidation of dopamine during metabolism (Figure 15).286,287  Therefore, the development and 
usage of MAO-B inhibitors is of a particular interest against the treatment of PD.288 A 
characteristic example of a MAO-B inhibitor is Selegiline, which can selectively inhibit the MAO-
B on the striatum and not the peripheral MAO-A, hence it can be co-administered with L-DOPA 
(Figure 18).289  
 
Figure 18: Structure of MAO-B inhibitor used against PD 
 
However, the major disadvantage of this drug is its toxic metabolites; amphetamine and 
methamphetamine, which can cause anxiety and insomnia.290 
1.8.2.4 Dopamine agonists 
 
Another important class of drugs that are widely used against PD are dopamine agonists.291 
Dopamine agonists have the capability to cross the BBB, and they can act directly on dopamine 
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receptors by mimicking the endogenous neurotransmitter.292 Overall, they have similar effects to 
L-DOPA, however an important difference is that the dopamine agonist can act to the site of action 
without any enzymatic conversion.292 On the other hand, since they are selective for dopamine 
receptor binding, they usually have less side effects compared to L-DOPA.292 Among the 
dopamine agonists, the most commons ones are bromocriptin (Figure 19A) (an ergot alkaloid), 
ropinirole (Figure 19B) and pramipexole (Figure 19C).293–295  
 
Figure 19: Structure of dopamine agonist that used against PD. 
 
These dopamine agonist, can be orally absorbed and they have longer duration of action compared 
to L-DOPA.296 The therapeutic effect of these class of drugs relies on their interaction with 
postsynaptic receptors of dopamine but they can also activate the presynaptic autoreceptors.297–299 
The receptor stimulation leads to a decrease in production and release of endogenous dopamine 
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reducing the intracellular oxidative stress.297–299 The side effects that are associated with the 
administration of these drugs include hallucination, confusion and hypotension.300 A drug that is 
also used with fewer side effects is apomorphine (Figure 19D), which is available as a 
subcutaneous injection with immediate release.301,302 Apomorphine is a potent agonist with high 
affinity for D4 receptors, moderate activity for D2, 3 and 5 and low activity for D1 receptors.303,304 
1.8.3 New strategies - Metal chelators  
 
Despite the fact that a variety of drugs against PD have been designed and used in clinical trials 
none of them manage to prevent the development or affect the progression of the disease since 
they are only capable of treating the symptoms of PD.305 As it was mentioned above, the 
involvement of iron in the pathogenesis of PD is an important factor that should be taken into 
consideration for the treatment of the disease as iron and/or copper, via oxidative stress, increase 
the rate of protein aggregation and consequently the neuronal degradation.181,183,198,228,231,232,236 A 
variety of studies in the literature demonstrate the neurotoxic effect of iron on both in vitro and in 
vivo as well as the therapeutic effect of iron chelators (themselves or part of a multidrug regiment) 
that are capable of removing the iron liable pool.181,183,198,233,255 Additionally, it was suggested by 
Zheng et al. that iron chelators; VK28 (Figure 20A), M30A (Figure 20B) and M30 (Figure 20C) 
can pose anti-oxidant effect on iron mediated lipid peroxidation in brain homogenate been treated 
with 6-OHDA (as a PD-induced toxin).306 On the other hand, the presence of the propargyl side 
chain on both M30A and M30 leads to a dual mode of action as it was previously demonstrated 
that apart from the metal chelation, they can also inhibit the MAO-B enzymes.307 
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Figure 20: Selected structures of iron chelators used in several studies against PD. 
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Dexter D. et al. have shown using in vitro experiments the neuroprotection properties of iron 
chelators DFP (Figure 20D), DFO (Figure 20E) and desferal (DFO-mesylate) against 6-
OHDA.308 In the same study, treatment with DFP, rescued the loss of 6-OHDA tyrosine 
hydroxylase (an enzyme that is involved in biosynthesis of dopamine by hydroxylate tyrosine 
using molecular oxygen) from 15% to 45% whereas other clinically available chelators including 
desferal and DFO rescue to a lesser extent (25% and 35% respectively).308 The therapeutic effect 
of DFP against the iron-induced damage cortical neurons as well as human neuroblastoma SHSY-
5Y has also been observed by Molina H. et al.309 The same group, also documented that DFP 
manage to rescue almost 50% of cell death by preventing the neuronal morphology alteration to a 
higher extent than the neuroprotective 2,2’-dipiridyl (Figure 20F).  Chemical modification to DFP 
has also been conducted by Benbbington D. et al.310 According to this derivative of DFP (Figure 
20G) a dual mode of action has also been enclosed. Namely, the coordination group of this 
molecule has the capacity to chelate Fe(II) and Cu(II), but also its side chain can act as radical trap 
in a similar way to Trolox. Therefore, it can prevent the Fenton cycle from taking place and also 
trap the ROS that are produced by the cycle. Apart from DFP, Workman D. et al. have shown the 
neuroprotective property of 1,2-HOPOs (Figure 20H and I) in an in vitro model composed of 
human neuroblastoma SHSY-5Y cells been exposed to 6-OHDA.311 Moreover, synthetic metal 
chelator that has been previously used against PD is pyridoxal isonicotinoyl hydrazine (PIH) 
(Figure 20J).312 PIH as tridentate ligand has shown exceptional results against neurodegradation 
by chelating preferentially Cu(II) over Fe(III), preventing the ROS formation.312 To this end, 
numerous other reports have demonstrated the neuroprotective capacity of DFP (and analogues) 
against the related PD-induced toxins. In addition to this, the neuroprotective capacity of 
deferasirox (Figure 20K) has also been evaluated against neuroblastoma; BE2-M17 cells been 
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exposed to MPTP.313 The results suggested that the tridentate chelator has the ability to act as a 
neuroprotective agentwith therapeutic potency against the disease.313 
Another class of chelators that show excellent neuroprotective capacity is 8-hydroxyquinoline and 
derivatives. It was reported in various citations in the literature that 8-hydroxyquinoline and 
derivatives of it have the ability to improve the motor function by preventing the formation of 
toxic aggregates of α-synuclein by inhibiting the liable iron pool.314 In addition to this, it was 
shown that this class of chelators has the ability to prevent the oxidative neuronal damage induced 
by the PD-related toxins including 6-OHDA and MPP+ by posing antioxidant activity.315,316 
Additionally, it has been demonstrated that 8-hydroxyquinoline derivatives have also the capacity 
to act as MAO inhibitors.317  
 
1.8.3.1 Toxicity of metal chelators 
Despite the exceptional results obtained by DFP, some major disadvantages have been noticed 
during clinical trials. For example, DFP possessed relative low brain penetration (as it has been 
proven that DFP can pass the BBB via passive diffusion) and fast metabolism.318–320 Additionally, 
the occurrence of some dangerous – albeit rare and transient – side effect including 
agranulocytosis requires constant monitoring especially for chronic treatment.321 Therefore, it is 
of high importance the improvement of brain penetration as this might lower the rate of 
metabolism and consequently prevent the development of side effects due to lower drug 
concentration needed in systemic blood circulation.  
Clioquinol (Figure 20L) a derivative of 8-hydroxyquinoline managed to enter clinical trials in the 
beginning of the 20th century and had many applications including; anti-parasite, anti-diarrhea .322  
Additionally, this specific compound show exceptional results against neurodegenerative disease 
including PD and Alzheimer’s disease as it shown ability to prevent the neuronal degradation, by 
inhibiting the formation of α-synuclein aggregates.322 Additionally, it has been shown that is can 
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prevent the formation of Tau proteins as well as the formation of Aβ-amyloids.322 However, it was 
withdrawed from the market as its administration was associated with the development of sub-
acute meylo-optic neuropathy in Japanese patients.322 This syndrome, mainly involves disturbance 
in the sensor and motion of the lower limbs as well as visual changes due to symmetrical 
demyelination of lateral and posterior funiculi of the spinal cord, optic nerve and peripheral 
nerves.322 It has also been reported that the majority of the symptoms were versatile however in 
1/10 of the cases cause permanent disability. Nowadays, a big effort is being made in order to 
redesign clioquinol in a manner that would abolish the associated-side effects.322 A derivative of 
clioquinol; PBT2 (Figure 20M) has shown a great potency against neurodegenerative diseases 
mainly AD and Huntington’s disease due to its capacity to chelate the redox active Cu(II) and the 
redox inactive Zn(II) and it has successfully managed to enter clinical trials.323 
In addition to this, as in the case of cancer, metal chelators were found to act as inhibitors of many 
metallo-enzymes including tyrosine hydroxylase (TH) mainly because TH contains Fe(III) as a 
cofactor.324 Inhibition of TH can cause perturbations in L-DOPA biosynthesis by preventing its 
biosynthesis.325 Therefore, the design of metal chelators with limited side effects should be 
considered against the treatment of PD.325 
1.9 Transportation across the BBB 
One of the key properties that a drug should have in order to treat neurodegenerative diseases is 
its ability to reach the brain. Therefore, the study of delivery systems that would allow the 
transportation of drugs to the brain is been of high interest for many years.326 The main issue that 
has to be taken into consideration during the design of the active compounds is the BBB which its 
existence was confirmed in the beginning of the 20th century by Goldmann.327 Not surprisingly, 
only a few classes of drugs are capable to be transported across the BBB. In 1999 Ghose et al. 
examined the capability of the 7000 drugs from the Comprehensive Medicinal Chemistry database 
to penetrate the BBB and interestingly it was found that only a 5% of these were CNS active 
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regardless of their mode of penetration (See below).328 Of these drugs all are used for the treatment 
of depression, schizophrenia and other mental disorders but none for the treatment of 
neurodegenerative diseases.328 CNS active drugs tend to be small with a recommended molecular 
weight of <400 Da however that doesn’t mean that and compound with a molecular weight of 
<400 Da can enter the CNS and reach the brain.329  This is mainly because the drug molecules 
need to have some properties to penetrate the BBB which are dictated by the properties of the 
BBB.330,331 Therefore, the design of compounds that would be capable to reach the brain (by means 
of BBB penetration) requires profound understanding of the BBB structure and function. 
1.10 The Blood-Brain Barrier 
The BBB is composed by a well-defined multicellular layers that exists in all species with a 
developed CNS (Figure 21).332,333  
 
Figure 21: Cellular composition of Blood-Brain Barrier.332 
46 | P a g e  
 
The main role of BBB is to separate the brain from the systemic blood circulation maintain in that 
way the homeostasis of CNS for the proper synaptic signalling, hence the optimal neuronal 
function.332–334 In mammalian species the BBB is built-up by endothelial cells of cerebral 
capillaries.334 On the contrary, to the peripheral blood vessels the endothelium of the brain 
vasculature is not leaky due to the absence of fenestrations and consequently the tight junctions 
between the cells.335 The role of tight junctions is mainly to prevent plasma proteins and other 
solutes found in the blood to enter the brain via paracellular diffusion.335 Therefore the 
transportation of any compound from and to the brain has to be done through transcellular passage 
through the endothelium.335 Another important aspect of the BBB is its ability to express metabolic 
enzymes; cytochrome P450, MAO, transaminases and glucoronosyl transferases that are capable 
to detoxified or degrade potentially harmful compounds during the transportation.336–338 Moreover, 
the BBB is comprised of transporter systems that can efflux solutes entering endothelial back to 
the blood.334 Despite the fact that other CNS barriers exist including the blood cerebrospinal fluid 
at the choroid plexuses and the arachnoid membrane under the dura mater have significantly 
smaller area play a localised role during the transportation.334  
1.11 Overcoming the BBB 
So far, multiple strategies have been employed in order to overcome the issue that BBB causes in 
the drug delivery to the brain. For examples, drugs can be deliver to the brain by direct injection 
to the CNS (intrathecal administration).339 For the synthetic point of view, it has been previously 
shown that the transportation across the BBB could be improved or achieved by utilising 
nanoparticle carrier systems for large drug delivery.340–342 For smaller molecules, chemical 
modifications to their structure can be beneficial as they can either be transported via passive 
diffusion or they can take the advantage of the active or energy-independent transport systems of 
the BBB.343 
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1.11.1 Passive diffusion 
 
As mentioned previously, some drugs can enter to the brain by passively diffusing the lipid bilayer 
of the BBB. The transportation is mainly driven by the gradient between the intra- and 
extracellular concentrations.344 Moreover, the permeability of molecules is influence by several 
factors including their lipophilicity, polarity and size.344 Large molecules are mostly unlikely to 
cross the biological membranes via passive diffusion as large amount of lipid has to be displaced 
and the overall process is energetically disfavoured. The diffusion rate of the molecules is 
therefore inversely related to their size.345,346 Additionally, the passive transportation of 
hydrophilic molecules is also disallowed as it cannot be partitioned into the lipophilic core of the 
membrane.346 On the contrary, high lipophilicity increases the chances of molecule’s permeability 
via diffusion, however it can reduce the aqueous solubility.347,348 This can lead to low absorption 
and high plasma protein binding, hence the free drug concentration will be lower resulting in a flat 
concentration gradient and significantly slower diffusion rate.347,348 For this reason, Lipinski 
suggested a set rules for the drug discovery and development in terms of both oral, intestinal and 
hence CNS permeability.344 To this end, a variety of free web-tools have been generated allowing 
the prediction of the ability of a compound to penetrate the BBB via passive diffusion taking into 
consideration of the physicochemical parameters associated with the passive diffusion.349–351 
These will be discussed in more details in 2.8 and 2.8.1.  
In 1999, Habgood et al. documented that the transportation of 3, 4-HOPOs via passive diffusion 
can be affected by varying the N-substituent as this affect the logP value.352 Namely, lengthening 
the N-alkyl chain leads to an elevation of the logP value and consequently the brain penetration.352 
In contrast the addition of hydroxyl groups abolished the brain penetration, whereas the non-
hydroxylated derivatives with similar logP can enter the brain more easily. The more lipophilic 
HOPO was not advanced further as the increased lipophilicity can lead to higher partitioning into 
liver, where HOPOs can be metabolised and excreted.319,352 
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1.11.2 Prodrugs to improve passive diffusion 
 
Prodrugs are derivative of drugs in which the active group is conjugated with a pro-moiety in order 
to avoid peripheral metabolism and/or improve uptake in the target area. Once the molecule enters 
the target tissue, the pro-moiety is cleaved, releasing the active drug.353,354 A common strategy to 
improve the permeability of the drug is to mask the polar group (which they act as hydrogen bond 
donors) with non-polar groups and cross the BBB via passive diffusion or even using an active 
transporter.354–356 In addition to this, once the prodrug reaches the brain, it is converted into the 
active drug via bioconversion.353,354 Usually, the hydroxyl or carboxylic group of the molecule are 
been converted into the corresponding esters and once the compound reaches the target area 
(brain), the esters are cleaved by the action of esterases.353,354 Example of a naturally occurring 
prodrugs is L-DOPA. As it is mentioned previously, dopamine cannot enter the CNS due to its 
hydrophilicity. Therefore its precursor, L-DOPA exploits LAT-1 to reach the CNS and afterwards 
is metabolised by ADDC into dopamine. Therefore, a pro-moiety can also be used in order to 
direct the drug to the brain via one of the endogenous systems. An example of synthetic metal pro-
chelators can be found in (Figure 22).357  
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Figure 22: Selected boronic ester masked pro-chelators. 
 
The addition of a boronic ester can mask the N-OH group of the hydroxypyridinone core and also 
can increase the lipophilicity of the molecule allowing its diffusion through the BBB (Figure 
22A).357 Due to the high concentration of hydrogen peroxide that is produced (mainly) by the 
action of MAO-B, the boronic ester can be cleaved eliminating the active chelator (Figure 23).357  
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Figure 23: Conversion of the boronic ester masked pro-chelator into active chelator by the action 
of H2O2. 
This approach has also been applied to 8-hydroxyquinoline (Figure 22B) derivatives as well as 
PIH (Figure 22C) and deferasirox (Figure 22D) based analogues and with promising results.357  
1.12 Transportation process 
The BBB has the capacity of utilising a variety of different classes of transporter mechanisms in 
order to supply all the brain regions with nutrients and also in order to remove the metabolites of 
those out of the brain (Figure 24).333,358  
 
Figure 24: Transporter systems located in the endothelium of BBB.326 
 
Additionally, the transporters that are located in the BBB can also be used to maintain the entry 
of xenobiotic and toxins into the CNS. Therefore, these transport systems can be used as for the 
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improvement of delivery systems and/or to be used as targets by means of selective 
inhibition.343,359,360  
1.12.1 The transport system 
 
1.12.1.1 Active Efflux Transporter (AET) 
 
AET is one of the three transport systems of the BBB and it is mainly responsible for the 
exportation of molecules from the brain endothelium.334 The exportation process is usually 
achieved by the utilisation of ATP molecules or by the sodium-dependent co-transport. Some of 
the members of proteins that belong to this system are; P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP) and the multidrug resistance associated proteins (MRP 1-5).361,362 
Interestingly, this transport system can preferentially transport lipophilic molecules and increasing 
lipophilicity makes molecules a more likely substrate of the active efflux transporters.362–364  
Significant examples of drugs which exploit AETs include anti-retroviral such as; amperanivir, 
indinavir and saquinavir, anticancer agents such as; vincristine, vinblastine, etoposide, and 
doxorubicin, antibiotics such as; erythromycin, tetracycline and fluoroquinolones.362  
1.12.1.2 Receptor Mediated Transport 
This transport system is mainly responsible for the transportation of large molecules and 
macromolecules including signalling peptides and proteins across the BBB and the transportation 
relies in two sub-transportation process; the non-specific transcytosis and the specific 
transcytosis.365 In both cases the (macro)molecule is transported to the brain enclosed in a vesicle. 
Initially, non-specific transcytosis occurred by absorptive-mediated transcytosis (AMT).366,367 
Positively charged macromolecules are the main substrates of such transportation process. The 
interaction between the charged macromolecules and the cell surface binding sites, triggers the 
internalisation via a conformational change, leads into the formation of a vesicle which is then 
transported across the cell (Figure 25).366,367  
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Figure 25: Formation of vesicles currying macromolecules for their transportation across the BBB 
via RMT.368 
On the other hand, the receptor mediated transcytosis (RMT) requires specific ligand binding into 
specific receptor of the endothelial cell membrane.368,369 The binding of the ligand to the receptor 
triggers the internalisation via the formation of a vesicle.368,369 The vesicle is transported across as 
receptor-ligand pairs undergoing RMT include transferrin, insulin-like growth factor and LDL as 
well as particular large molecules such as ‘Trojan horse’.370–374 
1.12.1.3 Carrier mediated transport (CMT)  
 
The role of CMT which is located to the brain endothelium as well is primarily to supply the brain 
with the essential nutrients needed for metabolism purposes.375,376 The transportation is often 
facilitated by sodium-depended channels or it is driven by an exchange with other ions. Numerous 
drugs are known to enter the brain via CMT and the most important once are depicted in Table 
2.377 
Table 2: Selective drugs that uses CMT for their transportation across the BBB. 
COMPOUND TRANSPORTER 
 
Valproic acid 
MCa fatty acid carrier378 
 MC fatty acid carrier 
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DHAb-dideoxycytidine379 
DHA-taxol360 
 
MC fatty acid carrier 
L-DOPA360 
 
LAT-1 
α-methyl-dopa360 
 
LAT-1 
 
Tyrosine phosphoformate353 
LAT-1 
 
Mepyramine360 
OCT familyc 
 
Diphenyldramine380 
OCT family 
 
Lidocaine381 
OCT family 
 
Imipramine360 
OCT family 
 
Lovostanined360 
MCT1e 
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Oxazolamines360 
Purine carrier 
 
Abacavir360 
Nucleoside carrier 
 
Morphine glucoronide382 
GLUT1f 
Sugars and/or drugs carrying a sugar 
moiety383 
GLUT-1 
                 a=Medium Chain fatty acid carrier 
                 b=DocosaHexanoic Acid 
                 c= Organic Cation Transporter 
                d= open lactone form 
                e=MonoCarboxyl Acid transporter 
                f= Glucose Transporter-1 
 
1.12.1.3.1 The Glucose-Transporter-1 (GLUT-1) 
 
In order for the mammalian cells to acquire the essential for energy production glucose they 
acquire two transport mechanism one of which is the sodium-dependent glucose transporter 
(SGLT).384–386 SGLT is responsible for the glucose uptake in the intestine and glucose re-uptake 
in nephron.386 The GLUT-1 transporter belongs to a sodium independed glucose transporter family 
(GLUT) and its main endogenous substrate is D-glucose but not the L-glucose. More specifically, 
GLUT-1 belongs to a class of major facilitators superfamily (MFS) which is a very large 
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transporter superfamily.386–388 The common structural characteristic of the MFS is that they 
composed of 12 transmembrane domain (Figure 26).389  
                  
 
Figure 26: Predicted secondary structural components of GLUT-1. The polar and aromatic 
residues involved into the D-glucose binding (red and yellow shaded respectively). The residue 
whose mutation were found in GLUT1 deficiency syndrome are shaded in purple and blue for 
invariant and variant residues respectively.389  
The presence of the GLUT-1 transporter in the brain can almost exclusively found to be in the 
BBB whereas other members of the GLUT family can also be found in astrocytes and 
neurons.390,391 Interestingly, GLUT-1 is also expressed in erythrocyte membranes, retina, testes 
and the placenta.386,387,390–393  
1.12.1.3.1.1 Transportation of metal chelators through GLUT-1 
 
 
In order to facilitate the delivery of DFP and/or its derivatives, for the treatment of 
neurodegenerative diseases, researchers modified the active molecule in order to exploit the 
GLUT1 transporter (active transport mechanism) making it as a prodrug.320,357,394–396 This was 
achieve by conjugating the hydroxyl group of the pyridine core to a glucose, whereas other, have 
built an N-amide coupled to the glucose.320,357,394–396 Orvig et al. have synthesised a variety of 
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glycosylated metal chelators based on the hydroxypyridinone (Figure 27A) and tetrahydrosalen 
(Figure 27B) classes as they assumed that the introduction of a glucose moiety on the chelators 
can lead into direct brain uptake.394–397  
 
 
Figure 27: Structures of glycosylated metal chelators. 
 
As it is mentioned above, glycosylated hydroxypyridinones were screened as prodrugs for the 
treatment of neurodegenerative diseases by copper chelation.394,395 In another study, Roy et al. 
glycosylate DFP (Figure 27C and D) in an attempt to facilitate its transportation in the brain.320 
The brain uptake was measured by in situ brain perfusion of guinea pigs, however HPLC analysis 
could not detect the presence of the compound in the brain, showing that this methodology in 
probably not universal.320    
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1.12.1.3.2 Large Amino acid Transporter-1 (LAT-1) 
 
LAT-1 (SLC7A5) is a sodium and pH-independed transmembrane protein (protein) that forms a 
heterodimeric complex with the glycoprotein 4F2hC (CD98 and SLC3A2) to bring large neutral 
amino acid in the CNS in exchange for intracellular amino acid.398,399 Studies shown that the LAT-
1 is the sole transport compete unit whereas the 4F2hc does not participate in the intrinsic 
transportation as it only functions as chaperone that allows LAT-1 to reach its definitive 
localisation in the cellular membrane.400 This transported is overexpress into the BBB due to the 
continuous necessity of the neuron and glial cells for amino acids.401,402 It has been suggested that 
LAT-1 in the BBB is stereospecific with preferential selectivity to the L enantiomers rather than 
the D ones, whereas the LAT-1 of the peripheral tissues is not.402,403 It has also been demonstrated 
that the LAT-1 possess higher affinity for intracellular amino acid compared to the extracellular 
ones, denoting in that way that the transportation ratio is controlled by the concentration of 
intracellular amino acid.402,404 Moreover, LAT has a preferential order of amino acid transportation 
as follow; Phe > Trp > Ile > Met > His > Tyr > Val.402 
1.12.1.3.2.1 Structure of LAT-1-4F2hc 
 
LAT-1 transporter belongs to the family of Heterodimeric Amino acid Transporters (HATs) that 
are composed of a light chain (SLC7), which is responsible for the mediation of the amino acid 
transportation, and a heave chain (SLC3) which is responsible for the catalysis of the plasma 
membrane localisation and stabilisation of the light chains (Figure 28).405  
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Figure 28: Topological representation of LAT-1 – 4F2hc. LAT-1 is consisted of 12 putative TM 
and is associated with 4F2hc though a disulphide bond. The crystal structure of the extracellular 
domain of human 4F2hc is shown as ribbon.399,406  
Moreover, LAT1 is built up by 12 putative transmembrane segments (TMs) arranged in two layers. 
The inner layer is composed of TM1, 3, 6, 8 and 10 and is surrounded by the outer layer which is 
consisting of TM2, 4, 5, 7, 9, 11 and 12.405 Moreover, N- and C- terminal of ends of LAT-1 are 
located intracellularly whereas the respective terminal ends of 4F2hc are located 
extracellularly.398,405,407 As it is mentioned above, 4F2hc is a glycoprotein with the for putative N-
glycosylation sites; N264, 286, 323 and 405.405 Additionally, it has one TM domain and a large 
extracellular domain (ED).405 LAT-1 and 4F2hc are covalently linked together by a disulphide 
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bond between the cysteine residues which are located in closed proximity with TM of the heave 
subunit and in the putative extracellular loop-2 of the light subunit (between TM3 and TM4).405 
In a protein-protein docking study performed by Rosel et al. it was found that the desolvation 
energy of hydrophobic residues contributes to the binding of LAT-2 and 4F2hc-ED suggesting 
that LAT-1 and 4F2hc might be involved in a similar interactions.408 
Since the beginning of 2019 the crystal structure of human LAT-1 – 4F2hc heterodimer was 
unknown.409 Therefore, the arginine-bound AdiC crystal structure was previously used as a 
reliable template for molecular modelling studies.405,410 Moreover, the broad-specific amino acid 
transporter (ApcT), the glutamate/ γ-aminobutyic acid (GABA), the antiporter (GadC) and the 
Leucine trasporter (LeuT) pose some structural and sequence similarities with the AdiC and 
therefore they were used as alternative templates (however of less preference) for LAT-1 
transporter.405,411,412 
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2 Design and Synthesis of Metal Chelators  
2.1 Factors affecting the Fe(III)-chelator stability  
 
2.1.1 Redox activity – Fenton Chemistry 
 
The catalysis by Fe(III) and Cu(II) in the production of ROS in biological systems has been 
extensively documented in the past in attempt to characterise the pathological conditions (inducing 
cancer and PD) that are arisen due to elevation of toxic ROS levels.413–416 It is also documented 
that Fe(II) can be oxidised into Fe(III) by the reduction of hydrogen peroxide, during the Fenton 
reaction, something that leads to the formation of hydroxyl radicals. This can also be confirmed 
from the fact that the redox potential of hydrogen peroxide/hydroxyl radical (Eo=+ 0.32 V, pH 7, 
25oC, NHE) is significantly higher  compared to the potential of Fe3+/Fe2+ (been coordinated by 
either EDTA or citrate).417  Therefore, it is expected that hydrogen peroxide is more likely to 
oxidised Fe3+ into Fe2+ and the redox process is favourable with the respect to the ROS formation. 
On the other hand, according to the Haber-Weiss net reaction oxidation of hydrogen peroxide into 
superoxyl radicals can cause the reduction of Fe(III) can reduced back to Fe(II) (Figure 29).  
         
Figure 29: Formation of hydroxyl and superoxyl radicals through Fenton and Haber-Weiss 
reaction respectively. 
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Therefore, the inhibition of ROS formation can be achieved by preventing the redox cycling of 
metals. Liu et al reported that the high affinity Fe(III) ligands can indeed prevent redox cycling in 
biological systems.418  
2.2 Thermodynamic considerations of complex formation 
 
The complexation of a metal centre with a ligand is a process that is mainly controlled by 
thermodynamic factors. The thermodynamics of complex stability can therefore be described by 
the Gibbs free energy of reaction ΔGO (Equation 1).  
ΔGO = ΔHO − TΔSO  
Equation 1: Gibbs free energy of reaction (J mol-1), ΔHo is the standard enthalpy of the reaction 
(Jmol-1), T is the temperature (K) and ΔSo is the standard entropy of the reaction (JK-1 mol-1) 
The existence of charged ion species in a solution that are mainly surrounded by solvent molecules 
that formed dipole interactions can be consider as a thermodynamically unfavourable process in 
terms of entropic contribution. As a result, the complexation process, which involves the 
participation of charged species leads to partial or complete cancelation of the charges of those 
species providing in that way favourable contribution to the entropic considerations within the 
free energy. In addition to this, the total or partial cancellation of the charges in solution has also 
a favourable enthalpic contribution due the combination of the oppositely charged species. 
Therefore, the partial or complete cancelation holds a significantly negative ΔHo favoured in terms 
of Gibbs free energy. Furthermore, for ligands of high denticity, an important impact in the 
thermodynamically favoured complexation process. Therefore, it appears that the chelate effect 
will have enthalpic and entropic contributions towards the stability of the complex. The 
stabilisation of the enthalpic contribution of the chelate effect would be the inductive contribution 
of the electron density gained from the atom adjacent to the coordinating sites. As a result of this 
the donor strength of the binding sites will be increased and hence the stability of the complex. 
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The overall entropic contribution is driven by two factors. Firstly, the entropy surrounding the 
metal-ligand complex formation is often favoured for reaction in which polydentate. This is 
because polydentate ligands can cause the dissolvation of the metal centre leaving more species 
(eg. water molecules) on the product side of the reaction. Furthermore, this interaction increases 
the entropy of the system and thus increases the thermodynamic favourability.  
 
𝐾∗ = {
[[𝐹𝑒(𝐶ℎ𝑒𝑙𝑎𝑡𝑜𝑟)3]
3+ ][𝐻2𝑂]
6[𝐻+]3
[[𝐹𝑒(𝐻2𝑂)6]3+][𝐶ℎ𝑒𝑙𝑎𝑡𝑜𝑟𝐻]3
} 
Scheme 1A: Bidentate chelators displaces water molecules from ferric iron centre. 
 
Based on the Scheme 1A, we can ignore he contribution of water as [H2O] is constant and we 
can focus on K* for (Scheme 1B); 
 
𝐾∗ = {
[[𝐹𝑒(𝐶ℎ𝑒𝑙𝑎𝑡𝑜𝑟)3]
3+ ][𝐻+]3
[𝐹𝑒3+][𝐶ℎ𝑒𝑙𝑎𝑡𝑜𝑟𝐻]3
} 
Scheme 1B: Revised equilibrium constant for bidentate chelators and Fe(III), ignoring the 
contribution of water 
Therefore, in order to have a thermodynamically favoured reaction it is essential to shift the 
equilibrium towards the product formation, having in that way as high as possible K* value. 
However, the [Fe3+] (non-complexed Fe3+) should be as low as possible in order to have fully 
metal coordination.  
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2.3 Stability of Fe3+- chelator complexes 
 
Since most of the ligands are in their protonated state at neutral pH, the dissociation of protons is 
pivotal for the binding to Fe(III).  The competition between the Lewis acids (Fe(III) and H+), is 
taken into consideration when calculating equilibrium constants K for Fe(III)-ligand complex 
formation as depicted in Scheme 1 that encompasses that various equation in Scheme 2.419,420 
𝐿𝐻 
K𝑎
 𝐿− + 𝐻+                 K𝑎 = {
[𝐿−][𝐻+]
[𝐿𝐻]
} 
L + Fe3+  
K1
 FeL2+                 K1 = {
[FeL2+ ]
[L−][Fe3+]
} 
L + FeL2+  
K2
 FeL2
+                 K2 = {
[FeL2
+ ]
[L−][FeL2+]
} 
L + FeL2
+  
K3
 FeL3                K3 = {
[FeL3  ]
[L−][FeL2
+]
} 
Scheme 2: Stepwise addition of monoprotic bidentate ligand (L) to Fe(III) upon proton 
dissociation. 
To simplify the expression of the stepwise stability constants it is often the case that these are 
expressed as the product of the overall stability constant (β).420 The overall stability constant when 
multiple ligands are incorporated (same denticity and structure) is displayed along with subscript 
notation in the form of βMLH where, L= number of the same ligands involved, M= number of metal 
ligands involved and H= number of proton involved in the stoichiometry of the equilibrium 
process (Scheme 3).  
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Fe3+ + 3LH  
𝐾 ∗
 FeL3 + 3H
+                
K∗ = {
[𝐹𝑒𝐿3]
3+][𝐻+]3
[𝐹𝑒3+][𝐿𝐻]3
} = Ka x β130 
where Ka is the dissociation constant and β130= K1 x K2 x K3 
Scheme 3: Overall stability constant defined for the complexation of 3 bidentate monoprotic 
ligands and 1 Fe(III) centre. 
The most powerful chelators are mainly hexadentate and for these the overall stability constant 
will be expressed as β110 for the fully deprotonated hexadentate ligand (Scheme 4). 
LH3 
Ka1
 LH2
− + H+                 Ka1 = {
[LH2
−][H+]
[LH3]
} 
LH2
− 
Ka2
 LH2− + H+                 Ka2 = {
[LH2−][H+]
[LH2
− ]
} 
LH2− 
Ka3
 L3− + H+                 Ka3 = {
[L3−][H+]
[LH2− ]
} 
L3− + Fe3+ 
β110
 FeL                 Koverall = {
[FeL]
[L3−][Fe3+]
} 
Scheme 4: Stepwise deprotonation of a triprotic hexadentate ligand and the overall stability 
constant of such a ligand binding Fe. 
Due to the fact the equilibrium is only favourable upon deprotonation of the ligand it can be 
concluded the overall stability constant is pH dependant. However, when we look at the 
equilibrium constant of the chelator, is often simpler to measure the condition for the proton free 
reaction, which is the β measured for the Fe(III)-ligand complex at equilibrium.421 
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2.4 pFe3+ as measure of ligand binding efficiency 
 
An accepted way to measure the efficacy of the complex is to measure the equilibrium 
concentration of the free Fe(III) in solution. This is the pFe3+ value and is defined by analogously 
with pH; 
pFe3+ = - log10 [ Fe3+ ]free 
The pFe3+ value is a conditional value that takes into account all thermodynamic (Ka and β) and 
conditional (pH= 7.4, [ Fe3+ ]total= 1 µM and [ Chelator]total = 10 µM) values. The Lewis acid 
competition of dissociated protons, ligand denticity and basicity as well as difference in metal – 
ligand stoichiometry is accounted for by the pFe3+ and hence it is a more acceptable measure of 
the ability of a ligand to bind Fe3+. The [Fe3+]free  refers to the unbound (non-complexed) Fe3+ that 
remains in solution. Therefore, this value allows for the direct comparison of metal chelator 
strength as long as the conditions in which are taken are conserved in both cases. The one with the 
highest pFe3+ value, will be the stronger chelator.422 
2.5 Metal sensitivity  
 
For the design of iron chelators as potential therapeutic agents, the properties of metal sensitivity 
should be examined. The design of a chelator for a particular metal complexation can be 
rationalised by the segregation of metals and ligands to the concept of soft and hard acids.423 
Despite the fact that Pearson’s classification is overall outdated, in our case is still useful. 
Theoretically, iron chelators should be able to exhibit affinity for Fe(II) and Fe(III) species 
however according to the soft/ hard Lewis acids theory, this is not applicable. Mainly because 
high-spin Fe(III) is a spherically, symmetrical tri positive cation with radius 0.65 Å and due to its 
high charge density it can be classified as hard Lewis acid.418 In contrast Fe(II) has a lower charged 
density and it can be said that less hard Lewis acid. Due to this effect, it is expected that Fe(III) 
would have higher affinity to hard Lewis bases (such as oxygen contained ligands) whereas, Fe(II) 
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should have less affinity to hard Lewis base and greater affinity to the soft ones (nitrogenous 
ligands) eg; 2,2’-bipyridyl and 1, 10-phenanthroline (Figure 30). 418 
 
                  Figure 30: Structure of (A) 2,2’-bipyridyl and (B) 1, 10-phenanthroline 
Furthermore, ligands with affinity to Fe(II) are expected to present some affinity for other bivalent 
metals including Cu(II) and Zn(II).418 Therefore, this prevents the design of  Fe(II) selective 
ligands difficult. On the contrary, Fe(III) ligands, (mainly oxyanions) have high selectivity over 
tri basic cations over dibasic. Due to the fact that tri basic cations such as Al(III) and Ga(III) are 
not essential for living cells, Fe(III) provides the best target for iron chelator under biological 
conditions (Table 3).424 
Table 3: Metal affinity constants for selected ligands.424 
Ligand Log cumulative stability 
 Fe(III) Al(III) Ga(III) Cu(II) Zn(II) Fe(II) 
DFO 
 
30.6 25.0 27.6 14.1 11.1 7.2 
 
2, 2’-Biphenyl 
16.3 - 7.7 16.9 13.2 17.2 
 
14.1 - 9.2 21.4 17.5 21.0 
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1, 10- Phenanthroline 
 
DMHB 
40.2 - - 24.9 13.5 17.5 
 
Acetohydroxamic acid 
28.3 21.5 - 7.9 9.6 8.5 
 
Deferiprone 
37.2 35.8 32.6 21.7 13.5 12.1 
EDTA 
25.1 16.5 21.0 18.8 16.5 14.3 
DTPA 
28.0 18.6 25.5 21.6 18.4 16.5 
 
 Previously, Harris and co-worker demonstrate that high affinity Fe(III) chelators can bind to 
Fe(II) and these are rapidly oxidised them into the corresponding Fe(III) species under aerobic 
conditions.425 Therefore, it is suggested that high affinity Fe(III) chelators can coordinate both 
Fe(II) and Fe(III) under physiological conditions, eventually leading to the ferric complex.  
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2.6 Dioxygenated coordination units 
Some of the more commonly observed coordination units in siderophoresare catechols, 
hydroxamic acids and α-hydroxycarboxylic acid binding units. The common feature in all of 
these, is that their structure includes oxygen donor atoms as shown in (Table 4).418  
Table 4: Common binding units of chelators and selected non-biologically occurring coordinating 
groups.418 
 Name Structure pKa1 pKa2 logβ130 pFe3+a 
B
IO
L
O
G
IC
A
L
L
Y
 O
C
C
U
R
IN
G
  
N,N-Dimethyl-2,3-
dihydroxybenzamine (DMHB) 
 
8.4 12.1 40.2 15 
Acetoxyhydroxamic Acid 
 
- 9.4 28.3 13 
α-hydroxyethanoic acid 
 
3.8 14.8 - - 
3-methyl-3-hydroxyl-pyran-4-
one 
 
- 8.7 28.5 15 
1-hydroxypyridin-2-one 
 
-0.8* 5.8 27 16 
N
O
N
-B
IO
L
O
G
IC
A
L
L
Y
 
O
C
C
U
R
IN
G
 
1-methyl-3-hydroxypyridin-2-
one 
 
0.2** 8.6 32 16 
1,2-dimethyl-3-
hydroxypyridin-4-one 
 
3.6*** 9.9 37.2 19 
(a) [ligand]= 10 µM, [Fe3+]total= 1 µM, pH= 7.4  
* for          
    
** for  
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*** for 
  
 
2.6.1 Catechols 
As it can be observed by Table 4, catechols (represented by DMHB) exhibit the highest pKas (8.4 
and 12.1) and logβ130 (40.2). Those values are common for the biologically occurring Fe(III) 
coordinating units for siderophores demonstrating in that way the strongest binding interaction 
with Fe(III). This effect can be attributed to the fact that the high electron density located across 
the vicinal oxygen atoms as well as from the electron density across the aromatic ring. 
Interestingly despite their exceptional properties, catechols, at physiological pH the  
Fe(III)-catechol binding is inhibited due to competition by proton (hard Lewis). Therefore, the 
pFe3+ value (=15) drops significantly. In addition to this, the production of high negatively Fe(III) 
species (Fe(DMHB)33-) also affect the complexation through increased charged repulsion of the 
diprotic molecules. This is shown by statistically greater than expected decreases in the stepwise 
equilibrium, constants of the order K1= 20.4> K2= 15.5> K3= 9.4.426 
2.6.2 Hydroxamic acids 
Hydroxamic acids are monoprotic acids with relatively lower pKa (~9.4) compared to catechols. 
It is expected that the Fe(III) affinity will be lower something which is validated by the logβ130 
value (=28.3) for acetoxyhydroxamic acid. However, at physiological pH, hydroxamic acids, are 
less dependent to pH compared to catechols, hence the pFe3+ value of the complexation with metal 
is low (in comparison with catechols). In addition to this, as the acid is monoprotic, the 
coordination is occurring through the carbonyl and charged N-hydroxyl functionalities to the metal 
centre by 3 hydroxamate groups. Therefore, there is not any net charge something which is 
energetically more favourable compared to the formation of charged complexes. Moreover, it has 
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been proven before, that the dissociation rates of Fe(III) complexed hydroxamates has also been 
shown to be more kinetically inert compared to catecholates.427,428 A major limitation of 
hydroxamic acids is the free rotation around the C-N bond which caused unfavourable chelation 
mode though the E isomer, as the Z/E ratio seems to have an impact in the rate of complex 
formation. In example, desferioxamine B (DFO-B) has a Z/E ratio of 0.25 and rotational rate 
constants (krot) of 9, 15 and 12 s-1 whereas N-acetoxyhydroxamic acid, has values of 4 and 3 s-1 
respectively. Ring closure to form the Fe(III) chelate is rapid relative to the rate of C-N bond 
rotation in the latter however it becomes slow for DFO-B.429  
2.6.3 α-hydroxycarboxylic acid 
α - hydroxycarboxylic acid are the weakest of the common naturally occurring oxygenated 
chelators for Fe(III) in siderophores. Nevertheless, they are important molecules for iron 
acquisition by microbes in highly acidic environment such as fungi, where other coordinating 
groups would be fully protonated and hence less effective Fe(III) chelators. Additionally, α - 
hydroxycarboxylic acid, demonstrate useful reductive properties under UV-light for Fe(II) release 
mechanism in marine bacteria.430  
2.6.4 Hydroxypyridinones  
Hydroxypyridinones combine the characteristics of both hydroxamates and catechol groups 
‘forming’ 5-membered chelate rings in which the metal is chelated by two vicinal metal atoms. 
HOPOs are characterised by having a hydroxyl group ortho-  to a carbonyl functionality within a 
pyridine ring of which there are three isomers; 1-hydroxypyridin-2(H)-one (1, 2-HOPO), 3-
hydroxypyridin-2(H)-one (3, 2-HOPO) and 3-hydroxypyridin-4(H)-one (3, 4-HOPO).418,431 
The HOPO coordinating groups are extremely close analogues to catechols in terms of electronic 
distribution and size.  However, the fact that HOPOs have significantly lower pKa values 
compared to catechols is making them preferable for applications in biological systems. In 
addition to this, the HOPOs forms neutral ion complexes they do not show the dramatic decrease 
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in stepwise equilibrium constants been observed for catechols due to charged repulsion (Figure 
31).432,433  
 
Figure 31: Acid dissociation constants and deprotonation reaction of (A) DMHB (catechol), (B) 
1, 2-HOPO, (C) 1-Me-3, 2-HOPO (3, 2-HOPO) and (D) DFP (3, 4-HOPO). Resonance forms for 
the fully deprotonated HOPOs are represented to show their bioisosteric equivalence to catechol 
binding unit.432  
Despite the fact that HOPO’s lower pKa values, decrease the logβ value compared to DBMH, 
acetohydroxamic acid and maltol, however they can have a comparable or higher pFe3+ value. In 
example, DFP has ~ 5 orders of magnitude greater pFe3+ value compared to the catecholate DMHB 
(mainly due to relative high affinity of catechols for protons) and ~ 7 order of magnitude greater 
than acetohydroxamic acid. This suggests that the pKas of HOPOS are optimally balanced for the 
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formation of strong Fe3+ coordination spheres (trivalent complexes) and significant deprotonation 
at pH 7.4, similarly to hydroxamates.418  
2.6.4.1 HOPOs can induced redox silencing  
HOPOs as high affinity Fe(III) chelators can be employed in order to inhibit the redox cycle. It 
has also been proven that upon fully complexation of iron by 3, 4- HOPO (DFP), the redox 
potential of the couple [Fe(III)(DFP)3]/ [Fe(III)(DFP)n]+x was found to be extremely low (Eo= ~ -
0.45 V, pH 7, 25oC, NHE) than the redox potential of hydrogen peroxide.417 As a result of this, 
hydrogen peroxide is not capable of reducing Fe(III) back to Fe (II), hence Fenton reaction was 
quenched. This statement was validated later on by Devanur and co-workers who demonstrated 
that the fully coordinated [(DFP)3Fe(III)] complex wasn’t able to produced hydroxyl radicals. In 
contrast, the hydroxyl production was maximised in the partially coordinated [(DFP)2Fe(III)]+ 
complex.434 This suggested that the redox silence of Fe(III) is strongly depended in the 
concentration of chelators, as a 3:1 molar ratio allows full coordination of Fe(III), preventing in 
that way the access of the reductant to the iron cation.418,434 In contrast, 2:1 or 1:1 stoichiometry, 
allows the generation of ROS since there is free site on iron centre, which allows the reduction of 
hydrogen peroxide and the oxidation of Fe(III).434,435 This evidence was later confirmed by 
Timoshnikov VA et all which they prove that the formation of a [Fe(III)(DFP)3] complex was 
redox inactive in an experimental model of photo-Fenton chemistry.436 Furthermore, the formation 
of the unstable Fe (II) complex will dissociated to hexaquo Fe (II) that is a major endogenous 
source of labile iron pool.434 Eventually they concluded that fully occupation of the binding sites 
by chelators can prevent the binding of hydrogen peroxide on Fe(II) hence the silence of Fenton 
reaction. Finally, it has been demonstrated that 3, 4-HOPOs are also capable to inhibit Cu(II) 
catalysed hydroxyl radical formation.437,438 Therefore, it can be concluded that HOPOs are capable 
to act as antioxidants by inhibiting the Fenton reaction.438–444 This is achieved by the formation of 
fully coordination Fe(III) spheres that prevent the reduction of Fe(III) to Fe(II). Nevertheless, the 
saturation of Fe(III) doesn’t abolish the formation of ROS from already existing as Fe(II) will 
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oxidised once and a hydroxyl radical will be formed however this process is expected that is going 
to be irreversible since the Fe(III) will be blocked. 
2.7 Denticity 
 
In the case of PD, we have already suggested that full saturation of Fe(III) is important. This is 
strongly influenced by denticity. Iron chelators can posse a variety of denticities with the bidentate, 
tridentate, tetradentate and hexadentate being the most common.  However, the various 
contributions to the stability of Fe(III)-chelator complex are not entirely enthalpic driven in nature, 
but also have significant entropic contributions upon complexation. As noted above, the 
hydroxypyridinone unit is a bidentate ligand that provide more thermodynamically stable complex 
with iron than the mono dentate ligand. This is something that is validated (with some exceptions) 
by the ‘chelate effect’ which states that the increase of the denticity will cause increase in the 
stability of the complex as denoted by both pFe3+ and logβ.421 
Therefore, it is expected that hexadentate ligands will form more Fe(III) stable complexes in an 
octahedral arrangement. A general trend of ligand denticity and Fe(III) ligand formation constant 
in displayed in (Table 5).421 
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Table 5: Binding affinity for a range of ligands for Fe3+, displayed in descending order of 
pFe3+.421 
Ligand Denticity logβ (Fe3+) pFe3+ 
Enterobactin 
 
6 49.0 35.5 
MECAM 
 
 
6 45.9 29.1 
Ferrioxamine E 
  
6 32.5 26.6 
Amonabactin 4 34.5 26.0 
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Ferrichrome A 
 
 
6 32.0 25.2 
Ferrioxamine B 
 
6 30.5 25.0 
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Ferrichrome 
 
 
6 29.1 25.0 
EDTA 
  
6 25.1 23.4 
Rhodotorulic acid 
 
4 31.2 22.0 
 
Rhizoferrin 
6 25.3 20.0 
 
N,N-Dimethyl-2,3-dihydroxybenzene 
2 40.2 15.0 
 
Acetohydroxamic acid 
2 28.3 14.8 
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DFP 
2 37.2 19 
OH- 
Hydroxide anion 
1 11.7 14.6 
 
Interestingly, this denticity is not always found. Hider and co-workers have denoted an exception 
of this trend, which correlated the complex stability and the increased denticity.445 Namely, it has 
been demonstrated that a hexadentate chelator containing a tripodal 3, 2-HOPO coordination unit; 
CP130 exhibited lower logβ value (logβ= 28.1) when compared to the logβ value of its bidentate 
analogue 2-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl) acetic acid (logβ= 32.5) (Figure 32).445 
 
 
Figure 32: Structure of (A) CP130 and (B) 2-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl) acetic 
acid. 
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This might be due to steric entropic effects.446 Namely, the limited rotation of the amide bond 
might inhibit the Fe(III) coordination. In contrast, 2-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl) 
acetic acid which lacks the amide bond can access to Fe(III) centre much more easily. Hence, apart 
from the coordination group, the skeletal backbone and the linker are important factors for 
biological functions.446   
A concentration effect is also apparent when we consider different denticities of ligands and those 
of higher denticity are favoured (Scheme 5).447 
3 L− + [Fe(OH2)6]
3+ 
β130
 FeL3 + 6 H2O                 β130 = {
[FeL3]
[Fe3+][L−]3
} 
2 L2− + [Fe(OH2)6]
3+ 
β120
 FeL2 + 6 H2O                 β120 = {
[FeL2]
[Fe3+][L2−]2
} 
L3− +  [Fe(OH2)6]
3+ 
β110
 FeL + 6 H2O               β110 = {
[FeL]
[Fe3+][L3−] 
} 
Scheme 5: Equations displaying the equilibrium constants for bi-, tri- and hexadentate  
Fe3+- ligand complexation. 
 
Namely, it is expected that the increased denticity of hexadentate ligand reduced the concentration 
of ligand required for complete Fe(III) coordination, whereas higher ligand concentration is 
required in the case of bidentate ligands to achieve Fe(III) saturation. As a consequence of this, 
the iron-hexadentate ligand complex pFe3+ it is expected to be higher than the respective 
complexation constant of a bidentate ligand-iron complex. 
In the case of PD we aimed to inhibit the redox cycling by increasing the concentration of Fe(III)L3 
in the brain i.e. the full coordination of Fe(III). It has been previously shown that labile ligands on 
Fe(III) are required for the production of hydroxyl radicals via the hydrogen peroxide redox 
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cycling.435 The authors, provided evidences that at least one free coordination site in the iron centre 
is required for the generation of hydroxyl radicals from hydrogen peroxide. Moreover, the 
availability of a free coordination site (upon EDTA or DTPA binding) (or a site that is occupied 
by easily displaceable ligands – water) facilitates the reduction of Fe(III) by superoxyl radicals. 
Even if the ligand is hexadentate, full saturation is not guaranteed as shown in Figure 33.435  
                                                         
Figure 33: EDTA-Fe(III) complexation allows a free binding site.  
Despite the various advantage of hexadentate ligands, the dioxygenated bidentate ligands have 
been utilised in this study. This is mainly because, hexadentate ligands exhibit high molecular 
weights >500 Da making them not appropriate lead candidates for orally bioavailable drugs.418  
On the other hand the synthesis of tridentate ligand with only oxygen anion coordination sites is 
not feasible for HOPOs. Even if an extra hydroxyl group employed in the pyridinone core, will 
cause distortion of the geometry of the coordinated complex by forming macrocyclic rings, which 
are thermodynamically unstable (Figure 34).  
                                      
Figure 34: (A)Schematic representation of chelate ring formation in metal-bidentate ligand 
complex (B) formation of thermodynamically unstable macrocycle by a tri-oxygen tridentate 
ligand.                             
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Therefore, tridentate ligands typically contained nitrogen atoms at the coordination sites (Figure 
35).448  
 
Figure 35: Selected nitrogenous tridentate ligands. (A) 2-substituted -6-[(Z)-substituted [2-(6-
substituted pyridin-2-yl)hydrazin-1-ylidene]methyl]pyridine449 (B) [2-(1-methyl-1H-imidazol-2-
yl)ethyl][2-(pyridin-2-yl)ethyl]amine450 and (C) 6-(pyridin-2-yl)-4-substituted 2,2'-bipyridine451. 
Furthermore, the presence of nitrogen atoms in the coordination spheres is associated with 
cytotoxicity since; it reduced the selectivity of Fe(III) over Zn(II).452 In addition issue that is arisen 
from the use of tridentate ligands is that they can formed charged complexes with Fe(III) which is 
an undesirable feature for the efficient Fe extraction from intracellular sites (Scheme 6).418  
 
Scheme 6: Formation of charged Fe(III) complexes with tridentate ligands. 
 
Finally, it has been demonstrated that tridentate ligands can generate complexes which are more 
susceptible towards redox cycling and ROS formation.453  
2.8 Pharmaco–physicochemical parameters 
 
The exact link between chemical structure and various biological and pharmacological activity is 
usually extremely difficult to establish. This is due to the complex influence of primary mode of 
action (e.g. metal chelation in this case) with need for low toxicity, stability towards metabolic 
transformations, systemic distribution.  The ability of the molecule to cross the BBB, penetrate 
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inside neuron, distribute in the neuron and general pharmacokinetics will be influenced by pKa, 
logP, number of H-bond donor and acceptors.  The biological activity will be largely influenced 
by the following physicochemical parameters that can be somewhat controlled/studied in our case 
2.8.1 Lipophilicity and molecular weight 
 
An important property for an orally active iron chelator is its ability to be efficiently absorbed by 
the gastrointestinal tract and cross through the biological membranes in order to reach the desire 
targets sites (eg brain in the case of PD or lymph nodes in the case of a metastatic cancer). The 
major factors that can affect the ability of the compounds to freely permeate a biolipid membrane 
are the molecular weight, the ionisation state and eventually the lipophilicity. It has suggested that 
the partition coefficient (ClogP) of a molecule should be >-1 in order to penetrate the 
gastrointestinal tract, whereas highly lipid soluble chelators can diffuse through the BBB and 
placental barriers potentially causing toxic side effects.454 The anticipate optimal logP for an ideal 
iron chelator, clearly indicates that there is no single compound that fulfil these criteria since the 
ideal logP for the gastrointestinal tract differ for the optimal value for access to brain and placenta 
(Table 6).418  
Table 6: Anticipated optimal logP of an ideal chelator.418 
 logP 
Good absorption from the gastrointestinal tract > -1 
Efficient liver extraction > 0 
Poor entry intro peripheral cells (thymus, muscles, heart, bone marrow) < -3 
Poor ability to penetrate the BBB and maternal/placental barriers  < -3 
 
Hider and co-workers shown before that some lipophilic HOPOs manage to enter the BBB 
whereas via passive diffusion.455 
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The permeability across the biological membranes is also affected by the ionic states of the 
compounds as uncharged molecules can penetrate faster compared to the charged ones.418 
Finally, the molecular weight is a crucial factor for the effective transportation and absorption of 
the chelator.418,456 Generally, it has been stated that passive diffusion is mainly followed by drugs 
with molecular weight > 200, whereas the ‘cut-off’ molecular weight value for the paracellular in 
the human small intestine is ~ 400 and thus is not quantitatively important for drugs with molecular 
weight > 200. In contrast, the penetration of compounds with molecular weight > 500 falls rapidly 
as indicated by PEG permeability.457,458 Furthermore, it was recommended that the molecular 
weight of a chelator should be >300 for a ~70% absorption.457 The limited range of molecular 
weights excludes therefore, the use of hexadentate chelators as orally available drugs. 
Interestingly, it was found the EDTA (as a hexadentate ligand) with molecular weight 292 (too 
small to fully encompass the chelated iron) promoted the toxicity of the metal possibly by 
promoting Fenton chemistry.459 On the contrary, bidentate chelators have significantly lower 
molecular weights and it has been proven before that 3, 4-HOPOs were absorbed between 50 and 
70% in rabbit.460 
2.8.2 Protonation constants 
 
If the pKa of the acidic groups (-OH, -CO2H) is too low, or the pKa of conjugate acid of the amine 
group too high, the molecule will be present is its ionic form at physiological pH. It is known that 
molecules in their ionic form are less likely to be drug-like and have poor cell penetration. Also, 
the overall charge of the compounds (associated with their lipophilicity as measured by logP) will 
likely influence their distribution in the cell’s organelle. The amino-acid moiety is expected to be 
in the zwitterion form. However, that should not be an issue as it has been previously demonstrated 
that gut contains amino acid sensing receptors and transporters in order to supply the organism 
with nutrients.461 Moreover The form taken by the coordinating hydroxyl group is unknown until 
pKa values are determined. The pKa will also influence the efficacy of metal chelation via the 
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pFe3+. Therefore, the pKa will have a complex influence on cell penetration, cell distribution and 
metal chelation.  
2.8.3 Stability constants  
 
β130(Fe3+) and β130(Fe2+): The stability constant for coordination of Fe(III) will influence the 
affinity of the compound to efficiently coordinate iron at low concentration (together with pKa) 
as it critically influences the pFe3+. The aim is to reach a pFe3+ value that is high enough to make 
the dose-response pharmacologically relevant but not too high as there are then risks of 
demetallation/inhibition of essential metallo-enzymes as it was previously proven.462–464 
Furthermore, β values for other biologically relevant metals will have an impact on dose response, 
safety, distribution and overall metal redox-silencing. 
 
2.8.4 Partition coefficient 
 
A Lipinski rule of 5, the molecule must not be too hydrophilic to be able to penetrate cells (this is 
linked to the pKa and existence of atoms with high electronegativity like N and O). The logP is 
also likely as mentioned to influence the distribution of the compounds in the cell’s organelles. 
2.8.5 Lipinki’s rule 
 
The synthesised compounds should pose some essential characteristics in order to make them 
orally bioavailable drug candidate. Namely, the structure of the synthesised compounds should 
contain ≤10 hydrogen bonds acceptor and ≤ 5 hydrogen bond donor elements. In addition to this, 
the molecular weight should be maintained bellow 500. 
  
84 | P a g e  
 
3 Rational LAT-1 substrate design 
3.1 LAT-1 active site 
For the design and synthesis of molecules that would be capable of being transported across the 
BBB, exploiting the LAT-1 active mechanism the substrate-binding site was studied. Initially, 
Uchino and co-workers, suggested that both amino- and carboxylate group of the substrate should 
be in the zwitterion form.465 This is because, it has been proposed that LAT-1 transporter contains 
specific recognition sites in the peptide backbone that mediates the binding of charged head groups 
of amino acids through electronic interactions. Therefore, a LAT-1 substrate should contain a free 
α-carboxylated group, an unsubstituted α-amino group. Interestingly, either a hydrogen or a 
methyl group can be present on the Cα.  Furthermore, the binding of the substrate in the active site 
is mediated by hydrophobic residues (F252, C335, S342, C407) denoting the need of lipophilic 
side chain in order to be able to fit in this zone (Figure 36).466 
 
 
Figure 36: The essential features of the binding site of LAT-1 in relation to the amino acid 
phenylalanine.  
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3.2 Interactions of the amino acid group. 
In an in silico study, where a model of arginine bound to AdiC active site has been employed, the 
α-amino group of arginine (as hydrogen bond donor) interactions with the TM1 and TM6 by 
forming hydrogen bonds with the backbone oxygen atom of I23, W202 and I205.272 In addition to 
this, the α-amino group seems to contribute in a cation-π interaction with the indole ring of 
W202.467 On the other hand, the α-carboxyl group (as hydrogen bond acceptor) accepted two 
hydrogen bonds from S26 and G27 at the TM1 site (Figure 37). 467 
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Figure 37: (A) Arginine is bound at the active site of ‘putative LAT-1’ forming interactions with 
TM1, TM3, TM6, TM8 and TM10. (B) The amino group donates three hydrogen bonds whereas 
the carboxylic group accepts two hydrogen bonds.467 
In contrast, the respective residues that interacted with phenylalanine in LAT-1 include I63 (TM1), 
F252 (TM6) and G255 (TM6) (by accepting hydrogen bonds from the α-amino group) and S66, 
G67 (TM1) (by donating hydrogen bonds to α-carboxyl group) (Figure 38). 272 
 
Figure 38: Predicted binding of Phenylalanine in ‘putative LAT-1’ active site.272  
 
In another study, it has been shown that the residues F252, C335, S342 and C407 are mediating 
the binding of histidine in the active site of the transporter.468 However, it was suggested that since 
the α-amino and α-carboxyl group are conserved among the LAT-1 substrates it has been assumed 
that most of the compounds will display a similar binding mode.468  
3.3 Pharmacophore design 
For the determination of the ‘ideal’ pharmacophore, Ylikangas and co-worker generated a small 
library of LAT-1 substrates with various side chains.469 The pharmacophore was designed based 
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on four features including hydrogen bond donor, hydrogen bond acceptor negative charge and 
aromatic ring (Figure 39).469 
 
Figure 39: 3D pharmacophore model for LAT-1 with four features; hydrogen bond 
donor/acceptor, aromatic ring and negative charge.469  
The structure activity relationship (SAR) of the substrates suggested that the present of negatively 
charged features, as well as moieties capable to donate hydrogen bonds were essential for good 
activity since their removal or modification resulted in a weaker affinity (or completely lost of 
affinity) for LAT-1 binding.469 In addition to this, it has been proven that the present of aromatic 
(planar) rings in the compounds were preferred towards the ligand affinity compared to the equally 
lipophilic non-planar cores. Moreover, the introduction of hydrogen bond acceptor groups follow 
the aromatic region demonstrated an improve substrate binding in LAT-1 active site.469 In another 
study 3D-Quantitative SAR (3D-QSAR) was performed in 39 substrates using classical and 
topomer comparative molecular field analysis (CoMFA).470,471 The outcome of this analysis was 
that the contribution of steric interactions was stronger than the electrostatic once in two 
tomomers; R1: amino acid group, R2: side chain, prodrug and parent drug) (Figure 40). 470,471 
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Figure 40: CoMFA model for LAT-1. Green and red represent areas where adding steric features 
and negative charge or hydrogen bond acceptors are favoured, respectively. Blue represents areas 
where a more positive charge or hydrogen bond donors are preferred, whereas yellow contours 
designate sterically disfavoured regions. R1 and R2 indicate the common core, amino acid 
function and variable topomer, side chain and parent drug.470,471 
Through this model it was revealed that the addition of steric features above the aromatic core and 
below the amino acid terminal (yellow contour in R1) decrease the affinity. In contrast, by 
increasing the positive charge near the amino group (blue contour in R1) and by adding negatively 
charged moieties closed to carboxylic acid (red contour in R1) can lead to an increase LAT-1 
affinity.470,471 In addition to this, the model suggested that the moiety for the design of prodrugs 
should be relatively planar as large branched substituent can reach areas that can lower the affinity 
(yellow contour in R2). 470,471Therefore, the addition of steric groups near the 5- and 6- position of 
L-tryptophan is favourable for ligand binding as depicted by the green contour in R2. These 
position are equivalent to the 3- and 4- position of phenylalanine.470,471 Considering this substituent 
pattern, the cytotoxicity of the three structural analogues of the alkylating phenylalanine mustards 
with a bis(2-chloroethyl) amine chain in ortho- (Figure 41D), meta- (Figure 41A) and para- 
(Figure 41B) positions has been assessed in a human neoplasm model.472–475  
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Figure 41: Structure of (A) meta- phenylalanine alkylating mustard and (B) para- phenylalanine 
alkylating mustard.  
The results denoted that the ortho- substituted substrate was the most effective once (as it exhibits 
the highest IC50), whereas the para substituent shown the least activity.474 These observations 
demonstrated a clear selectivity of the position that each pharmacophore should have in order to 
exploit LAT-1. Previously, Augustyn et al demonstrate that by adding lipophilic substituents in 
the planar pharmacofore can induced inhibition of LAT-1.476 For example, compound 41 (Figure 
42A) KYT-0353 (Figure 42B), KYT-0285 (Figure 42C), 3-([1,1’-biphenyl]-3-yl)-2-
aminopropionic acid (Figure 42D), 2-amino-3-(3-benzylphenyl)propanoic acid (Figure 42E) 
were able to inhibit the [3H]-gabapentin uptake in HEK human LAT-1 cells.476–478  
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Figure 42: Structure of (A) compound 41, (B) KYT-0353, (C) KYT-0285, (D) 3-([1,1’-biphenyl]-
3-yl)-2-aminopropionic acid and (E) 2-amino-3-(3-benzylphenyl)propanoic acid.476 
Interestingly 3-([1,1’-biphenyl]-3-yl)-2-aminopropionic acid (Figure 42D) with a phenyl group at 
the meta position, prevented strongly the [14C]Phenylalanine update by LAT-1. The ortho and 
meta analogs of phenylalanine were found to be lesser active substrates relative to meta isomer.476 
SAR- guide computational modeling suggested that large lipophilic groups (such as phenyl group 
in 3-([1,1’-biphenyl]-3-yl)-2-aminopropionic acid) can increase the affinity towards the LAT-1 
active site due to hydrophobic interactions that are developed with the subpocket PA.476 However, 
the strong interactions resulted in decreased transport capacity (low Vmax). As a consequent of this, 
the compound behaves more like an inhibitor rather than a substrate. Similar observations have 
been seen with compounds; KYT-0353 (Figure 42B) 2-amino-3-(3-benzylphenyl)propanoic acid 
(Figure 42E).476 Namely, the increase lipophilicity on both meta position developed strong 
interactions with the subpocket generating in that way strong inhibitors of LAT-1.476 On the other 
hand, compound 41 has a large lipophilic group in the para position which can rotate around the 
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two flexible rotatable atoms (oxygen and -CH2 group). As a result of the rotation, it can mimic the 
meta conformation and therefore it can acquire the same positon in the subpocket and develop 
similar interactions. 476 
3.3.1 Side Chain design 
 
Docking studies where thyroxine (T4) (Figure 43A), 3,3’,5-triiodothyroxine (T3) (Figure 43B), 
Gabapentin (Figure 43C) and Melphanal (Figure 43D) have been used as substrates, demonstrate 
that the residues that are located near the helix break of TM1 (I63, S66 and G67) and TM6 (F252 
and G255) are mainly responsible for the substrate binding through hydrogen bond interactions. 
On the other hand, it is assumed that residues I139, V148, F252, F252, F402 and W405 facilitate 
the binding of the site chain via hydrophobic interactions.468 
 
Figure 43: Structure of (A) Thyroxine (T4), (B) 3,3’,5-triiodothyroxine (T3), (C) Gabapentin,  
(D) Melphanal, (E) 3, 3’-diiodothyronine, (F) 3,5-diiodo-L-tyrosine and (G) 3-iodo-L-tyrosine. 
Ligands,  such as T4 (Figure 43A), T3 (Figure 43B), 3,3’-diiodothyronine (Figure 43E), 3,5-
diiodo-L-tyrosine (Figure 43F) and 3-iodo-L-tyrosine (Figure 43G) might be involved in the 
halogen bond interaction of polarized halogens contributing substantially to the to the binding 
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affinity for LAT-1.477  Moreover, the halogen bond is an electrostatic interaction where halogens 
can exhibit electropositive crown in the σ-hole, that acts as a Lewis acid with high affinity towards 
electron-rich Lewis bases (oxygen, nitrogen sulfur) in a similar manner as hydrogen bonds. 479 In 
addition to this, the ability of halogens to act as both halogen bond donors to carboxyl/carbonyl 
oxygen and aromatic π-systems in the direction of the σ-hole and hydrogen bond acceptor in the 
perpendicular direction.479,480 These factors can explain why the active site of LAT-1 is not 
consisting only with aromatic residues which provide π-electrons, but it is also consist of polar 
residues (S143, N258, T345) contributing hydrogens for the hydrogen bond interaction.476 
Furthermore, the carboxyl group of E236 and the backbone oxygen of residues in LAT-1 may 
serve as halogen bond acceptor.476  
It has been previously demonstrated that halogen substituents in the meta position of phenylalanine 
can also lead to either the formation of an excellent LAT-1 substrate or inhibitor depending on the 
size of the halogen.481 In example, the addition of iodine in the meta position can lead to a powerful 
inhibitor whereas the addition of fluorine can generate a very potent LAT-1 substrate. This 
suggests that halogen substituted analogues might be developed higher affinity for halogen 
bonding increase in lipophilicity with halogen size of both.479,480  
3.4 Lipophilicity of LAT-1 substrates 
Another factor that should be taken into consideration during LAT-1 substrates design is the 
lipophilicity. In example, the LAT-1 affinity of phenylalanine, tyrosine, and L-DOPA varies with 
the number of phenolic hydroxyl groups in the aromatic ring and therefore the trend of affinity 
can be drawn as follow; L-DOPA (2 –OH) < L-Tyrosine (1 –OH) < Phenylalanine, with L-DOPA 
to behave more like an inhibitor rather than substrate.482,483 The inhibitor constant (Ki) trend (L-
DOPA> L-tyrosine> phenylalanine) in in agreement with the ClogP values (determined by 
octanol/water method); 0.0984> -0.0524> -0.0498 demonstrating in that way that the lipophilicity 
is an important parameter for the binding of the side chain of LAT-1 substrates.482,483 According 
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to the Connolly accessible surface area and ClogP calculations for the studied compounds, authors 
concluded that a LAT-1 substrate becomes an inhibitor when its Connolly accessible surface 
becomes > 500 Å2 and/or has a calculated ClogP>2.0 such as for melphanal (Figure 43D), T3 
(Figure 43B)and T4 (Figure 43A).484  
3.5 Stereochemistry of LAT-1 substrates 
Since the amino acid moiety of the LAT-1 substrate contains a chiral centre, the effect of 
stereochemistry should also be taken into consideration during the design of LAT-1 substrates. To 
begin with, it has been reported that the LAT-1 transporter that is expressed in the BBB is a 
stereospecific transporter with the preference on L- enantiomeric amino acid.405 This statement 
was confirmed by which they observed that the L- enantiomer of phenylalanine mustards exhibits 
a significantly higher cytotoxicity in an experimental model of human neoplasm compared to the 
respective D- enantiomer.472 In addition to this, Schlessinger et al, demonstrated the inability of 
D- enantiomers to inhibit (i) the L- phenylalanine efflux and (ii) the LAT-1 transporter in general 
(Table 7).485  
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Table 7: The ability of selected amino acids with the side chain being in deferent stereochemistry 
to inhibit L-Phe uptake and LAT-1. 485 
 
(%) L-Phe efflux (%) Inhibition 
L-Phe 
R=  
100 85 
D-Phe 
R=  
96 74 
L-Ala R= (CH3)2CHCH2- 120 73 
D-Ala R= (CH3)2CHCH2- 100 56 
L-Trp 
R=  
81 79 
D-Trp 
R=  
59 29 
 
On the other hand, others claimed that the stereochemistry is not necessarily a factor that should 
be taken into account since it has been proven that some D- amino acids can inhibit the [14C]-
Leucine uptake.485–489 
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4 Scope of the study  
The first aim of this study is associated with the design and synthesis of neuroprotective HOPOs 
iron derived chelators with the capability of transportation across the BBB in a similar manner to 
L-DOPA in order to prevent the Fe(III) redox cycling in the brain that is responsible for the 
development of PD by the excessive ROS formation. As it was stated previously, HOPOs are 
analogues of catechols; therefore, the compounds would be analogues of L-DOPA that will contain 
several of HOPO coordination group instead of catechol. In addition to this, our HOPOs will carry 
an amino acid vector that would be essential for the transportation across the BBB in the same 
manner as L-DOPA (Table 8).   
Table 8: Structure of HOPO based chelators – analogues of L-DOPA- with the potential 
capability of transportation across the BBB. 
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L-DOPA 
 
1,2- HOPOs 
                 
3, 2- HOPOs 
                
3, 4- HOPO 
 
N-substituted 3, 4-HOPOs 
 
                
 
Hydroxypyranone 
 
 
Of all the coordinating groups that appear suitable, there is not one of them that provides the 
optimum combination of structural features. We therefore had to investigate a library of 
compounds to select the lead candidate.  The second aim was to evaluate whether, the synthesised 
compounds would have the potency to target the cancer cells and induced cytotoxicity once again 
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by minimising the essential for cancerous cell survival, ROS levels. Our proposed compounds can 
be regarded as the first HOPO derivatives specifically designed for LAT-1 
The pharmacological properties of all the proposed compounds were also calculated in an 
attempt to rationalise the overall design (Table 9) 
Table 9: Pharmacological properties calculated by SwissADME – Swiss Institute of 
Bioinformatics. 
Compound 
Molecular 
Weight 
logP 
TPSA 
(Å) 
 
H-
Bond 
donor 
H- 
Bond 
acceptor 
 
198.18 -2.22 120.86 3 4 
 
212.20 -2.39 110.0 2 4 
 
198.18 -2.19 110.0 2 4 
 
198.18 -2.29 111.0 2 4 
 
198.18 -2.13 120.86 3 4 
 
 
198.18 
-2.22 120.86 3 4 
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199.16 -2.22 118.21 2 5 
 
According to (Table 9), all of the proposed compounds will exist as zwitterions and based on the 
predicted pharmaco-physicochemical properties, all of them fulfil Lipinski’s rule of 5 apart from 
the logP as the respective values were significantly below 5 Therefore, it is expected that these 
compounds will not be able to be cross the BBB via diffusion. Additionally, as demonstrated in 
(Table 6), these chelators cannot be absorbed from the gastrointestinal tract (by diffusion – but 
possibly can be absorbed due to the presence of amino acid receptors/channels in the GI) as the 
logP<-1. However, the proposed chelators can potentially penetrate the BBB as the corresponding 
logP > -3.   
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5 Organic synthesis of the target molecules and control compounds 
During the last years, much work has been conducted towards the development of the chemistry 
associated with the synthesis, functionalisation and characterisation of the physicochemical 
parameters of the HOPO coordinating group.  
5.1 1, 2- HOPOs 
The chemistry of 1, 2-HOPO is overall undeveloped in terms of variety and accessibility of the 
functionalities currently been available as previously published in tetra-, hexa- and octadentate 
chelate literature. The synthesis of the 1, 2- HOPOs mainly relies into two synthetic approaches 
(Figure 44).  
 
Figure 44: The two synthetic approaches for the synthesis of 1, 2- HOPOs 
 
The first strategy involves the N-oxidation of the 2-halogenated pyridine and afterwards the 
substitution of the halogen atom with hydroxides (Figure 44A). The second approach involves 
the participation of a 2-alkoxy substituted pyridine. The N-oxidation of this starting material leads 
to the formation of a 2-O-protected N- oxide pyridine intermediate which its deprotection (mainly) 
under acidic conditions gives the pyridone (Figure 44B) The expected product in both cases 
predominates as 1, 2-hydroxypyridone rather than 1,2-dihydroxypyridine. 
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5.2 Synthesis of the amino acid moiety 
 
The synthesis of unnatural amino acid is widely report into the literature. Herein, the most common 
ways of synthesising amino acids were described. One of the most abundant method for 
synthesising an amino acid is using the Strecker reaction (Figure 45).490  
 
 
Figure 45: Strecker amino acid synthesis.490 
 
According to this procedure, the first step involves the condensation of an aldehyde or a ketone 
with ammonia or (substituted amine) towards the formation of an imine.491 Afterwards, 
nucleophilic substitution of the cyanide salt with the imine can lead to the formation of versatile 
α-aminonitrile intermediates Eventually, treatment of the α-aminonitrile with acidic aqueous 
solution could afford the α-amino acid as a racemic mixture.491  
The synthesis of amino acids can be also be achieved by applying a modified version of Strecker 
synthesis which involves the synthesis of hydantoins as amino acid precursors (Figure 46).492,493 
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Figure 46: Bucherer-Bergs amino acids synthesis.494  
 
According to this reaction an aldehyde or a ketone can react with potassium cyanide in order to 
form a cyanohydrin which in the presence of ammonium carbonate it is cyclised in to the 
corresponding hydantoin.492–494 Hydrolytic ring opening of the hydantoin core can lead to the 
formation of N-carbamoyloamino acid which in the presence of acid or an appropriate enzyme (N-
carbamoylase) can yield to racemic amino acid mixture.492–494 The overall pathway is known as 
Bucherer-Bergs reaction.  
It has been previously reported that an alternative method for synthesising α- amino acids can be 
achieved by using a Gabriel synthesis.495 According to this methodology, alkyl halides react with 
phthalimide core and the formed intermediate can then be deprotonated and substituted with the 
alkyl or aryl halide. Alkaline hydrolysis of this intermediate can cause the elimination of the amino 
acid precursor as a dicarboxylate intermediate which after heat in the present of acid it can be 
mono-decarboxylated eliminating the amino acid as a racemic mixture (Figure 47).495   
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Figure 47: Gabriel Synthesis of amino acids.495 
 
Another way of introducing an amino acid synthesis involved the condensation of a substituted 
(aromatic) aldehyde with glycine anhydride (diketopiperazine) and sodium acetate in acetic 
anhydride (Figure 48).496  
 
Figure 48: Synthesis of amino acids via the formation of aldehyde-glycine anhydride 
intermediate.  
The formed intermediate was then reduced to the corresponding amino acid in the presence of 
phosphorus red, hydriodic acid.496  
The synthesis of amino acids in the following chapter afforded the final products as racemic 
mixtures (unless the starting material was available as pure enantiomer). Racemic mixture 
resolution was performed if the compound presents any biological activity towards melanoma 
cancer and/or PD. 
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5.2.1 Synthesis of rac-SK-3 
 
Reports regarding the synthesis of HOPO carrying an amino acid functionality have been 
previously established by Harris in attempt to synthesised analogues of L-mimosine in order to 
minimise its toxicity which has shown to act as a de-fleecing agent.497,498  
The synthesis of novel 5-substituted 1, 2-HOPO, was initiated primarily by constructing the amino 
acid functionality prior to the coordinating group.  Moreover, the synthetic procedures that have 
been followed for the introduction of amino acid moiety involved the participation of aldehyde as 
a precursor hence, the first part of the synthesis aimed to the formation of such intermediate 
(Scheme 7).  
 
Scheme 7: Retrosynthetic approach for the synthesis of 2-methoxy-5-pyridine carbaldehyde (2). 
 
The synthesis was initiated by the bromination of 2-methoxypyridine at the 5- position. It has been 
previously reported in the literature, that the bromination reaction of the substituted pyridine can 
be achieved by the addition of bromine in acetic acid solution containing the substrate and sodium 
acetate.499 However, this approach is known to lead to the formation of both 3- and 5- brominated 
intermediates and that their separation could not be performed.499 Therefore, the bromination 
reaction was performed using N-bromosuccinimide as a source of electrophilic bromine and the 
reaction proceed affording exclusively the brominated intermediate (1) which was purified by 
column chromatography. However, in our hands the yield of the reaction was significantly lower 
(18%) compared to what others obtain.500 Afterwards, intermediate (1) underwent formylation 
reaction as it was previously described in the literature with some modifications.500 The addition 
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of n-BuLi in a solution of (1) in dry diethyl ether led to the formation of organolithium which was 
then reacted further with N,N-dimethylformamide in order to introduced the carbonyl functional 
group. Elimination of dimethylamine led to the formation of aldehyde (2) as yellow crystals which 
were purified by column chromatography.  
Initially, for the introduction of the amino acid functionality, the experimental method described 
by Kunishima M. et al. using glycine anhydride was followed.496 However, the first part of the 
reaction where the aldehyde (2) reacted with glycine anhydride in the present of sodium acetate 
and acetic anhydride failed to produce the expected intermediate (as mixture of E/E, E/Z and Z/Z 
isomers) even after several attempts to repeat the reaction varying the stoichiometry of the 
reactants, the temperature as well as the time of the reaction (Scheme 8). 
 
Scheme 8: Attempted synthetic approach for the introduction of the amino acid functionality. 
Reagents and conditions; (i) glycine anhydride, AcONa, Ac2O reflux, 6 hr.  
Therefore, in order to overcome this issue, a slightly different approach was followed. For the 
introduction of the amino acid functionality we followed the Erlenmeyer’s azalactone synthesis 
by reacting (2) with N-acetyl glycine, sodium acetate and refluxed in acetic anhydride as it was 
previously described (Scheme 9).501–503  
 
Scheme 9: Reagents and conditions for the synthesis of azalactone intermediate (3); (i) Ac2O, 
AcONa, reflux, 7 hr, 63%. 
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The cyclisation reaction that took place led to the formation of an azalactone intermediate 3 that 
is was precipitated out by the hydrolysis of acetic anhydride in the present of ice, as a yellow solid 
which was purified by recrystallization from methanol (Scheme 10).  
 
Scheme 10: Proposed mechanism for the formation of the azalactone intermediate. 
 
An attempt to reduce the synthesised alkene prior to hydrolytic ring opening of the azalactone was 
contacted by bubbling H2 gas in a solution of (3) containing a catalytic amount of Pd/C (10%) 
(Scheme 11). The expected reduced product has not been formed and the starting material was 
almost fully recovered. Attempts to allow the reaction to proceed for longer with a slight increase 
of the reaction temperature were conducted, however, TLC shown almost exclusively the 
existence of the starting material.  
106 | P a g e  
 
 
Scheme 11: Unsuccessful reduction of the alkene (3) prior to hydrolysis of azalactone. Reagents 
and conditions: (i) H2(g), Pd/C (10%), MeOH, RT, 6 hr; (ii) See Table 10; same as (i), 53% 
Therefore, hydrolysis of the azalactone ring before reduction (Scheme 11) was attempted using 
various conditions that were reported in the literature with some modifications (Table 10).  
Table 10: Various experimental conditions towards the hydrolysis of azalactone (3) 
Conditions[a] Yield (%) 
Water504 Reflux 4  hr 81 
Acetone/ water505 Reflux 9 hr 60 
HClaq (5% v/v)506 RT 18 hr No reaction 
HClaq (5% v/v)506 Reflux 18 hr 10  
MeOH/ NaOH507 RT 2 hr 92 
       [a] Based upon literature procedure upon some modifications. 
As it can be observed from Table 10 the alkali hydrolysis of the azalactone afforded intermediate 
(4) as a pale brown crystals that was precipitated by acidification of the MeOH/NaOH mixture to 
pH ~1. Afterwards, the reduction of the alkene was conducted successfully in methanol solution 
containing a catalytic amount of Pd/C (10%), under hydrogen atmosphere (Scheme 11). The crude 
product was purified by column chromatography affording intermediate (5) as a pale yellow oil 
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which solidified on standing. Afterwards the HOPO core had to be formed and for this purpose, 
intermediate (5) underwent N-oxidation using m-CPBA (Scheme 12).  
 
Scheme 12: Reagents and conditions for the synthesis of N-oxide intermediate (6); (i) m-CPBA, 
MeOH, DCM, RT, 48 hr, 77%. 
Due to the poor solubility of the starting material in dichloromethane, a small volume of methanol 
was added and the overall reaction mixture as stirred at RT for 48 hrs. The unreacted mCPBA as 
well as the by-product; m-CBA were removed by trituration of the crude product in diethyl ether, 
causing in that way the precipitation of the N-oxidised intermediate (6). The formation of the N-
oxide was verified by the change of the chemical shift in both 1H and 13C-NMR as well as the 
change of mass as denoted by HRMS. Eventually, reflux of the intermediate (6) in conc. HCl 
caused the demethylation of the methyl ether and also the deprotection of the amine group by 
cleavage of the acetyl group, affording the final product racemic product as a hydroscopic HCl 
salt. The overall pathway that followed can be found in Scheme 13. 
 
Scheme 13: Reagents and conditions for the synthesis of rac-SK-3. (i) NBS, CH3CN, 90oC, 2 hr, 
18%; (ii) n-BuLi, Et2O, DMFdry, -35oC, 7 hr, 67%; (iii) N-acetyl glycine, AcONa, Ac2O, 130oC, 4 
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hr, 63%; (iv) see Table 10; (v) H2, Pd/ C (10%), MeOH, RT, 9 hr, 53%; (vi) m-CPBA, DCM, 
MeOH, RT, 48 hr, 77%; (vii) conc. HCl, reflux, 1 hr, 54%. 
5.2.2 Synthesis of rac-SK-6 
 
The synthesis of 4- substituted 1, 2-HOPO was the most challenging part of the overall synthesis 
since numerous synthetic approaches have been optimised and applied for the formation of the 
expected product. Despite the fact that the synthesis of rac-SK-6 was reported in the literature, 
the overall synthesis involved several steps with the overall yield been significantly low (Scheme 
14).498  
 
Scheme 14: Reagents and conditions for the synthesis of 4-substituted 1, 2-HOPO according to 
the literature; (i) HBF4, NaNO2 ; 60%, (ii) NBS, dibenzoyl peroxide, CCl4, reflux, 48%; (iii)diethyl 
acetamidomalonate, NaH (60% in mineral oil), DMFdry, RT, 16 hr; (iv) Na(s), EtOH, reflux, 16 hr, 
73%; (v) H2O2 (30%), AcOH, 50%; HCl conc. reflux, 16 hr, 31%.498 
Several attempts were conducted towards the reproducibility of the compounds without any results 
as the formation of the expected N-oxide intermediate couldn’t be synthesised under the literature 
procedures. Therefore, herein we attempted to identify a procedure that would allow the synthesis 
of the compound within less synthetic steps (if possible) and higher overall yield. 
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Initially, as in the case of rac-SK-6, the synthesis of the 4- substituted 1, 2-HOPO was initiated 
by the synthesis of amino acid prior to the formation of the HOPO core using the same established 
methodologies with some modifications (Scheme 15).  
 
Scheme 15: Reagents and conditions towards the formation of azalactone intermediate: (i) NaNO2, 
HCl conc., H2SO4 conc., 0oC, 3 hr, 96% ; (ii) SeO2, 1, 4- dioxane, reflux, 12 hr, 46%; (iii) N-acetyl 
glycine, AcONa, Ac2O, 130oC, 4 hr. 
Therefore, the synthesis was initiated by the conversion of 2-aminopicoline into the 2-
chloropicoline (7) via the formation of a diazonium salt using sodium nitrate and concentrated 
hydrochloric acid as it was described before with some modifications.508 The expected 
intermediate was afforded in excellent yield (96%) and used directly without further purification 
to the next step which involved the oxidation of the methyl group of intermediate 7 into the 
corresponding aldehyde 8. This was done by using an established procedure from the literature 
using selenium dioxide in 1, 4-dioxane.509 The aldehyde 8 was obtained in a moderate to low yield 
(46%). However, the cytotoxicity of selenium containing species was reported several times in the 
literature.510–512 Therefore, as it was used in the early steps of the synthesis we hoped that any 
traceses of selenium would have been removed after purification of the followed intermediates. 
The Erlenmeyer reaction of azalactone formation was attempted however the reaction failed even 
after several changes of the reaction conditions.  
In order to overcome this issue a different synthetic approach was attempted. One of the most 
abundantly used method for the formation of amino acids is the alkylation of diethyl 
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acetamidomalonate followed by SN2 substitution of an intermediate with a good leaving group (eg 
halogen or tosylate, mesylate, triflate) (Scheme 16).  
 
Scheme 16: Synthesis of amino acid using diethyl acetamidomalonate as an amino acid precursor. 
 
Therefore, the synthesis was initiated with an SN2 substitution of the chlorine atom of 2-
chloroisonicotinic acid using sodium methoxide (Scheme 17).513  
 
 
Scheme 17: Reagents and conditions for the formation of amino acid moiety or rac-SK-6 : (i) for 
9 MeI, NaH (60%), DMF, 60oC, 3 hrs, 73%; for 10 (a), MeONa, 1, 4- dioxane, reflux, 12 hr, 80%, 
(b) MeI, NaH, DMF, 60oC, 3 hr, 84% (ii), NaBH4, CaCl2, THFdry, 12 hr, RT, 48% (for 11), 53% 
(for 12); (iii) SOCl2, CHCl3 0oC, 2 hr,  89% (for 14), (87% for 15). 
The etherification reaction was successful as the expected intermediated was formed in high yield 
(80%). Esterification of the carboxylic acid of the intermediates using iodomethane afforded the 
respective esters 9 and 10 intermediates in good yield (73% and 84% respectively).513 Afterwards, 
the reduction of the ester was performed upon a literature procedure using calcium chloride and 
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sodium borohydride forming the respective alcohols 11 and 12 in a moderate yield (48% and 53% 
respectively).514 Then the formed alcohols (11 and 12) were converted into the respective aryl 
alkyl chlorides (13 and 14) after treating them with thionyl chloride .513  
Additionally, a small portion of alcohol 12 was oxidised to the respective aldehyde (15) using the 
Swern oxidation method as a last attempt to follow the Erlenmeyer reaction (Scheme 18).515  
 
Scheme 18: Reagents and conditions for the formation of azalactone intermediate using aldehyde 
13 as a starting material; (i) oxalyl chloride, DMSO, DCM, 2 hr, -78 oC, 84%; (ii)  N-acetyl glycine, 
AcONa, Ac2O, 130oC, 4 hr 
 
Therefore, the aryl alkyl chlorides (13 and 14) have been considered as the key intermediate 
towards the formation of the amino acid (Scheme 19). 
 
Scheme 19: Attempted synthetic approach for the introduction of amino acid moiety. Reagents 
and conditions; NaH (60%), DMFdry, various temperatures, 48 hr. 
Intermediates 13 and 14, were then added (separately) in a solution N,N-dimethyl formamide 
containing the sodium salt of acetamidomalonate (been prepared by treatment of 
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acetamidomalonate with sodium hydride). The overall reaction was monitoring by TLC anh 1H-
NMR at RT initially for 48 hrs without any sight of product formation. As a result of this the 
temperature of the reaction was gradually increased and once again the reaction didn’t proceed as 
expected as there wasn’t any indication of the product. A possible explanation of this behaviour 
can be attributed to the fact that possibly the negative charge that has been introduced to diethyl 
acetamidomalonate upon treatment with sodium hydride is stabilised by sodium ion (Figure 49), 
making the carbanion too weakly nucleophilic.  
 
Figure 49: Stabilisation of the negative charge of diethyl acetamidomalonate by sodium cation. 
 
The reaction was therefore repeated, this time by adding a 15-crown-5 in an attempt to coordinate 
sodium and prevented it from stabilising the charge. Surprisingly, the reaction failed to proceed 
neither after prolong monitoring nor after increasing the reaction temperature.  
In an attempt to identify the best precursor molecule, a small library of analogues have been 
performed varying the aryl alkyl substituent (Table 11).  
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Table 11: Small library of intermediates that have been prepared in an attempt to optimise the 
reaction procedure. 
 
Reagents and Conditions[a] 
Yield 
(%) 
Intermediate 
R1= -Cl 
R2=    
-Br PBr3, DCM, 0OC, 2 hr516 57 16 
-OTs TsCl, KOH, THF, 0OC, 18 hr517 69 17 
-OMs MsCl, Et3N, DCM, 0OC, 3 hr518 89 18 
R1= -OMe 
R2=    
-Br CBr4, PPh3, DCM, 0OC, 2 hr519 63 19 
-OTs TsCl, KOH, THF, 0OC, 12 hr517 75 20 
-OMs MsCl, Et3N, DCM, 0OC, 3 hr518 82 21 
[a] Based upon literature procedure upon some modifications. 
The same experimental procedures have been repeated varying the time of the reaction and the 
temperature however unfortunately none of them gave the expected intermediate.   
According to the literature, the amino acid functionality can also be introduced by the nucleophilic 
substitution of benzophenone imine glycine ester as a starting material (O'Donnell Amino Acid 
synthesis) as shown in (Scheme 20).520 
 
Scheme 20: Retrosynthesis of amino acids using benzophenone imine glycine ethyl ester as the 
carrier of amino acid functionality. 
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Therefore, benzophenone imine glycine ethyl ester was synthesised by reacting benzophenone 
imine with glycine ethyl ester hydrochloride as it was previously described in the literature 
(Scheme 21).521  
 
Scheme 21: Reagents and conditions for the synthesis of the precursor of rac-SK-6. (i) Mg, I2, 
Et2O, 40 oC, 3 hr, 90%; (ii) glycine ethyl ester hydrochloride, RT, 20 hr, 95%; (iii) KOtBu, THF, 
-78oC - -40oC; (vii) HCl (1M), Et2O, H2O, RT, 18 hr, 52% for 26, 63% for 27; (viii) Ac2O, NaOH, 
H2O, 0 oC – RT, 4 hr, 98% for 28 and 29; (vi) see Table 10. 
 
Afterwards, the product (23) has been deprotonated by the addition of potassium tert butoxide in 
order to generate the nucleophile and then it was exposed with the electrophilic compounds listed 
in Table 11. The process of the reaction was monitored by TLC and after a few hours  
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(~3 hr) the expected intermediates (24-25) were formed, isolated and used directly to the next step 
which involved the acid hydrolysis of the imine to towards the formation of (26-27). The amine 
of the formed amino acids was then protected by acetylation as it was previously described. The 
expected intermediates (28-29) were formed in an almost quantitative yield (~98%) and they were 
taken directly to the next step which involved the N-oxidation. For the N-oxidation several 
oxidising agents have were employed however none of them gave the expected N-oxide 
intermediate even after varying the time and the temperature of the reaction (Table 12).  
              Table 12: Reagents and conditions for the N-oxidation of intermediates 28 and 29. 
 Conditions[a] Yield 
R= -Cl 
mCPBA, DCM, reflux, 48-96 hr522 
No reaction 
R= -OMe No reaction 
R= -Cl 
AcOOH, H2O2, 80oC, 12 -72 hr311 
No reaction 
R= -OMe No reaction 
R= -Cl 
UHP, TFAA, DCM, RT, 24 hr523 
No reaction 
R= -OMe No reaction 
R= -Cl 
TFA, H2O2, 80 oC, 48 hr311 
No reaction 
R= -OMe No reaction 
R= -Cl 
HOReO3, H2O2, DCM, RT, 48 hr524 
No reaction 
R= -OMe No reaction 
                         [a] Based upon literature procedure upon some modifications. 
Due to the numerous unsuccessful attempts to N-oxidise the intermediates 28 and 29 moiety we 
decided that the HOPO group could be built prior to construction of the amino acid functionality 
as it was concluded that the presence of amino acid moiety at the 4- position prevented the N-
oxidation. The synthesis was directed towards the formation of intermediate 35 as the key 
intermediate that would allowed to the introduction of the amino acid moiety (Scheme 22). 
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Scheme 22: Reagents and conditions for the synthesis of intermediates 35-38. (i) See Table 13, 
(ii) KOH (10% w/v), 70oC, 16-18 hr, 92%; (iii) SOCl2, MeOH, reflux, 6 hr, 95%; (iv) BnBr, 
K2CO3, DMF, 80oC, 18 hr, 54 %; (v) NaBH4, MeOH, THFdry, reflux, 2 hr, 95 %; (vi) See Table 
14. 
The formation of 1, 2-HOPO was begun by the N-oxidation of 2-chloroisonicotinic acid using 
various oxidising methods in order to determine the optimum one that would afford the expected 
N-oxide (30) in the highest yield and purity (Table 13). 
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Table 13: Reagents and conditions for the N-oxidation of the 2-chloroisonicotinic acid 
Oxidant Conditions[a] Yield (%) 
 
mCPBA, DCM, reflux, 48hr522 28 
 
AcOH, H2O2, 80oC, 12hr311 42 
 
TFA, H2O2, 80 oC, 18 hr311 74 
 
UHP, TFAA, DCM, RT, 6 
hr523 
82 
                                    [a] Based upon literature procedure upon some modifications. 
The  in situ formation of trifluoro peracetic acid led to the formation of a strong oxidant which has 
the capacity to N-oxidise the starting material in an excellent yield without any by-products, 
whereas the other methods either gave the final product in poor yield (e.g. AcOH/H2O2) or the 
purification of the final product was difficult (e,g. mCPBA). Afterwards, the reaction of 30 with 
aqueous solution of potassium hydroxide (10% w/v) led to the formation of the ortho 1,2-HOPO. 
The next step evolved the functionalisation of the carboxylic acid group and thus it was converted 
to the respective methyl ester (32) by treatment with thionyl chloride in methanol. Then the N-
oxide group was protected by the addition of benzyl group using benzyl bromide in the present of 
potassium carbonate. Afterwards, the intermediate 33 was reduced to the respective alcohol (34) 
according to the procedure obtained by Boechat N. et al. in an excellent yield.525 The alcohol was 
functionalised further in a range of molecules with various leaving groups (Table 14). 
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Table 14: Reagents and conditions for the functionalisation of intermediate 34. 
 
Reagents and Conditions[a] Yield 
(%) 
Intermediate 
R= 
Cl- CCl4, PPh3, RT, 1 hr526 36 35 
Br- CBr4, PPh3, DCM, 0OC, 3 hr519 89 36 
-OMs MsCl, Et3N, DCM, 0OC, 1 hr518 61 37 
-OTs TsCl, KOH, THF, 0OC, 5 hr517 70 38 
 [a] Based upon literature procedure upon some modifications. 
 
Subsequently, the two pathways that have been follow above, were repeated as it was previously 
described using various temperatures and time (Scheme 23) Unfortunately, none of the above 
listed intermediates gave the expected product.  
 
Scheme 23: Attempted synthesis for the introduction of the amino acid group at the 4- position of 
the 1, 2-HOPO. Reagents and conditions; (i) intermediate 23, KOtBu, THF, -78oC - -40 oC; (ii) 
NaH (60%), diethyl acetamidomalonate, DMFdry, RT, 48 hr.  
In another literature report, by Quanxuan Z. and co-workers, it was suggested that the amino acid 
synthesis would be achieved by reacting tosylate intermediates with diethyl acetamidomalonate in 
the presence of potassium tert butoxide rather than sodium hydride and also by using aprotic non 
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polar solvent such as 1, 4-dioxane rather than N,N-dimethyl formamide (polar solvent).527 In 
addition to this, they recommend to maintain the reaction initially at 50-60oC and then reflux.527 
Taking into account the above recommendation the tosylate intermediate (38) was used as a proper 
starting material towards the formation of the amino acid group (Error! Reference source not 
found.). 
 
 
Scheme 24: Reagents and conditions for the synthesis of rac-SK-6; (i) diethyl acetamidomalonate, 
KOtBu, 1, 4-dioxane, reflux, 16 hr, 73%; (ii) HCl conc, reflux, 9 hr, 23%. 
 
Therefore, 38 reacted with diethyl acetamidomalonate potassium salt (generated by heating at 
60oC a solution of diethyl acetamidomalonate in 1, 4-dioxane in the present of potassium tert 
butoxide) forming the expected intermediate 40 in a good yield (73%). Acidic hydrolysis by means 
of reflux in conc. HCl of the intermediate (40) led to the cleavage of the ethyl esters, the acetyl de 
protection, affording the expected amino acid (rac-SK-6) as (a racemic mixture) in a low yield 
(23%). This can be attributed to the fact the potassium tert-butoxide has a pKa of ~17 whereas the 
pKa of sodium hydride that has been previously used is ~35. The use of a stronger base migh cause 
the deprotonation of the amide bond (and the α-proton) forming an intermediate which it could 
react further with the series of pyridines, whereas the use of a milder non-nucleophilic base led to 
the selective deportation of the acidic protons allowing the SN2 reaction to proceed. 
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In order to solve those issues, a different approach has been followed. It has been previously 
reported that an alternative method for synthesis of  α- amino acid precursors is the conversion of 
aldehydes into the respective α- amino esters (Henry’s reaction) (Scheme 25).  
 
Scheme 25: Proposed mechanism for the synthesis of α-nitro esters using ethyl nitroacetate.   
 
For this purpose, the alcohol 34 was oxidised into the corresponding aldehyde via the Swern 
oxidation in a low yield (32%) (Scheme 26).515  
 
Scheme 26: Attempted synthesis of α-nitro ester via Henry’s reaction. Reagents and conditions: 
(i) oxalyl chloride, DMSO, DCM, 2 hr, -78 oC, 32%; (ii) Ethyl nitroacetate, Et3N, THFdry, MS (4 
Å MS), ZrCl4, reflux, 3 hr.  
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Afterwards, the aldehyde 39 was reacted with ethylnitroacetate in the presence of trimethylamine 
and molecular sieves.528,529 It has been also recommended the use of a catalytic amount of 
zirconium tetrachloride as a Lewis acid catalyst.529 However, the reaction failed to proceed. The 
1H-NMR revealed the decomposition of the HOPO core and therefore further attempts were 
avoided.  
5.3 3, 2- HOPOs 
 
5.3.1 Synthesis of rac-SK-5 
 
The synthesis of rac-SK-5 (ortho- substituted) 3, 2-HOPO was first reported by Harris and co-
workers and the same methodology was followed (Scheme 27).498  
 
Scheme 27: Reagents and conditions for the synthesis of rac-SK-5: (i) BnBr, NaOH, MeOH, 18 
hr, reflux, 82%; (ii)conc. NH4OH, 5 hr, 120oC, 80%; (iii) POCl3, 40 min, 120oC, 87%; (iv) Diethyl 
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acetamidomalonate, NaH (60% in mineral oil), DMFdry, 18 hr, RT, 98%; (v) H2 (g), Pd/C (10%), 
MeOH, RT, 68%; (vi) Na2CO3 aq, I2, KI, 18 hr, RT, 98%; (vii)  a) Ba(OH)2 aq, 24 hs, 120oC, 24 hrs 
b) conc. HCl, 180oC, 1 hr, c) conc. NH4OH, pH 5, 5oC, 95%. 
The overall synthesis was initiated by the formation of the amino acid moiety, prior to the 
development of HOPO core. Initially, for the O-protection of the reactive hydroxyl group of kojic 
acid its deprotonation in the present of sodium hydroxide towards the formation of nucleophile 
was necessary.498 Afterwards the formed nucleophile reacted with benzyl bromide forming the O-
benzyl protected intermediate in a high yield (41). The O-benzyl protected pyranone was then 
converted to the respective pyridinone (42) by heating it in a solution of concentrated ammonium 
hydroxide in a stainless steel bomb (Scheme 28).498  
 
Scheme 28: Proposed mechanism for the conversation of O-benzyl protected pyranone into the 
respective O- benzyl pyridinone by condensation with ammonium hydroxide.  
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The O- benzyl pyridinone was then converted into to the corresponding chloropyridine (43) after 
reflux with phosphorous oxychloride. That reaction also led to the conversion of the primary 
alcohol into the respective alkyl chloride.498 This substrate was then reacted further with diethyl 
acetamidomalonate in the present of sodium hydride.498 As a result of this substitution reaction the 
amino acid precursor (44) was generated in almost quantitatively yield (98%). The next part of the 
synthesis begun by the formation of the HOPO core. Namely, intermediate 44 was reductively de-
chlorinated via catalytic (Pd/C – 10%) hydrogenation in the presence of sodium acetate.498 Apart 
from the reduction of chloropyridine, the hydrogenation deprotected the O-benzyl group, leading 
to the formation of the hydroxypyridine intermediate 45 in good yield (68%). Afterwards, 
iodination of 45 using I2, KIaq led to the formation of the 46 in excellent yield (98%).498 The next 
step involved the nucleophilic aromatic substitution (SNAr) reaction using barium hydroxide 
forming the HOPO core. The formed intermediate barium salt was taken directly to the next step 
which evolved the acid cleavage of the diethyl ester group and the acetyl de-protection of the 
amino group.498 The final product (rac-SK-5) was formed as salt free racemic mixture after its 
dissolution in water and its re-precipitation by the addition of conc. ammonium hydroxide until 
pH~5 in an excellent yield (95%). 
5.3.2 Results – Synthesis of rac-SK-7 
 
Being inspired from the Gabriel synthesis of amino acids we utilised the phthalimide core as a 
carrier of the amine component of the amino acid functionality (Scheme 29). 
 
Scheme 29: Retrosynthetic analysis towards the synthesis of the amino acid group using N-alkyl 
phthalimide. 
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Additionally, one of the two building blocks would also carry an electrophilic centre that would 
allow the nucleophilic addition towards the formation of the amino acid group. 
Therefore, the synthesis of the novel compound; rac-SK-7 was initiated with the synthesis of both 
building blocks; the HOPO core and amino acid precursor (Scheme 30). 
 
 
Scheme 30: Reagents and conditions: (i) CsCO3, BnBr, DMF, RT, 7 days, 80%;  (ii) Br2, DCM,  
RT,  40 hr, 69%;  (iii) a) TPP, AcONa, toluene, reflux, 10 min, b) AcOH, ethyl propiolate, reflux. 
18 hr, 46% (iv) see Table 15. 
The synthesis of the HOPO core involved the protection of both nitrogen atom and the 3- hydroxyl 
group of the 2, 3-dihydroxypyridine using caesium carbonate in the present of DMF, as it was 
previously described with some modifications. The di-benzyl protected product (47) was afforded 
in a good yield (80%) upon purification by recrystallization from ethanol.530 Afterwards, 
intermediate 47 underwent bromination at the 4 position by treating it with bromine.. The synthesis 
of the amino acid precursor 49 was carried out by refluxing the phthalimide in toluene in the 
presence of methyl propiolate, triphenylphosphine, sodium acetate and acidic acid (Scheme 
31).531,532  
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Scheme 31: Proposed mechanism of the triphenylphosphine catalysed nucleophilic addition to 
methyl priopiolate towards the synthesis of α-substituted alkyl acrylate. 
Afterwards, the Heck coupling was used in order to from a new C-C bond between the two 
building blocks. The overall procedure failed to afford the expected intermediate even after 
optimizing the reagents and the conditions of the reaction (Table 15).  
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Table 15: Optimization of the reagents and the conditions for the synthesis of the amino acid 
group via Heck coupling. 
Attempt 1533,534 Attempt 2535,536 
PdCl2 Pd(OAc)2 
P(O-tol)3 P(O-tol)3 
DMF ACN 
NaHCO3 Et3N 
100oC 90oC 
4 hr 18 hr 
Tetrabutylammonium 
bromide 
- 
Afterwards, an alternative method was followed for the formation of the C-C group between the 
alkene 49 and the brominated intermediate 48 towards the synthesis of the target molecule (Scheme 
32).537  
 
Scheme 32: Attempted Grignard conjugated addition to the electrophilic centre of 49. Reagents 
and conditions: (i) Mg grinds, I2 cat, THFdry, RT, 2 hr; (ii) THFdry, 0oC to reflux, 3-6 hr.  
Namely, 48 has been converted to the respective Grignard reagent by treating it with magnesium 
in the presence of a catalytic amount of iodide crystals in THF. Moreover, the conjugated Grignard 
addition proceed by mixing the organomagnesium product with the electrophile 49in the presence 
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of a catalytic amount of copper iodide as it was previously suggested by Gardhellicchio C. and co-
workers.537 The overall reaction occurred at 0oC and after several hours there was no sight of 
product formation and hence, the reaction was heated gradually until reflux. The 1H-NMR of the 
reaction suggested the decomposition of the HOPO group and as a result of this, further 
optimisations were not conducted.  
Therefore, the synthesis was oriented towards the Erlenmeyer synthesis as it was described before 
(Scheme 33).  
 
Scheme 33: Reagents and conditions for the synthesis of rac-SK-7: (i) MeI, K2CO3, Acetone, RT, 
48 hr, 98%; (ii) MeONa, DMFdry, 60oC, 18 hr, 76%; (iii) Br2, NaHCO3sat, DCM, RT, 4 hr, (iv) n-
BuLi, Et2O, DMFdry, -35oC, 2 hr, 53%; (iv) N-acetyl glycine, AcONa, Ac2O, 130oC, 3 hr, 80%; 
(vi) MeOH, NaOHaq, RT, 2 hr, 95%; (vii) H2 (g), Pd/ C (10%), MeOH, RT, 4 hr, 63%; (viii) HBr 
(48%), AcOH, reflux, 4 hr, 40%. 
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Initially, the HOPO core was built first by using 2-chloro-3-hydroxy pyridine. Therefore, the 
synthesis was initiated by alkylation with iodomethane.538 The formed intermediate (50) was then 
treated with sodium methoxide in dry N,N-dimethyl formamide in order to substitute the chlorine 
atom.539  It can be noticed that this sequence is necessary as direct demethylation of the 2,3-
dihydroxypyridine leads instead to the N-methyl-3-methoxypyridinone. Afterwards bromination 
of 51 by using bromine in solution mixture of sodium bicarbonate/ dichlomethane afforded the 5-
bromo intermediate as the major isomer.540 In addition to this, the 1H-NMR revealed the present 
of the 6-bromo intermediate as the minor isomer. According to the literature, the separation of the 
two regioisomers is not feasible, whereas the separation of their respective aldehydes is.541 
Therefore, the reaction mixture was taken directly to the next step without further purification. 
The formylation reaction was performed as it was described above by treating the cool solution of 
the mixture (52) in diethyl ether with n-BuLi, followed by the aadition of dry DMF. 540 The two 
aldehydes were separated by recrystallization and the aldehyde (53) was afforded in a moderated 
yield (53%). Afterwards, the azalactone 54 intermediate was formed as described before by 
refluxing the aldehyde (53) in acetic anhydride with sodium acetate and N-acetyl glycine. The 
azalactone then underwent alkali hydrolysis as described previously, affording the alkene (55) in 
a good yield (95%). The reduction of the 55 into the respective alkane (56) was achieved via 
catalytic (Pd/C-10%) hydrogenation. Reflux of the 56 in a solution mixture of hydrobromic acid 
(48%) and acetic acid lead to the demethylation of the two ethers and also the acetyl de-protection 
of the amino group of the amino acid affording the rac-SK-7 as salt which was dissolved in water 
and re-precipitated by the addition of ammonium hydroxide until pH 5.  
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5.4 3, 4- HOPOs 
 
The synthesis of 3, 4- HOPOs began almost 30 years ago where Kontoghiorghes and Sheppard 
reported a cost effective conversion of the O-benzyl protected maltol to the corresponding  
3, 4- HOPO following reaction with primary amine and subsequent deprotection (Figure 50).542  
 
Figure 50: The various methodologies for the preparation of 3, 4-HOPOs. Reagents: (i) BnBr, 
K2CO3, (ii) RNH2, NaOH, (iii) Pd/C, MeOH. 
 
 
5.4.1 Synthesis of rac-SK-1 and rac-SK-2 
 
The synthesis rac-SK-1and rac-SK-2 was based upon a modified literature procedure (Scheme 
34).497  
 
Scheme 34: Reagents and conditions for the synthesis of rac-SK-1 and rac-SK-2; (i) TsCl, 
NaOH(aq), acetone, 20 min, RT, 94%; (ii) Diethyl acetamidomalonate, NaH (60% in mineral oil) 
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DMF(dry), overnight, RT, 95%; (iii) a) conc. HCl, 180oC, 3 hr, b) conc. NH4OH, pH 5, 5oC, 89%; 
(iv) a) conc. NH4OH, 130oC, 3 hr, b) conc. HCl, 180oC, 3 hr, c) conc. NH4OH, pH 5, 5oC, 91%. 
The free primary alcohol was converted to the corresponding tosylate upon exposure of 41 with 
tosyl chloride as was previously described by Thomas F.A.543 Then, intermediate 57 was reacted 
with diethyl acetamidomalonate (sodium salt been prepared upon its reaction with sodium hydride 
in DMFdry) via an SN2 reaction affording intermediate 58 in a good yield. Acidic cleavage (by 
means of refluxing in conc. HCl) of the ethyl esters and decarboxylation as well as de-protection 
of the O-benzyl protected hydroxide group and the acetyl protected amine afforded the novel 
hydroxypyranone (rac-SK-1) as a hydrochloric acid salt which was dissolved in water and re-
precipitated by the addition of ammonium hydroxide until pH 5, in an excellent yield (89%). In 
addition to this, intermediate 58 was converted to the respective pyridinone by heating with 
ammonia in a stainless still bomb. The formed intermediate then underwent the acidic cleavage as 
described before for rac-SK-1. Rac-SK-2 was also afforded as the hydrochloric acid salt which 
was dissolved in water and re-precipitated by the addition of ammonium hydroxide until pH 5, in 
an excellent yield (91%).  
 
5.4.2 Synthesis of N-substituted 3, 4-HOPOs 
 
5.4.2.1 Synthesis of L- and D- SK-4 
 
The synthesis of the enantiomerically pure N-substituted 3, 4-HOPOs (L and D- SK-4) 
(methylated analogues of L-mimosine) was achieved by condensing the O-benzyl protected maltol 
(60) with intermediate 59 (Scheme 35).544  
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Scheme 35: Reagents and conditions for the synthesis of L-SK-4; (i) a) N-Boc-L-Asn, 
Iodosobenzene diacetate, EtOAc: MeCN: H2O, RT, 4hr, 76%; (ii) BnBr, K2CO3, DMF, 80oC, 1 
hr, 76%; iii) a) EtOH: H2O, NaOH (aq) 8 days, b) conc. HBr,  reflux, 20 mins, c) conc. NH4OH, 
pH 5, 5oC,72 hr, 90%. For D-SK-4 (47%) the same procedure followed for D-SK-4 
Intermediate 59 was performed by applying Hoffmann rearrangement of carboxamides ( L and D- 
N-Boc-protected asparagine) as it was previously described by Mitra R. et al. using hypervalent 
iodine species (iodosobenzene diacetate) (Scheme 36)545. 
 
Scheme 36: Proposed mechanism for the conversion of L- and D- N-Boc protected asparagine into 
intermediate 59.546,547 
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The condensation reaction occurred in the present of sodium hydroxide and after a week, the crude 
product was refluxed with hydrobromic acid (48%). That, caused the O-benzyl as well as the N-
Boc deprotection affording the enantiomerically pure compound (L- and D- respectively SK-4) as 
a hydrobromic acid salt which was dissolved in water and re-precipitated by the addition of 
ammonium hydroxide until pH 5, in moderated yields (90% for the L- and 47% for the D- 
enantiomer.  
5.4.2.2 Synthesis of L-SK-8 
The next part involved the synthesis of a novel isomer of L-SK-4 where the methyl group would 
be in the position 5- rather than 2- (Scheme 37)  
 
Scheme 37: Reagents and conditions for the synthesis of L-SK-8: (i) SOCl2,  RT, 1 hr, 97%; (ii) 
Zn (dust), conc. HCl, 70-80oC, 5 hr, 82%; (iii) BnBr, K2CO3, DMF, 18 hr, 80oC, 68%; (iv) a) 
NaOH, RT, 8 days, b) HBr (48%), reflux, 20 min, c) NH4OH, pH 5, 5oC, 2 weeks, 18%. 
Therefore, the synthesis was initiated with the conversion of the primary alcohol of kojic acid into 
the respective alkyl chloride intermediate (61) by using thionyl chloride.548 Then the alkyl chloride 
group of intermediate 61 reduced to the respective methyl group using zinc dust and hydrochloric 
acid forming the allo maltol (62) in 81%.549  
Then, the hydroxyl group of 62 underwent O-benzylation via benzyl chloride in the present of 
potassium carbonate.550 The protected intermediate 63 formed in a good yield (68%). Afterwards, 
63 was condensed with L-59 as it was described previously forming the protected L-SK-8 which 
it was de-protected using the same methodology as described for L-SK-4. The hydrobromic acid 
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salt of L-SK-8 was dissolved in water and re-precipitated by the addition of ammonium hydroxide 
until pH 5 affording the salt free L- enantiomer in a poor yield (18%).  
5.5 Synthesis of the control compounds  
 
5.5.1 Controls of L-SK-4 
Due to the high biological potency of L-SK-4 in both cancer and PD biological evaluation control 
compounds have been synthesised (full justification of control compounds can be found in 7.2 and 
7.2.2) (Scheme 38) 
 
 
Scheme 38: Reagents and conditions for the synthesis of the control compounds; SK-4C1-3: (i) 
MeI, K2CO3, acetone, reflux, 3 hr, 94%; (ii) (a) 60, NaOH, RT, 8 days, (b) HBr (48%), reflux 20 
min, (c) NH4OH, pH 5, 5 oC, 72 hrs, (iv) Ethylenediamine, NaOH, MeOH, H2O, reflux, 4 hr, 95%, 
(v) H2(g), Pd/C (10%), MeOH, 3 hr, 95%; (vi) β-alanine, NaOH, MeOH, H2O, reflux, 18 hr, 73%; 
(vii) H2, Pd/C (10%), MeOH, 6 hr, 83%; 
Initially, for the synthesis of SK-4C1, the hydroxyl group of maltol underwent methylation using 
iodomethane in the present of potassium carbonate according to the literature.551 The formed 
intermediate (64) was condensed with 59 as it was described above forming the control compound 
in a moderate to low yield (42%). Afterwards, 60 underwent condensation reaction with 
ethylenediamine and β-alanine towards the formation of SK-4C2 and SK-4C3 O-benzyl protected 
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intermediates (65 and 66 respectively) as it was previously suggested.552,553 In addition, the de-
protection of intermediates 65 and 66 was achieved via catalytic hydrogenation (Pd/C – 10%) 
affording both SK-4C2 and SK-4C3 as solids with yields 95 and 83% respectively. 
5.5.2 Control of rac-SK-2 
The ability of rac-SK-2 to exert neuroprotective properties against various Parkinsonian induced 
toxins suggested the synthesis of a control compound (Scheme 39).  
 
Scheme 39: Reagents and conditions for the synthesis of SK-2C1: (i) conc. HCl, reflux, 5 hr, 95% 
 
The amino acid vector of this control; SK-2C1 was retained and the coordination group has been 
modified in manner that either would prevent the metal binding or would have minimal binding 
affinity. The synthesis was straight forward as intermediate 44 underwent directly acidic cleavage 
(by means of refluxing in conc. HCl), and the expected control compound afforded in an excellent 
yield (95%).  
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5.6 Synthesis of LAT-1 non-selective substrate  
It has been previously suggested by the literature that compound 72 has the ability to act as 
competitive substrate LAT-1 preventing the uptake of 14C-Leucine.554 This would allow us to 
investigate whether the synthesised SK-n compounds have the capability to exploit LAT-1 
transporter and therefore been delivered to the targeted area. Since 72 is not commercially 
available it has to be synthesised. The synthesis of the competitive LAT-1 substrate was achieved 
upon a modified literature procedure (Scheme 40).555  
 
Scheme 40: Reagents and conditions for the synthesis of the LAT- 1 none selective substrate: (i) 
Na, EtOH, diethyl acetamidomalonate, reflux, 18 hr, 77%; (ii), NaOH (aq) 4M,  RT, 45 min, 57%; 
(iii) 1, 4-dioxane,  reflux, 2 hr, 87%; (iv) Subtilisin (Type VIII), KCl (aq) (0.01 M), NaHCO3, H2O, 
MeCN, RT, 18  hr, pH 7.8, 57% for 69 and 42% for 70; (v) HCl aq) 6M, reflux, 4 hr, 92%; (vi) HCl 
aq) 6M, reflux, 4 hr 90%. 
Several reports suggested that the stereoselectivity of the LAT-1 substrates is not an important 
factor that can affect the transportation, whereas others suggest that this transporter has a 
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preference for the L-enantiomers.405,485 As a result of this, compound 72 has been synthesised and 
isolated as pure enantiomers and the biological activity of both enantiomers has been evaluated.  
The overall reaction was initiated by the SN2 substitution of bromide with diethyl 
acetamidomalonate using sodium ethoxide as base (77%). Intermediate 67 underwent initially 
mono- (alkaline) hydrolysis of the diethyl ester (68) and following by mono- decarboxylation by 
refluxing in 1, 4-dioxane, affording intermediate racemic 69 as solid in good yield (87%). The 
next step involved the utilisation of the enzyme; Subtilisin (type VIII) in order to resolve the 
racemic 69. Namely upon addition of the enzyme, the S ester (70) was precipitated out of the 
solution upon removal of the volatiles (51%) and the R acid (71) was isolated upon acidification 
of the filtrates (from which the S ester was precipitated) (42%). Acidic cleavage of the ethyl ester 
and also acetyl de-protection afforded the S-72 as white solid (92%) whilst acidic acetyl de-
protection afforded R-72 as white solid (90%). 
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6 Physicochemical characterisation 
The potentiometric data were refined with the Hyperquad 2008 program, which uses non-linear 
least-squares methods, taking into account the formation of metal hydroxide species.556 The 
distribution curves as a function of pH of the protonated forms of rac-SK-2, rac-SK-3 and L-SK4 
and their complexes were calculated using the Hyss2009 program.557 All the spectrophotometric 
data were fitted with Hypspec software (http://www.hyperquad.co.uk), which allowed the 
determination of the protonation constants (Kan) of the chelators,the stability constants (log β) of 
the formed species and the coordination model of the studied systems.556 The following results on 
pages 137-156 were kindly prepared by our collaborator: Dr Jérémy Brandel at the University of 
Strasbourg, France.  
 
6.1 Protonation constants  
The protonation properties of ligands rac-SK-2, rac-SK-3 and L-SK-4 were studied by both 
potentiometric titrations and UV–vis absorption spectrophotometric titrations versus pH between 
pH 2 and 12 (Figure 51B, D and F). The acido-basic properties of the three chelators were also 
studied in strongly acidic conditions between p[H] −0.75 and 2.25 by means of spectrophotometric 
batch titrations vs p[H] (brackets indicate that the pH value was calculated) (Figure 51A, C and 
E).  
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Figure 51: Spectrophotometric titrations vs pH of rac-SK-2 between (A) −0.75≤p[H]≤2 ([rac-
SK-2] = 2.56×10−4 M, batch titration) and (B) 2.50<pH<11.08 ([rac-SK-2] = 3.00×10−4 M, direct 
titration); of rac-SK-3 between (C) −0.75≤p[H]≤1.5. (batch titration, [rac-SK-3] = 2.56×10−4 M 
and (D) 2.50≤pH≤11.51 (direct titration, [rac-SK-3] = 1.59×10−4 M) and of  L-SK-4 between (E) 
−0.75 ≤ p[H] ≤ 2.0. (batch titration, [L-SK-4] = 2.59×10−4 M and (F) 2.48 ≤ pH ≤ 11.34 (direct 
titration, [L-SK-4] = 2.59×10−4 M). 
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The exported results suggested that the protonation constants of the functional features of rac-SK-
2; -OH, -NH2 and -NH/-CO are in agreement with those reported in the literature for isomimosine 
(rac-SK-2), considering the differences in experimental conditions eg. 37oC in 0.15 M KNO3 
rather than 25oC in 0.1 M NaClO4 (Table 16).558  
Table 16: Correlation between the obtained by the literature and experimental determined pKas of 
rac-SK-2 ±  SD expressed to the last significant digit.  
 pKa1 pKa2 pKa3 pKa4 
 LH4 LH3 LH2 LH 
Literature558 1.4 3.13 7.84 9.29 
Experimental determination < -0.5 4.72±0.001 7.48±0.001 8.84±0.01 
 
However, titration at very low pH showed small spectral variations that may be due to the 
protonation of the HOPO’s carbonyl group but the Ka1 of this functional could not be calculated 
and can only be suggested inferior to -0.5.  
In the case of rac-SK-3 the protonation of its hydroxyl function is in agreement with the respective 
values found in the literature for a 1, 2-HOPO based molecule (Table 17).418,559  
Table 17: Correlation between the obtained by the literature and experimental determined pKas of 
rac-SK-3, 1, 2-HOPOs and phenylalanine, ±  SD expressed to the last significant digit.  
 pKa1 pKa2 pKa3 pKa4  
 LH4 LH3 LH2 LH Conditions 
1, 2-
HOPO418,560 
 
- - 5.8 - 25oC,  0.1M KNO3 
Phenylalanine 
 
- 1.83 - 9.13  
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rac-SK-3 -1 
2.86 
±0.001 
7.0 
±0.001 
9.82 
±0.002 
25oC, 0.1M NaClO4 
 
The second (Ka2) and forth (Ka4) protonation constants were attributed to the amino and carboxylic 
acid functions, respectively, by comparison to phenylalanine (Table 17). Strong spectral 
variations were observed between p[H] -0.5 and 1.5, suggesting an additional protonation on the 
chromophoric group that was attributed to 2-oxo group of the pyridine core as it was suggested 
before by Scarrow RC.560  
Finally, the protonation constants of L-SK-4 in agreement with those reported for Mimosine, with 
one significant difference on pKa3 (7.18 ± 0.001 vs 5.58 ± 0.003) due to the presence of an 
additional methyl substituent in position 2 of the pyridine ring of L-SK-4 (Table 18).558,561  
Table 18: Correlation between the obtained by literature and experimental determined pKas of L-
SK-4, L-mimosine and P1 ±  SD expressed to the last significant digit.. 
 pKa1 pKa2 pKa3 pKa4  
COMPOUND LH4 LH3 LH2 LH CONDITIONS 
5-hydroxy-2-
(hydroxymethyl)pyridine4(1H)-
one (P1)562 
 
3.37 9.00 12.16 12.6 
25oC in 0.1 M 
KCl 
L-Mimosine558,561 
 
<1 
2.56 
 ±0.001 
7.18  
± 0.001 
9.02  
± 0.001 
25oC in 0.1 M 
KNO3 
DFP418,563 
 
- - 3.6 9.9 
25oC in 0.1 M 
KNO3 
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L-SK-4 
-0.2 
2.0  
±0.001 
5.58  
±0.003 
8.89  
±0.007 
25oC  
0.1 M NaClO4 
 
In addition to these, the exported data seems to be consistent with Hider’s work on methyl 
substituted 3, 4-HOPOs (however lack the amino acid group) as they pose similar pKas with the 
calculated ones for L-SK-4 (Table 18).418,563,564 In addition to this, similar protonation constants 
seems to be noticed between L-SK-4 and P1 ligand (3, 4-HOPO).562 Some, significant spectral 
variations could be observed under very acidic conditions in the batch titration suggesting that the 
carboxylate moiety pKa would be inferior to -1. Based on literature and the values of the 
protonation constants, the following protonation schemes were proposed for ligands rac-SK-2 
(Figure 52A), rac-SK-3 (Figure 52B) and L-SK-4 (Figure 52C). 
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Figure 52: Protonation scheme of (A) rac-SK-2, (B) rac-SK-3, (C) L-SK-4. 
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Since the pKas of rac-SK-1 and rac-SK-5 have not been measured experimentally, the pKas of the 
compounds that contained either the hydroxypyranone or the 3, 2-hydroxypyridinone core, were 
estimated from the literature of parent compounds (Table 19).  
Table 19: pKas of kojic acid, maltol and 1-methy-3-hydroxypyridin-2-one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, based on the product of protonation constants (Ka1 x Ka2, x Ka3 x Ka4) (calculated and 
ones obtained from the literature), the order of acidy between the SK-n compounds can be drawn 
as follow; rac-SK1> rac-SK5> rac-SK3> rac-SK2 > > L-SK4, demonstrating that L-SK-4 is the 
weakest acid of all.  
From these protonation constants of the rac-SK2, 3 and L-SK-4, the electronic spectra of the 
protonated species of each ligand and their distribution curves as function of pH were calculated 
(Figure 53).   
COMPOUND pKa1 pKa2 
Kojic acid565,566 
 
-1.86  7.70 
Maltol418 
 
- 8.7 
1-methyl-3-hydroxypyridin-2-
one567 
 
0.2 8.6 
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Figure 53: Electronic spectra of the protonated species of (A) rac-SK-2, (C) rac-SK-3 and (E) L-
SK-4 and distribution curves as function of pH of the protonated species of (B) rac-SK-2 ([rac-
SK-2] = 2.56×10−4 M), (D) rac-SK-3 ([rac-SK-3] = 2.56×10−4 M) and (F) L-SK-4 ([L-SK-4] = 
2.59×10−4 M). Solvent: H2O, I = 0.1 M (NaClO4), T= 25.0°C. 
Afterwards, based on the distribution curves of the protonated species, the percentage of each 
protonated species at pH 7.4 was calculated (Table 20).  
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Table 20: Percentage (%) of the protonated species or rac-SK-2, 3 and L-SK-4 at pH 7.4 and 
structure of the protonated state for each compound most likely to be a LAT-1 substrate. 
 LH3 LH2 LH L 
rac-SK-2 
0.1
 
53.5 44.7 1.2 
rac-SK-3 0.0 
1.5 
 
96.0 2.5 
L-SK-4 0.0 
28.3 
 
71.4 0.3 
 
The calculation suggested that at physiological (pH 7.4), the majority of rac-SK-2 (53.5%) exists 
as LH2, followed by 44.7% of LH form and 1.2% at the fully deprotonated (L) state. In addition 
to this, just 0.1% exists in its neutral form (LH3) with the zwitterion form of amino acid. Moreover, 
96% of rac-SK-3 exists at LH form whereas 2.5% and 1.5% exists in the L and LH state 
respectively. Interestingly at this pH there is not any neutral species as expected for amino acids. 
In the case of L-SK-4, 71.4% exists as LH whereas 23% exists as neutral molecule with amino 
acid group as zwitterion. A 0.3% of the total species is also appeared in the fully de-protonated 
state. Those data could give insights into the quantity of each of these compound that enters the 
cells. Namely, based on the fact that LAT-1 transporter can only accommodate neutral amino acids 
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(amino acid group as zwitterion) it is suggested that only a 0.1% of rac-SK-2 can enter the cell (if 
it exploids the LAT-1), whereas a 1.5% of the total rac-SK-3 will be transported through the LAT-
1.568 In contrast, ~ 30% of the total concentration of L-SK-4 will be able to be transported in the 
cells. Therefore, it can be assumed from these findings that biological order of activity if only 
influenced by penetration will be L-SK-4>> rac-SK-3> rac-SK-2. As a validation of the biological 
activity of the SK-n compounds, the % of the neutral species should also be taken into 
consideration.   
6.2 Stability constants 
 
6.2.1 Complexation with Fe(III) 
 
Similar to the protonation study, spectrophotometric batch (-0.5<p[H]<2) and classic titrations 
(2<pH<12) were then carried out on the Fe(III) complexes of ligands rac-SK-2 (Figure 54A, B), 
rac-SK-3 (Figure 54C, D) and L-SK-4 (Figure 54E, F). 
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Figure 54: Spectrophotometric titrations vs pH of the Fe(III) complexes of ligands rac-SK-2 
between (A) −0.75≤p[H]≤2 (batch titration, [rac-SK-2] = 2.77×10−3 M, [Fe]/[rac-SK-2]= 0.33) 
and (B) 2.50<pH<11.08 (classic titration, [rac-SK-2] = 2.97×10−4 M, [Fe]/[rac-SK-2]= 0.31); of 
rac-SK-3 between (C) −0.75≤p[H]≤1.5. (batch titration, [rac-SK-3] = 2.56×10−4 M, [Fe]/[rac-SK-
3]= 0.33) and (D) 2.50≤pH≤11.51 (classic titration, [rac-SK-3] = 3.03×10−4 M, [Fe]/[rac-SK-3]= 
0.30) and of L-SK-4 between (E) −0.75 ≤ p[H] ≤ 2.25. (batch titration, [L-SK-4] = 2.59×10−4 M, 
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[Fe]/[L-SK-4]= 0.33) and (F) 2.53 ≤ pH ≤ 11.25 (classic titration, [L-SK-4] = 1.47×10−4 M, 
[Fe]/[L-SK-4]= 0.31) 
The averaged overall stability constants of the Fe(III) complexes were calculated in the pH range 
where the species were soluble (Table 21). 
Table 21: Overall stability constants (log β) of the Fe(III) complexes of ligands rac-SK-2, rac-
SK-3 and L-SK-4 ± SD (expressed to the last significant place). H2O, I = 0.1 M (NaClO4), T = 
25.0 °C. βMLxHy = [MLxHy]/([M][L]x[H]y); charges were omitted for the sake of clarity 
 
 
  
 rac-SK-2 rac-SK-3 L-SK-4 P1562 1, 2-
HOPO55
9 
DFP569 
ML2H2 
( β122) 
22.9 39.06 
±0.001 
40.65 
±0.0011 
49.12 
±0.001 
- - 
MLH 
(β111) 
- 21.83 
±0.001 
21.58 
±0.001 
25.92 
±0.009 
- - 
ML 
( β110) 
- - - - 10.6 15.0 
ML2 
( β120) 
- - - - 19.3 27.3 
ML3H3 
 (β133) 
- 53.89 
±0.001 
58.87 
±0.006 
71.43 
±0.006 
- - 
 ML3H2 
(β132) 
- - - 65.33 
±0.003 
- - 
 ML3 
(β130) 
- - 40.62 
±0.007 
46.03 
±0.005 
27.2 37.43 
 ML2(OH)2 
 
- - 13.54 
±0.002 
- - - 
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According to the results obtained, the appearance of a typical ligand-to-metal charge transfer band 
(LMCT) in the 400-700 nm region of the spectra in the titrations of the three chelators with Fe(III) 
versus pH showed that complexation started at very low pH.  
The batch titration of Fe(III) and rac-SK-2 between p[H] -0.25 and 2.25 showed the appearance 
of a LMCT band at 500 nm suggesting the formation of a single species in this range of p[H] that 
was tentatively attributed to the formation of the FeLH2 species in accordance with rac-SK-2 
protonation scheme (Figure 52A). Titration between pH 2.50 and 11.56 showed a hypsochromic 
shift of this band, suggesting the formation of a new species but precipitation, indicated by 
simultaneous increase of the baseline and the spectral noise on the whole spectrum, occurred 
around pH 3.7 and precluded further analysis of the data. 
In the case of rac-SK-3, the Fe(III) complex LMCT band appeared at 487nm at p[H] -0.5 and 
shifted gradually hypsochromically to 458 nm (pH 2.48) and 411 nm (pH 6.93), suggesting the 
successive formation of FeLH, FeL2H2 and FeL3H3 (possibly Fe(LH)2 and Fe(LH)3) with the 
amino group protonated, in accordance with rac-SK-3 protonation scheme (Figure 52B). The 
LMCT band then started to decrease gradually with simultaneous precipitation, sign of release of 
Fe(III) from the ligand and its precipitation as Fe(OH)3. 
The spectral variations of the Fe(III)-L-SK-4 titrations also showed the successive formation of 
the FeLH, FeL2H2 and FeL3H3 complexes. We suggest that Fe(III) is coordinated by the (CO, O-) 
donor set as it was observed previously for mimosine.7 Further increase of the pH till around 9 
lead to the formation of the deprotonated FeL3 complex, possibly due to the deprotonation of the 
ammonium functions. Above pH 9, the LMCT band started to gradually decrease but it was still 
present at the end of the titration (pH 11.29) with no sign of precipitation, which suggested the 
presence of a hydroxylated FeL2(OH)2 species.  
No evidence of dinuclear species could be observed in our experimental conditions for any of the 
three ligands. 
Since the stability constants for both rac-SK-1 and 5 has not been determined experimentally, the 
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respective values obtained from the literature suggested that maltol and kojic acid (as 
hydroxypyranones) have logβ130= 28.5 and 24.15 respectively, whereas 3, 2-hysroxypyridinone 
and 1-methyl-3-hydroxypyridin-2-one have logβ130= 29.3 and 32 respectively.418,562,566,570 
From these stability constants, the electronic spectra of the complexed species and their 
distribution curves were calculated for rac-SK-3 (Figure 55A, B) and L-SK-4 (Figure 55C, D) 
 
 
Figure 55: Electronic spectra of the protonated species of (A), Fe-rac-SK-3 and (C) Fe-L-SK-4 
and distribution curves of the protonated species of (B) Fe-rac-SK-3 ([rac-SK-3] = 3.03×10−4 M, 
[Fe]/[rac-SK-3]=0.3) and (D) Fe-L-SK-4 ([L-SK-4] = 1.54×10−4 M, [Fe]/[L-SK-4]=0.30). Solvent: 
H2O, I = 0.1 M (NaClO4), T= 25.0°C for all measurements. 
The distribution curves show that, at physiological pH (pH 7.4), ligand rac-SK-3 exists primarily 
as its Fe(rac-SK-3)3H3 (Figure 56A) species and L-SK-4 as almost exclusively its Fe(L-SK-4)3 
complex (Figure 56B).  
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Figure 56: Main (A) Fe(III) – rac-SK-3 and (B) Fe(III) – L-SK-4 complexes being formed at pH 
7.4. 
To compare the chelation power of the three chelator, and other chelators from literature, for 
Fe(III), the amount of metal not complexed by the chelators ([Mn+]free) was calculated at every pH 
from the distribution curves (with [Chelator]tot = 10-5M and [Mn+]total = 10-6M) and –log([Mn+]free) 
was plotted against pH for clarity (Figure 57). A higher value thus indicates a higher chelation 
power. 
 
                         
Figure 57: Chelating power of selected chelators versus pH, represented by the inverse log of the 
non-complexed (free) Fe3+ concentration, (- log([Mn+]free) ([Chelator]=10-5M, [Fe3+]=10-6M), 
taking into confederation the precipitation of Fe2O3 species.  
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If we consider the affinity for Fe(III), we can observe that rac-SK-3, possessing a 1,2-HOPO 
chelating group, is the best chelator (when compared with the 1, 2-HOPO) between pH 2 and 5.8. 
From this pH, ligands based on the 3, 4-HOPO chelating unit like L-SK-4, DPF and ligand P1 
become the best chelators. Interestingly, those data suggested that L-SK-4 exhibits a higher affinity 
than DFP however lower than ligand P1. As for rac-SK-2, its precipitation above pH 4 precluded 
any calculation. Therefore, the order of stability constants towards Fe(III) binding can be drawn 
as follow; L-SK-4 >> rac-SK-5> rac-SK-3> rac-SK-1. 
Our bidentate ligands are giving a series of different complexes of stoichiometry LFe, L2Fe, L3Fe. 
Based on literature, only the L3Fe complex is considered suitable to prevent redox cycling and 
thus formation of ROS.434,571,572 Therefore, the concept of pFe3+ (-log[Fe3+]free) is not entirely 
satisfactory as it only considers [Fe3+]free to quantify the efficacy of a ligand but does not give any 
information about the 1:1 and 2:1 stoichiometries. Therefore, by defining pL3Fe3+ as –log[L3Fe3+] 
complex, in the same conditions: [Fe3+]total = 10-6 M with [L]total = 10-5 M, pH 7.4, the closest 
pL3Fe3+ is to 6 (full Fe(III) chelation) the more effective the ligand to prevent redox cycling and 
formation of ROS (Figure 58). 
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Figure 58: Saturated Fe3+ binding of selected chelators versus pH, represented by the inverse log 
of the FeL3 species (- log([FeL3]) ([Chelator]=10-5M, [Fe3+]=10-6M). 
Table 22: Percentage (%) of Fe3+ redox silenced based on the p[L3Fe3+] at pH 7.4 
 p[L3Fe
3+] at pH 7.4 % of Fe3+ redox silenced 
Fe-L-SK-4 6.00 100 
Fe-rac-SK-3 6.45 35.5 
Fe-1, 2-HOPO 6.18 66 
Fe-P1 6.00 100 
DFP 6.00 100 
 
According to the exported data (Table 22), it can be concluded that at the given conditions; 
[Fe3+]total = 10-6 M with [L]total = 10-5 M, pH 7.4, 3, 4-HOPOs were capable of forming fully 
saturated coordination spheres. As a result of this, 100% of the Fe3+ is redox inactive (silenced). 
In contrast, the Fe3+ centre of the 1, 2-HOPO-Fe3+ complexes, is more susceptible to promote ROS 
formation since only the % of chelatable Fe3+ is below 100%. This approach could give as insights 
into whether the treatment with these compounds can prevent the redox cycling and ROS 
formation in biological system. However, the challenging part of this would be the calculation the 
liable iron pool (LIP) in the different cellular systems as LIP can found in various organelles 
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including cytosol, mitochondria and liposomes and the concentration of chelators there too. In 
addition to these, the pH at these organelles is not strictly 7.4.  
6.2.2  Complexation with Cu(II) and Zn(II)  
 
The next part of this study involved the potentiometric determination of the stability constants and 
the binding efficacy of the SK-n compounds against Cu(II) and Zn(II). It has been previously 
demonstrated that Cu(II) is also a redox active metal that can catalyzed the ROS formation, 
whereas Zn(II) is not.438,573,574 Therefore, the determination of the stability constant could give 
insights on whether the SK-n compounds can prevent the Cu(I)/Cu(II) redox cycle and inhibit the 
ROS formation. In addition to this, the binding efficacy against Zn(II) could illustrate whether it 
can bind to HOPOs and remove some of them, preventing in that way the complete inhibition of 
Fenton chemistry (Table 23). 
Table 23: Overall stability constants (log β) of the Cu(II) and Zn(II) complexes of ligands rac-
SK-2, rac-SK-3 and L-SK-4 ± SD expressed to the last significant place. Solvent: H2O, I = 0.1 M 
(NaClO4), T = 25.0 °C.  
 MLH ML2H2 ML2H ML2 
rac-SK-2 nd nd nd nd 
Zn-rac-SK-3 13.9 
±0.002 
27.86 
±0.007 
21.56 
±0.007 
12.5 
±0.002 
Cu-rac-SK-3 nd nd nd nd 
Zn-L-SK-4 14.56 
±0.006 
28.35 
±0.006 
22.00 
±0.005 
13.55 
±0.007 
Cu-L-SK-4 16.7 
±0.002 
33.44 
±0.006 
25.79 
±0.007 
15.8 
±0.002 
Zn-P1562 18.79 
±0.006 
36.70 
±0.004 
26.02 
±0.009 
- 
Cu-P1562 21.78 
±0.007 
41.42 
±0.007 
34.21 
±0.005 
24.68 
±0.005 
 
In the case of L-SK-4, a successive formation of MLH, ML2H2, followed by successive 
deprotonation to ML2H and ML2 for both Cu(II) and Zn(II) with stronger stability constants for 
Cu(II) than for Zn(II) was observed  (Table 23). 
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Rac-SK-3 exhibited the same complexation pattern as L-SK-4 with Zn(II) but the stability of the 
Cu(II) complexes could not be determined as the complex was already fully formed at pH 2 due 
to the lower pKa values of this 1,2-HOPO-based ligand. This suggested, as observed for L-SK-4, 
a stronger stability of the Cu(II) complex than the Zn(II) complex. No evidence of dinuclear 
species could be observed in our experimental conditions. 
To compare the chelation power of the three chelator, and other chelators from literature, for 
different metals, the amount of metal not complexed by the ligands ([Mn+]free) was calculated at 
every pH from the distribution curves (with [Chelator]tot = 10-5M and [Mn+]total = 10-6M) and –
log([Mn+]free) was plotted against pH for clarity (Figure 59). A higher value thus indicates a higher 
chelation power. 
 
                  
Figure 59: Chelating power of selected ligands versus pH, represented by the inverse log of the 
non-complexed (free) Mn+ concentration, (- log([Mn+]free) ([Chelator]=10-5M, [Mn+]=10-6M 
[Fe3+]=10-6M), taking into confederation the precipitation of Fe2O3 species. 
As for divalent cations, both rac-SK-3and L-SK-4 show a high selectivity for Fe(III) over Cu(II) 
and Zn(II), similarly to other ligands of the 3,4-HOPO family like DFP or ligand P1. That means 
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that even if cells contained elevated amount of Cu(II) or Zn(II), the redox silencing of Fe(III) is 
expected to dominate. As PD is linked with the abnormal elevation of Fe(III), treatment with the 
chelators can lead to the beneficial inhibition of ROS production by the prevention of redox 
cycling of Fe(III) and consequently Cu(II).  
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7 Results and Discussion – Evaluation of the anticancer capacity of the 
chelators in an in vitro model of Malignant Melanoma. 
7.1 Biological Characterization  
7.1.1 Assessing the cytotoxicity of the SK-n compounds 
 
The ability of a series of hydroxypyridinone (HOPO) including 1, 2-HOPO (rac-SK-3), 3, 2-
HOPO (rac-SK-5), 3, 4-HOPO (rac-SK-2 and L/D-SK-4) as well as a hydroxypyranone (rac-SK-
1) to induce cytotoxic effect has been evaluated in an in vitro model of malignant melanoma 
consisting of human malignant melanoma (A375) cells. (The cytotoxicity of 6 out of the 9 
compounsd has been evaluated due to the fact that the rac-SK-6, rac-SK-7 and L-SK-8 weren’t 
synthesised by the time of biological characterisation). For the cytotoxicity assay, all the 
compounds have been assessed in a range of concentrations (10-1000 µM) and time points (24-72 
hr)(Figure 60A-F). The results revealed that A375 cells appeared to be more resistant to the 
treatment of rac-SK-1 and 5 since the viability levels after the exposure remained in the same 
levels as their respective untried controls, whereas some noteworthy activity has been noticed on 
rac-SK-2 and 3 as at high concentrations as 1000 µM, 72 hr post-treatment (Figure 60A-D). In 
contrast, both enantiomeric forms of a methylated analogue of L-mimosine (L/D-SK-4) shown a 
potency to induce cytotoxic effect on A375 cells in a dose (concentration)-time dependent manner. 
In particular, a statistically significant reduction (p<0.01) in viability levels was initially observed 
when A375 cells were treated with 10 µM of L-SK-4, an effect which was further potentiated as 
the concentration of the compound and/or time of exposure were increased (Figure 60E). Overall, 
cell viability levels reached an EC50 at a concentration of 100 µM after 48 hr. In the case of the 
evaluation of the D-enantiomer (D-SK-4), a similar time- and concentration-dependent response 
was evident to that L enantiomer (Figure 60F). However, this was the case only at 48-72 hr of 
exposure while at 24 hr it remained almost at control levels (90-100%) except at very high 
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concentrations (e.g. 1000 µM). Furthermore, such treatment was not as potent as with L-SK-4, 
evident by a much higher EC50 value of approximately 250 µM at 48-72 hr of exposure. Although 
it is appeared  that both enantiomers have similar activity, the preference for the L enantiomer is 
more likely to occur due to the small preference of LAT-1 for the L-enantiomers of amino acids.476 
In addition to this, it seems that the structure of L-SK-4 (N-substituted 3,4 HOPO) can fit 
preferentially into the active site of the transporter compared to the structure of other 
screened molecules. 
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Figure 60: The ability of hydroxypyridones to induce cytotoxicity in A375 cells. Cells were 
exposed to a range of 10-1000 µM concentrations of (A) rac-SK-1, (B) rac-SK-2, (C) rac-SK-3, 
(D) rac-SK-5, (E) L-SK-4 and (F) D-SK-4 for 24, 48 and 72 hr. Data shown are means ± SD of 5 
replicates from three independent experiments.  
The cytotoxic phenotype that has been induced by the treatment of 100 µM of L-SK-4 has also 
been observed under inverted phase contrast microscopy (Figure 61) as the number of cells in the 
treated groups decreases over the time compared to their respective untreated controls.  
 
 
 
Figure 61: The ability of L-SK-4 to induce cytotoxicity in A375 cells. Control cells and those 
exposed to 100 µM of L-SK-4 at 24 hr, 48, and 72 hr were visualized under inverted phase contrast 
microscope. 
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Finally, we evaluated the cytotoxic effect of 100 µM of L-SK-4 in a non-melanoma epidermoid 
cancer (A431) and a non-malignant immortalized human keratinocyte (HaCaT) cell line in order 
to demonstrate any specificity towards the melanoma (A375) cell line. Our observations revealed 
that these cells were also affected at 100 µM of L-SK-4 but nevertheless were shown to be more 
resistant than A375 (Figure 62). More specifically, in the case of A431 cells, the effect was 
comparable with that of A375 (at 24 hr of exposure) but it was a lot more intensified at 48 and 72 
hr of exposure respectively as the number of viable cells was significantly higher compared to 
A375 cells (Figure 62A). In contrast, a comparable cytotoxicity pattern was also observed in the 
case of HaCaT cells as well (Figure 62B). Together, our cytotoxicity data indicate that L-SK-4 
exerts a higher degree of cytotoxic potency against A375 cells while A431 and HaCaT cells were 
more resistant. 
 
 
Figure 62: The ability of L-SK-4 to induce cytotoxicity in (A) non-melanoma (A431) cells and 
(B) non-malignant keratinocyte (HaCaT) cells. Cells were exposed to100 µM of L-SK-4 for 24, 48 
and 72 hr. Data shown are means ± SD of 5 replicates from three independent experiments.  
 
The resistant phenotype of A431 and HaCaT cells post exposure to 100 µM of L-SK-4 was also 
observed under inverted phase contrast microscopy (Figure 63A and B). Initially, the A431 cell 
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clusters that can be seen in the 24 hr control are retained upon the treatment whereas some 
shrinkage of the clusters is indicated on the 48 hr. In the case of 72 hr, cell clusters can still be 
seen, however the induced cytotoxicity, de-touched them from the bottom of the plate and they 
appeared as floaters. Similar observations are pointed for the HaCaT cells, since the cells remained 
in clumps as their respective untreated controls for 24 and 48 hr, whereas at 72 hr they appear as 
floaters.   
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Figure 63: The ability of L-SK-4 to induce cytotoxicity in (A) A431 and (B) HaCaT cells. Control 
cells and those exposed to 100 µM of L-SK-4 at 24 hr, 48 hr and 72 hr were visualized under 
inverted phase contrast microscope. 
7.2 In vitro validation of Structure Activity Relationship (SAR) 
 
7.2.1 Transportation through LAT-1 
 
As mentioned before, the screened HOPOs contain an amino-acid vector in order to be transported 
through the LAT-1 transporters as proposed in the literature.465,469,484 However, even if SK-n were 
designed to be LAT-1 substrates, it does not mean they use it. This hypothesis needed to be 
checked. In order to validate the assumption, the active site of the LAT-1 transporter has been 
blocked with either an inhibitor or a non-selective substrate which competes the efflux/uptake of 
amino-acids. For the purpose of this experiment, L-thyroxin (Figure 64A) was used as LAT-1 
inhibitor, whereas 2-amino-norbornanecarboxylic acid (BCH) (Figure 64B) was used as a LAT-
1 non selective substrate as it competes with leucine towards the same active site of the transporter. 
554,575–577  
 
 
Figure 64: Structure of (A) L-Thyroxin and (B) BCH.  
  
The addition of the either the inhibitor or the non-selective substrate will induce cell death due to 
the cell starvation of amino acids, masking in that way the toxic effect of the lead compound. In 
order to overcome this effect both L-thyroxin and BCH have been applied to A375 cells,  in a 
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range of concentrations (0.1-1 mM and 0.5-10 mM respectively) and time (24-72 hr) in the absence 
of L-SK-4 in order to determine the tolerated dose (Figure 65A and B). 
 
 
Figure 65: Determination of cytotoxicity of LAT-1 inhibitor; L-Thyroxin and non-selective 
substrate; BCH.  A375 cells have been exposed  in a range of concentrations (0.1-1 mM) of L-
thyroxin (A) and (0.5-10 mM) of BCH (B) for 24, 48 and 72 hr.  Data shown are means ± SD of 
5 replicates from three independent experiments.  
The optimum concentration was found to be equal to 100 µM for L-Thyroxin and 5 mM for BCH 
as at higher concentrations they induced toxicity. To investigate the use of LAT-1 by L-SK-4,  
A375 cells have been treated with L-Thyroxin (100 µM) and BCH (5 mM) (separately) in the 
presence or the absence of 100 µM of L-SK-4 for 24, 48 and 72 hr and the viability levels were 
monitored again utilizing Alamar Blue assay (Figure 66).  
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Figure 66: A375 cells have been exposed  to 100 µM of L-SK-4 in the presence or the absence of 
100 µM of L-Thyroxin or 5 mM of BCH respectively for 24, 48 and 72 hr. Data shown are means 
± SD of 5 replicates from three independent experiments.  
The results revealed that inhibition of the active site of LAT-1 transporter, and therefore 
preventing the entrance of L-SK-4 into the cells, leading to a significant cell rescue, since the 
viable levels of the co-treated groups were significantly higher compared to the respective ones 
been treated just with L-SK-4 (Figure 66). However, the limitations of this study didn’t allow for 
final conclusions. This is because L-Thyroxin appears to be less selective towards LAT-1 
inhibition compared to other synthetically accessible inhibitors which they can inhibit the Leucine 
uptake by 99±4%.272,465,484,578,579,580 In addition to this, BCH is reported to cause inhibition of 
Leucine uptake by 75.3±6.7, 78±3.5 and 73±4.5% in KB, Saos2 and C6 cell lines respectively.577 
Therefore, the use of alternative inhibitor with higher inhibitory capacity was essential. Moreover, 
since BCH as a non-specific LAT substrate it might present some selectivity and/or specificity 
over LAT-2 or LAT-4 as it was demonstrated before.581,582 Therefore, in an attempt to optimize 
and improve the above findings, two enantiomerically pure forms of a 2-amino-3-(2-naphthyl) 
propanoic acid were synthesized (Figure 67). 580 
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Figure 67: Structure of (A) L- and (B) D-2-amino-3-(2-naphthyl) propanoic acid. 
 
According to the literature, the L- enantiomer form of this molecule exerts  higher selectivity over 
LAT-1 with the capability of inhibiting Leucine uptake by 94±2%.580 The addition of the LAT-1 
inhibitors is expecting to induce cytotoxicity concealing in that way the cytotoxic effect of the L-
SK-4. In order to overcome this effect both L- and D- 2-amino-3-(2-napthyl) propanoic acid have 
been applied to A375 cells,  in a range of concentrations (2-10 mM) and time (24-72 hr) in the 
absence of L-SK-4 in order to determine the tolerated dose (Figure 68). 
 
 
Figure 68: Determination of cytotoxicity of LAT-1 inhibitor; L- and D- 2-amino-3-(2-naphthyl) 
propanoic acic. A375 cells have been exposed  in a range of concentrations (2-10 mM) of L- and 
D- 2-amino-3-(2-naphthyl) propanoic acic for 24, 48 and 72 hr respectively.  Data shown are 
means ± SD of 5 replicates from three independent experiments. 
The optimum concentration was found to be equal to 2 mM for the L- enantiomer (Figure 68A) 
and 4 mM for the D- enantiomer (Figure 68B) as at higher concentrations it became cytotoxic. 
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However, for the rationalization of their inhibitory potency, both enantiomers have been screened 
under the same conditions and concentrations. For the validation of all the above, A375 cells have 
been treated with L- and D- 2-amino-3-(2-napthyl) propanoic acid (2 mM) in the presence or the 
absence of 100 µM of L-SK-4 for 24, 48 and 72 hr and the viability levels were monitored as 
described previously (Figure 69).  
 
Figure 69: A375 cells have been exposed  to 100 µM of L-SK-4 in the presence or the absence of 
100 µM of L- and D- 2-amino-3-(2-naphthyl) propanoic acic for 24, 48 and 72 hr respectively. 
Data shown are means ± SD of 5 replicates from three independent experiments. 
The results obtained, suggested that indeed, the L-2-amino-3-(2-naphthyl) propanoic acid is 
preferred as LAT-1 inhibitor over the respective D- enantiomer validating once again the 
previously reported findings for the preference of LAT-1 on L- enantiomers.485 Namely, the 
viability levels of the cell groups that have been exposed to L- enantiomer were lower compare to 
the once been treated with the D- enantiomer (Figure 69). Moreover, an almost 100% cell rescue 
was noticed in the cell groups that have been co-treated with both L-SK-4 and L-2-amino-3-(2-
naphthyl) propanoic acid mainly after 24 hr, whereas a small drop in the viability levels has been 
noticed at 48 and 72 hr (Figure 69). This can be attributed to either to the cell starvation of amino-
acid or because some percentage of the L-SK-4 managed to penetrate the cell. Some inhibition has 
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also been illustrated by the cell groups exposed to both L-SK-4 and the D-2-amino-3-(2-naphthyl) 
propanoic acid. However, the viability levels were lower compared to the respective once of the 
L- enantiomer (Figure 69). 
7.2.2 Control compounds of L-SK-4 
 
Eventually, in order to establish an in vitro Structure Activity Relationship (SAR), by means of 
investigating which structural features of the lead molecule (L-SK-4) are essential for its activity-
potency and transportation as well as to demonstrate the importance of the chelating group, a range 
of control has been synthesized and screened on A375 cells (Figure 70). Control compounds 1-3 
are derivatives of the parental molecule (L-SK-4) with a functional inactivation of one of their 
active features. Control-1 and -2 are primary amine and a carboxylic acid respectively,  rather than 
amino acids and Control 3 has a methyl ether protected pyridone rather than hydroxypyridone 
(Figure 70A). 
 
 
Figure 70: Metal chelators that have been used in this study were designed for both strong and 
selective Fe3+ binding and coordination and enhanced transportation to the cytosol. (A) Structures 
of the control compounds. (B) Cytotoxic evaluation of the control compounds on A375. A375 
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cells, were treated with a 100 µM of Control compounds 1-3 in a range of time (24-72 hr). Data 
shown are means ± SD of 5 replicates from three independent experiments.  
The results revealed that Control-1 was totally inactive since it couldn’t induce any cytotoxic 
effect not even after 72 hr of exposure. Additionally, similar observation has been noticed when 
A375 have been treated with Control-2 especially after 24 and 48 hr as there wasn’t any significant 
drop of the viability levels. A significant decrease on the number of viable cells has only been 
noticed 72 hr post-exposure to the compound. Eventually, Control-3 shown some cytotoxic effect 
which has been induced at 24 hr and slightly intensified over the course of 72 hr, however the 
magnitude of cytotoxic induction was not as intense as it was in the case of L-SK-4 (Figure 70B). 
The small decrease of the viability levels can be attributed to the fact, that either the methyl ether 
protected pyridone can still bind to the Fe3+ but with less affinity or it can exhibit a weak alternative 
activity which is not related to Fe3+ chelation. On the other hand, it has been previously shown, 
that cytochrome P450s can de-methylate aryl ethers during the process of compounds 
metabolism.583  
7.3 Characterization of molecular mechanism of action  
 
7.3.1 Ability of L-SK-4 to induce ROS 
 
The next part involved a synoptic characterization of the main mode of action of L-SK-4 on the 
three working cell line by means of investigating the mode of cell death induction. The ability of 
100 µM of L-SK-4 to induce intracellular reactive oxygen species (ROS) has been evaluated by 
means of flow cytometry, utilizing the DHR-123 fluorescent probe on A375, A431 and HaCaT 
cells as a ROS detector. The results obtained indicated that the treatment with 100 µM of L-SK-4 
had the ability to increase dramatically the FITC spectrum in the exposed A375 group compared 
to the unexposed (control) group (Figure 71A). Interestingly, treatment of A375 cells with 100 
µM of L-SK-4 induced a significant increase (p<0.001) in intracellular ROS levels, during the first 
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24 hr, which were sustained at each time point thereafter (Figure 71B).  In the case of A431, the 
FITC spectrum retained at the same levels as the respective control (untreated cells) after the 
exposure to 100 µM of L-SK-4 (Figure 71C). This observation was an indication that the 
treatment with the chelator couldn’t promote any statistically significant alteration in the ROS 
levels (Figure 71D). Eventually, 100 µM of L-SK-4 have the ability to induce ROS on HaCaT 
cells in a time dependent manner since the FITC spectrum increased with respect to the time 
(Figure 71E). Namely, an almost 1.5 fold of ROS induction has been observed during the first 24 
hr with the effect been intensified over the time as at the 48 and 72 hours the ROS fold of induction 
was approximately and 3.1 respectively (Figure 71F). Overall it appears that A375 and HaCaT 
cells seems to be more vulnerable to the induction of ROS by the treatment with A375 been even 
more sensitive. In contrast, the ROS fold of induction on A431 was not of any statistically 
significant change. 
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Figure 71: The ability of L-SK-4 to induce generation of oxidative stress in A375, A431 and 
HaCaT cells. A375, A431 and HaCaT were exposed to 100 µM of L-SK-4 for 24, 48 and 72 hr and 
monitored by means of (A), (C), (E) flow cytometry in addition to being quantitated as (B), (D), 
(F) ROS fold induction respectively. Data shown are means ± SD of 3 replicates from three 
independent experiments. 
7.3.2 Determination of mode of cell death 
 
In an attempt to evaluate the mode of cell death as a result of the induced cytotoxicity of the lead 
compound, the number of apoptotic and necrotic A375, A431 and HaCaT cells was evaluated after 
exposure to 100 µM of L-SK-4. The importance of this study was to give insights into whether the 
treatment can induce either necrosis which is correlated to acute inflammation or apoptosis which 
is linked to the programmed cell death. To distinguish between the two modes of cell death, the 
CellEvent Caspase 3/7 Green detection reagent was utilized as an activated caspase 3/7 activity 
indicator whereas DAPI as an indicator for necrosis (Figure 72A, C, E) on A375, A431 and 
HaCaT respectively.  Our data showed significant cell death on A375 that have been treated with 
100 µM of L-SK-4 during the first 24 hr (p<0.01), an effect which was intensified, over time, in a 
manner where live cells were significantly reduced (p<0.001) while necrotic cells remained at 
steady levels (Figure 72B). On the other hand, the number of apoptotic cells is increasing 
significantly over the time (Figure 72B). The same pattern seems to be followed by A431 as the 
treatment with 100 µM of L-SK-4 induce a significant drop in the number of live cells during the 
first 24 hr (p<0.001), with the effect been intensified over 72 hr (Figure 72D). In this case, the 
number of necrotic cells is elevated significantly (p<0.001) over 72 hr while the number of the 
apoptotic cells remained steady at the control levels (Figure 72D). Finally, the number of live 
HaCaT cells drops significantly (p<0.01) at 48 hr and (p<0.001) at 72 hr (Figure 72F). Although 
the drop of live cells seems to be accompanied with a necroptotic effect as both apoptotic and 
necrotic cells are elevated at almost the same levels by the end of 72 hr (Figure 72F).  
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Figure 72: The ability of L-SK-4 to induce apoptosis in A375, A431 and HaCaT cells. Briefly, 
A375, A431 and HaCaT cells were exposed to 100 µM of L-SK-4 at 24, 48 and 72 hr and then the 
number of live, apoptotic and necrotic cells were recorded by means of (A), (C), (E) flow 
cytometry and also quantified as (B), (D), (F) percent of total cell population. Data shown are 
means ± SD of 3 replicates from three independent experiments. 
7.3.3 Ability of L-SK-4 to arrest cell cycle growth 
 
Finally, the ability of 100 µM of L-SK-4 to induce cell cycle growth arrest was assessed by using 
the FxCycle PI/RNase staining solution for quantification of DNA content under each phase of 
the cell cycle and subsequent analysis by flow cytometry (Figure 73A, C, E) on A375, A431 and 
HaCaT cells respectively. Our results show that, 24 hr after exposure, there was a statistically 
significant elevation of the G1 phase on A375, followed by a reduction of the G2/M phase 
(p<0.001) while the S phase remained unaffected. Interestingly, at 48 hr, a significant increase of 
the sub-G1 phase was also observed followed by a marked reduction of the G1 phase (p<0.001) 
while the S- and G2/M phases remained relatively unaffected. Furthermore, this effect was 
intensified at 72 hr of exposure (Figure 73B). In the case of A431, there wasn’t any significant 
alterations in the phases of cell growth during the first 24 hr (Figure 73D). However, a statistically, 
significant increase of the G1 phase is observed at 48 hr with this effect been intensified over 72 
hr. The increase of the G1 phase was also correlated with the statistically significant decrease of 
the S phase at 48 and 72 hr. Additionally, a statistically significant drop of the DNA levels been 
accumulated in the G2/M phase is also observed at 72 hr post treatment with 100 µM L-SK-4 
(Figure 73D). Finally, in the case of HaCaT cell a similar cell cycle growth arrest seems to be 
observed as it was in A431, with the exception that the significant increase of the G1 phase began 
at 24 hr and continues over 72 hr (Figure 73F). Once again, the increase of the G1 phase is 
accompanied with the statistically significant decrease; p>0.01 and p>0.001 of the S- and G2/M 
phase respectively (Figure 73F).  
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Figure 73: The ability of L-SK-4 to induce cell cycle growth arrest in A375, A431 and HaCaT 
cells. Cells were exposed to 100 µM of L-SK-4 at 24, 48 and 72 hr and then the number of cells 
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were recorded at each stage of the cell cycle by means of (A), (C), (E) flow cytometry and also 
quantified as (B), (D), (F) percent of total DNA cellular content accumulated at each phase of the 
cell cycle (e.g. sub-G1, G1, S or G2/M). Data shown are means ± SD of 3 replicates from three 
independent experiments. 
The main outcome of this study is that in the case of A375 cells, the compound induced growth 
arrest at the late of sub-G1 – early G1- phase of the cell cycle. This is strongly associated with the 
acute effect of the lead compound as it prevents the cell cycle to be completed due to the arrest at 
the very early stages. Therefore, the cell proliferation in inhibited. In contrast, the treatment of 100 
µM of L-SK-4 seems to arrest the cell cycle of A431 at the late G1 - early S-, whereas the growth 
arrest on HaCaT noticed at the G1- phase. That was an evidence of the resistance that two cell 
lines have to the treatment. Namely, in these cases, the treatment does not influence the cell cycle 
progression especially during the first 24 hr. In addition to this, it is demonstrated that cell cycle 
is allowed to progress unless its arrest to the mid stage of the procedure. Our findings are in 
agreement with the literature as it has been shown previously that L-mimosine and DFP (both 3, 
4-HOPOs) have the ability to induced cell cycle growth arrest at the G1- phase before the entrance 
to the S- phase of the cell cycle.584–586 It has been also suggested that the metals chelators interfere 
with the cell cycle by chelating the iron that exist in the active site of enzymes that are regulating 
the progression and maintenance of cell cycle grow.587 In example, DFP, chelates the Fe2+ ion that 
exist in the active site of essential for cell cycle enzymes; iron-depended histone lysine 
demethylases (KDMs).587 In addition to this it has been shown before, that DFP, inhibits 
ribonucleotide reductase by chelating the intracellular liable zinc pool, whereas in other cases it 
prevents the demethylation of H3K4me3 and H3K27me3; enzymes that participate in the post 
translation modifications of chromatins.588–590  
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7.4 Biological mode of action   
 
7.4.1 Time-dependence determination of ROS fold of induction 
 
A kinetic characterization of the ability of HOPO metal chelators to induce toxic levels of ROS 
was evaluated in human malignant melanoma cells including those of 1,2-HOPO (rac-SK-3), 2, 
3-HOPO (rac-SK-5), 3, 4-HOPO (rac-SK-2, D/L-SK-4) and a hydroxypyranone (rac-SK-1). Each 
compound was assessed on a range of concentrations (25-500 µM) at three time points (24, 48 and 
72 hr) (Figure 74). Our results shown that none of the compounds; rac-SK-1, 2, 3 and 5 was able 
to induce elevation of ROS, not even at concentrations as high as 500 µM after 72 hr of treatment 
since the ROS levels were remained almost at the same as to their respective controls levels 
(Figure 74A-C and F). On the other hand, two enantiomerically pure forms of an N-substituted-
3, 4-HOPO (L- and D-SK-4) had the capacity to induce a statistically significant elevation of ROS 
at a concentration of 100 µM after 24 hr of exposure (Figure 74D and E). However, the magnitude 
of ROS fold of induction was much more intense in the case L-SK-4 (~ 4x VS ~2.5x higher than 
the control). Additionally, when A375 cells have been treated with 100 µM of L-SK-4 the ROS 
levels were maintained over the course of 72 hr at the same levels whereas in the case of D-SK-4 
there was a slight elevation of the ROS level over the time of exposure. Interestingly, when cells 
were treated with 500 µM of L-SK-4, the ROS levels were of less magnitude compare with the 
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once been induced by 100 µM whereas in the case D-SK-4 the ROS fold of induction at the 
respective concentration retained almost at the same levels (Figure 74D and E). 
 
 
Figure 74: The ability of hydroxypyridinones to induce alterations on the ROS levels in A375 cell 
lines. A375 cells were exposed to a range of concentrations (0-500 µM) of (A) rac-SK-1, (B) rac-
SK-2, (C) rac-SK-3, (D) L-SK-4, (E) D-SK-4 and (F) rac-SK-5 for 24, 48 and 72 hr. Data shown 
are means of ± SD of 3 replicated from 3 independent experiments.  
Finally, we evaluated the pro oxidant capacity of L-SK-4 in a range of concentrations (25-500 
µM) and time (24-72 hr) against non-malignant melanoma (A431) as well as non-malignant 
keratinocytes (HaCaT) cells in an attempt to document any potential selectivity over A375 cells. 
Our observations revealed that the ROS levels, in A431 and HaCaT cells were also affected by 
the treatment with L-SK-4 (Figure 75B and C). In the case of HaCaT cells an elevation of ROS 
has been noticed at 100 µM with the effect been intensified over 72 hr whereas at 500 µM the 
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ROS levels were sustained almost the same over time. Despite the fact, that an increase on the 
ROS levels has been noticed, the magnitude of the induction was significantly lower that the 
respective one on A375 (Figure 75B and Figure 74D). On the other hand, a none-meaningful 
elevation of ROS has been noticed on A431 (Figure 75B).  Taken together, our data, indicate that 
L-SK-4 exerts a higher degree of potency to induce ROS in A375 rather than A431 and HaCaT. 
 
 
Figure 75: The ability of L-SK-4 to induce alterations on the ROS levels in (A) A431 and (B) 
HaCaT cells. Data shown are means of ± SD of 3 replicated from 3 independent experiments.  
 
7.5 L-SK-4 generates oxidative stress on malignant melanoma cells 
7.5.1 Effect of oxidative stress been induced by L-SK-4 
 
Afterwards, a descriptive characterization of the oxidative stress that 100 µM of L-SK-4 can 
induce on A375 was performed by means of investigating its effect on lipid, protein and DNA 
level, at 24, 48 and 72 hr. Initially, the concentration of MDA, a marker of lipid peroxidation was 
measured (Figure 76A).591,592 The results obtained indicated a statistically significant elevation of 
MDA at 24 hr whereas sharp elevation was noticed at 48 and 72 hr. Furthermore, we analyzed the 
levels of protein carbonyl as marker of proteins that underwent oxidative damage (Figure 
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76B).593,594 According to the exported results, there was not any significant change between the 
untreated cells and the ones that have been treated with L-SK-4 at the first 24 hr. On the other 
hand, a reverse effect seems to be illustrated, as a dramatic increase has been noticed at 48 hr and 
the effect was then intensified at 72 hr. Eventually, we examined whether the ROS induction could 
cause any DNA oxidative damage, by means of measuring the levels of its respective marker; 8-
oxo-2-deoxy guanosine (8-OHdG) (Figure 76C).595,596 Our observations suggested that there is an 
elevation of 8-OHdG at 24 hr which is not of statistical importance. However the concentration of 
the examined marker was significantly elevated at 48 hr and at the end-point (72 hr) of the 
experiment it reached the maximum levels. 
 
 
Figure 76: The effect of ROS induction on lipids, proteins and DNA in A375 cell line. (A) The 
level of MDA on A375 cells post-treated with 100 µM of L-SK-4 for 24, 48 and 72 hr. (B) The 
carbonyl protein content on A375 cells been treated with 100 µM of L-SK-4 for 24, 48 and 72 hr. 
(C) The quantification of 8-OHdG species on DNA of A375 cells been treated with 100 µM of L-
SK-4 for 24, 48 and 72 hr. Data shown are means of ± SD of 3 replicates from 3 independent 
experiments.  
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7.5.2 ROS scavenging effect by GSH 
 
We subsequently, attempted to introduce a ROS scavenger; reduced glutathione (GSH), in order 
to examine whether we can reverse the phenotype from the cell survival rate point of view as the 
elevation of ROS in combination with oxidative stress induced by the treatment appeared to be 
the determinant factors for cell death induction. 597,598 Primarily, a dose-response curve was 
performed in A375 cells, with a range of concentrations of GSH (1.5-6 mM) and time (24-72 hr) 
in order to determine the optimum concentration that would not mask the cytotoxic effect of L-
SK-4 (Figure 77). 
  
Figure 77: The cytotoxicity of GSH on A375 cell line. A375 cells were exposed to a range of 1.5-
6 mM concentrations of GSH for 24, 48 and 72 hr. Data shown are means ± SD of 5 replicates 
from three independent experiments.  
The results obtained shown that 1.5 mM of GSH was the tolerated concentration that could applied 
in cells, as at higher concentrations (3 and 6 mM) GSH exerts a toxic effect.   Cell viability assay 
was then performed where cells were co-treated with 100 µM of L-SK-4 and 1.5 mM GSH and 
interestingly our experimental data were in agreement with our initial assumption (Figure 78).  
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Figure 78: The ability of the GSH to rescue cell from cell death induced by L-SK-4. A375 cells 
were treated with 100 μM of L-SK-4in the presence of the absence of 1.5 mM of GSH for 24, 48 
and 72 hr. Data shown are the means ± SD of 5 replicates from 3 independent experiments. 
Namely, the co-treatment with GSH and L-SK-4 leaded to cell rescue rather than cell death as the 
viability levels were at higher levels compared to respective cells which were treated only with 
GSH. As it can be observed from Figure 78 there is a significant decrease of the viability levels 
in the co-treated group (L-SK-4 + GSH), however that magnitude was significantly elevated 
compared to the L-SK-4 treated group. That was a strong indication that the increasing 
accumulation of ROS can promote cell death in A375 and this is reduced by the antioxidant GSH. 
In order to validate this assumption, ROS levels were re-measured in the presence of GSH and L-
SK-4. Our data showed that the FITC spectrum decreased dramatically in the co-treated groups 
compared to those been treated with only L-SK-4 (Figure 79A). Not surprisingly, co-treatment of 
A375 cells with 100 µM of L-SK-4 and 1.5 mM of GSH can cause a significant drop of the ROS 
levels compared to the respective values of ROS induction by just L- SK-4 (Figure 79B). 
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However, despite this difference, the ROS levels in the co-treated cells we significantly higher at 
24, 48 and 72 hr compared to their respective control which has been treated simply with GSH. 
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Figure 79: The ability of GSH to scavenge intracellular ROS that have been induced by L-SK-4 
in melanoma cell lines. A375 cells were treated with 100 μM of L-SK-4 in the presence of the 
absence of 1.5 mM of GSH for 24, 48 and 72 hr and ROS levels were monitored by means of (A) 
flow cytometry in addition to being quantified as (B) ROS fold of induction. 
Finally, we have examined the capacity of 100 µM of L-SK-4 to induce ROS and also the potency 
of 1.5 mM of GSH to scavenge any accumulation of ROS in different classes of melanoma such 
brain metastatic melanoma (VMM-1) (Figure 80A and D), lymph node metastatic melanoma (Hs 
294T) (Figure 80B and E) as well as murine malignant melanoma (B16 F10) (Figure 80C and 
F). 
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Figure 80: The ability of GSH to scavenge intracellular ROS that have been induced by L-SK-4 
in VMM-1, Hs 294T and B16 F10. All cell lines were treated with 100 μM of L-SK-4 in the 
presence or the absence of 1.5 mM of GSH for 24, 48 and 72 hr and ROS levels were monitored 
by means of flow cytometry(A), (B) and (C) in addition to being quantified as ROS fold of 
induction for (D), (E) and (F) for VMM-1, Hs 294T and B16 F10 respectively. Data shown are 
means of ± SD of 3 replicates from 3 independent experiments.  
 
The exported phenotype was the same in all three cell lines. Namely, the treatment has the ability 
to induce a significant increase of ROS levels during the first 24 hr, which were sustained at each 
time point thereafter. More specifically in VMM-1 (Figure 80A and D) and Hs 294T (Figure 80B 
and E) the ROS induced levels were almost at the same magnitude. In contrast the ROS levels 
been induced in B16-F10 (Figure 80C and F) were not at the same high levels as they observed 
previously in VMM-1 and Hs 294T. Ultimately, the co-treatment with 1.5 mM of GSH and 100 
µM of L-SK-4 shown that the ROS levels were dropped, almost back to their respective control 
levels (Figure 80). However, it is also demonstrated that the ROS levels of induction were not as 
intense as it was in the case of A375, an indication that is pointing out a predominant selectivity 
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of the treatment on the primary class of malignant melanoma (A375) rather than the metastatic 
ones.  
7.5.3 Cell death driven by ROS 
 
The number of apoptotic and necrotic A375, VMM-1, Hs 294T and B16-F10 cells, was evaluated 
after exposure to L-SK-4 in the presence and the absence of GSH in order to verify that cell death 
is ROS driven.  To distinguish between the two mode of cell death in all cells, the CellEvent 
Caspase 3/7 Green reagent detection reagent was used as an indicator of activated Caspase 3/7 
whereas DAPI as an indicator for necrosis (Figure 81A-I, B-I, C-I and D-I).
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Figure 81: The ability of GSH to prevent (A) A375, (B) VMM-1, (C) Hs 294T and (D) B16 F10 
cell from undergoing apoptosis after been treated with L-SK-4. Briefly cells were treated with 100 
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μM of L-SK-4 in the presence or the absence of 1.5 mM of GSH or 24, 48 and 72 hr and the 
distinction between the live, apoptotic and necrotic cells has been done by means of flow 
cytometry (A-I, B-I, C-I and D-I) and then live (A-II, B-II, C-II and D-II), apoptotic (A-III, B-
III, C-III and D-III) and necrotic (A-IV, B-IV, C-IV and D-IV) cells were quantified as 
percentages. Data shown are means of ± SD of 3 replicates from 3 independent experiments. 
 
Our data showed significant cell death (by means decreasing live cells) on A375 which was 
initiated during the first 24 hr, and intensified over time (Figure 81A-II). At the same time, the 
number of apoptotic cells was significantly increased at 24 hr and boosted at 48 and 72 hr (Figure 
81A-III) while the necrotic population remained unaffected at low levels (Figure 81A-IV). 
However, the co-treatment with GSH reversed that phenotype. Namely, the addition of GSH 
caused significant elevation of the live cells levels by scavenging ROS, whereas the previously 
elevated apoptotic cell levels have been decreased dramatically (Figure 81A-II and III). Once 
again the levels of necrotic cells remained steady as to the control (Figure 81A-IV). Additionally, 
it appeared that 100 µM of L-SK-4 can be cytotoxic in the other malignant melanoma cell lines 
that have been used in the in vitro model; VMM-1, Hs 294T and B16 F10 with the mode of cell 
death been differed in each cell line (Figure 81B, C and D). Primarily, in the case of VMM-1 
cells, the treatment with 100 µM of L-SK-4 has the ability to decrease significantly the levels of 
live cells at 24 hr with the effect to be retained over 48 hr and intensified at 72 hr (Figure 81B-
II). Additionally, it can be observed that there is significant elevation of the number of apoptotic 
cells at 48 and 72 hr whereas the necrotic cell population was increasing over the time (Figure 
81B-III and B-IV). The co-treatment of GSH seems that cause some cell rescue mainly after 72 
hr of exposure as the number of live cells remained steady at 24 and 48 hr and increased at 72 hr 
(Figure 81B-II). Moreover, addition of GSH abolished the elevated levels of apoptosis and drops 
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the levels of necrosis after 24 hr (Figure 81B-III and B-IV). A small reduction of necrosis levels 
was also noticed at 48 and 72 hr (Figure 81B-IV). 
Afterwards, treatment with 100 µM of L-SK-4 induced cytotoxicity on Hs 294T cells 24 hr after 
the exposure with the effect be intensified at 48 hr and retained until 72 hr (Figure 81C-II). 
Interestingly, the treatment did not promote any apoptosis, however it induced necrosis at 24 hr 
and those levels were generally sustained over 72 hr (Figure 81C-III and IV). Co-treatment with 
GSH didn’t cause any significant cell rescue at 24 and 48 hr, whereas a statistically significant 
(p>0.05) has been noticed at 72 hr (Figure 81C-II). In this case, GSH didn’t decrease the necrosis 
levels as those were remained unaffected over the entire course of screening (Figure 81C-IV).  
Finally, exposure of B16 F10 to 100 µM of L-SK-4 induced a statistically significant (p<0.01) 
cytotoxic effect as the level live cells dropped at 24 hr and those levels decreased further after 48 
and 72 hr of exposure (Figure 81D-II). The analysis of the mode of cell death didn’t show any 
activation of apoptosis as the apoptotic levels were retained at almost the same levels as the 
controls (Figure 81D-III). In contrast a statistically significant elevation of the necrotic 
population seems to be illustrated 24 hr post treatment with the effect been intensified over 48 and 
72 hr (Figure 81D-IV). Co-treatment with GSH didn’t cause any beneficial cell rescue at 24 and 
48 hr whereas a statistically significant cell rescue was noticed at 72 hr (Figure 81D-II). In this 
case it can be observed that GSH couldn’t manage to cause any significant decrease of the necrotic 
cell population (Figure 81D-IV).  
Overall it has been demonstrated that treatment with L-SK-4 can be cytotoxic in VMM-1, Hs 294T 
and B16 F10. However, those cell lines seem to be more resistance to the treatment compared to 
A375. This can be attributed to the fact, that melanoma cells have generally low levels of GSH 
and therefore they cannot overcome the high levels of ROS been induced by the pro-oxidant 
chelator.599 Additionally, the elevated levels of ROS induced different mode of cell death in each 
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cell line. In some cases, the mode of cell death was not driven by ROS as scavenging them didn’t 
cause any alterations to the either live or dead (including apoptotic and necrotic) cells. 
 
7.5.4 ROS elevation activate apoptotic cascades 
 
Finally, a more descriptive characterization of a variety of proteins that are associated with 
intrinsic and extrinsic apoptotic cascades was performed (by means of western immunoblotting) 
in A375 cells that have been exposed to 100 µM of L-SK-4 with or without pre-treatment with 1.5 
mM of GSH (Figure 82).  
 
 
Figure 82: The ability of GSH to prevent A375 cell from undergoing apoptosis after been treated 
with L-SK-4. Cell were subjected to 100 μM of L-SK-4 in the presence of the absence of 1.5 mM 
of GSH for 24, 48 and 72 hr and protein expression levels of full length and cleaved caspases-8 
and -9 were recorded in addition to those of BID and Apaf-1. 
 
The expression levels of cleaved and full length Caspase-8 (indication of extrinsic apoptosis) and 
also the respective levels of cleaved and full length Caspase-9, as well as the Apoptotic protease-
activating factor (Apaf-1) which are indicative markers for the intrinsic apoptosis were 
observed.600–606 In addition to these, the expression levels of BID were determined due to its ability 
BID   22 kDa 
Caspase-8 (full length) 
Caspase-8 (cleaved) 
57 kDa 
43 kDa 
Caspase-9 (full length) 
            
Caspase-9 (cleaved) 
            
Caspase-9 (cleaved) 
47 kDa 
            
37 kDa 
            
35 kDa 
Apaf-1  135 kDa 
β-Tubulin  55 kDa 
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to link the two apoptotic pathways.607–611  Overall, the activation of Caspase-8 was proved by the 
present of increased cleaved length protein expression levels which was observed as early as 24 
hr after the exposure to L-SK-4 and remained as such through the entire time course. In contrast, 
when cells co-treated with GSH and L-SK-4, the respective proteins expression levels were 
sustained at the same levels as the control (cell been treated with just GSH) for 24 and 48 hr. A 
small activation of Caspase-8 (by means of Cleaved length protein expression) was observed at 
72 hr.  Furthermore, the expression levels of BID were also elevated during 24-48 hr on the groups 
been exposed to L-SK-4 (indication of a concomitant activation of the intrinsic apoptosis) while 
reduced back to the control levels after 72 hr of exposure. The expression levels of BID in the cell 
population being co-treated with GSH were remained at the control levels over 24 and 48 hr 
whereas a small activation seems to be denoted after 72 hr. Further evidence for the concomitant 
activation of the intrinsic apoptotic activation was documented after examining the expression 
levels of caspase-9 and Apaf-1 through the time course in the groups been treated with L-SK-4 
either with or without pre-treatment with GSH. To this end, several studies revealed the activation 
of Caspase-8 as well as that of Caspase-9 and Apaf-1 (via the formation of apoptosome) can 
eventually lead to the activation of Caspase-3 which is an establish mechanism for the execution 
of apoptosis.607–615 On the other hand, we proved that accumulation of ROS is strongly associated 
with the activation of apoptotic pathways. These observations were documented by the expression 
levels of apoptotic markers that were remained at low levels (or slightly elevated after 72 hr of 
exposure) by scavenging the ROS that L-SK-4 has induced (by adding GSH). Therefore, this 
finding can lead us to the conclusion that (i) low levels of GSH cannot scavenge the excessive 
amount of ROS been induced by the chelator and also (ii) the cell death/rescue is well regulated 
by the ROS levels since scavenging them can rescue cell from apoptotic cell death. Our findings 
are in agreement with literature as it has been proven before that metal chelators can induce 
oxidative stress driven apoptosis.114,616–618 Additionally, the ability of GSH to prevent the 
activation of apoptosis has been previously reported. 619–622 
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7.6 Lipidomic analysis 
In order to see how the elevated levels of ROS affect the lipidome profile of the A375 cells a 
lipidomic analysis was performed between the A375 cells treated for 24 hr with 100 µM L-SK-4 
and the respective untreated controls. The results suggested that 1800 lipidome MS1 features 
differentiated between the control and the treated group (Figure 83). 
 
  
A (I) 
(II) 
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Figure 83: Overlapped (A) (I)Total Ion Chromatograph (TIC) and (II) Base Peak chromatograph 
of the A375 untreated cells (red chromatograph) and A375 24 hr treated with 100 µM of L-SK-4 
(blue chromatograph) (B) (I) Total Ion Chromatograph (TIC) and (II) Base Peak chromatograph 
of the A375 untreated cells (red chromatograph) of the A375 24 hr 100 µM of L-SK-4 (blue 
chromatograph) and A375 untreated cells (red chromatograph) treated with respectively using 
positive Electron Ionization Mode (+ev EIM). 
 
Principal Component Analysis (PCA) and visualization was used in order to examine the presence 
of any underlying trends within the data sets and the results revealed a planar separation between 
B (I) 
 (II) 
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the control, treated cells and quality control (Figure 84A). Afterwards, partial least square-
discriminated analysis (PLS-DA, 1 latent variable) was then performed to identify and retain the 
most statistically significant features (VIP<1)  (Figure 84B). 
  
Figure 84: (A) 3D PCA of the the 1800 upregulated lipidated features present in A375 cells 
generated by MetaboAnalyst 4.0 using the ‘Statistical Analysis’ node. Blue spheres represent the 
quality control whereas red and green represent the lipidated features of 24 hr treated with 100 
µM L-SK-4 and untreated control respectively. (B) PLS-DA analysis of A375 untreated cells VS 
24 hr A375 cells treated with 100 µM L-SK-4. 
  
A 
B 
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The outcome of this analysis is that approximately 400 MS-1 validated features were upregulated 
in the treated cells compared to the respective control ones (Figure 85).   
 
Figure 85: Heatmap representing the top 400 discriminated feutures that were significantly up or 
down regulated in the A375 cells treated with 100 µM of L-SK-4 compared to the respective 
untreated control.  
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From those it can be confirmed (via MS-1) that the elevated lipid classes were associated with the 
de novo biosynthesis of sphingolipids with the most significant unregulated species of this class 
been known as ceramides (Figure 86). 
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Figure 86: (A) Heatmup showing the relative fold of change in the biosynthesis of sphingolipids 
in A375 cell line, 24 hr post-treatment with 100 µM of L-SK-4 for 24 hr. Lipidomic analysis 
revealed the significant elevation of sphingolipids. (B) Overall sphingolipids de novo biosynthetic 
map shows the upregulation of sphingolipids (Whisker’s  box) in the cell groups been treated with 
100 µM of L-SK-4 (red bar) compared with the respective control (green bar). 
7.6.1 Effect of myriocin in cell survival - The role of ceramide. 
 
According to the literature, it is suggested that elevation of ROS can stimulate the release of 
ceramide species which they can serve messengers for the activation of apoptotic cascades.623 Our 
findings seems to agree with the literature since elevation of ROS stimulates the biosynthesis and 
release of ceramide lipids (as well as other sphingolipids) via ceramide releasing enzymes 
resulting in the generation of a ceramide-enriched membrane, suggesting that this is a response – 
adaptation –  mechanism that cells tend to follow before the activation of the downstream apoptotic 
cascades.624–635 Moreover, in order to validate whether the elevated (by ROS) levels of ceramide 
species  can induce cell death, we treated the cells with myriocin, an inhibitor of serine polmitoyl 
transferase, an enzyme that catalyze the first step in de novo sphingolipids biosynthesis (Figure 
87A and B).636–640  Initially, cells were exposed to a range of concentrations of myriocin (0-50 
µM) and time (24-72 hr) for the determination of the tolerated dose which was found to be 50 nM 
(Figure 87C).  
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Figure 87: (A) Myriocin prevents ceramide biosynthesis by inhibiting the enzyme Serine 
Palmitoyl Transferase. (B) The structure of myriocin. (C)The ability of myriocin to induce 
cytotoxicity in A375 cells. Cells were exposed to a range of 0.01-50 μM concentrations of 
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myriocin for 24, 48 and 72 hr. Data shown are the means ± SD of 5 replicates from 3 independent 
experiments. 
Finally, cells were pretreated with 100 µM of L-SK-4 either in the presence or the absence of 50 
nM of myriocin in order to determine whether inhibition of sphingolipids biosynthesis and 
consequently ceramide elevation can prevent the induction of cell death (Figure 88). 
 
Figure 88: Myriocin can rescue cells from cell death by inhibiting the overproduction of ceramide 
been induced by L-SK-4. A375 cells were treated with 100 μM of L-SK-4 in the presence of 
absence of 50 nM of myriocin for 4 24, 48 and 72 hr. Data shown are the means ± SD of 5 
replicates from 3 independent experiments. 
 
Not surprisingly, a significant drop in the viability levels of the cells been exposed to L-SK-4 was 
noticed once again. However, the viability levels of the cell population that it was co-treated with 
L-SK-4 and myriocin was significantly elevated compared to those been treated with L-SK-4 
implying in that way that myriocin has the ability to induce cell rescue rather than cell death 
(Figure 88).   
Afterwards, we evaluated whether the treatment with myriocin can prevent the induction of 
apoptosis been induced by L-SK-4 by measuring the number of apoptotic and necrotic A375 cells 
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after exposure to L-SK-4 either with or without co-treatment with myriocin by means of flow 
cytometry (Figure 89). To distinguish between the two mode of cell death in all cells, the 
CellEvent Caspase 3/7 Green reagent detection reagent was used as an indicator of activated 
Caspase 3/7 whereas DAPI as an indicator for necrosis (Figure 89A). 
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Figure 89: The ability of myriocin to prevent A375 cell from undergoing apoptosis after been 
treated with L-SK-4. Briefly, A375 cells were treated with 100 μM of L-SK-4 in the presence or 
the absence of 50 nM of myriocin for 24, 48 and 72 hr and the distinguish between the live, 
apoptotic and necrotic cells has been done by means of (A) flow cytometry and then (B) live (C) 
apoptotic and (D) necrotic cells were quantified as percentages. Data shown are means of ± SD of 
3 replicates from 3 independent experiments. 
 
The same pattern as described above was observed once again since the number of live cells in 
the cell population been treated with 100 µM of L-SK-4 dropped significantly over the whole time 
course whereas the respective population of the cell being co-treated with L-SK-4 and myriocin 
sustained at almost the same levels as control for 24 and 48 hr (Figure 89B). After 72 hr of co-
treatment a significantly drop of the viable levels has been noticed, which is not as intense as in 
the case of the treatment with L-SK-4 (Figure 89B).  Similar pattern seems to be followed by 
apoptotic cells, since the significant elevation that has been noticed at 24 hr and intensified over 
72 hr, abolished after the co-treatment with myriocin (Figure 89C), whereas not any significant 
alterations have been noticed on necrotic population (Figure 89D).  
 
7.6.2 Ceramide triggers the direct activation of the extrinsic apoptosis 
 
The capacity of ceramide to activate the extrinsic apoptosis by inducing FasL activation is well 
documented in the literature.641–645 Therefore we examined how the elevated levels of ceramide 
can influence the expression level of Fas as well as this of Fas-Associated Death Domain (FADD) 
and how these levels can then correlated with the activation of extrinsic apoptosis by means of 
expression of full and/or cleaved length caspase-8 and BID in A375 cells been treated with L-SK-
4 either in the presence or the absence of myriocin (Figure 90).  
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Figure 90: The ability of myriocin to prevent the activation of intrinsic apoptotic markers that 
have been elevated by the treatment of L-SK-4 in A375 cells. Cell were subjected to 100 μM of 
L-SK-4 in the presence of absence 50 nM of myriocin for 24, 48 and 72 hr and protein expression 
levels of full length and cleaved caspases-8 were recorded in addition to those of BID, FADD and 
FAS. 
 
According to the results exported it is indicated that the expression levels of Fas and FADD 
induced the activation of caspase-8 in the treated with L-SK-4 population. In contrast, the 
expression levels of those proteins are dropped when the inhibitor of ceramide is added illustrating 
that the activation of the extrinsic apoptosis is driven and modulated by the levels of ceramide. 
Furthermore, the expression levels of BID were shown to be elevated during the 24 and 48 hr in 
the group that has been treated with L-SK-4 whereas in the respective group where myriocin was 
added, the expression levels sustained to the same levels as control.  
 
7.6.3 Ceramide elevation triggers the indirect activation of intrinsic apoptosis. 
 
Finally, we analyzed whether the elevation of ceramide can trigger the activation of intrinsic 
apoptosis by examination of mitochondrial membrane depolarization (ΔΨm) (as a marker of 
57 kDa 
43 kDa 
Caspase-8 (full length) 
Caspase-8 (cleaved) 
40-50 kDa FAS 
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mitochondrial dysfunction) in flow cytometry by utilizing the JC-1 stain (Figure 91A) and ΔΨm 
was calculated as the ratio of JC-1 aggregates over the JC-1 monomers. (Figure 91B). 646–651
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Figure 91: Myriocin prevents the mitochondria membrane depolarization by inhibiting the 
overproduction of ceramide been induced by L-SK-4. A375 cells were exposed to 100 μM L-
SK-4 in the presence or the absence of 50 nM of myriocin for 24, 48 and 72 hr and the number 
of JC-1 monomers and aggregates by means of (A) flow cytometry and also quantified as (B) 
the ratio of JC-1 aggregates over JC-1 monomers. Data shown are means of ± SD of 3 
replicates from 3 independent experiments. 
 
According to the results, it is suggested that the treatment with 100 µM of L-SK-4 can induce 
a dramatic depolarization of mitochondria even after 24 hr of treatment with the effect been 
intensifies over 48 and 72 hr (Figure 91B). Interestingly, co-treatment with L-SK-4 and 
myriocin managed to show much lower membrane depolarization; however, the depolarized 
levels were significantly higher compared to the respective control (Figure 91). Those results 
demonstrate that the depolarization of mitochondrial membrane is regulated by the levels of 
ceramide been released by stimulation of ROS.  
 
In order to validate our findings, we examined the levels of proteins that are associated with 
the formation of apoptosome by means of Apaf-1 as well as these of full and/ or cleaved length 
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Caspase-9 as markers of intrinsic apoptosis (Figure 92).  
 
 
Figure 92: The ability of myriocin to prevent the activation of extrinsic apoptotic markers that 
have been elevated by the treatment of L-SK-4 in A375 cells. Cell were subjected to 100 μM 
of L-SK-4 in the presence of absence 50 nM of myriocin for 24, 48 and 72 hr and protein 
expression levels of full length and cleaved caspases-9 were recorded in addition to this of 
Apaf-1. 
 
The results suggest that elevation of the expression levels of Apaf-1 and the activation of 
caspase-9 in the treated with L-SK-4 population were following the same pattern as before, 
whereas the addition of ceramide biosynthesis inhibitor caused a significantly dropped into the 
expression of the respective proteins. In addition to this, we examined the expression levels of 
the pro-apoptotic factors - regulators; BAX and BAK as markers of mitochondria degradation 
(Figure 93). 652–658  
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Figure 93: Effect of myriosin to the decrease of the pro-apoptotic markers that were elevated 
by the treatment of L-SK-4 in A375 cells. Cells, were subjected to 100 μM of L-SK-4 in the 
presence of absence 50 nM of myriocin for 24, 48 and 72 hr and the protein expression levels 
of BAK and BAX were recorded. 
 
The results revealed that there was an activation of those proteins at 48 and 72 hr in the cell 
population been treated with L-SK-4, with these findings been in agreement with the activation 
of intrinsic apoptosis. In contrast, the expression levels of BAK and BAX to the cells which 
were exposed to L-SK-4 and myriocin remained steady to the same levels as the respective 
control, implying in that way that ceramide is needed for the activation of the pro-apoptotic 
proteins and consequently the activation of the downstream intrinsic apoptotic cascade.  
This is mainly because ceramide as bioactive lipid plays the role of a secondary messenger 
that modulated (directly) the activation of extrinsic apoptotic pathway and also (indirectly) the 
activation of intrinsic apoptotic pathway.659–663 Therefore, in this model we were able to see 
that L-SK-4 has the ability to induce enough ROS just after 24 hr that allowed the stimulation 
of lipid biosynthesis (sphingolipids) and consequently, the elevation of ceramide. However, 
48 and 72 post treatment the ROS level were still at the same levels as those of 24 hr. The 
excessive exposure of the cells to ROS leaded eventually to lipid peroxidation, protein 
carbonylation and DNA oxidative damage after 48 hr with the effect retained or intensified 
after 72 hr of the treatment, something that is confirmed by the findings above (Figure 76). 
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8 Results and Discussion – Evaluation of the neuroprotective capacity of 
the SK-n compounds in an in vitro model of Parkinson’s disease (PD) 
The neuroprotective capacity of a series of hydroxypyridinones including 1, 2-HOPO (rac-
SK-3), 3, 2-HOPO (rac-SK-5), 3, 4-HOPO (rac-SK-2 and L-SK-4) as well as a 
hydroxypyranone (rac-SK-1), was evaluated in an in vitro model of PD consisting of Lund 
Human Mesecephalic (LUHMES) cells that have been differentiated to mature post-mitotic 
cells with biochemical morphological and functional features of dopaminergic neurons. For 
the induction of parkinsonian phenotype, LUHMES cells were exposed in a range of 
neurotoxins including; 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenylpyridinium 
(MMP+) and erastin. Our collaborators; Dr Simon Gutbier, Dr Stefan Schildknecht and Prof 
Marcel Leist at the Kostanz University, Germany have kindly generated the results obtained.  
8.1 Neuroprotection against 6-OHDA 
 
8.1.1 Cytotoxicity of the SK-n compounds 
 
LUHMES cells, have been treated with a range of concentration (12.5-500 µM) of the SK-n 
compounds 1 hr prior to exposure to 6-OHDA (50 µM). Then, cells were incubated for further 
24 hr before taking further measurements. The neuroprotective or neurotoxic ability of the  
SK-n compounds assessed using two metabolic assays: (A) reasazurin reduction and (B) 
Lactate Dehydrogenase (LDH) release (Figure 94).  
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Figure 94: The ability neuroprotective capacity of hydroxypyridones against 6-OHDA 
induced parkinsonian phenotype. LUHMES cells have been exposed to a range of 12.5-500 
µM concentrations of the SK-n compounds prior to the addition of 6-OHDA (50 µM). Red 
bars represent the viability assays performed by means of resazurin reduction whereas the blue 
bars show the outcome of LDH release assay. Data shown are means ± SD of at least 3 
replicates from 3 independent experiments. 
 
Primarily, the results revealed that treatment with 6-OHDA led to a significant cell death as 
the viability levels (by means of resazurin reduction) were at almost zero, whereas the LDH 
that has been released decreased by almost 50% (Figure 94A). In contrast, none of the SK-n 
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compounds induced further cytotoxicity as the levels of viabilities as well as those of LDH 
been released did not go below the respective levels of 6-OHDA treated groups (Figure 94A-
E).  In addition to this, rac-SK-1, 3 and 5 did not show any cell rescue event at high 
concentrations when compared with their respective control (cells treated with 6-OHDA) 
(Figure 94A, C and E). This can be attributed to the fact that either these compounds cannot 
penetrate the neuronal cell wall (by means of LAT-1) or they cannot prevent the extensive 
ROS production been Induced by the by the toxin. On the other hand, two 3, 4-HOPOs; rac-
SK-2 and L-SK-4 seems to induce a statistically significant cellular protection against the 
neurotoxin. Namely, rac-SK-2 protects the cells at a concentration of 50 µM with the effect 
been intensified at higher concentrations as the viability levels reached almost 80% implying 
an approximately 75% cellular rescue (from the viability perspective) (Figure 94B). In 
addition to this, the levels of the extracellular LDH decreased by approximately 50% compared 
to the respective control, showing in that way the neuroprotective potency of the compound 
(Figure 94B). Interestingly, these finding suggest that the treatment with rac-SK-2 is even 
more potent compared to the positive control (DFP) (Figure 94F). Furthermore, L-SK-4 
demonstrated a neuroprotective capacity, which has not the same magnitude as this of rac-SK-
2. Namely, L-SK-4, shown neuroprotective potency at 100 µM with the effect to be intensified, 
showing almost 50% increase in the viability levels (Figure 94D). Moreover, these 
observations are in agreement with the level of LDH measured extracellularly as a significant 
decrease in its concentration has been notice (Figure 94D). In this case, the neuroprotective 
potency of DFP and L-SK-4 is towards the same line, due to the almost identical effect that 
they present in the evaluation.  
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8.2 Neuronal protection 
 
For the verification of the above findings, LUHMES cells were visualised under automated 
fluorescent microscope in the presence or the absence of 6-OHDA with or without the SK-n 
compounds or DFP. The neuronal density (by means of neurite area determination) was then 
measured using Calcein [channel 2 (475±40/525±15 nm)] for the detection of viable cells and 
H-33342 dye [channel 1 (365±50/461±15 nm] for the execution of non-viable cells. All calcein 
positive pixels outside of these masks (somatic area) were counted as neurite area. (Figure 95) 
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Figure 95: The ability of the SK-n compounds to protect from neuronal degradation 
phenotype been induced by 6-OHDA. LUHMES cells were exposed to a range of 12.5-500 
µM concentrations of each compound prior to the addition of 6-OHDA (50 µM). (A) 
LUHMES cells were labelled with Calcein-AM (1 µM) and H-33342 (1 µg/ mL). Images were 
collected using automated microscome. (B) An algorithm quantified all calcein positive cells 
as viable and only H-33342 positive nuclei as “not viable” cells. All calcein positive pixels 
outside of these masks (somatic area) were counted as neurite area.   
 
The exported data confirmed the loss of the neuronal cells upon exposure with 6-OHDA. That 
was indicated by the existence of the blue stained nucleus (indicative of non-viable LUHMES 
cells) predominate the viable cells been stained with Calcein (Figure 95A). In addition to this, 
the inability of rac-SK-1, 3 and 5 to protect neuronal cells from the toxin, can also be visualised 
since the H-33342 positively stained nucleus are the most prevalent cellular components 
(Figure 95A). Moreover, the neurite area of the exposed to rac-SK-1 and 3 groups retained at 
the same significantly low levels (compared to positive control) even after high concentration 
treatment (Figure 95A and B). On the other hand, a reverse phenotype seems to be illustrated 
in the cases where cells have been exposed to rac-SK2 and L-SK-4 confirming the above 
findings. More specifically, pre-incubation with rac-SK-2 protects from neuronal degradation 
been induced by 6-OHDA as the existence of the Calcein stained somatic components of the 
neurons seems to be retained (compared to the both positive and negative control) (Figure 
95A). Furthermore, the neurite area of the rac-SK-2 treated cells group was increased 
significantly at a concentration as high as 500 µM (Figure 95B). At this particular 
concentration, the neurite area was even larger compare to the positive control. Once again, 
the phenotype of cells been exposed to DFP was almost the same with the respective one of 
the cells been treated with L-SK-4, something which can be attributed to the structural 
similarity of the two compounds (Figure 95A). This is also be confirmed by the densitometric 
analysis as both L-SK-4 and positive control follow the same trend (Figure 95B).  
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Our findings suggested that the observed order of activity (L-SK-4 ~ rac-SK-2 >> rac-SK-5 
> rac-SK-3 > rac-SK-1) match the order expected from their metal binding 
activity.442,452,570,664,665 Namely, the higher the logβ3[Fe3+] the least free iron and consequently 
better neuroprotective capacity. Additionally, our data are in agreement with the current 
literature findings as it has been demonstrated before that 3, 4-HOPOs shown as exceptional 
ability of neuroprotection against the cytotoxic effect of 6-OHDA, mainly by chelating the 
elevated by the toxin levels of iron.439,666 On the other hand, Workman DG and co-workers 
suggested that 1, 2-HOPOs can also exert neuroprotective potency against 6-OHDA.311  
Interestingly, the order of compounds activity differs from the one shown against cancer 
(7.1.1). Namely, it appears that the chelators presented different sensitivity and potency. This 
can be attributed to the fact, that either the compounds exploited other transport mechanism 
(apart of LAT-1) that is located in the neuronal cells, or because the concentration of redox 
active metals was in different proportions across the model of the two diseases.  
8.3 Neuroprotection against MPP+ 
 
8.3.1 Cytotoxicity of the SK-n compounds 
 
The next part involved the induction of parkinsonian phenotype on LUHMES cells by utilizing 
a different toxin such as MPP+, the active metabolite of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) that induces dopaminergic neuronal toxicity by inhibiting 
mitochondrial complex I activity.250,667 Therefore, LUHMES cells have been treated with a 
range of concentration (12.5-500 µM) of the SK-n compounds 1 hr prior to exposure to MPP+ 
(5 µM). Then, cells were incubated for further 72 hr before taking further measurements 
(Figure 96).  
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Figure 96: The ability neuroprotective capacity of hydroxypyridones against MPP+ induced 
parkinsonian phenotype. LUHMES cells have been exposed to a range of 12.5-500 µM 
concentrations of the SK-n compounds prior to the addition of MPP+ (5 µM) . Red bars 
represent the viability assays performed by means of resazurin reduction whereas the blue bars 
show the outcome of LDH release assay. Data shown are means ± SD of at least 3 replicates 
from 3 independet eexperiements. 
 
The results suggested that the treatment with MPP+ induced a statistically significant of 
toxicity since the viability levels of the exposed to the toxin cells, were decreases dramatically 
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(Figure 96A-E). In addition to this, the LDH that is been released due to the cytotoxicity of 
the compound reached almost the 80% of the total (Figure 96A-E). Moreover, as it can be 
observed from Figure 96, none of the screened molecules induced any further cytotoxicity 
since comparison of the viability and the LDH release levels of treated with MPP+ and those 
that have been treated with MPP+ did not revealed any statistically significant alterations. 
Furthermore, according to (Figure 96A), rac-SK-1, does not have any capacity of rescuing 
cells as the viability levels remained steady even after treatment with high concentrations. 
Similar behaviour can be illustrated by the LDH release profile, since there is not any reduction 
in the levels of the released LDH (Figure 96A).  Interestingly, a significant cell rescue was 
noticed in the cell population that have been co-treated with rac-SK-2, 3 as well as L-SK-4. 
Namely, rac-SK-2 managed to increase the viability levels by approximately, 45% even at the 
lowest concentration (12.5 µM) and prevented the release of LDH by approximately 40% 
(Figure 96B). This phenomenon was intensified in a dose-depended manner since at the 
maximal concentration the viability levels reached 80% and only a 20% of LDH has released 
(same as control – untreated cells) (Figure 96B). In the case of rac-SK-3, a similar dose-
depended cell rescuing is also been observed. However, the effect was not as intense as the 
positive control (Figure 96C and F). This observation would suggest that rac-SK-3 can 
penetrate the cell.  Hence lack of activity against 6-OHDA is more likely explained by rac-
SK-3 been able to rich mitochondria and act on them (as the lesion of MPP+ is strongly 
associated with mitochondria). Furthermore, co-treatment with L-SK-4 shown almost a 
dramatic cellular rescue even at 12.5 µM (Figure 96D). The increase of the viability levels in 
combination with the reduced LDH been released at this concentration were significantly 
elevated compared with the respective levels of the positive control (Figure 96D and F). 
Interestingly, at high concentration an almost complete recovery has been notice (Figure 
96D). These results also revealed that rac-SK-5 could demonstrated some minor potency at 
concentration as high as 500 µM (Figure 96E) 
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The ability of the SK-n compounds to act as neuroprotective agents was also evaluated under 
fluorescent microscope. LUHMES cells were treated with MPP+ in the presence of absence of 
SK-n compounds and DFP and imaging was occurred as mentioned in the previous section 
(8.2) (Figure 97).  
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Figure 97: The ability of the SK-n compounds to protect from neuronal degradation 
phenotype been induced by MPP+. LUHMES cells were exposed to a range of 12.5-500 µM 
concentrations of each compound prior to the addition of MPP+ (5 µM). (A) LUHMES cells 
were labelled with Calcein-AM (1 µM) and H-33342 (1 µg/ mL). Images were collected using 
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automated microscome. (B) An algorithm quantified all calcein positive cells as viable and 
only H-33342 positive nuclei as “not viable” cells. All calcein positive pixels outside of these 
masks (somatic area) were counted as neurite area.   
The results indicated that rac-SK-1and 5 were the least active compounds (Figure 97). This 
is because the H33342 positively stained nucleus were dominating over Calcein stained 
features. In addition to this, the densitometric analysis does not shown any significant 
elevation on the neurite area. In the case where cells were treated with both MPP+ and rac-
SK-2 or L-SK-4, a reverse phenotype was noticed (Figure 97A). Namely, the treatment with 
the compounds had the ability to protect the dopaminergic neuronal precursor cells from the 
cell death induced by toxin. In addition to this, a statistically significant increase (p<0.001) in 
the neurite area, has been noticed in a concentration as low as 25 µM (Figure 97B). These 
observations seem to follow the same trend as the positive control (DFP) (Figure 97B). In 
addition to this, treatment with rac-SK-3 seems to induce statistically significant neuronal 
rescue at 25 µM, however the cellular recovery was not as intense as it was in the case of rac-
SK-2, L-SK-4 and DFP (Figure 97B). 
The ability of DFP (as a 3, 4-HOPO) to rescue from the lesion induced by the treatment with 
MPP+ has been documented before.309,668,669 Interestingly, in this case it can be observed that 
HOPOs do not follow the same trend of activity as shown before for 6-OHDA. Namely, it is 
shown here that 3, 4-HOPOs > 1, 2-HOPO >> 3, 2-HOPO ~ hydroxypyranone. This suggest 
that the activity is guided by a more complex combination of molecular properties. To the very 
best of our knowledge, there is not any documented statements that proves that activity of 1, 
2- and 3, 2-HOPO against MPP+ induced toxicity, only using 6-OHDA. 
8.4 In vitro model of ferroptosis. 
In this section an in vitro model of ferroptosis as an alternative parkinsonian induced 
phenotype, was generated by the exposure of LUHMES cells to erastin, which is an eradicator 
of RAS and small t antigen (ST) expressing cells.670–672 Similar to other conditions, the SK-n 
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compounds were pre-applied to the cells in a range of concentrations (12.5-500 µM) 1 hr prior 
to the addition erastin (1.25 µM) and cells were incubated for 24 hr before taking any 
measurements. As described above, the cytotoxic ability of the SK-n compounds has been 
assessed via resazurin reduction and LDH release assay (Figure 98).  
 
Figure 98: The neuroprotective capacity of the SK-n compounds against erastin induced 
ferroptosis. LUHMES cells were exposed to a range of 12.5-500 µM concentrations of the SK-
n compounds prior to the addition of erastin (1.25 µM). Red bars represent the viability assays 
performed by means of resazurin reduction whereas the blue bars show the outcome of LDH 
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release assay. Data shown are means ± SD of at least 3 replicates from 3 independet 
experiements. 
  
The results revealed the treatment of LUHMES cells with erastin caused a statistical 
significant reduction of the % of viable cells. The induction of erastin’s toxicity was also 
demonstrated by the statistically significant elevation of LDH levels extracellularly (Figure 
98). Interestingly, when cells were exposed to rac-SK-1 (12.5-50µM) a statistically significant 
(p<0.001) elevation of the viable cells (indicating cellular protection) has been noticed, 
whereas at higher concentration ≤50 ≤500 µM the effect seems to be abolished (Figure 98A). 
The similar pattern seems to be reflected into the LDH release profile. The treatment with the 
rac-SK-1 compound could not manage to induce any statistically significant decrease of the 
previously elevated levels of extracellular LDH (Figure 98A). In contrast, the treatment in the 
range of 100-500 µM cause a statistical elevation (p<0.05) of LDH implying in that way that 
the compound acquires a cytotoxic rather than neuroprotective profile (Figure 98A). The 
ability of rac-SK-2 to act an excellent neuroprotective potency against erastin induced 
parkinsonian phenotype is demonstrated in (Figure 98B). The results show a sharp elevation 
with statistical significance (p<0.001) of viability levels in the cell groups exposed to the rac-
SK-2 even at the lowest concentration (12.5 µM) (Figure 98B). The same pattern is also 
reflected into the LDH release profile. Treatment with rac-SK-2 managed to decrease 
dramatically the elevated by erastin levels of LDH; bringing the LDH levels to the same 
magnitude as to the untreated control (Figure 98B). Interestingly, it seems that rac-SK-2 was 
even more potent when compared to the positive control (DFP) (Figure 98B and F). 
Additionally, a neuroprotective potency seems to be illustrated by the treatment with rac-SK-
3 (Figure 98C). Despite, the statistically significant elevation of the viable levels and the drop 
of the extracellularly LDH, the magnitude of protection was not as effective as it was in the 
case of the rac-SK-2. In the case of L-SK-4, the same pattern as rac-SK-2 seems to be repeated 
in almost the same magnitude (Figure 98D). Eventually, the neuroprotective inability of rac-
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SK-5 has been assessed with the results showing the disability of the compound to protect 
cells. Interestingly, at the concentration range (100-500 µM) the compound excretes a 
cytotoxic character as a statistically significant elevation (p<0.05) of the LDH levels has been 
noticed (Figure 98F).  
The neuroprotective properties of the SK-n against erastin’s toxicity has been visualised under 
fluorescent microscope and the neurite area has been measured as described before (Figure 
99). The results suggested that neither rac-SK-1 nor rac-SK-5 have any neuroprotective 
capacity since the H33346 stained nucleus (non-viable cells) are the main observable features. 
This observation is also confirmed by neurite area determination, as the densitometry results 
did not show any increased in the neurite area. Additionally, the potency of rac-SK-2, 3 and 
L-SK-4 is also validated by the Calcein-AM stained cells, which seems to be the most 
prevalent features. Furthermore, densitometry, validated those findings as there was a 
statistically significant elevation of the neurite are of the cell groups been exposed to rac-SK-
2, 3 and L-SK-4 respectively. The increase in the neurite is been noticed mainly at 25 µM and 
becomes plateau even at the higher concentrations (Figure 99).   
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Figure 99: The ability of the SK-n compounds to protect from ferroptosis been induced by 
erastin. LUHMES cells have been exposed to a range of 12.5-500 µM concentrations of each 
compound prior to the addition of erastin (1.25 µM). (A) LUHMES cells were labelled with 
Calcein-AM (1 µM) and H-33342 (1 µg/ mL). Images were collected using automated 
microscome. (B) An algorithm quantified all calcein positive cells as viable and only H-33342 
positive nuclei as “not viable” cells. All calcein positive pixels outside of these masks (somatic 
area) were counted as neurite area.    
         
 
A 
rac-SK-5 
CONTROL ERASTIN rac-SK-1 DFP 
rac-SK-2 rac-SK-3 L-SK-4 
0
2
5
5
0
7
5
1
0
0
0
20
40
60
80
100
2
0
0
5
0
0
SK-3
SK-4
SK-5
DFP
SK-2
SK-1
[TEST COMPOUND] (µM)
N
E
U
R
IT
E
 A
R
E
A
(%
 O
F
 C
O
N
T
R
O
L
)
✱✱✱ SK2;SK3;SK4;DFPB 
243 | P a g e  
 
The ability of rac-SK-2 and L-SK-4 to protect cells from the erastin induced ferroptosis was 
correlated (by means of cytotoxicological evaluation as well as neurite area determination) 
with the neuroprotective capacity of two ferroptosis inhibitors; Ferrostatin-1 (Figure 100A) 
and Liproxstatin-1 (Figure 100B) which have been introduced as alternative positive controls.  
 
 
Figure 100: Structure of (A) Ferrostatin-1 and (B) Liproxstatin-1 
 
Ferrostatin-1 has the ability to inhibit ferroptosis been induced by erastin by trapping peroxyl 
radicals preventing in that way the autooxidation of lipids.257,673–675 In addition to this, it has 
been proven that Ferrostastin-1 prevents the cell death been induced by L-glutamate in a rat 
organotypic hippocampal slice culture model.676 On the other hand, Liproxstatin- 1 can inhibits 
ferroptosis by preventing the suppression of glutathione peroxidase (Gpx4) by ferroptotic 
agents.674,677–679  LUHMES cells have been treated with the ferroptosis inhibitors 1 hr prior to 
exposure to erastin in a range of concentrations (0.3-10 µM) and were incubated for 24 hrs 
before taking any measurements. The results suggested that both compounds manage to 
protect from the neurotoxicity of erastin as there is a statistically significant elevation of the 
viable cells even at the lowest concentration (0.3-10 µM) of the inhibitor (Figure 101).  
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Figure 101: The ability  of Ferrostatin-1 and Liproxstatin-1 to inhibity the erastin induced 
ferroptosis. LUHMES cells were exposed to a range of 0.3125-10 µM concentrations of each 
inhibitor prior to the addition of erastin (1.25 µM). Red bars represent the viability assays 
performed by means of resazurin reduction whereas the blue bars show the outcome of LDH 
release assay. Data shown are means ± SD of at least 3 replicates from 3 independet 
eexperiements.  
More specifically, Ferrostastin-1 elevated the viable levels by approximately 70% and the 
effect seems to be retained in a non-dose depended manner as the effect reached plateau for 
all the concentrations. In the addition to this, the treatment lowers, in a statistically significant 
manner, the elevated (by erastin) LDH levels, demonstrating in that way its neuroprotective 
capacity. Similar observations have been exported for Liproxstatin-1. However, in this case 
high concentrations of the inhibitor seems to lowers the neuroprotective capacity as the levels 
of viable cells were considerably lower compared to the lowest concentrations. Moreover, this 
observation seems to be reflected to the percentage of the LDH been release extracellularly, 
as at high concentrations the respective percentage tends to be elevated. 
In addition to this the neurite area of the cell groups been exposed to erastin has been measured 
in the presence or the absence of either Ferrostatin-1 or Liproxstatin-1 (Figure 102).     
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Figure 102: The ability of Ferrostatin-1 and Liproxstatin-1 to inhibity the erastin induced 
ferroptosis. LUHMES cells were exposed to a range of 0.3125-10 µM concentrations of each 
inhibitor prior to the addition of erastin (1.25 µM). LUHMES cells were labelled with Calcein-
AM (1 µM) and H-33342 (1 µg/ mL). Images were collected using automated microscome. 
All calcein positive pixels outside of these masks (somatic area) were counted as neurite area.   
According to the results, a statistically significant elevation of the neurite area was noticed in 
both cells groups that were with Ferrostatin-1 and Liproxstatin-1 confirming the above 
findings. In the case of Ferrostatin-1, increasing concentrations of the inhibitor doesn’t seem 
to influence the neurite area whereas in the case of Liproxstatin-1 at concentrations higher than 
1.25 µM a decrease in the neurite area is noticed. These results suggest, that the active 
compounds; rac-SK-2 and L-SK-4 can act as inhibitors of ferroptosis as both compounds 
shown the same phenotype as the Ferostatin-1 and Liproxstatin-1. However, the mode of 
inhibition seems to be different.  
8.5 In vitro validation of Structure Activity Relationship (SAR) 
In order to examine the SAR of L-SK-4, two control compounds have been designed and 
synthesised; SK-4C1, which has the site for metal coordination blocked and SK-4C2, which 
is a primary amine without the carboxylated group. The justification of the design and 
synthesis of the control compounds can be found in 7.2 and 7.2.2. Briefly, LUHMEN cells, 
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were treated with the control compounds (12.5-500 µM) 1 hr prior to the addition of erastin 
(1.25 µM) and they incubated for 24 hr before taking any measurements (Figure 103).  
 
Figure 103: The ability of the control compounds; SK-4C1 and SK-4C2 to inhibity Erastin 
induced ferroptosis. LUHMES cells were exposed to a range of 12.5-500 µM concentrations 
of each inhibitor prior to the addition of erastin (1.25 µM). Red bars represent the viability 
assays performed by means of resazurin reduction whereas the blue bars show the outcome of 
LDH release assay. Data shown are means ± SD of at least 3 replicates from 3 independet 
experiements.  
The results suggested that SK4C1 compound did not manage to rescue neuronal cells at 
concentrations of 12.5-100 µM. Interestingly, at concentrations of 200 and 500 µM a 
statistically significant elevation of the viability levels was observed. The reasons are not clear. 
This might be attributed to the fact that the compound might be de-methylated by cells upon 
compounds insertion. It is known that cells expressing P450 enzymes have the capacity to 
metabolically de-methylate allyl ether substrates. However, to the best of our knowledge there 
is no literature report that claims the expression of any class of P450 enzymes in LUHMES 
cells. Some level of metal chelation (hence cell protection) might be occurred through the 
amino acid vector as it is known that amino acids can act as metal chelators. In contrast there 
was not any significant dropped of the levels of LDH. On the other hand, SK4C2 did not show 
any cell rescue, (as it was expected) due to the fact that this control compound lacks the amino 
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acid moiety, preventing it in that way to exploit LAT-1 (if LUHMES cells express this 
particular transporter). This particular control compound it is expected to be in its protonated 
state at physiological pH, and possibly it cannot diffuse through the neuronal cells (and 
consequently BBB) due to its hydrophilic character (Figure 104).  
                                                               
Figure 104: Structure of SK-4C2 at physiological pH. 
 
The neurite area determination also confirmed the above findings as none of the control 
compounds could exert any neuroprotective property. The neurite area of the treated with the 
control compounds cell groups remain steady in the same levels as to those of erastin (Figure 
105).   
 
Figure 105: The ability of the control compounds; SK-4C1 and SK-4C2 c to protect from 
ferroptosis been induced by erastin. LUHMES cells have been exposed to a range of 12.5-500 
µM concentrations of each compound prior to the addition of erastin (1.25 µM). LUHMES 
cells were labelled with Calcein-AM (1 µM) and H-33342 (1 µg/ mL). Images were collected 
using automated microscome. All calcein positive pixels outside of these masks (somatic area) 
were counted as neurite area.    
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8.6 Antioxidant properties of SK-n. 
8.6.1 Interaction of the SK-n compounds with superoxide  
 
The neuroprotective capacity of the synthesised SK-n compounds is shown and validated in 
the previous sections. In this section, an attempt to document any antioxidant potency (by 
means of ROS or RNS scavenging) towards the deamination of the mode of action of 
compounds is presented. Primarily the ability of the SK-n compounds to interact with trap 
superoxide radicals has been examined in LUHMES cells, using xanthine oxide alone with its 
substrate as a source of superoxide anions (Figure 106A). 
 
Figure 106: (A) Generation of superoxide radicals by the reduction of molecular oxygen and 
oxidation of hypoxanthine into xanthine in a reaction catalysed by xanthine oxidase. (B) 
Briefly, LUHMES cells were treated with the SK-n compounds (0.1-100 µM) in the presence 
of xanthine oxidase (1 mU/ mL), hypoxanthine (500 µM) and DHE (5 µM). The levels of DHE 
A 
B 
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oxidation were representative for the Antioxidant capacity of SK-n compounds against 
superoxide anions.  
According to the results obtained, none of the examined compounds had the ability to trap 
superoxide anions, whereas the positive control (ascorbic acid) shown a massive superoxide 
scavenging at a concentration of 1 µM (Figure 106B) as it was demonstrated before.680–682 In 
the case of L-SK-4 and rac-SK-2, those findings are in agreement with the literature as it has 
been previously documented that 3, 4-HOPOs derivatives are extremely poor radical 
scavengers.441 In addition to this, Ramsaywack S and co-workers support this statement by 
proving with kinetics of radicals autoxidation that indeed HOPO are not antioxidant by 
trapping ROS as it has previously suggested.394,396,438 However, they can exert antioxidant 
capacity by preventing he radical oxidation catalysed by toxic metals.438 The application of 
these findings can be applied in this case, as the ability of the SK-n compounds to protect 
neuronal cells against the oxidative damage is not linked to ROS trapping. On the contrary, 
they protect neuronal cells by preventing the oxidation catalysed by both; Fe3+ and Cu2+ during 
the Haber-Weiss reaction (in a stoichiometric ratio 3:1 for complete redox 
silencing).417,434,438,440,441,443,444 Moreover, according to the literature, 3-hydroxy-2(1H)-
pyridinones (3, 2 HOPOs) are significantly better ROS traps compared to 3, 4-HOPOs and 
least active when compared to other classes of chelators including hydroxamic acids and 
phenols. In our case rac-SK-5, a 3, 2-HOPO was expected to demonstrate some scavenging 
activity, such observation has not been noticed.441 On the other hand, rac-SK-1, which shares 
the same pyranone core with maltol, was also expected to present some activity as it has been 
previously proven that maltol can exhibit some minor trapping activity (however more active 
compared to DFP).441 Finally, to the very best of our knowledge, there is exciting work that 
shows the ability of 1-hydroxy-2(1H)-pyridinones (1, 2-HOPO) to trap ROS.683 Although our 
data suggested that 1,2 HOPOs (by means of rac-SK-3) are not capable for trapping ROS.  
8.6.2 Interactions of SK-n compounds with peroxynitrite 
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The antioxidant capacity of the SK-n compounds to scavenge peroxynitrite species was 
assessed on LUHMES cells, using 3-Morpholinosydnonimine hydrochloride (SIN-1) as a 
generator of peroxynitrite (Figure 107A).  
 
 
  
A 
B 
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Figure 107: (A) Proposed mechanism for the formation of peroxynitrite species. Briefly, 
LUHMES cells were treated with the SK-n compounds (0.1-100 µM) in the presence of SIN-
1 (5 µM). As readout, DHR 123 (1 µM) was added and its oxidation was followed by the 
detection of Rhodamine fluorescence.  (B) Antioxidant capacity against peroxynitrite of 
known scavengers and chelators and (C) Antioxidant capacity of the SK- compounds against 
peroxynitrite species.  
The results suggested that all the examined compounds, except rac-SK-3 shown some 
antioxidant capacity against peroxynitrite species but not in the same magnitude (Figure 
107C). Namely, exposure of the LUHMES cells with rac-SK-1, 3 and 5 shown some decrease 
in the fluorescence intensity of rhodamine in a dose-depended manner (Figure 107C). 
However, the observed decreased is not of statistically significant even after treatment with 
100 µM of each compound. In contrast, exposure of the cells to rac-SK-2 and L-SK-4 
(respectively) shown a dramatic decrease in the rhodamine fluorescence intensity, in a dose-
depended manner, meaning that both compounds were able to counteract with peroxynitrite 
species or react with SIN-1 (Figure 107C). In addition to this, it seems that both compounds 
are significantly better peroxynitrite scavengers compared to desferoxamine and less active 
compared to uric and ascorbic acid (Figure 107B).684–687  Furthermore, more L-SK-4 and rac-
SK-2 shown a similar potency as DFP. This could be attributed to the fact that either the SK-
C 
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n compounds (as nucleophiles) reacted themselves with SIN-1, thus preventing the elimination 
of NO. and consequently, the formation of ONOO-. Additionally it has been previously shown 
that peroxynitrite can nitrate tyrosine at the ortho position. Initially, reaction of peroxynitrile 
with carbon dioxide lead to the formation nitrocarbonate (Figure 108). Homolysis of 
nitrocarbonate, generates carbonate and nitrite radical (Figure 108). Afterwards, the carbonate 
radical abstracts homolytically the phenolic proton of tyrosine, generating tyrosyl radicals. 
Then, it was suggested that the nitrite radical can react with the tyrosyl radical at the ortho 
position forming 3-nitrotyrosine. Beside this reaction, it has been previously demonstrated, 
that tyrosyl radicals can react with themselves and dimerised forming the oxidation product; 
3,3’-dityrosine.  (Figure 108).688–691 
 
Figure 108: Proposed tyrosine oxidation pathways.  Tyrosine is oxidised, by several oxidants, 
(eg CO3.-) forming the tyrosyl radical which can react further with nitrite radical yielding 
nitrotyrosine or dimerised into the respective 3,3’-dityrosine.  
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Bases on the above, it can be hypothesised that the SK-n compounds reacted with nitrite 
radicals and nitrated (Figure 109).  
            
Figure 109: Proposed nitration mechanism of  a 3, 4-HOPO.  
 
This could explain the reduction of peroxynitrite concentration. Since the pKa of the ipso 
hydroxyl group differs across the series of HOPOs that could explain the potency of 3,4-
HOPOs over the 3, 2- and 1, 2-HOPOs.  
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9 Final discussion  
9.1 Summary and Conclusions  
Due to high therapeutic potential of metal chelators against various types of cancer and 
neurodegenerative diseases, there is a need to develop novel ones or improved the already 
existing therapies in order to generate more robust compounds that would be able to reach the 
central nervous system (CNS) (in the case of PD) or the site of action while retaining their 
metal chelation properties [chelation of the redox active metals eg. Fe(III), Cu(II)]. Various 
mechanisms can be exploited to cross the BBB in order to reach the brain for the treatment of 
PD or brain metastatic cancers, a passive and several active routes eg. GLUT-1 and LAT-1 
transporters. Herein, a series of novel hydroxypyridinone (HOPO) based metal chelators 
including a 1,2-HOPO (rac-SK-3 and rac-SK-6), 3,2-HOPO (rac-SK-5 and rac-SK-7), 3,4-
HOPO (rac-SK-2, L and D-SK-4, rac-SK-8) and a hydroxypyranone (rac-SK-1) were 
designed, synthesised and characterised in terms of experimental calculation of their 
protonation constants (pKa) as well as their stability constant upon complexation with Fe(III), 
Cu(II) and Zn(III) and the exported data were in agreement with those of the literature which 
refers to closed analogues or parts of the molecule. The rational design behind the synthesis 
of this molecules was the introduction of an amino acid moiety in order to facilitate the 
transportation across the BBB (in case of PD) or the cell membrane (in case of melanoma 
cancer) using an active transport mechanism; the LAT-1 transporter, which has been shown 
that is overexpressed in BBB and in various cancer cells.  
The scientific impact of the current work is reflected in various sectors of medicinal chemistry 
and drug design. Initially, novel compounds (rac-SK-1, rac-SK-3, L/D-SK-4, rac-SK-7, L-
SK-8) have been synthesised and fully characterised. In addition to this, the biological 
evaluation of those compounds (rac-SK-1, rac-SK-2, rac-SK-3, L/D-SK-4, rac-SK-5) against 
an in vitro model of both melanoma cancer and PD, demonstrated a unique capacity to exhibit 
opposed dual mode action which includes in both cases the metal coordination and the 
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transportation through LAT-1. Additionally, it has been proven that these compounds can 
induce cytotoxicity against melanoma cancer and neuroprotection against PD. In addition to 
this, the extensive characterisation of the mode of cell death (in the case of cancer) shown 
significant insights into their mode of action. The outcome of this study, can lead us to the 
development of second generation of these compounds taking into consideration the structural 
optimization of the active compounds, aiming to reduce to EC50 value that is associate with 
their activity and place them on the radar of pharmaceutical companies as potential candidates 
for development. 
The biological evaluation of these (rac-SK-1, rac-SK-2, rac-SK-3, L/D-SK-4, rac-SK-5) 
molecules involved their screening against an in vitro model of malignant melanoma 
composed of human (A375, VVM1, Hs-294T) and rodent (B16F-10) melanoma cells as well 
as non-melanoma epidermoid carcinoma (A431) and immortalized, non-malignant 
keratinocyte (HaCaT) cells. The results obtained from the cytotoxicological assays revealed 
that the order of anticancer activity is as follow; L-SK-4 >>> rac-SK-2 ~ rac-SK-3 with the 
most active compound (L-SK-4) to have an EC50 of 100 µM at 48 hr of exposure. Our data are 
in agreement with the already existing data that are reported in the literature concerning the 
anticancer activity of L-mimosine and DFP (as both compounds exhibit structural similarity 
with L-SK-4).138,139 In example, the EC50 value of those compounds is ~100 µM when their 
cytotoxicity was examined in various cell lines of prostate, breast and lung cancer.692–696 
However, due to the general high EC50 value of L-SK-4 (100 µM) it can be concluded that 
overall the compound is not considered as cytotoxic. In example, cisplatin, which its anticancer 
capacity has been listed several times in the current literature, has an EC50 value of  ~6 µM on 
A375 whereas other chemotherapeutic drugs (that are used against melanoma) such as 
etoposide, topotecan and doxorubisine  have EC50 value of 10 µM, 1 µM and 35 µM 
respectively on the same working cell line (A375).697–699 
In addition to this, the effect of structural changes was reflected into the biological activity and 
capacity of the SK series. Namely, the fact the rac-SK-1, 2, 3 and 5 did not shown any activity 
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(at low concentrations) can be attributed to several factors. In example, it might be that the 
compounds exploited LAT-1, however they could not develop interactions with the active site 
of the transporter and therefore their transportation was prevented. Furthermore, the solvation 
effect might be another reason that influence the capacity of these compounds as the water 
molecules displacement from the active site of the LAT-1 transporter by the compounds is not 
energetically favoured.700 It has also been proven that the protonation state of these compounds 
at pH 7.4 can affect both the pFe value of the compounds (hence the metal binding) and also 
their transportation ability as LAT-1 transporter can accommodate neutral species, whereas 
rac-SK-1, 2, 3 and 5 are expected to be charged at physiological pH. Another possible factor 
that prevent the activity of these molecules can be attributed to possible formation of 
interactions with the proteins that are located in the cell surface and are responsible for the 
recognition of xenobiotics (eg p-glycoproteins).701,702 Interactions with such proteins can 
prevent their cellular uptake and hence its activity. Also, the lack of activity of these 
compounds might be due to a result of their rapid metabolism once they enter the cell. Also, 
the lack of activity of these compounds might be due to a result of the rapid metabolism once 
they enter the cell. 
Afterwards, the selectivity of this compound to target specifically melanoma cells and not the 
cancerous (control) cells, has also been evaluated and interestingly, the results shown a 
significant preference of cytotoxicity induction in melanoma cell line (A375) as the control 
cell lines (A431 and HaCaT) appeared to be more resistant to the treatment. The next part of 
the biological evaluation involved a descriptive characterisation of the mode of action of the 
active molecule using flow cytometry and western immunoblotting approach. The results 
suggested that at the given concentration of 100 µM the compound has the ability to elevate 
the levels of ROS almost three times higher compared to the untreated control with the effect 
being sustained over the course of 72 hr. The elevation of ROS levels was accompanied with 
cell cycle growth arrest at the G1 phase in a similar way as L-mimosine does and also the 
activation of both intrinsic and extrinsic apoptosis. Moreover, a detailed characterisation of 
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the induced oxidative stress has been constructed by measuring the levels of ROS induction in 
a various concentrations of drug at several time points proving that the maximum ROS of 
induction was denoted at 100 µM whereas at higher concentrations the ROS levels were 
dropped. Additionally, the ROS elevation was found to selectively been induced on melanoma 
cell lines (A375, VVM1, Hs-294T and B16F-10) rather than the control cell lines (A431 and 
HaCaT). Furthermore, the levels of lipid peroxidation (by means of MDA), protein 
carbonylation as well as the levels of DNA oxidative damage (by means of 8-OHdG) have 
been determined experimentally. The results shown that during the first 48 hr all the examined 
metabolites reached the maximum level and afterwards the effect either dropped or sustained 
whereas during the first 24 hr there was not any significant alteration regardless the elevation 
of ROS. Furthermore, the addition of ROS scavenger (GSH) confirmed that the apoptosis is 
ROS driven as ROS abolishment prevented the activation of apoptosis. A detailed 
metabolomic approach has confirmed significant changes in the lipidomic profile of A375 
cells, upon exposure to 100 µM L-SK-4 for 24 hr. The results shown that there was a 
significant elevation in the production of sphingolipids. To this end, we correlate that ROS 
induction with the activation of apoptosis and the sphingolipids elevation by the use of an 
inhibitor of the de novo synthesis of sphingolipids (myriosin). The overall relation suggests 
that upon exposure to L-SK-4, there is a massive increase in the production of ROS, which 
stimulated that biosynthesis of sphingolipids as an adaptation of the response mechanism of 
the cell. Afterwards, the elevation of sphingolipids and more specifically the elevation of 
ceramide triggers the direct activation of the extrinsic apoptosis via FASL activation and 
indirectly the activation of intrinsic apoptosis by means of mitochondrial depolarisation and 
formation of apoptosome. In addition to this, it appears that after 48 and 72 hr of exposure the 
cell is unable to counteract the amount of ROS that been produced as the oxidative stress is in 
a progressive stage, hence the apoptosis reached it maximum levels.  
The formation of ROS via redox cycle of hydrogen peroxide catalysed by Fe(III) or Cu(II) has 
been shown to contribute in the development of PD. Herein, it has been demonstrated that the 
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use iron chelators based on the HOPO core can act as neuroprotective agents against a variety 
of PD-induced neurotoxins including; 6-hydroxydopamine (6-OHDA), which generates 
superoxide radicals, 1-methyl-4-phenylpyridinium (MPP+), a mitochondrial complex I 
inhibitor, and the ferroptosis activator, erastin in an in vitro model of immortalised human 
dopaminergic neuronal precursor cells (LUHMES). The results suggested that the 
neuroprotective capacity of the compound varies across the different toxins. Namely, the 
neuroprotective effectiveness trend of the HOPO compounds against 6-OHDA was; rac-SK-
2 > L-SK-4 >>> rac-SK-5 whereas rac-SK-1 and rac-SK-3 were totally inactive. Additionally, 
the respective trend on MPP+ and erastin was rac-SK2 ~ L-SK-4 ~ rac-SK-3 >>> rac-SK-5 
and rac-SK-2 ~ 4 >> rac-SK-3 respectively. Once again rac-SK-1 and rac-SK-5 were not 
shown any neuroprotective ability. The possible reason that prevent there activity might be 
their protonation state at physiological pH, the solvation effect (that is related to the 
transporter) and also the development of interactions between the cell surface and the 
compounds. Furthermore, an attempt to characterise the antioxidant capacity of the chelators 
has been conducted by examining whether the compounds can act as superoxide and/or 
peroxynitrite scavengers. The results obtained suggested that none of the chelators could act 
as superoxide scavengers. Although it appeared that rac-SK-2 and L-SK-4 can act as 
peroxynitrite scavengers.  
In order to validate which structural features were essential for the transportation and the action 
of the compound, a series of control compounds of the potent L-SK-4 have also been designed 
and screened against both melanoma cancer as well as PD cell lines. The exported data 
documented that that the HOPO core is essential for the metal binding and the amino acid side 
vector for the transportation using the LAT-1 as the various control compounds didn’t show 
any anticancer activity against melanoma and or any neuroprotection against PD. Additionally, 
in order to confirm that the active compounds are using the LAT-1 transporter, A375 cells 
have been treated with both L-SK-4 and three competitive (non-specific)  LAT-1 substrates 
(BCH and L and D- 2-amino-3-(2-napthyl) propanoic acid)  and a LAT-1 inhibitor (L-
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thyroxin) (separately). The outcome of this analysis shown a significant cell rescue rather than 
cell death demonstrating in that way that the inhibition of the LAT-1, prevent the entrance of 
the molecule to the cell and hence its action. Therefore, the control compounds of the 
associated molecule supported the rational design behind it. These compounds, therefore, 
constitute a new develop on the therapeutic ability of HOPOs, that deserves further studies.  
9.2 Further studies 
This research has identified many avenues of interest that would lead in a better understanding 
of how metal chelators can have multiple mode of actions (eg, cytotoxicity against cancer, 
neuroprotection against PD) and how to design new improved compounds of this class.  
9.2.1 Novel Molecules  
 
One of the most promising research direction that maybe highly beneficial to pharmaceutical 
sector is the synthesis of more lipophilic analogues of the above series capable to penetrate 
BBB that would lower the EC50 value and increase the therapeutic index using computational 
modelling tools based on the newly discovered structure of human LAT-1. This structural 
optimisation of the active compounds would facilitate the transportation to the brain, hence it 
could be used for the treatment of both neurodegenerative diseases and brain metastatic 
cancers (Figure 110A, B, C). Additionally, the synthesis of  a glycosylated masked analogue 
of L-SK-4 would be noteworthy compound as it would combined essential features for both 
activity and transportation including; the HOPO core, the pro-chelator masked with glucose 
hydroxyl group, and the amino acid vector that would allow the transportation through LAT-
1. These chemical modifications would lead to the formation of a prodrug that would 
hydrolysed in situ and release the active L-SK-4 (Figure110D). Alternatively, the addition of 
sugar maybe facilitates the transportation through the GLUT-1 transporter.  
 
260 | P a g e  
 
 
Figure 110: Proposed compounds with increased lipophilicity and a suggested pro-drug form 
of L-SK-4 in an attempt to optimise its structure for the improvement of BBB penetration.  
9.2.2 Mode of action 
 
In the case of cancer evaluation, we could potentially measure the liable iron pool in the 
different organelles and also calculate how much of the active compound enters the cell in 
order to have a better understating of the mode of action of the chelator; L-SK-4. This can give 
insights into the stoichiometry of the total iron and the chelator and consequently an 
understanding whether the chelator acts as pro-oxidant or anti-oxidant. Additionally, a 
metabolic analysis of the active compound could be of high interest as the mode action could 
be relied on its metabolites rather than the actual molecule itself. Another potential orientation 
and improvement of the current study would be the combinational therapy, where the 
synthesised HOPOs would be administered in combination with already existing 
chemotherapeutic agents and try to identify synergies. Furthermore, the use of in vivo models 
could be a powerful tool that would allow the determination of both the pharmacokinetic and 
the pharmacodynamics properties of the synthesised molecules.  
From the point of view of application of metal chelators against PD, a potent development of 
the research would be the use of animal models (in vivo) that we could use the loco motor 
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phenotype as an end point of the activity of the compounds. Furthermore, the ability of the 
synthesized molecules to act as COMT inhibitors (due to the structural similarities with the 
currently existing COMT inhibitors) could give a better understanding on the mode of action 
of these molecules. Finally, racemic resolution of rac-SK-2 and rac-SK-3 followed by 
biological evaluation of the pure enantiomers could potentially increase the therapeutic index 
and lower the EC50. 
. 
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10 Experimental procedures – organic synthesis 
10.1 Equipment and chemical reagents.  
 
All chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), Alfa Aesar 
(Lancashire, UK), Fluorochem (Derbyshire, UK), TCI (Oxford, UK) and were used without 
any further purification unless otherwise specified. All chemical solvents were purchased from 
Fisher Scientific (Hampton, NH, USA) and Sigma Aldrich (St. Louis, MO, USA), at either 
HPLC or reagent grade. When required, solvents were dried over activated 3 or 4 Å molecular 
sieves. NMR Spectroscopy was performed on JEOL ELS400 Delta Spectrometer at 
frequencies of 400 MHz for 1H NMR, 101 MHz for 13C NMR. Chemical shifts were recorded 
as parts per million (ppm) with tetramethylsilane (TMS) as the internal standard. Solvents used 
included deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), 
deuterated methanol (CD3OD), deuterated water (D2O) and deuterated TFA (CF3CO2D). 
Chemical shifts were observed with integrals, splitting and J values, multiplicity of the signals 
were recorded as singlet (s), doublet (d), triplet (t), quartet (q). In addition, the multiplicities 
(which have further coupling) were recorded e.g. double doublet (dd). For broad signal (br) is 
indicated. High Resolution Mass Spectrometry (HRMS) was carried out at Northumbria 
University using Thermo Q-Exactive spectrometer with electrospray ionisation (ESI) (Thermo 
Fisher Scientific, Cramlington, UK). High Performance Liquid Chromatography (HPLC) 
(Agilent Technologies, 1260 Infinity) analysis was carried out at Northumbria University 
using Phenomenex Column (HYPERSIL 5u C18, 150x4.60 mm). Automated Flash 
Chromatography was performed on Biotage® Isolera One using Biotage® SNAP-Ultra flash 
chromatography cartridges 10-100g size (Biotage, Uppsala, Sweden).  Melting points were 
recorded in open capillary tubes using a Stanford Research System MPa160 Melting Point 
Apparatus and are reported uncorrected.  
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10.2 Synthesis of 1.2 HOPOs 
10.2.1 Synthesis of rac-SK-3 
 
10.2.1.1 Synthesis of 5-bromo-2-methoxypyridine (1) 
 
 
The product was prepared based upon a literature procedure.500 In a solution of 2-
methoxypyridine (15 g, 138 mmol, 1 eq) in acetonitrile (415 mL), N-bromosuccinimide (30 g, 
169 mmol, 1.22 eq) was added and the resulting mixture was refluxed for 20 hr. Upon 
completion of the reaction, as indicated by TLC (SiO2, eluent: Petroleum Ether 60-80: Ethyl 
acetate, 8:2; UV-light), the mixture was filtered over a pad of silica. The solvent was 
evaporated, under reduced pressure, affording the crude product as orange oil which was then 
purified by an automated flash chromatography column (Isolera); Rf= 0.83 (Petrol Ether 60-
80: Ethyl acetate, 95:5; UV light) affording intermediate (1) as a pale-yellow oil (4.7 g, 25 
mmol, 18%). 1H-NMR (400 MHz, CDCl3) δH: 3.90 (s, 3H, H-7), 6.64 (d, J= 8.8 Hz, 1H, H-3), 
7.61 (dd, J=2.8 Hz, J= 8.8 Hz, 1H, H-4), 8.18 (d, J= 2.8 Hz, 1H, H-6) ppm; 13C-NMR (100 
MHz, CDCl3) δC: 53.6 (C-7), 111.6 (C-5), 112.5 (C-3), 140.9 (C-4), 147.5 (C-6), 162.8 (C-2) 
ppm. 
 
10.2.1.2 Synthesis of 6-methoxypyridine-3-carbaldehyde (2) 
 
 
The product was prepared based upon a literature procedure.500 In a solution of 5-bromo-
2-methoxypyridine (1) (4.7 g, 25 mmol, 1 eq) in dry diethyl ether (50 mL) and under inert 
atmosphere, n-Butyl Lithium (2.5 M in hexanes, 12 mL, 30 mmol, 1.2 eq) was added at -35oC, 
and stirred until the formation of a brown precipitate. Then, dry N,N-dimethyl formamide (5.4 
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mL, 70 mmol, 2.8 eq) was added dropwise for 5 min. The resulting mixture was stirred at 0oC 
(~2 hr), under inert atmosphere. Upon completion of the reaction, as it was indicated by TLC 
(SiO2, eluent Petroleum Ether 60:80: ethyl acetate, 80:20; UV light), the reaction was 
quenched by aqueous solution of ammonium chloride (5%, 25 mL). The aqueous layer was 
extracted with dichloromethane (3 x 50 mL). The combined organic extracts were dried over 
magnesium sulphate and concentrated under reduced pressure, forming the crude product as 
orange oil. The crude product was purified by automated flash chromatography column 
(Isolera); Rf = 0.43 (Petrol Ether 60-80: diethyl ether, 60:40; UV light) affording intermediate 
2 as yellow crystals (2.53 g, 16.7 mmol, 67%). Mp: 42-44oC, [lit: 42-46oC].500 1H-NMR (400 
MHz, CDCl3) δH: 4.03 (s, 3H, H-9), 6.84 (d, J= 8.4 Hz, 1H, H-3), 8.05 (dd, J= 2.4 Hz, J= 8.4 
Hz, 1H, H-4), 8.63 (d, J= 2.4 Hz, 1H, H-6), 9.96 (s, 1H, H-8) ppm; 13C-NMR (100 MHz, 
CDCl3) δC: 54.4 (C-9), 112.2 (C-4), 126.7 (C-6), 137.5 (C-5) 153.5 (C-3), 167.8 (C-2), 189.6 
(C-7) ppm.  
 
10.2.1.3 Synthesis of 4-[(6-methoxypyridin-3-yl)methylidene]-2-methyl-4,5-dihydro-
1,3-oxazol-5-one (3) 
 
 
The synthesis was performed according to a modified method that was previously published.503 
Briefly, in a solution of 6-methoxypyridine-3-carbaldehyde (2) (1.84 g, 12.17 mmol, 1 eq) in 
acetic anhydride (8 mL), a sample of N-acetyl glycine (2.04 g, 17.44 mmol, 1.5 eq.) and a 
sample of sodium acetate (1.5 g, 18.29 mmol, 1.5 eq) were added sequentially. The resulting 
mixture was stirred at 125oC for 4 hr. Upon completion of the reaction, the mixture was poured 
into ice-water and stirred for a further 1 hr leading to the formation of a yellow solid of the 
crude product which was collected by vacuum filtration, washed with water and dried in air. 
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The crude product was purified by recrystallization from methanol affording the pure product 
(3) as pale-yellow solid (1.66 g, 7.6 mmol, 63%). Mp: 152-154oC. 1H-NMR (400 MHz, 
CDCl3) δH: 2.40 (s, 3H, H-11), 4.00 (s, 3H, H-12), 6.83 (d, J= 8.8 Hz, 1H, H-3), 7.12 (s, 1H, 
H-7), 8.6 (d, J= 2.4 Hz, H-6), 8.67 (dd, J= 2.4 Hz, J= 8.8 Hz. H-4) ppm; 13C-NMR (100 MHz, 
CDCl3,) δC: 15.8 (C-11), 54.1 (C-12), 111.8 (C-3), 123.3 (C-7), 128.1 (C-5), 132.0 (C-8), 140.9 
(C-4), 152.1 (C-6), 165.4 (C-10), 165.7 (C-9), 167.7 (C-2) ppm. HRMS (ESI) for C11H10N2O3; 
Theoretical [M+H]: 219.0769.  Measured [M+H]: 219.0766. 
 
10.2.1.4 Synthesis of 2-acetamido-3-(6-methoxypyridin-3-yl)prop-2-enoic acid (4) 
 
 
The synthesis was performed according to a modified method previously published.505  Briefly, 
a sample of 4-[(6-methoxypyridin-3-yl)methylidene]-2-methyl-4,5-dihydro-1,3-oxazol-5-one 
(3) (2 g, 9.16 mmol) was dissolved in a mixture of water (30 mL)/acetone (50 mL) and the 
resulting mixture was refluxed for 9 hr. The solution was allowed to cool down to RT and then 
was concentrated, under reduced pressure, forming the crude product as yellow solid. The 
crude product was purified by recrystallization from methanol affording (4) as pale brown 
crystals (1.76 g, 7.45 mmol, 81%). Mp: 162-164oC. 1H-NMR (400 MHz, DMSO-d6) δH: 2.00 
(s, 3H, H-10), 3.89 (s, 3H, H-13), 6.88 (d, J= 8.8 Hz, 1H, H-3), 7.25 (s, 1H, H-7), 7.98 (dd, J= 
2.4 Hz, J= 8.8 Hz, 1H, H-4), 8.40 (d, J= 2.4 Hz, 1H, H-6), 9.48 (s, 1H, H-12) ppm; 13C-NMR 
(100 MHz, DMSO-d6) δC: 23.2 (C-10), 54.0 (C-13), 111.1 (C-3), 124.1 (C-7), 127.1 (C-5), 
128.7 (C-8), 139.8 (C-4), 149.7 (C-6), 164.1 (C-10), 166.8 (C-9), 169.7 (C-2) ppm. HRMS 
(ESI) for C11H12N2O4; Theoretical [M+H]: 237.0875. Measured [M+H]: 237.0871.  
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10.2.1.5 Synthesis of rac-2-acetamido-3-(6-methoxypyridin-3-yl)propanoic acid (5)  
  
 
In a suspension of 2-acetamido-3-(6-methoxypyridin-3-yl)prop-2-enoic acid (4) (1.76 g, 7.45 
mmol) in methanol (50 mL), Pd/C (10%) was added. The reaction mixture was stirred under 
hydrogen gas at RT for 9 hr. Upon completion of the reaction, the solution mixture was 
filtrated over a pad of Celite and concentrated under reduced pressure forming a yellow slurry. 
The resulting slurry was purified by automated flash chromatography column (IsoleraTM 
Biotech) (SiO2); Rf = 0.89 (dichloromethane: methanol 9:1; UV light) affording (5) as a pale-
yellow oil which was solidified on standing (940 mg, 3.94 mmol, 53%). Mp: 181-183oC. 1H-
NMR (400 MHz, CD3OD) δH: 2.01 (3H, s, H-10), 2.95-2.30 (1H, m, H-7), 3.20-3.25 (m, 1H, 
H-7), 3.95 (s, 3H, H-13), 4.70-4.73 (m, 1H, H-8), 6.83 (d, J= 8.4 Hz, 1H, H-3), 7.67 (dd, J= 
2.4 Hz, J= 8.4 Hz, 1H, H-4), 8.15 (d, J= 2.4 Hz, 1H, H-6) ppm; 13C-NMR (100 MHz, CD3OD) 
δC: 21.6 (C-10), 34.1 (C-7), 53.4 (C-13), 54.1 (C-8), 110.7 (C-3), 126.4 (C-4), 140.7 (C-5), 
147.2 (C-6), 164.0 (C-2), 172.5 (C-11), 173.7 (C-9) ppm. HRMS (ESI) for C11H14N2O4; 
Theoretical [M+H]: 238.0953. Measured [M+H]: 238.0961. 
 
10.2.1.6 Synthesis of rac-5-(2-carboxy-2-acetamidoethyl)-2-methoxypyridin-1-ium-1-
olate (6) 
 
In a suspension of 2-acetamido-3-(6-methoxypyridin-3-yl)propanoic acid (5) (560 mg, 2.35 
mmol, 1 eq) in a solution mixture of dichloromethane/methanol (9:1, 30mL) a sample of  m-
chloroperoxy benzoic acid (1 g, 5.8 mmol, 2.5 eq) was added. The resulting mixture was stirred 
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at RT for 48 hr under nitrogen atmosphere. Upon completion of the reaction, the solvents were 
removed under reduced pressure and the resulting yellowish slurry residue was washed several 
times with diethyl ether. Filtration of the product led to isolation of the title compound (6) as 
a white powder (460 mg, 1.80 mmol, 77%). Mp: 189-192oC. 1H-NMR (400 MHz, DMSO-d6) 
δH: 1.79 (s, 3H, H-10), 2.71-2.77 (m 1H, H-7),  2.95-2.99 (m, 1H, H-7), 3.93 (s, 3H, H-13), 
4.38-4.43 (m, 1H, H-8),  7.13 (d, J= 8.7 Hz, 1H, H-12), 7.23 (dd, J= 2.0 Hz, J= 8.7 Hz, 1H, 
H-3), 8.11 (d, J= 2.0 Hz, 1H, H-6), 8.23 (d, 1H, J=8.7 Hz, H-4) ppm; 13C-NMR (100 MHz, 
DMSO-d6) δC: 22.8 (C-10), 33.2 (C-7), 53.2 (C-8), 57.5 (C-13), 109.0 (C-3), 128.1 (C-6), 
128.3 (C-5), 139.9 (C-4), 157.5 (C-2), 169.8 (C-11), 173.2 (C-9) ppm. HRMS (ESI) for 
C11H15N2O5; Theoretical [M+H]: 255.0908. Measured [M+H]: 255.0912. 
 
10.2.1.7 rac- 2-amino-3-(1-hydroxy-6-oxo-1,6-dihydropyridin-3-yl)propanoic acid (rac-
SK-3)  
 
A sample of rac-5-(2-carboxy-2-acetamidoethyl)-2-methoxypyridin-1-ium-1-olate (6) (460 
mg, 1.80 mmol) was dissolved in concentrated solution of HCl (20 mL). The resulting mixture 
was refluxed for 3 hr. Upon completion of the reaction, the mixture was concentrated to 
dryness leading to the formation of brownish crystals the target molecule (300 mg, 1.51 mmol, 
84%). Mp: 120-122oC. 1H-NMR (400 MHz, D2O/CF3COOD 8:2) δH: 2.96-3.10 (2H, m, H-7), 
4.13 (d, J= 4.8 Hz, 1H, H-8), 6.63 (t, J= 9.2 Hz, 1H, H-4), 7.43 (d, J= 9.2 Hz, 1H, H-3), 7.94 
(s, 1H, H-6), 8.49 (s, 3H, H-10) ppm; 13C-NMR (100 MHz, D2O/CF3COOD 8:2) δC: 31.4 (C-
7), 52.9 (C-8), 118.9 (C-3), 136.6 (C-5), 140.7 (C-6), 140.8 (C-4), 157.8 (C-2), 170.4 (C-9) 
ppm. For analytical purposes, a small portion of the titled molecule was dissolved in water and 
basified (pH 5.0) with ammonium hydroxide solution and kept at 5oC for several weeks until 
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precipitation. HRMS (ESI) for C8H10N2O4; Theoretical [M+H]: 199.0718. Measured [M+H]: 
199.0711. 
10.2.2 Synthesis of rac-SK-6 
 
10.2.2.1 Synthesis of 4-carboxy-2-chloropyridin-1-ium-1-olate (30) 
 
 
A sample of 2-chloroisonicotinic acid (5.1 g, 32.37 mmol) was dissolved in trifluoroacetic 
acid (90 mL) and mixed with hydrogen peroxide (50% in water, 12 mL). The resulting solution 
was heated at 80 OC overnight. Upon completion of the reaction, half of the volume was 
evaporated under reduced pressure and then diethyl ether (200 mL) was added leading to the 
precipitation of a beige powder of the title compound (30) that was isolated by vacuum 
filtration (4.92 g, 28.35 mmol, 88%). Mp: 178-183 OC [lit. 175-185 OC].703 1H-NMR (400 
MHz, DMSO-d6) δH: 7.76 (s, 1H, H-3), 7.78 (d, J=2.4 Hz, 1H, H-5), 8.55 (d, J= 2.4 Hz, 1H, 
H-6) ppm; 13C-NMR (100 MHz, DMSO-d6) δC:125.0 (C-5), 127.6 (C-2), 127.8 (C-3), 141.2 
(C-6), 141.3 (C-4), 164.6 (C-7) ppm. 
10.2.2.2 Synthesis of 1-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylic acid (31) 
 
 
The product was prepared based upon a literature procedure.704 A sample of 4-carboxy-2-
chloropyridin-1-ium-1-olate (30) (3.94 g, 51.51 mmol) was dissolved in aqueous solution of 
potassium hydroxide (10%, 150 mL). The resulting solution mixture was heated at 70oC 
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overnight. Then it was allowed to cool at RT and concentrated hydrochloric acid was added 
until pH 1. White crystals of the title compound (31) were precipitated and collected by 
filtration and allowed to dry in air (7.34, 47.38 mmol, 92%). Mp: 179-182oC. 1H-NMR (400 
MHz, DMSO-d6) δH: 6.58 (dd, J= 2.0 Hz, 7.0 Hz, 1H, H-5), 6.99 (d, J= 2.0 Hz, 1H, H-3), 8.04 
(d, J= 7.0 Hz, 1H, H-6) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 103.5 (C-5), 150.5 (C-3), 
136.9 (C-6), 140.2 (C-4), 157.9 (C-2), 166.0 (C-7) ppm. HRMS (ESI) for C6H5NO4; 
Theoretical [M+H]: 156.0296.  Measured [M+H]: 156.0292. 
10.2.2.3 Synthesis of methyl 1-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylate (32) 
 
 
 
 
The product was prepared based upon a similar literature procedure.704,525 In a suspension of 
1-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylic acid (31) (7 g, 45.13 mmol, 1 eq) in dry 
methanol (180 mL), cooled to 0 OC, thionyl chloride (15 mL, 190 mmol, 14.6 eq) was added 
dropwise over a period of 1 hr. Then resulting mixture was refluxed for 6 hr. Upon completion 
of the reaction, solvents were evaporated to dryness and the resulting residue was co-
evaporated several times with toluene affording the title compound (32) as off-white crystals 
(7.25, 42.56 mmol, 95%). Mp: 190-191oC. 1H-NMR (400 MHz, DMSO-d6) δH: 2.46 (s, 3H, 
H-8), 6.66 (d, J= 6.8 Hz, 1H, H-5), 6.99 (br, 1H, H-3), 8.06 (d, J= 6.8 Hz, 1H, H-6) ppm; 13C-
NMR (100 MHz, DMSO-d6) δC: 53.4 (C-8), 103.3 (C-5), 120.5 (C-3), 137.4 (C-6), 138.8 (C-
4), 157.8 (C-2), 164.9 (C-7) ppm. HRMS (ESI) for C7H7NO4; Theoretical [M+H]: 170.0453.  
Measured [M+H]: 170.0443. 
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10.2.2.4 Synthesis of methyl 1-(benzyloxy)-2-oxo-1,2-dihydropyridine-4-carboxylate 
(33) 
 
 
The product was prepared based upon a similar literature procedure with some 
modifications.705 In a suspension of potassium carbonate (18 g, 129 mmol, 3 eq.) in dry N,N-
dimethylformamide (160 mL), methyl 1-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylate 
(32) (7.25, 42.86 mmol, 1 eq) and benzyl bromide (6.1 mL, 51.43 mmol, 1.2 eq) was added 
The resulting solution mixture was stirred at 80oC for 16 hr and then it was allowed to cool at 
RT. The excess of solvents were removed under reduced pressure and the resulting slurry was 
taken up in dichloromethane (30 mL) and washed with water (2x25 mL). The organic layer 
was dried over magnesium sulphate and concentrated under reduced pressure affording the 
crude product as black oil. Purification by automated flash chromatography column (Isolera); 
Rf = 0.52 (Petrol Ether 60-80: ethyl acetate, 1:1; UV light) title compound (33) as a dark orange 
oil (6 g, 23.14 mmol, 54%). 1H-NMR (400 MHz, CDCl3) δH: 3.88 (s, 3H, H-8), 5.28 (s, 2H, 
H-9), 6.40 (dd, J= 2.4 Hz, J= 5.2 Hz, 1H, H-5), 7.13 (d, J= 2.4 Hz, 1H, H-3), 7.32 (d, J= 5.2 
Hz, 1H, H-6), 7.33-7.4 (m, 5H, H-11, H-12, H-13) ppm; 13C-NMR (100 MHz, CDCl3) δC : 
53.0 (C-8), 78.5 (C-9), 103.2 (C-5), 124.6 (C-2), 128.4 (Ar), 128.9 (Ar), 128.9 (Ar), 129.6 (Ar), 
130.2 (Ar), 133.4 (Ar), 158.4 (C-2), 164.7 (C-7) ppm. HRMS (ESI) for C14H13NO4; Theoretical 
[M+H]: 260.0922.  Measured [M+H]: 260.0936. 
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10.2.2.5 Synthesis of 1-(benzyloxy)-4-(hydroxymethyl)-1,2-dihydropyridin-2-one (34) 
 
 
In a suspension of methyl 1-(benzyloxy)-2-oxo-1,2-dihydropyridine-4-carboxylate (33) (5 g, 
19.28 mmol, 1 eq), in dry tetrahydrofuran (100 mL), sodium borohydride (6 g, 139 mmol, 7.2 
eq) was added. The resulting mixture was refluxed for 15 min. Then methanol (12 mL) was 
added dropwise at refluxing temperature for a period of 2 hr. The reflux was continued for 
further 20 min and upon completion of the reaction as it was indicated by TLC (SiO2, eluent; 
hexanes: ethyl acetate, 5:2; UV light) the reaction mixture was cooled to 0OC and it was 
quenched carefully by the addition of a saturated aqueous solution of ammonium chloride (25 
mL). The resulting solution was stirred for further 15 min before it was concentrated under 
reduced pressure. The resulting slurry residue was extracted from dichloromethane (3x50 mL). 
The combined organic extracts were dried over magnesium sulphate and concentrated under 
reduced pressure affording compound 34 as a pale yellow oil (4.22 g, 18.25 mmol, 95 %), Rf= 
0.35 that solidified on standing. Mp: 49-52oC.  1H-NMR (400 MHz, CDCl3) δH: 4.43 (s, 2H, 
H-7), 4.64 (s, 1H, H-8), 5.17 (s, 2H, H-9), 5.92 (d, J= 5.2 Hz, 1H, H-5), 6.65 (s, 1H, H-3), 7.03 
(d, J= 5.2 Hz, 1H, H-6), 7.25-7.35 (m, 5H, H-11, H-12, H-13) ppm; 13C-NMR (100 MHz, 
CDCl3) δC: 62.4 (C-7), 78.7 (C-9), 104.2 (C-5), 117.3 (C-3), 127.0 (Ar), 128.5 (Ar), 128.8 (Ar), 
129.5 (Ar), 134.7 (C-6) 152.1 (C-4), 158.9 (C-2) ppm. HRMS (ESI) for C13H13NO3; 
Theoretical [M+H]: 232.0973.  Measured [M+H]: 232.0976. 
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10.2.2.6 Synthesis of [1-(benzyloxy)-2-oxo-1,2-dihydropyridin-4-yl]methyl 4-
methylbenzene-1-sulfonate (38)  
 
 
The product was prepared based upon a literature procedure with some modifications.705 In a 
suspension of 1-(benzyloxy)-4-(hydroxymethyl)-1,2-dihydropyridin-2-one (34) (830 mg, 3.72 
mmol, 1 eq) in tetrahydrofuran (10 mL) potassium hydroxide (320 mg, 5.56 mmol, 1.5 eq.) in 
water (3 mL) was added. The resulting solution was cooled to 0OC and then tosyl chloride 
(786 mg, 4.12 mmol, 1.2 eq) in tetrahydrofuran (10 mL) was added dropwise over a period of 
30 min. The resulting solution was stirred until it reached RT. Upon completion of the reaction 
as it was indicated by TLC (SiO2, eluent; petroleum ether 60:80: ethyl acetate, 1:1; UV light) 
the reaction was quenched by the addition of saturated aqueous solution of sodium hydrogen 
carbonate (20 mL) and extracted from ethyl acetate (3x50 mL). The combined organic extracts 
were dried over magnesium sulphate and concentrated under reduced pressure, affording the 
title compound (38) as a white solid (1.0 g, 2.59 mmol, 70%). Mp: 159-163oC. 1H-NMR (400 
MHz, CDCl3) δH: 2.44 (s, 3H, H-18), 4.8 (s, 2H, H-7), 5.24 (s, 2H, H-9), 5.86 (d, J= 7.2 Hz, 
1H, H-5), 6.52 (s, 1H, H-3), 7.06 (d, J= 7.2 Hz, 1H, H-6), 7.25-7.36 (m, 7H, H-11, H-12, H-
13, H-16), 7.80 (d, J= 8.4 Hz, 2H, H-15) ppm; 13C-NMR (100 MHz, CDCl3) δC: 21.8 (C-18), 
68.5 (C-7), 78.6 (C-9), 102.8 (C-5), 120.1 (C-3), 120.2 (Ar), 127.1 (Ar), 128.1 (Ar), 128.7 (Ar), 
128.9 (Ar), 130.2 (C-6), 133.2 (Ar), 137.0 (C-4), 140.3 (Ar), 146.2 (C-4), 158.2 (C-2) ppm. 
HRMS (ESI) for C20H19NO5S; Theoretical [M+H]: 386.1062.  Measured [M+H]: 386.1039. 
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10.2.2.7 Synthesis of 1,3-diethyl 2-{[1-(benzyloxy)-2-oxo-1,2-dihydropyridin-4-
yl]methyl}-2-acetamidopropanedioate (40) 
 
The product was prepared based upon a similar literature procedure with some 
modifications.527 In a solution of diethyl acetamidomalonate (820 mg, 3.77 mmol, 1.1 eq) in 
dry dioxane (30 mL), potassium tert-butoxide (460 mg, 4.1 mmol, 1.2 eq) were added and the 
resulting solution was heated at 60oC for 2 hr. Afterwards, a solution of [1-(benzyloxy)-2-oxo-
1,2-dihydropyridin-4-yl]methyl 4-methylbenzene-1-sulfonate (38) (1.43 g, 3.5 mmol, 1 eq) in 
dry dioxane (10 mL) was added dropwise at the same temperature over a period of 2 hr. The 
resulting solution mixture was allowed to reflux for 48 hr. Upon completion of the reaction, 
solvents were evaporated to dryness and the resulting slurry was taken up in water and 
extracted with dichloromethane (3x50 mL). The combined organic extracts were dry with 
magnesium sulphate and concentrated under reduced pressure affording the title compound 
(40) as a yellow oil (1.01 g, 2.55 mmol, 73%). 1H-NMR (400 MHz, CDCl3) δH: 1.29 (t, J= 7.2 
Hz, 6H, H-11), 2.02 (s, 3H, H-14), 4.26 (q, J= 7.2 Hz, 4H, H-10), 4.53 (s, 2H, H-7), 5.17 (s, 
2H, H-15), 5.58 (d, J= 6.8 Hz 1H, H-5), 6.63 (s, 1H, H-3), 6.65 (d, J= 6.8 Hz, 1H, H-6),7.24-
7.38 (m, 5H, H-17, H-18, H-19) 7.27 (s, 1H, H-12) ppm; 13C-NMR (100 MHz, CDCl3) δC: 
14.1 (C-11), 22.4 (C-14), 40.1 (C-7), 60.7 (C-10), 62.5 (C-8), 77.1 (C-9), 114.1 (C-5), 120.0 
(C-3), 128.3 (Ar), 128.9 (Ar), 129.7 (Ar), 134.82 (Ar), 142.3 (C-6), 150.1 (C-4), 159.3 (C-2), 
168.4 (C-9), 170.0 (C-13) ppm.  HRMS (ESI) for C22H26N2O7; Theoretical [M+H]: 431.1818.  
Measured [M+H]: 431.1823. 
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10.2.2.8 Synthesis of 2-amino-3-(1-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)propanoic 
acid (rac-SK-6) 
 
A suspension of 1,3-diethyl 2-{[1-(benzyloxy)-2-oxo-1,2-dihydropyridin-4-yl]methyl}-2-
acetamidopropanedioate (40) (500 mg, 1.16 mmol) in HCl (8M, 20 mL) was allowed to reflux 
for 9 hr. Upon completion of the reaction, the solvents were removed under reduced pressure, 
forming a brown solid which was dissolved in water (20 mL). The solution was treated with 
charcoal, filtered and the pH of the filtrate was adjusted to 5 by the dropwise addition of conc. 
ammonium hydroxide. The resulting solution was kept at 5oC for 48 hr until complete 
precipitation. The titled compound (rac-SK-6) was afforded as yellow/brown crystals (53 mg, 
0.26 mmol, 23%). Mp: 189-193oC. 1H-NMR (400 MHz, D2O/CF3COOD) δH: ppm; 2.93-3.11 
(m, 2H, H-7), 4.19 (t, J= 4.8 Hz, 1H, H-8), 6.29-6.31 (dd, J= 7.2 Hz, J= 2.0 Hz, 1H, H-5), 6.48 
(d, J= 2.0 Hz, 1H, H-3), 7.69 (d, J= 7.2 Hz, 1H, H-6) ppm; 13C-NMR (100 MHz, 
D2O/CF3COOD) δC: 35.9 (C-7), 53, 1 (C8), 108.9 (C-5), 115.92 (C-3), 136.3 (C-6), 152.2 (C-
4), 158.4 (C-2), 173.3 (C-9) ppm. HRMS (ESI) for C8H10N2O4; Theoretical [M+H]: 199.0718.  
Measured [M+H]: 199.0709. 
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10.3 Synthesis of 3,2-HOPOs 
 
10.3.1 Synthesis of rac-SK-5 
 
10.3.1.1 Synthesis of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (41) 
 
 
The synthesis was performed according to a modified method previously published.706 A 
sample of kojic acid (20 g, 141 mmol, 1 eq) was dissolved in methanol (30 mL) and mixed 
with a solution of sodium hydroxide (6.2 g, 155 mmol) in water (30 mL). The mixture was 
heated to reflux for 40 min followed by the dropwise addition of benzyl bromide (19 mL, 155 
mmol, 1.1 eq). The mixture was allowed to reflux overnight. Upon completion of the reaction, 
the solvents were evaporated under reduced pressure to give the crude product as yellowish 
crystals which were washed with diethyl ether and then with water. The crude product was 
recrystallized from isopropanol and dried in the air affording the pure product (41) as white 
crystals (29 g, 125 mmol, 87%). Mp: 126-129oC [lit: 128-130oC].706 1H-NMR (400 MHz, 
DMSO-d6) δH: 4.30 (s, 2H, H-7), 4.95 (s, 2H, H-6), 6.20 (s, 1H, H-4), 7.25-7.37 (m, 6H, H-1, 
H-9, H-10, H-11) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 60.3 (C-6), 71.0 (C-7), 111.6 (C-
1), 128.6 (Ar), 128.7 (Ar), 128.9 (Ar), 136.6 (C-8), 141.6 (C-4), 147.1 (C-3), 168.6 (C-3), 
173.8 (C-2) ppm.  
10.3.1.2 Synthesis of 5-(benzyloxy)-2-(hydroxymethyl)-1,4-dihydropyridin-4-one (42)  
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Prepared according to the literature.498 In a stainless-steel bomb, concentrated ammonium 
hydroxide (40 mL) was mixed with a sample of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-
4-one (41) (25 g, 107.64 mmol). The resulting mixture was heated at 120oC for 5 hr. Upon 
completion of the reaction, volatiles were removed under reduced pressure. The resulting 
slurry was extracted with hot acetone, filtrated and washed with excess of hot acetone 
affording the titled compound (42) as brown crystal (20 g, 86.48 mmol, 80%). M.p: 228-232oC 
[lit. 230-235oC]498. 1H-NMR (400 MHz, DMSO-d6) δH: 4.34 (s, 2H, H-8), 5.00 (s, 2H, H-11), 
6.23 (s, 1H, H-1), 7.25-7.35 (m, 6H, H-4, H-13, H-14, H-15) ppm; 13C-NMR (100 MHz, 
DMSO-d6) δC: 60.3 (C-8), 70.9 (C-11), 112.0 (C-1), 124.0 (C-4), 128.2 (Ar), 128.4 (Ar), 128.8 
(Ar), 137.8 (Ar), 147.0 (C-2), 149.7 (C-5), 171.6 (C-6) ppm.   
 
10.3.1.3 Synthesis of 5-(benzyloxy)-4-chloro-2-(chloromethyl)pyridine (43) 
 
 
Prepared according to the literature.498 A sample of 5-(benzyloxy)-2-(hydroxymethyl)-1,4-
dihydropyridin-4-one (42) (13.84 g, 60 mmol) was added to a suspension of phosphorus 
oxychloride (42 mL), in portions, thus increasing the temperature of the reaction. After the 
solution mixture was returned back to RT, it was heated at 150oC for 40 min. Upon completion 
of the reaction, the mixture was poured into ice-water and stirred vigorously. Addition of more 
ice into the stirred mixture enhanced the hydrolysis of phosphorous oxychloride and led to the 
precipitation of the pure product (43) (14.5 g, 60 mmol, 87%) as a black solid which was 
isolated by filtration and left to dry overnight. Mp: 77-79oC [lit: 80-81oC]498. 1H-NMR (400 
MHz, DMSO-d6) δH: 4.34 (s, 2H, H-7), 5.00 (s, 2H, H-8), 7.28-7.44 (m, 5H, H-10, H-11, H-
12), 7.75 (s, 1H, H-1), 8.51 (s, 1H, H-4) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 45.4 (C-
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7), 71.5 (C-8), 125.7 (C-1), 128.2 (Ar), 128.4 (Ar), 128.8 (Ar), 129.1 (C-6), 133.1 (C-2), 135.5 
(Ar), 136.2 (C-4), 149.4 (C-5) ppm. 
 
10.3.1.4 Synthesis of 1,3-diethyl-2-{[5-(benzyloxy)-4-chloropyridin-2-yl]methyl}-2-
acetamidopropane dioate (44)  
 
 
Prepared according to the literature.498 In dry N,N- dimethylformamide (62 mL) sodium 
hydride (60% in mineral oil, 2.16 g, 54 mmol, 1.7 eq) was added. The solution was stirred at 
RT and then diethyl acetamidomalonate (11.25 g, 51.8 mmol, 1.7 eq) was added in portion 
evolving hydrogen gas. Upon ceasing of hydrogen gas evolution, 5-(benzyloxy)-4-chloro-2-
(chloromethyl) pyridine (43) (13.84 g, 51.6 mmol, 1 eq) was added. The resulting solution 
mixture was stirred overnight at RT. Upon completion of the reaction, acetic acid (25 mL) was 
added to neutralise the reaction mixture which was then concentrated, under reduced pressure, 
and the resulting syrup was dissolved in water (200mL) and extracted with diethyl ether (2 x 
80 mL). The combined organic extracts were washed with brine, dried over magnesium 
sulphate and concentrated under reduced pressure, affording the titled compound (44) as white 
crystals which was recrystallized from ethanol (22.7 g, 50.6 mmol, 98%). Mp: 119-122oC 
[Lit=118-120oC]498. 1H-NMR (400 MHz, DMSO-d6) δH: 1.18 (t, J= 7.2 Hz, 6H, H-12), 1.82 
(s, 3H, H-9), 3.50 (s, 2H, H-6), 4.08 (q, J= 7.2 Hz, 4H, H-11), 5.25 (s, 2H, H-13), 7.13 (1H, s, 
NH), 7.30-7.44 (m, 5H, H-15, H-16, H-17), 8.02 (s, 1H, H-5), 8.34 (s. 1H, H-3) ppm; 13C-
NMR (100 MHz, DMSO-d6) δC: 14.3 (C-12), 22.5 (C-9), 40.1 (C-6), 62.3 (C-11), 66.6 (C-13), 
71.1 (C-7), 125.8 (C-5), 128.2 (C-1), 128.7 (Ar), 129.1 (Ar), 131.3 (Ar), 136.0 (Ar), 136.6 (C-
3), 149.6 (C-2), 149.9 (C-4), 167.5 (C-10), 169.9 (C-8) ppm. 
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10.3.1.5 Synthesis of 1,3-diethyl 2-acetamido-2-[(5-hydroxypyridin-2-yl) methyl] 
propanedioate (45) 
 
 
Prepared according to the literature.498 A suspension of diethyl 2-{[5-(benzyloxy)-4-
chloropyridin-2-yl]methyl}-2-acetamidopropanedioate (44) (6 g, 13.36 mmol, 1 eq) in 
methanol (75 mL), sodium acetate (6 g, 73.14 mmol, 5.5eq) and a catalytic amount of 10% 
Pd/C was stirred vigorously under hydrogen atmosphere. Upon completion of the reaction (4 
hr), as indicated by TLC (SiO2, ethyl acetate 100%), the solution mixture was filtered over a 
pad of Celite, washed with methanol and diluted with water (150 mL) forming the titled 
compound (45) as white crystals which were isolated by viltration (2.94 g, 9.06 mmol, 68%). 
Mp: 152-154oC [Lit: 150-153oC].498 1H-NMR (400 MHz, DMSO-d6) δH: 1.1 (t, J= 7.2 Hz, 6H, 
H-12), 1.81 (s, 3H, H-9), 3.43 (s, 2H, H-6), 4.07 (q, J= 7.2 Hz, 4H, H-11), 6.78 (d, J= 8.8 Hz, 
1H, H-5), 6.99 (dd, J= 3.2 Hz, J= 8.8 Hz, 1H, H-1), 7.87 (s, 1H, H-13), 7.91 (d, J= 3.2 Hz, 
1H, H-3) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 13.8 (C-12), 23.2 (C-9), 42.3 (C-6), 63.5 
(C-11), 65.2 (C-7), 124.1 (C-1), 128.0 (C-5), 137.9 (C-3), 147.5 (C-4), 153.0 (C-2), 166.2 (C-
10), 170.4 (C-8) ppm. 
10.3.1.6 Synthesis of 1,3-diethyl-2-acetamido-2-[(5-hydroxy-6-iodopyridin-2-yl)methyl] 
propanedioate (46) 
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Prepared according to the literature.498 A sample of diethyl 2-acetamido-2-[(5-hydroxypyridin-
2-yl)methyl] propanedioate (2.5 g, 7.7 mmol, 1 eq) (45) was dissolved in water (70 mL) 
containing sodium carbonate (1.54 g, 13.97 mmol, 1.8 eq). A solution of iodine (1.92 g, 15.13 
mmol, 2 eq) and potassium iodide (2.32 g, 13.97 mmol) in water (50 mL) was added dropwise 
to the previous solution. The resulting mixture was stirred overnight at RT. Upon completion 
of the reaction, the solution mixture was neutralized with glacial acetic acid (5 mL), leading 
to the precipitation of the title compound, which was collected by filtration, washed with water 
and dried at 90oC. The title compound (46) was obtained as a white powder (3.39 g, 7.54 
mmol, 98%). M.p: 200-203oC. [Lit: 196-197oC]498. 1H-NMR (400 MHz, DMSO-d6) δH: 1.1 (t, 
J= 7.2 Hz, 6H, H-12), 1.81 (s, 3H, H-9), 3.43 (s, 2H, H-6), 4.07 (q, J= 7.2 Hz, 4H, H-11), 6.78 
(d, J= 8.8 Hz, 1H, H-5), 6.99 (dd, J= 3.2 Hz, J= 8.8 Hz, 1H, H-1), 7.87 (s, 1H, -NH), 7.91 (d, 
J= 3.2 Hz, 1H, -OH) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 14.3 (C-12), 22.6 (C-9), 39.9 
(C-6), 66.8 (C-11), 69.0 (C-7)  122.8 (Ar), 125.1 (Ar), 137.6 (Ar), 146.5 (Ar), 152.8 (Ar), 167.7 
(C-10), 169.7 (C-8) ppm. 
 
 
10.3.1.7 Synthesis of rac-2-amino-3-(5-hydroxy-6-oxo-1,6-dihydropyridin-2-
yl)propanoic acid (rac-SK-5)  
 
 
Prepared according to the literature.498 A mixture of barium hydroxide (7.1 g, 41.43 mmol, 4.7 
eq) and diethyl 2-acetamido-2-[(5-hydroxy-6-iodopyridin-2-yl)methyl] propanedioate (46) (4 
g, 8.88 mmol, 1 eq) in water (70 mL) was refluxed for 24 hr. Upon completion of the reaction, 
the resulting barium salt was collected by filtration and refluxed with concentrated HCl (50 
280 | P a g e  
 
mL) for 1 hr. Once again, upon completion of the reaction, the solution mixture was evaporated 
to dryness yielding a yellowish salt of the crude product which was dissolved in water (20 
mL), treated with charcoal and filtered. The pH of the filtrates was adjusted to 5.0 by addition 
of concentrated ammonia and cooled at 5oC for 72 hr leading to precipitation of the titled 
compound appearing as white crystals (1.67 g, 8.44 mmol, 95%). M.p: 193-195oC. [Lit: 196-
197oC]498. 1H-NMR (400 MHz, DMSO-d6) δH: 2.86-2.99 (m, 2H, H-6), 4.07 (t, J= 7.6 Hz, 1H, 
H-7), 6.06 (d, J= 7.2 Hz, 1H, H-5), 6.75 (d, J= 7.2 Hz, 1H, H-1) ppm; 13C-NMR (100 MHz, 
DMSO-d6) δC: 32.4 (C-6), 52.0 (C-7), 110.8 (C-5), 121.2 (C-1), 131.3 (C-2), 144.7 (C-4), 
159.0 (C-3), 170.3 (C-8) ppm. HRMS (ESI) for C8H10N2O4; Theoretical [M+H]: 199.0718. 
Measured [M+H]: 199.0711. 
10.3.2 Synthesis of rac-SK-7 
 
10.3.2.1 Synthesis of 2-chloro-3-methoxy pyridine (50) 
 
 
The synthesis was performed according to a modified method previously published.538 In a 
solution of 2-chloro-3-hydroxy pyridine (20 g, 125.36 mmol, 1 eq) in acetone (1 L), 
iodomethane (11 mL, 169.23 mmol, 1.35 eq) and potassium carbonate (35 g, 253.24 mmol, 2 
eq) were added. The reaction was stirred for 48 hr at RT and upon completion of the reaction 
as it was indicated by TLC (SiO2, eluent; ethyl acetate: petrol ether 60:80, 1:1; UV light) (Rf 
= 0.73) water (100 mL) and ethyl acetate (200 mL) was added and the aqueous phase was 
extracted with ethyl acetate (3x100 mL). The combined organic extracts were, washed with 
brine, dried over anhydrous magnesium sulphate and concentrated under reduced pressure 
affording the titled compound (50) as brown oil (17.63 g, 122.8 mmol, 98%). 1H-NMR (400 
MHz, CDCl3) δH: 3.91 (s, 3H, H-7), 7.18 (s (br), 2H, H-4, H-5), 7.98 (s (br), 1H, H-6) ppm; 
13C-NMR (100 MHz, CDCl3) δC= 56.0 (C-7), 122.0 (C-5), 122.39 (C-4), 140.2 (C-2), 141.5 
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(C-6), 152.7 (C-3)ppm. 
 
10.3.2.2 Synthesis of 2, 3-dimethoxypyridine (51)  
 
 
The synthesis was performed according to a modified method previously published.707 In a 
suspension of 2-chloro-3-methoxy pyridine (11.32 g, 78.85 mmol, 1 eq) (50) in anhydrous 
N,N- dimethyl formamide (120 mL) sodium methoxide (12.55 g, 235.5 mmol, 3 eq) was 
added and the resulting solution mixture was stirred overnight at 60oC. Upon completion of 
the reaction, as it was indicated by TLC (SiO2, eluent; petrol ether 60:80: ethyl acetate, 7:3; 
UV light) (Rf = 0.82), the reaction mixture was allowed to cool down to RT and water (240 
mL) was added. The pH was adjusted to 2 by the addition of conc HCl and washed once with 
ethyl acetate (1x150 mL). Then, the aqueous layer was basified by the addition of NaOH 
(10M) to pH 10 and extracted with ethyl acetate (3x150 mL). The combined organic extracts 
were washed with water, brine, dried over anhydrous magnesium sulphate and concentrated 
under reduced pressure affording compound (51) as a yellow oil (8.34 g, 59.93 mmol, 76%). 
1H-NMR (400 MHz, CDCl3) δH: 3.87 (s, 3H, H-8), 4.02 (s, 3H, H-7), 6.84 (dd, J= 7.6 Hz, J= 
6.4 Hz, 1H, H-5), 7.04 (d, J= 7.6 Hz, 1H, H-4), 7.3 (d, J= 6.4 Hz, 1H, H-6) ppm; 13C-NMR 
(100 MHz, CDCl3) δC: 52.8 (C-7), 55.3 (C-8), 116.8 (C-5), 117.9 (C-4), 136.5 (C-6), 143.6 
(C-3), 153.6 (C-2) ppm.   
 
10.3.2.3 Synthesis of 5-bromo-2,3-dimethoxypyridine (52) 
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The synthesis was performed according to a modified method previously published.540 In a 
solution mixture of dichloromethane-saturated sodium bicarbonate (1:2, 250 mL: 133 mL), 
2,3- dimethoxypyridine (51) (8.34 g, 59.93 mmol, 1 eq) was added and cooled to 0oC. Then 
bromine (3.1 mL, 59.93 mmol, 1eq) was added and the solution mixture was stirred for 2 hr 
at RT. The process of the reaction was monitor by TLC (SiO2, eluent; petrol ether 60:80: ethyl 
acetate, 6:4; UV light) and after two hours another 0.5 eq of bromine was added. After 4 hr 
the starting material had been consumed and the reaction was quenched by the addition of 
sodium thiosulphate (20 g) and extracted with dichloromethane (3x100 mL). The combined 
organic extracts were dried over anhydrous magnesium sulphate and concentrated under 
reduced pressure affording a brown oil a non-separable mixture (11.25 g, 51.59 mmol). 1H-
NMR (of the major product) (52) (400 MHz, CDCl3) δH: 3.82 (s, 3H, H-7), 3.97 (s, 3H, H-8), 
7.09 (d, J= 1.6 Hz, 1H, H-4), 7.73 (d, J= 1.6 Hz, 1H, H-6) ppm; 13C-NMR (100 MHz, CDCl3) 
δC: 52.7 (C-7), 55.8 (C-8), 113.1 (C-5), 123.2 (C-4), 140.5 (C-6), 145.91 (C-3), 154.34 (C-2) 
ppm.  
10.3.2.4 Synthesis of 5,6-dimethoxypyridine-3-carbaldehyde (53) 
 
 
The synthesis was performed according to a modified method previously published.708 In a 
solution of 5-bromo-2,3-dimethoxypyridine (52) (10 g, 45.86 mmol, 1 eq) in anhydrous 
diethyl ether (50 mL), under nitrogen atmosphere and cooled down to -35oC, nBuLi (2.5 M 
in hexanes) (22 mL, 55.03 mmol, 1.2 eq) was added. The resulting solution was stirred until 
a brown precipitate formed. Then anhydrous N,N- dimethylformamide (9.9 mL, 128.4 mmol, 
2.8 eq) was added slowly and the mixture was allowed to stir until the temperature reached  
0oC. Upon completion of the reaction as it was indicated by TLC (SiO2, eluent; petrol ether 
60:80: diethyl ether, 6:4; UV light) Rf (0.85) the reaction was quenched carefully by the 
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addition of aqueous solution of ammonium chloride (5%, 50 mL). Then the aqueous layer 
was extracted with dichloromethane (3x100 mL). The combined organic extracts were 
washed with water, brine, dried over anhydrous magnesium sulphate and concentrated under 
reduced pressure affording the crude compound as orange oil which was solidified on 
standing. The solid was purified by recrystallization from methanol forming the title 
compound (53) as pale yellow crystals (4.06 g, 24.3 mmol, 53%). Mp: 125-127oC [lit: 
123oC].708 1H-NMR (400 MHz, CDCl3) δH: 3.94 (s, 3H, H-7), 4.12 (s, 3H, H-8), 7.48 (s, 1H, 
H-4), 8.21 (s, 1H, H-6), 9.94 (s, 1H, H-4) ppm; 13C-NMR (100 MHz, CDCl3) δC:  52.7 (C-7), 
56.4 (C-7), 120.7 (C-4), 125.4 (C-5),141.6 (C6), 146.0 (C-3), 157.1 (C-2), 190.3 (C-9) ppm.  
10.3.2.5 Synthesis of 4-[(5,6-dimethoxypyridin-3-yl)methylidene]-2-methyl-4,5-
dihydro-1,3-oxazol-5-one (54) 
 
 
The synthesis was performed according to a modified method previously published.505A 
mixture of 5,6-dimethoxypyridine-3-carbaldehyde (53) (2 g, 11.96 mmol, 1eq), N-acetyl 
glycine (1.82 g, 15.6 mmol, 1.3 eq) and sodium acetate (1.3 g, 15.6 mmol, 1.3 eq) in acetic 
anhydride (10 mL) was heated at 125oC for three hours. Upon completion of the reaction, ice 
(~50 g) was added into the solution mixture and stirred vigorously until a yellow precipitate 
formed. The crude product was collected by filtration and washed with excess of diethyl ether. 
Then it was recrystallized from methanol affording the title compound (54) as pale yellow 
crystals (2.55 g, 9.57 mmol, 80%). Mp: 158-160o C. 1H-NMR (400 MHz, CDCl3) δH: 2.38 (s, 
3H, H-13), 3.92 (s, 3H, H-7), 4.06 (s, 3H, H-8), 7.07 (s, 1H, H-9), 8.04 (d, J= 1.6 Hz, 1H, H-
4), 8.26 (d, J= 1.6 Hz, 1H, H-6) ppm; 13C-NMR (100 MHz, CDCl3) δC:  23.3 (C-13), 52.5 (C-
7), 55.8 (C-8), 121.4 (C-4), 121.7 (C-5), 131.8 (C-9), 131.3 (C-10), 144.0 (C-6), 147.2 (C-3), 
54 
284 | P a g e  
 
154.5 (C-2), 162.5 (C-12), 166.23 (C-11) ppm. HRMS (ESI) for C12H12N2O4; Theoretical 
[M+H]: 249.0797. Measured [M+H]: 249.0785. 
10.3.2.6 Synthesis of rac-3-(5,6-dimethoxypyridin-3-yl)-2-acetamidoprop-2-enoic acid 
(55) 
 
 
The synthesis was performed according to a modified method previously published.505 In a 
suspension of 4-[(5,6-dimethoxypyridin-3-yl)methylidene]-2-methyl-4,5-dihydro1,3-oxazol-
5-one (54) (1.5 g, 6.04 mmol, 1 eq) in methanol (30 mL) sodium hydroxide (290 mg , 7.25 
mmol, 1.2 eq) in water (final pH~8-9) was added. The resulting solution was stirred at RT for 
2 hours before methanol was removed under reduced pressure. The resulting aqueous solution 
was solution was acidified to pH 1 and cooled at 0oC for maximal precipitation. The resulting 
crystals were collected by filtration and washed with cold ether affording the title compound 
(55) as beige crystals (1.53g, 5.74 mmol, 95%). Mp: 192oC. 1H-NMR (400 MHz, DMSOd6) 
δH: 1.95 (s, 3H, H-15), 3.74 (s, 3H, H-7), 3.84 (s, 3H, H-8), 7.19 (s, 1H, H-9), 7.50 (s, 1H, 
H4), 7.90 (s, 1H, H-6), 9.48 (s, 1H, H-13) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 23.2 (C-
15), 52.5 (C-7), 22.8 (C-8), 119.2 (C-4), 122.9 (C-5), 125.8 (C-9), 126.8 (C-10), 141.5 (C-6), 
145.2  (C-3), 154.4 (C-2), 166.5 (C-11), 168.5 (C14) ppm. HRMS (ESI) for C12H14N2O5; 
Theoretical [M+H]: 267.0980. Measured [M+H]: 267.0969.  
10.3.2.7 Synthesis of rac-3-(5,6-dimethoxypyridin-3-yl)-2-acetamidopropanoic acid 
(56) 
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In a suspension of rac-(2Z)-3-(5,6-dimethoxypyridin-3-yl)-2-acetamidoprop-2-enoic acid 
(55) (1 g, 3.75 mmol, 1 eq) in methanol (30 mL) a catalytic amount of Pd/C (10%) was added. 
The resulting solution was stirred under hydrogen atmosphere for 4 hours. Upon completion 
of the reaction, as it was indicated by 1H-NMR, Celite was added into the solution mixture 
and filtrated through a pad of Celite which was then washed sequentially with ethyl acetate 
and methanol. The filtrates were concentrated under reduced pressure affording the title 
compound (56) as beige crystals (633 mg, 2.36 mmol, 63%). Mp: 201-203oC. 1H-NMR (400 
MHz, DMSO-d6) δH: 1.79 (s, 3H, H-15), 2.71-2.80 (m, 1H, H-9), 2.95-2.99 (m, 1H, H-9), 
3.75 (s, 3H, H-7), 3.83 (s, 3H, H-8), 4.35-4.40 (m, 1H, H-10), 7.17 (s, 1H, H-4), 7.50 (s, 1H, 
H-6), 8.13 (d, J= 8.0 Hz, 1H, H-13) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 22.9 (C-15), 
34.1 (C-9), 52.8 (C-7), 55.8 (C-7), 56.07 (C-10), 120.6 (C-4), 124.9 (C-5), 138.8 (C-6), 144.6 
(C-3), 151.7 (C-2), 170.8 (C-14), 172.9 (C-11) ppm. HRMS (ESI) for C12H16N2O5; 
Theoretical [M+H]: 269.1137. Measured [M+H]: 269.1168.  
10.3.2.8 Synthesis of rac-2-amino-3-(5-hydroxy-6-oxo-1,6-dihydropyridin-3-
yl)propanoic acid (rac-SK-7) 
 
 
In a solution mixture of HBr (48%, 15 mL) and glacial acetic acid (15 mL), rac-3-(5,6-
dimethoxypyridin-3-yl)-2-acetamidopropanoic acid (56) (500 mg, 1.86 mmol). The resulting 
solution was stirred under reflux for 4 hr. Upon completion of the reaction the reaction 
mixture concentrated under reduced pressure, and the resulting crystals were taken up in water 
and the pH was adjusted to 5 by the dropwise addition of ammonium hydroxide. The final 
solution was kept at 5oC for 72 hr and the pure off white crystals formed of the titled 
compound (rac-SK-7) were collect by filtration (178 mg, 0.74 mmol, 40%). Mp: 199oC. 1H-
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NMR (400 MHz, D2O/CF3COOD 8:2): δH: 2.91-3.11 (m, 1H, H-7), 2.95-2.99 (m, 1H, H-7), 
4.31 (s, 1H, H8), 6.72 (s, 1H, H-4), 6.85 (s, 1H, H-6) ppm; 13C-NMR (100 MHz, 
D2O/CF3COOD 8:2): δC: 32.3 (C-7), 53.1 (C-8), 112.4 (C-5), 129.3 (C-4), 132.8 (C-6), 147.6 
(C-3), 158.5 (C-2), 172.6 (C-9) ppm. HRMS (ESI) for C8H10N2O4; Theoretical [M+H]: 
199.0718. Measured [M+H]: 199.0713.  
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10.4 Synthesis of 3, 4-HOPOS 
 
10.4.1 Synthesis of rac-SK-1 and rac-SK-2 
 
10.4.1.1 Synthesis of [5-(benzyloxy)-4-oxo-4H-pyran-2-yl]methyl 4-methylbenzene-1-
sulfonate (57) 
 
 
The synthesis was performed according to a modified method previously published.543 A 
sample of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (41) (25 g, 108 mmol, 1 eq) was 
dissolved in acetone (350 mL) and mixed by vigorous stirring with tosyl chloride (21 g, 110 
mmol, 1.1 eq) at RT, followed by the addition of a solution of sodium hydroxide (4.3g, 72 
mmol) in water (18 mL). The mixture was stirred at RT for 20 min. The crude product was 
precipitated upon addition of water (50 mL). The crude product was purified by 
recrystallization from methanol/water affording the pure compound (57) as pale yellow 
crystals (38 g, 98 mmol, 94%). Mp: 111-114oC [lit: 112oC]543. 1H-NMR (400 MHz, DMSO-
d6) δH 2.47 (s, 3H, H-15), 4.77 (s, 2H, H-6), 5.02 (s, 2H, H-7), 6.33 (s, 1H, H-1), 7.25-7.36 (m, 
7H, H-8, H-9, H-10, H-13), 7.75 (s, 1H, H-1), 7.76 (d, J = 8 Hz, 2H, H-12) ppm; 13C-NMR 
(100 MHz, DMSO-d6) δC= 21.8 (C-15), 66.0 (C-6), 71.9 (C-7), 115.5 (C-1), 127.8 (Ar), 128.1 
(Ar), 128.6 (Ar), 128.9 (Ar), 130.2 (Ar), 132.3 (Ar), 135.5 (Ar), 141.5 (C-4), 145.8 (Ar), 147.4 
(C-3), 158.7 (C-5), 174.0 (C-2) ppm. HRMS (ESI) for C20H18O6S; Theoretical [M+H]: 
387.0902. Measured [M+H]: 387.0890. 
 
288 | P a g e  
 
10.4.1.2 Synthesis of 1,3-diethyl 2-{[5-(benzyloxy)-4-oxo-4H-pyran-2-yl]methyl}-2-
acetamidopropanedioate (58)  
 
 
The synthesis was performed according to a modified method previously published.497 In a 
solution of diethyl acetamidomalonate (10 g, 46 mmols) in dry N,N-dimethyl formamide (70 
mL), sodium hydride (60% in mineral oil, 2 g, 50 mmol) was added in portions. Upon the 
evolution of hygrogen gas, a sample of [5-(benzyloxy)-4-oxo-4H-pyran-2-yl]methyl 4-
methylbenzene-1-sulfonate (57) (8.5 g, 22 mmol) was added to the solution mixture and the 
final mixture was stirred overnight protected from moisture at RT. Upon completion of the 
reaction, the solvents were removed under reduced pressure forming a brown residue which 
was mixed with water (100 mL) and stirred vigorously forming the crude product as a brown 
solid which was filtered and left to dry overnight. The crude product was purified by 
recrystallization (acetone/petroleum ether 60:80) affording the pure compound (58) as light 
orange crystals (9.21 g, 21mmol, 95 %). Mp: 117-120oC [lit: 117-118oC].17 1H-NMR (400 
MHz, DMSO-d6) δH 1.18 (t, J= 7.2 Hz, 6H, H-10), 1.92 (s, 3H, H-12), 3.35 (s, 2H, H-6), 4.85 
(s, 2H, H-13), 4.14 (q, J1= 7.2 Hz, 4H, H-9), 6.05 (s, 1H, H-1), 7.35-7.37 (m, 5H, H-14, H-15, 
H-16), 8.08 (s, 1H, H-4), 8.45 (s, 1H, -NH) ppm; 13C-NMR (100 MHz, DMSO-d6) δC= 14.3 
(C-10), 22.4 (C-12), 31.2 (C-6), 62.8 (C-9), 65.6 (C-7), 71.0 (C-13), 116.1 (C-4), 128.7 (Ar), 
128.8 (Ar), 129.0 (Ar), 136.5 (Ar), 142.0 (C-1), 147.2 (C-3), 163.2 (C-8), 167.0 (C-11), 170.4 
(C-5), 173.4 (C-2) ppm. HRMS (ESI) for C22H25NO8; Theoretical [M+H]: 432.1658. 
Measured [M+H]: 432.1656. 
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10.4.1.3 Synthesis of 2-amino-3-(5-hydroxy-4-oxo-4H-pyran-2-yl)propanoic acid  
(rac-SK-1) 
 
 
A solution of conc. hydrochloric acid (40 mL) and 1, 3-diethyl 2-{[5-(benzyloxy)-4-oxo-4H-
pyran-2-yl] methyl}-2-acetamidopropanedioate (58) (5.1 g, 11.84 mmol) was refluxed at 
100oC for 3 hr. Upon completion of the reaction, the solvents were removed under reduced 
pressure, forming a brown solid which was dissolved in water (20 mL). The solution was 
treated with charcoal, filtered and the pH of the filtrate was adjusted to 5 by the dropwise 
addition of conc. ammonium hydroxide. The resulting solution was kept overnight at 5oC and 
white crystals precipitated. The crystals were collected, washed with water, acetone, light 
petroleum and dried in the air affording the pure compound (rac-SK-1) as white crystals (2.10 
g, 10.54 mmol, 89%), Mp: 116-117oC. 1H-NMR (400 MHz, D2O/CF3COOD 8:2) δH : 2.63-
2.75 (m, 2H, H-6), 3.84 (t, J= 6.8 Hz, 1H, H-7), 5.97 (s, 1H, H-1), 7.45 (1H, s, H-4) ppm; 13C-
NMR (100 MHz, D2O/CF3COOD 8:2): δC= 32.9 (C-6), 50.0 (C-7), 116.4 (C-1), 119.3 (C-4), 
142.5 (C-3), 144.2 (C-5), 169.4 (C-8), 175.5 (C-2) ppm. HRMS (ESI) for C8H9NO5; 
Theoretical [M+H]: 200.0558. Measured [M+H]:200.0550. 
10.4.1.3.1 Synthesis of 2-amino-3-(5-hydroxy-4-oxo-1,4-dihydropyridin-2-yl)propanoic 
acid (rac-SK-2) 
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Prepared according to the literature.497 A portion of 1,3-diethyl 2-{[5-(benzyloxy)-4-oxo-4H-
pyran-2-yl]methyl}-2-acetamidopropanedioate (58) (4.2 g,  9.73 mmol) was mixed with a 
solution of conc. ammonium hydroxide (25 mL) and the mixture was heated for 5 hr in a 
stainless steel bomb at 120oC. Upon completion of the reaction the mixture was evaporated to 
dryness and the resulting solid was dissolved in a solution of conc. HCl (30 mL). The resulting 
mixture was refluxed at 100 oC for 3 hr. The solvents were evaporated and the resulting crystals 
were dissolved in water (20 mL). The solution was treated with charcoal, filtered and the pH 
was adjusted to 5 using ammonia solution. The resulting solution was kept overnight at 5 oC 
forming white crystals. The crystals were collected, washed with water, acetone, and light 
petroleum and dried affording the pure compound (rac-SK-2) as white crystals (1.76 g, 8.9 
mmol, 91%) Mp: >250 oC [lit: >250oC].497 1H-NMR (400 MHz, D2O/CF3COOD 8:2): δH 2.73-
2.75 (m, 2H, H-6), 3.71 (t, J= 6.8 Hz, 1H, H-7), 6.52 (s, 1H, H-1), 7.3 (s, 1H, H-4) ppm; 13C-
NMR (100 MHz, D2O/CF3COOD): δC 30.1 (C-6), 51.2 (C-7), 113.6 (C-1), 116.4 (C-4), 142.5 
(C-3), 143.4 (C-5), 168.7 (C-8), 169.0 (C-2) ppm. HRMS (ESI) for C8H10N2O4; Theoretical 
[M+H]: 197.0718. Measured [M+H]: 197.0699. 
10.4.2 Synthesis of D-SK-4 
 
10.4.2.1 Synthesis of 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (60) 
 
 
 
Prepared according to the literature.544 In a solution of maltol (10 g, 79.26 mmol, 1 eq) in N, 
N- dimethyl formamide (100 mL) a solution of benzyl bromide (9.42 mL, 79.26 mmol, 1 eq) 
was added. The solution mixture was stirred at 80oC for 15 min. Then a sample of potassium 
carbonate (12.05 g, 87.18 mmol, 1.1 eq) was added to the reaction mixture and the final 
mixture was refluxed for further 1 hr. Upon completion of the reaction the excess of inorganic 
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salt was removed by filtration and the filtrates were concentrated under reduced pressure. The 
resulting residue was dissolved in tetrahydrofuran (50 mL) and any remaining of the inorganic 
salt was removed by filtration. Finally, the filtrate was concentrated under reduced pressure 
affording the title compound (60) as a viscous orange oil (16.28 g, 75.29 mmol, 95%). 1H-
NMR (400 MHz, CDCl3) δH: 2.00 (s, 3H, H-6), 5.07 (s, 2H, H-7), 6.28 (d, J= 5.6 Hz, 1H, H-
1), 7.25-7.33 (m, 5H, H-9, H-10, H-11), 7.53 (d, J= 5.6 Hz, 1H, H-2) ppm; 13C-NMR (100 
MHz, CDCl3) δC: 14.6 (C-6), 73.3 (C-7), 116.8 (C-1), 128.2 (Ar), 128.3 (Ar), 128.8 (Ar), 136.7 
(Ar), 143.6 (C-4), 153.9 (C-2), 159.8 (C-3), 175.02 (C-5) ppm.  
 
10.4.2.2 Synthesis of (2R)-3-amino-2-{[(tert-butoxy)carbonyl]amino}propanoic acid 
(D-59) 
 
 
Prepared according to the literature.545 In a solution mixture composed of ethyl acetate (24 
mL), acetonitrile (24 mL) and water (12 mL), N-Boc-D-asparagine (5.0 g, 21.5 mmol, 1 eq) 
and iodosobenzene diacetate (8.32 g, 25.8 mmol, 1.2 eq) were added. The resulting slurry, was 
stirred at 16OC for 30 min and then at RT for 4 hr. Upon completion of the reaction, the mixture 
was cooled at 0oC for 15 min forming a white salt which was collected by filtration. The 
filtercake was then washed with cold ethyl acetate (30 mL) affording compound (D-59) as a 
white solid (3.34 g, 16.35 mmol, 76%). Mp: 203-207oC [lit: 207-212oC]545. 1H-NMR (400 
MHz, DMSO-d6) δH: 1.33 (s, 9H, H-6), 2.67-2.73 (m, 1H, H-3), 2.93-2.98 (m, 1H, H-3), 3.57 
(m, 2H, H-2), 6.14 (s, br, 1H, H-7) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 28.6 (C-6), 41.2 
(C-3), 51.3 (C-2), 78.7 (C-5), 155.6 (C-4), 171.6 (C-1) ppm.  
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10.4.2.3 Synthesis of 2-amino-3-(3-hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-
yl)propanoic acid (D-SK-4) 
 
 
A sample of 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (60) (4.9 g, 22.66 mmol, 1 eq) 
was mixed with a sample of (2R)-2-amino-2-{[(tert-butoxy)carbonyl]amino}acetic acid (D-
59) (2.9 g, 14.2 mmol, 0.6 eq.) and dissolved in water (100 mL), ethanol (100 mL) containing 
sodium hydroxide (2 g, 50 mmol). The resulting solution was allowed to stir at RT for 8 days. 
Then, the solution was acidified to pH 2 by the addition of conc. hydrochloric acid. The excess 
of solvents were removed under reduced pressure. The resulting residue was mixed with 
hydrobromic acid (48% w/v, 20 mL) and refluxed for 20 min. The solution mixture was 
concentrated under reduced pressure, and then the resulting solid was dissolved in water (20 
mL), treated with charcoal and basified (pH 5) by the addition of ammonium hydroxide 
solution. The resulting solution was cooled to 5oC for 72 hr, where brown crystals were 
precipitated. The crystals were collected washed with a small portion of water and dried on air 
affording the title compound (D-SK-4) as pale brown crystals (3.23 g, 14.27 mmol, 63%). Mp: 
165-168oC [lit: 167-168oC].7 1H-NMR (400 MHz, D2O/CF3COOD) δH: 1.90 (s, 3H, H-6), 3.86 
(t, J= 7.2 Hz, 1H, H-8), 4.07-4.31 (m, 2H, H-7), 6.43 (d, J= 8 Hz, 1H, H-2), 7.35 (d, J= 8 Hz, 
1H, H-1) ppm; 13C-NMR (100 MHz, D2O/CF3COOD) δC: 13.4 (C-6), 49.17 (C-7), 52.24 (C-
8), 119.54 (C-2), 141.59 (C-1), 143.28 (C-5), 147.33 (C-4), 170.96 (C-8), 176.7 (C-3) ppm. 
HRMS (ESI) for C9H12N2O4; Theoretical [M+H]: 213.0869. Measured [M+H]: 213.0899. 
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10.4.3 Synthesis of L-SK-4 
 
10.4.3.1 Synthesis of (2S)-3-amino-2-{[(tert-butoxy)carbonyl]amino}propanoic acid (L-
59) 
 
 
Prepared according to the literature.545 In a solution mixture composed of ethyl acetate (24 
mL), acetonitrile (24 mL) and water (12 mL), N-Boc-L-asparagine (5.0 g, 21.5 mmol, 1 eq) 
and iodosobenzene diacetate (8.32 g, 25.8 mmol, 1.2 eq) were added. The resulting slurry, was 
stirred overnight at RT. Upon completion of the reaction, the mixture was concentrated and 
the resulting slurry was sonicated with ethyl acetate (30 mL). The precipitate was filtrate and 
filtercake was washed with cooled ethyl acetate (30 mL) affording compound (L-59) as a white 
solid (3.94 g, 19.3 mmol, 90%). Mp. 200-204oC [lit: 207-212oC].545 1H-NMR (400 MHz, 
DMSO-d6) δH: 1.35 (s, 9H, H-6), 2.67-2.74 (m, 1H, H-3), 2.95-2.97 (m, 1H, H-3), 3.57 (m, 
2H, H-2), 6.13 (s, br, 1H, H-7) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 28.5 (C-6), 41.4 (C-
3), 51.6 (C-2), 78.6 (C-5), 155.6 (C-4), 171.6 (C-1) ppm. 
10.4.3.2 Synthesis of 2-amino-3-(3-hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-
yl)propanoic acid (L-SK-4) 
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A sample of 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (60) (3.88 g, 17.93 mmol, 1 
eq) was mixed with a sample of (2S)-2-amino-2-{[(tert-butoxy)carbonyl]amino}acetic acid 
(3.94 g, 19.3 mmol, 1.1 eq.) and dissolved in water (200 mL), ethanol (100 mL) containing 
sodium hydroxide (2 g, 50 mmol). The resulting solution was allowed to stir at RT for 8 days. 
Then, the solution was acidified to pH 2 by the addition of conc. hydrochloric acid. The excess 
of solvents were removed under reduced pressure. The resulting residue was mixed with 
hydrobromic acid (48% w/v, 20 mL) and refluxed for 20 min. The solution mixture was 
concentrated under reduced pressure, and then the resulting solid was dissolved in water (20 
mL), treated with charcoal and basified (pH 5) by the addition of ammonium hydroxide 
solution. The resulting solution was cooled to 5oC for 72 hr, where brown solid were 
precipitated. The solid was collected washed and purified by recrystallization from water/ 
methanol, affording the title compound (L-SK-4) as pale brown crystals (1.78 g, 8.43 mmol, 
47%). Mp: 163-168oC. 1H-NMR (400 MHz, D2O/CF3COOD, 8:2) δH: 1.92 (s, 3H, H-6), 3.85 
(t, J= 7.2 Hz, 1H, H-8), 4.07-4.31 (m, 2H, H-7), 6.44 (d, J= 8 Hz, 1H, H-2), 7.36 (d, J= 8 Hz, 
1H, H-1) ppm; 13C-NMR (100 MHz, D2O/CF3COOD) δC: 13.4 (C-6), 49.2 (C-7), 52.2 (C-8), 
119.54 (C-2), 141.7 (C-1), 143.3 (C-5), 147. (C-4), 170.9 (C-8), 176.7 (C-3) ppm. HRMS 
(ESI) for C9H12N2O4; Theoretical [M+H]: 213.0869. Measured [M+H]: 213.0865. 
 
10.4.4 Synthesis of L-SK-8 
 
10.4.4.1 Synthesis of 2-(chloromethyl)-5-hydroxy-4H-pyran-4-one (61) 
 
 
The synthesis was performed according to a modified method previously published.550 A 
sample of kojic acid (10 g, 70.37 mmol, 1 eq) was dissolved in thionyl chloride (15 mL, 201.7 
mmol, 2.9 eq). The resulting solution was stirred at RT until yellow crystals of the title 
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compound were precipitated. The crystals were collect by filtration and washed with excess 
of hexanes, affording compound 61 as off-white crystals (11.15 g, 69.45 mmol, 97%). Mp: 
166-167oC [lit: 166-167oC]550. 1H-NMR (400 MHz, DMSO-d6) δH: 4.62 (s, 2H, H-8), 5.65 (s, 
br, 1H, H-7), 6.53 (s, 1H, H-1), 8.1 (s, 1H, H-4) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 41.8 
(C-8), 113.8 (C-1), 140.7 (C-4), 146.6 (C-5), 162.2 (C-2), 174.3 (C-6) ppm. 
 
10.4.4.2 Synthesis of 5-hydroxy-2-methyl-4H-pyran-4-one (62) 
 
 
The synthesis was performed according to a modified method previously published.549 A 
suspension of 2-(chloromethyl)-5-hydroxy-4H-pyran-4-one (61) (5 g, 31.14 mmol, 1 eq) in 
distilled water (60 mL) was heated at 50oC and stirred until complete dissolution. Then, zinc 
dust (4.1 g, 62.45 mmol, 2 eq) was added followed by the dropwise addition of concentrated 
hydrochloric acid (13 mL), for 1 hr maintaining the reaction temperature between 70-80oC. 
The reaction mixture was stirred for further 4 hr at the same temperature. Upon completion of 
the reaction, the solution mixture was filtered whilst hot in order to remove the zinc residues. 
Then, the filtrates were extracted (5x) with a mixture of ethyl acetate (10 mL) and 
dichloromethane (50 mL). The combined organic extracts were dried over magnesium 
sulphate and concentrated under reduced pressure affording the title compound (62) as white 
solid (3.23 g, 25.61 mmol, 82%). Mp: 148-150oC [lit: 145-150oC]549. 1H-NMR (400 MHz, 
DMSO-d6): δH: 3.32 (s, 3H, H-8), 6.19 (s, br, 1H, H-7), 7.93 (s, 1H, H-1), 8.9 (s, 1H, H-4) 
ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 19.6 (C-8), 112.4 (C-1), 140.2 (C-4), 145.4 (C-5), 
166.5 (C-2), 174.7 (C-6) ppm.  
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10.4.4.3 Synthesis of 5-(benzyloxy)-2-methyl-4H-pyran-4-one (63) 
 
 
The synthesis was performed according to a modified method previously published.564 In a 
stirred solution of 5-hydroxy-2-methyl-4H-pyran-4-one (62) (2 g, 15.86 mmol, 1 eq) in dry N, 
N- dimethylformamide (100 mL), potassium carbonate (4.82 g, 34.9 mmol, 2.2 eq.) and benzyl 
bromide (2.26 mL, 19 mmol, 1.2 eq) were added. The resulting solution mixture was stirred 
overnight at 80oC. Upon completion of the reaction, the solvents were evaporated to dryness 
and the resulting slurry was taken up with water (30 mL). Then, it was extracted with 
dichloromethane (3x50 mL). The combined organic extracts were washed with sodium 
hydroxide (1M, 50 mL) dried over magnesium sulphate and concentrated under reduced 
pressure affording compound 63 as a dark red oil that solidified on standing (2.33 g, 10.78 
mmol, 68%). Mp: 50-52oC [lit: 48-53oC].564 1H-NMR (400 MHz, DMSO-d6) δH: 3.32 (s, 3H, 
H-8), 4.88 (s, 2H, H-9), 6.2 (s, 1H, H-1), 7.26-7.37 (m, 5H, H-11, H-12, H-13), 8.08 (s, 1H, 
H-4) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 19.5 (C-8), 70.9 (C-9), 113.9 (C-1), 128.6 
(Ar), 128.7 (Ar), 128.9 (Ar), 136.8 (C-10), 141.8 (C-4), 146.8 (C-5), 165.8 (C-2), 173.7 (C-6) 
ppm.  
10.4.4.4 Synthesis of (2S)-2-amino-3-(5-hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-
yl)propanoic acid (L-SK-8) 
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In a solution mixture of ethanol: water (42 mL: 85 mL) sodium hydroxide pellets (370 mg, 
9.25 mmol, 1 eq) were added adjusting the pH to 12. To this solution mixture, 5-(benzyloxy)-
2-methyl-4H-pyran-4-one (63) (2.0 g, 9.25 mmol, 1eq) and (2S)-3-amino-2-{[(tert-
butoxy)carbonyl]amino}propanoic acid (L-59) (1.89 g, 9.25 mmol, 1 eq) were added. The 
resulting solution mixture was stirred at RT for 8 days. Upon completion of the reaction, the 
pH was adjusted to 2 by the careful addition of conc. Hydrochloric acid. Then the solvents 
were evaporated to dryness under reduced pressure. To the resulting residue, hydrobromic acid 
(30%, 20 mL) was added and the suspension was refluxed for 20 min and then it was 
evaporated to dryness forming the crude product as brown solid. The crude product was 
dissolved in water (20 mL) and the pH was adjusted to 5 by the dropwise addition of 
ammonium hydroxide solution. The resulting solution was kept in at 5oC for two weeks where 
white crystals of compound (L-SK-8) were formed. The crystalline product was collected by 
vacuum filtration and washed with cold water affording compound (L-SK-8) as pure white 
needles (350 mg, 1.65 mg, 18%).  Mp: 172-173oC. 1H-NMR (400 MHz, D2O/CF3COOD, 8:2): 
δH: 1.8 (s, 3H, H-7), 3.79 (t, J= 7.6 Hz, 1H, H-9), 3.9-395. (m, 1H, H-8), 4.1-4.16 (m, 1H, H-
9), 6.32 (s, 1H, H-1), 7.3 (s, 1H, H-4) ppm; 13C-NMR (100 MHz, D2O/CF3COOD, 8:2): δC: 
17.9 (C-7), 50.9 (C-6), 52.7 (C-9), 114.2 (C-1), 130.6 (C-4), 143.2 (C-5), 160.0 (C-2), 161.2 
(C-10), 167.2 (C-6) ppm. HRMS (ESI) for C9H12N2O4; Theoretical [M+H]: 213.0869. 
Measured [M+H]: 213.0823. 
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10.5 Synthesis of the control compounds  
 
10.5.1 Synthesis of L-SK-4 control compounds  
 
10.5.1.1 Synthesis of 3-methoxy-2-methyl-4H-pyran-4-one (64) 
 
 
The synthesis was performed according to a modified method previously published.551 In a 
suspension of maltol (5 g, 41.28 mmol, 1 eq.) in acetone (50 mL) potassium carbonate (16.4 
g, 118.66 mmol, 3 eq) and iodomethane (7.4 g, 49.31 mmol, 1.2 eq) were added sequentially. 
The resulting solution mixture was refluxed for 3 hr. Upon completion of the reaction, the 
solvents were removed under reduced pressure and the resulting residue was partitioned in a 
mixture of dichloromethane/water (1:1) (100 mL). Then the aqueous phase was extracted with 
dichloromethane (3x50 mL). The combined organic extracts were washed with brine, dried 
over magnesium sulphate and concentrated under reduced pressure to afford compound (64) 
as a brown-orange oil (5.44 g, 38.85 mmol, 94%). 1H-NMR (400 MHz, CDCl3) δH: 2.13 (s, 
3H, H-7), 3.65 (s, 3H, H-6), 6.14 (d, J= 10.8 Hz, 1H, H-1), 7.49 (s, J= 10.8 Hz, 1H, H-2) ppm; 
13C-NMR (100 MHz, CDCl3) δC: 14.5 (C-7), 59.8 (C-6), 117.8 (C-1), 145.5 (C-2), 163.7 (C-
3), 159.1 (C-4), 174.8 (C-5) ppm. 
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10.5.1.2 Synthesis of (2S)-amino-3-(3-methoxy-2-methyl-4-oxo-1,4-dihydropyridin-1-
yl)propanoic acid (SK-4C1) 
 
 
In a suspension of 3-methoxy-2-methyl-4H-pyran-4-one (64) (5.44 g, 38.85 mmol 1 eq) in 
water (145 mL) and ethanol (73 mL) containing sodium hydroxide (1.5 g, 37.5 mmol), a 
sample of 3-amino-2S-{[(tert-butoxy)carbonyl]amino}propanoic acid (L-59) (2.11 g, 10.28 
mmol, 0.3 eq) was added. The resulting solution mixture was stirred at RT for 7 days. Upon 
completion of the reaction, the pH was adjusted to 2 by the addition of conc. HCl and the 
solvents were evaporated to dryness under reduced pressure. The resulting residue was 
refluxed with hydrobromic acid (30% w/v, 20 mL) for 20 min. Then the solvents were 
evaporated and the residue was dissolved in water (30 mL), treated with charcoal and filtered. 
Addition of conc. ammonium hydroxide solution to the filtrates until pH 5 cause the 
crystallisation of the product which was collected and by filtration as a brown solid (2.37 g, 
10.5 mmol, 42%). Mp: 170-173oC. 1H-NMR (400 MHz, D2O/CF3COOD, 8:2) δH: 2.13 (s, 3H, 
H-7), 3.27 (s, 3H, H-6), 4.09 (t, J= 7.2 Hz, 1H, H-9), 4.28-4.51 (m, 2H, H-8), 6.7 (d, J= 7.2 
Hz, 1H, H-1), 7.76 (d, J= 7.2 Hz, 1H, H-2) ppm; 13C-NMR (100 MHz, 400 MHz, 
D2O/CF3COOD, 8:2) δC: 12.8 (C-7), 49.3 (C-6), 51.1 (C-8), 60.9 (C-9), 119.5 (C-1), 142.9 (C-
2), 144.7 (C-3), 150.7 (C-4), 167.5 (C-10), 176.3 (C-5) ppm. HRMS (ESI) for C10H14N2O4; 
Theoretical [M+H]: 227.1031. Measured [M+H]: 227.1069. 
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10.5.1.3 Synthesis of 1-(2-aminoethyl)-3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-
one (65) 
 
 
The synthesis was performed according to a modified method previously published.552 In a 
suspension of 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (60) (3 g, 13.9 mmol, 1 eq) 
in EtOH/water mixture (20/15 mL) sodium hydroxide (0.5 g, 12.5 mmol) was added. 
Ethylenediamine (3.3 mL, 49.3 mmol, 3.5 eq.) was added to the stirred solution was heated at 
70oC for 4 hr and then it was allowed to cool to RT overnight. The solution mixture was 
acidified to pH 1 by the addition of concentrated hydrochloric acid. The resulting mixture was 
concentrated under reduced pressure affording an orange salt which was washed with excess 
of acetone. The salt was collected by filtration, dissolved in water (20 mL), basified to pH 12 
by aqueous solution of sodium hydroxide (10 M) and extracted in dichloromethane (4x50 mL). 
The organic extracted were concentrated under reduced pressure affording the title compound 
(65) as brown oil (2.79 g, 10.8 mmol, 77%). 1H-NMR (400 MHz, D2O) δH: 2.30 (s, 3H, H-6), 
3.30 (t, J= 7.6 Hz, 2H, H-13), 4.47 (t, J= 7.6 Hz, 2H, H-12), 5.01 (s, 2H, H-7), 7.03 (d, J= 6.8 
Hz, 1H, H-1), 7.29-7.36 (m, 5H, H-9, H-10, H-11), 8.06 (d, J= 6.8 Hz, 1H, H-2) ppm; 13C-
NMR (100 MHz, D2O) δC= 13.2 (C-6), 38.1 (C-13), 52.5 (C-12), 75.6 (C-7), 114.1 (C-1), 
128.9 (Ar), 129.3 (Ar), 129.7 (Ar), 135.2 (Ar), 142.5 (C-2), 143.2 (C-3), 147.01 (C-4), 166.0 
(C-5) ppm.  
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10.5.1.4 Synthesis of 1-(2-aminoethyl)-3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-
one (SK-4C2) 
 
 
The synthesis was performed according to a modified method previously published.552 In a 
suspension of 1-(2-aminoethyl)-3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (65) (2 g, 
7.74 mmol, 1 eq)  in methanol (30 mL) a catalytic amount of Pd/C (10%, 580 mg, 5.45 mmol, 
0.7 eq.) was added. The reaction mixture was stirred under hydrogen gas at RT for 3 hr. Upon 
completion of the reaction, the solution mixture was filtrated over a pad of Celite, and 
concentrated under reduced pressure affording the title compound (SK-4C2) as pale yellow 
crystals (1.17 g, 6.97 mmol, 90%). Mp: 143-148oC. [lit: 142-146oC].552 1H-NMR (400 MHz, 
D2O) δH: 2.56 (s, 3H, H-6), 2.86 (t, J= 6.8 Hz, 2H, H-8), 4.52 (t, J= 6.8 Hz, 2H, H-7), 7.37 (d, 
J= 6.8 Hz, 1H, H-1), 8.28 (d, J= 6.8 Hz, 1H, H-2) ppm; 13C-NMR (100 MHz, D2O) δC: 12.9 
(C-6), 34.1 (C-7), 52.1 (C-8), 111.0 (C-1), 138.9 (C-2), 142.4 (C-3), 143.2 (C-4), 159.0 (C-5) 
ppm. HRMS (ESI) for C8H12N2O2; Theoretical [M+H]: 169.0977. Measured [M+H]: 
169.0859. 
 
10.5.1.5 Synthesis of 3-[3-(benzyloxy)-2-methyl-4-oxo-1,4-dihydropyridin-1-
yl]propanoic acid (66) 
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The synthesis was performed according to a modified method previously published.553 In a 
suspension of 3-(benzyloxy)-2-methyl-1,4-dihydropyridin-4-one (60) (14.0 g, 65.4 mmol, 1 
eq) in a mixture of ethanol/H2O (1:1, 100 mL), β-alanine (7.0 g, 78.47 mmol, 1.2 eq) was 
added and the pH was adjusted to 13 by the addition of aqueous sodium hydroxide solution 
(10M, ~50 mL). The reaction mixture was refluxed overnight and then it was allowed to cool 
at RT. Then the reaction mixture volume was reduced by ~1/3 followed by the addition of 
water and the re-adjustment of pH to 4 by the dropwise addition of aqueous solution of 
hydrochloric acid (6M). The resulting solution was extracted with dichloromethane (4x75 
mL). The combined organic extracts were washed with brine, dried over anhydrous 
magnesium sulphate and concentrated under reduced pressure to afford a pale brown solid of 
compound 66 (12.21 g, 42.5 mmol, 65%). Mp: 169-172oC [lit: 172-173oC].553 1H-NMR (400 
MHz, D2O/CF3COOD, 8:2) δH: 2.10 (s, 3H, H-6), 2.70 (t, J= 7.0 Hz, 2H, H-13), 4.11 (t, J= 7.0 
Hz, 2H, H-12), 5.21 (s, 2H, H-7) 6.42 (d, J= 7.5 Hz, 2H, H-1), 7.28-7.42 (m, 6H, H-2, H-9, H-
10, H-11) ppm; 13C-NMR (100 MHz, D2O/CF3COOD, 8:2) δC: 12.8 (C-6), 34.73 (C-13), 46.5 
(C-12), 71.3 (C-7), 118.4 (C-1), 127.1 (Ar), 127.6 (Ar), 128.3 (Ar), 135.3 (Ar), 141.8 (C-3), 
143.6 (C-4), 142.8 (C-2), 174.5 (C-14), 176.4 (C-5) ppm.  
10.5.1.6 Synthesis of 3-(3-hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-yl)propanoic 
acid (SK-4C3) 
 
The synthesis was performed according to a modified method previously published.709 In a 
suspension of 3-[3-(benzyloxy)-2-methyl-4-oxo-1,4-dihydropyridin-1-yl]propanoic acid (66) 
(1 g, 3.48 mmol, 1 eq)  in ethanol (20 mL) a catalytic amount of Pd/C (10%) was added. The 
reaction mixture was stirred under hydrogen gas at RT for 6 hr. Upon completion of the 
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reaction, the solution mixture was filtrated over a pad of Celite, and concentrated under 
reduced pressure affording the crude compound as brown crystals which was then purified by 
recrystallization from acetone/ diethyl ether, forming the titled compound (SK-4C3) as white 
crystals (600 mg, 2.99 mmol, 86%). Mp: 207-208oC. [lit: 200-205oC]709. 1H-NMR (400 MHz, 
D2O/CF3COOD, 8:2) δH: 2.13 (s, 3H, H-6), 2.65 (t, J= 7.0 Hz, 2H, H-8) 4.16 (t, J= 7.0 Hz, 
2H, H-7), 6.42 (d, J= 7.5 Hz, 2H, H-2), 7.63 (d, J= 7.5 Hz, 2H, H-1) ppm; 13C-NMR (100 
MHz, D2O/CF3COOD, 8:2) δC: 11.2 (C-6), 35.0 (C-8), 46.9 (C-7), 119.0 (C-1), 132.4 (C-3), 
140.1 (C-4), 142.2 (C-2), 176.5 (C-9), 178.1 (C-5) ppm. HRMS (ESI) for C9H11NO4; 
Theoretical [M+H]: 198.0766. Measured [M+H]: 198.0966. 
10.5.2 Synthesis of rac-SK-2 control 
 
10.5.2.1 Synthesis of rac-3-amino-3-(4-chloro-5-hydroxypyridin-2-yl)propanoic acid 
(SK-2C1) 
 
 
In a solution of conc. hydrochloric acid (25 mL), a sample of 1,3-diethyl 2-{[5-(benzyloxy)-
4-chloropyridin-2-yl]methyl}-2-acetamidopropanedioate (44) (3 g, 6.68 mmol) were added. 
The resulting solution mixture was refluxed for 5 hr and then the solution was evaporated to 
dryness, forming a yellow powder which was dissolved in water (10 mL), treated with charcoal 
and filtered. The pH of the filtrates was adjusted to 5 by the dropwise addition of conc. 
ammonium hydroxide solution, which was led to precipitation of the title compound (SK2C-
1). The product was collected by filtration and washed with water, acetone and light petroleum 
affording compound (SK-2C1) as  pale yellow crystals. (1.35 g, 6.34 mmol, 95%). Mp: 178-
179oC. 1H-NMR (400 MHz, D2O/CF3COOD; 8:2) δH: 2.96-3.07 (m, 2H, H-7), 3.9 (t, J= 6.4 
Hz, 1-H, H-8). 7.49 (s, 1H, H-3), 7.75 (s, 1H, H-6) ppm; 13C-NMR (100 MHz, 
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D2O/CF3COOD; 8:2) δC: 31.6 (C-7), 51.0 (C-8), 116.3 (C-3), 119.2 (C-4), 140.6 (C-6), 151.6 
(C-2), 160.6 (C-5), 168.7 (C-9) ppm. 
10.6 Synthesis of LAT-1 competitive substrate  
 
10.6.1 Synthesis of 1,3-diethyl 2-acetamido-2-[(naphthalen-2-yl)methyl]propanedioate 
(67)  
 
 
The synthesis was performed according to a modified method previously published.710 In a 
stirred solution of ethanol (50 mL) cooled to 0oC and under nitrogen, metallic sodium (260 
mg, 11.3 mmol, 1 eq) was added and allowed to stir until complete dissolution. Then diethyl 
acetamidomalonate (2.45 g, 11.3 mmol, 1 eq) was added and the resulting solution mixture 
was stirred for further 10 min before the addition of 2-(bromomethyl) naphthalene (2.5 g, 11.3 
mmol, 1 eq). The resulting mixture was allowed to reflux overnight. Upon completion of the 
reaction, the solution was allowed to cool at RT before it was cooled at 0oC, where white 
crystals of the title compound (67) were precipitated. The crystals were collected by filtration 
and washed with excess of ethanol affording intermediate 67 as white crystals (3.1 g, 8.67 
mmol, 77%). Mp: 117-122oC. [lit: 120-122oC]710. 1H-NMR (400 MHz, DMSO-d6) δH: 1.19 (t, 
J= 7.2 Hz, 6H, H-18), 1.97 (s, 3H, H-12), 3.60 (s, 2H, H-11), 4.18 (q, J= 7.2 Hz, 4H, H-17), 
7.08 (d, J= 8.8 Hz, 1H, H-8), 7.42-7.46 (2H, H-2, H-3), 7.77 (s, 1H, H-5), 7.76-8.06 (m, 3H, 
H-1, H-4, H-13) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 14.4 (C-18), 22.7 (C-12), 38.2 (C-
11), 62.4 (C-17), 67.7 (C-15), 126.29 (Ar), 126.58 (Ar), 126.59 (Ar), 127.88 (Ar), 128.01 (Ar), 
128.7 (Ar), 129.2 (Ar), 132.6 (Ar), 133.35 (Ar), 133.4 (Ar), 165.7 (C-16), 170.2 (C-13) ppm.  
305 | P a g e  
 
10.6.2 Synthesis of rac-2-acetamido-3-ethoxy-2-[(naphthalen-2-yl)methyl]-3-
oxopropanoic acid (68) 
 
 
 
 
 
The synthesis was performed according to a modified method previously published.555 In a 
suspension of 1,3-diethyl 2-acetamido-2-[(naphthalen-2-yl)methyl]propanedioate (67) (2.0 g, 
5.59 mmol) in ethanol (15 mL), aqueous solution of sodium hydroxide (4M, 5 mL) was added 
and the resulting solution was stirred at RT for 45 min. The solution was then acidified to pH 
2 by the addition of conc. HCl, and it was evaporated to dryness. The resulting white solid was 
washed with water and dried on air overnight affording the titled compound (68) as white solid 
(1.0 g, 3.21 mmol, 57%). Mp: 133-134oC [lit: 137-139oC].555 1H-NMR (400 MHz, DMSO-d6) 
δH= 1.19 (t, J= 6.8 Hz, 3H , H-18), 1.97 (s, 3H, H-12), 3.56-3.7 (m, 2H, H-11), 4.16 (q, J= 6.8 
Hz, 2H, H-17), 7.17 (d, J= 8.4 Hz, 1H, H-7), 7.48-7.9 (m, 7H, H-1, H-2, H-3, H-4, H-8, H-5, 
H-14) ppm; 13C-NMR (100 MHz, DMSO-d6) δC= 14.3 (C-18), 22.7 (C-12), 38.4 (C-11), 61.9 
(C-17), 67.5 (C-15), 116.9 (Ar), 119.8 (Ar), 126.1 (Ar), 126.5 (Ar), 127.8 (Ar), 127.9 (Ar), 
128.0 (Ar), 128.7 (Ar), 129.0 (Ar), 133.8 (Ar), 167.9 (C-16), 169.5 (C-19), 169.9 (C-13) ppm. 
10.6.3 Synthesis of rac- ethyl 2-acetamido-3-(naphthalen-2-yl)propanoate (69) 
 
 
 
 
 
The synthesis was performed according to a modified method previously published.555 A 
solution of 2-acetamido-3-ethoxy-2-[(naphthalen-2-yl)methyl]-3-oxopropanoic acid (68) (900 
mg, 2.86 mmol)  in 1, 4-dioxane (20 mL) was refluxed for 2 hr . The solution was allowed to 
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cool at RT and then it was concentrated under reduced pressure affording a yellow slurry that 
it was taken up in ethyl acetate (20 mL) and washed with aqueous solution of sodium hydrogen 
carbonate (5%, 15 mL). The organic phase washed with brine, dried over anhydrous 
magnesium sulphate and concentrated under reduced pressure affording the titled intermediate 
(69) as a yellow oil which crystallized on standing (670 mg, 2.48 mmol, 87%). Mp: 133-134oC 
[lit: 137-139oC].555 1H-NMR (400 MHz, DMSO-d6) δH: 1.06 (t, J= 8.4 Hz, 3H, H-18), 1.8 (s, 
3H, H-12), 3.03-3.2 (m, 2H, H-11), 4.05 (q, J= 8.4 Hz, 2H, H-17), 4.53-4.58 (m, 1H, H-15), 
7.4-7.55 (m, 3H, H-2, H-3, H-7), 7.72 (s, 1H, H-5), 8.41 (d, 1H, J= 4 Hz, H-7), 7.83-7.88 (m, 
3H, H-1, H-4, H-8) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 14.6 (C-18), 22.7 (C-12), 37.5 
(C-11), 54.2 (C-15), 60.9 (C-17), 117.0 (Ar), 126.0 (Ar), 126.5 (Ar), 127.9 (Ar), 128.0 (Ar), 
128.1 (Ar), 128.2 (Ar), 132.4 (Ar), 133.4 (Ar), 135.4 (Ar) 169.8 (C-16), 172.2 (C-13) ppm. 
 
10.6.4 Synthesis of ethyl (2S)-2-acetamido-3-(naphthalen-2-yl)propanoate  (70) and 
(2R)-2-acetamido-3-(naphthalen-2-yl)propanoic acid (71) 
 
 
 
The synthesis was performed according to a modified method previously published.555 In a 
suspension of rac- ethyl 2-acetamido-3-(naphthalen-2-yl)propanoate (69) (660 mg, 2.31 
mmol, 1 eq) in a mixture of acetonitrile/water (1:1, 24 mL), an aqueous solution of potassium 
chloride (0.01 M, 20 mL) was added. The resulting mixture was stirred vigorously and sodium 
hydrogen carbonate (11.37 mg, 135.3 µmol, 0.05 eq) was added followed by Subtilisin (Type 
VIII, 1.1 mg). The pH was maintained at 7.8 by the manual addition of fractions (5-10 µL) of 
aqueous solution of sodium hydroxide (1M, 10 mL). The solution mixture was stirred at RT 
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until no more sodium hydroxide was used up (pH stabilization). Then the volatiles were 
removed under reduced pressure and the resulting off white solid of the (S)-ester (70) was 
removed by vacuum filtration and dried on air overnight (320 mg, 1.18 mmol, 51%). Mp: 133-
134oC [lit: 137-139oC]555. 1H-NMR (400 MHz, DMSO-d6) δH: 1.06 (t, J= 8.4 Hz, 3H, H-18), 
1.8 (s, 3H, H-12), 3.03-3.2 (m, 2H, H-11), 4.05 (q, J= 8.4 Hz, 2H, H-17), 4.53-4.58 (m, 1H, 
H-15), 7.4-7.55 (m, 3H, H-2, H-3, H-7), 7.72 (s, 1H, H-5), 8.41 (d, 1H, J= 4 Hz, H-7), 7.83-
7.88 (m, 3H, H-1, H-4, H-8) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 14.6 (C-18), 22.7 (C-
12), 37.5 (C-11), 54.2 (C-15), 60.9 (C-17), 117.0 (Ar), 126.0 (Ar), 126.5 (Ar), 127.9 (Ar), 
128.0 (Ar), 128.1 (Ar), 128.2 (Ar), 132.4 (Ar), 133.4 (Ar), 135.4 (Ar), 169.8 (C-16), 172.2 (C-
13) ppm 
The filtrates were then extracted with ethyl acetate (3x30 mL) and then acidified to pH 1 with 
aqueous solution of hydrochloric acid (6 M, ~15 mL), and cooled to 0 oC for 5 hr. The white 
precipitate of the (R)-amino acid (71) was collected by filtration and dried on air overnight 
(250 mg, 0.96 mmol, 42%). Mp: 187-189oC [lit: 188-189oC].555 1H-NMR (400 MHz, DMSO-
d6) δH: 1.73 (s, 3H, H-12), 2.94-3.33 (m, 2H, H-11), 4.46-4.85 (m, 1H, H-15), 7.37 (d, J= 8.4 
Hz, 1H, H-7), 7.42-7.44 (m, 3H, H-1, H-4, H-8), 7.68 (s, 1H. H-5), 7.78-7.83 (m, 2H, H-2, H-
3), 8.22 (d, 1H, J= 5.6 Hz, H-14) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 22.8 (C-12), 37.5 
(C-11), 54.0 (C-15), 126.0 (Ar), 126.5 (Ar), 127.9 (Ar), 127.95 (Ar), 127.99 (Ar), 128.1 (Ar), 
128.3 (Ar), 132.3 (Ar), 133.4 (Ar), 135.9(Ar), 169.7 (C-16), 173.6 (C-13) ppm.  
10.6.5 Synthesis of (2R)-2-amino-3-(naphthalen-2-yl)propanoic acid (R-72) 
 
  
 
 
 
The synthesis was performed according to a modified method previously published.555 A 
suspension of (2S)-2-acetamido-3-(naphthalen-2-yl)propanoate  (71) (200 mg, 0.74 mmol) in 
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aqueous hydrochloric acid (6M, 20 mL) was refluxed for 4 hr. Upon completion of the reaction 
the excess of solvents were removed under reduced pressure affording the titled compound as 
a white solid (154 mg, 0.67 mmol, 90%). Mp: 250-252oC [lit: 251-252oC].555 1H-NMR (400 
MHz, DMSO-d6) δH: 3.18-3.26 (m, 2H, H-11), 4.20-4.23 (m, 1H, H-13), 7.35 (d, J= 8 Hz, 1H, 
H-7), 7.40-7.46 (m, 3H, H-1, H-4, H-8), 7.7 (s, 1H, H-5), 7.75-7.81 (m, 2H, H-2, H-3), 8.2 (s, 
2H, H-12) ppm; 13C-NMR (100 MHz, DMSO-d6) δC: 36.3 (C-11), 53.6  (C-13), 111.1 (Ar),  
114.0 (Ar), 114.1 (Ar), 116.8 (Ar), 128.2 (Ar), 158.3 (Ar), 158.7 (Ar), 158.7 (Ar), 159.1 (Ar), 
159.5 (Ar), 173.2 (C-14) ppm.  
 
10.6.6 Synthesis of (2S)-2-amino-3-(naphthalen-2-yl)propanoic acid (S-72) 
 
 
 
 
As described for (2R)-2-amino-3-(naphthalen-2-yl)propanoic acid (R-72). (155 mg, 0.72 
mmol, 92%).  Mp: 253-256oC [lit: 251-252oC].555 1H-NMR (400 MHz, DMSO-d6) δH: 3.18-
3.26 (m, 2H, H-11), 4.2-4.23 (m, 1H, H-1), 7.35 (d, J= 8 Hz, 1H, H-7), 7.40-7.46 (m, 3H, H-
1, H-4, H-8), 7.7 (s, 1H, H-5), 7.75-7.81 (m, 2H, H-2, H-3), 8.2 (s, 2H, H-12) ppm; 13C-NMR 
(100 MHz, DMSO-d6) δC: 36.3 (C-11), 53.6  (C-13), 111.1 (Ar),  114.0 (Ar), 114.1 (Ar), 116.8 
(Ar), 128.2 (Ar), 158.3 (Ar), 158.7 (Ar), 158.7 (Ar), 159.1 (Ar), 159.5 (Ar), 173.2 (C-14) ppm. 
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11 Experimental procedures – Biological screening and evaluation of the 
SK-n compounds 
11.1 Cell Culture and Methodologies  
 
11.1.1 Cell lines 
 
The experimental model that has been used consisted of three different skin cell lines: (A) a 
normal immortalized keratinocyte (HaCaT) cell line, (B) an epidermoid carcinoma (A431) cell 
line and (C) a primary malignant melanoma (A375) cell line. In addition to these, the 
experimental model include a variation of malignant melanoma cell lines from different tissues 
including: (D) human brain metastatic malignant melanoma (VMM-1) cell line, (E) human 
lymph node metastatic malignant melanoma (Hs 294T) cell line as well as (F) murine 
malignant melanoma (B16 F10) cell line (Table 24 and 25). 
 
Table 24: List of cell lines used for the in vitro human malignant melanoma model. 
Cell line Company 
HaCaT A kind gift from Dr Sharon Brody (Dermal Toxicology and Effects 
Group; Centre for Radiation, Chemical and Environmental Hazards; 
Public Health England, UK) 
A431 Purchased from Sigma-Aldrich (St. Louis, MO, USA) 
A375 Purchased from Sigma-Aldrich (St. Louis, MO, USA) 
VMM-1 Purchased from ATCC (Manassas, VA, USA) 
Hs 294T Purchased from ATCC (Manassas, VA, USA) 
B16 F10 Purchased from ATCC (Manassas, VA, USA) 
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Table 25: Characterization of the different cell lines used for the in vitro model of malignant 
melanoma. 
Cell Line HaCaT A431 A375 VMM-1 Hs 294T B16 F10 
Organism Homo sapiens (Human) 
Mus 
Musculus 
(Mouse) 
Ethnicity Caucasian - 
Gender Male Female Female Male Male - 
Tissue Skin Epidermis Skin Brain  
Lymph 
node  
Skin 
Morphology 
Monolayer, 
adherent 
Epithelial, 
adherent 
Epithelial, 
adherent 
Epithelial, 
adherent 
Mixed 
stellate 
and 
polygonal,  
adherent  
Adherent 
Mixture of 
Spindle-
shaped and 
epithelial-
like cells 
Description 
In vitro 
spontaneously 
transformed 
keratinocytes 
from 
histologically 
normal skin 
Established 
from solid 
tumors in the 
skin/epidermis  
Derived 
from  the 
skin  
Established 
from brain 
metastatic 
malignant 
melanoma 
(Stage IV)  
Established 
from lymph 
node 
malignant 
melanoma 
(Stage IV)  
Derived 
from the 
parental 
B16 cell 
lines as they 
display 
significantly 
greater 
tissue-
invasive 
abilities 
Disease N/A 
Epidermoid 
Carcinoma 
Malignant Melanoma 
Tumorigenic No Yes Yes Yes Yes Yes 
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11.1.2 Materials for cell culture 
 
Table 26: List of materials used for cell cultures [unless stated, chemicals were from Sigma 
Aldrich (St. Louis, MO, USA), Invitrogen (Carlsbad, CA, USA) and were of analytical grade. 
Reagents Components 
Complete Growth Media 
for A375, A431 and 
HaCaT cells 
DMEM (Dulbecco’s Modified Eagle Medium) (Labtech 
Internationl Ltd, East Sussex, UK) high glucose was 
supplemented with 10 fetal bovine resume heat-inactivated 
(Labtech), 2 mM L-Glutamine (Labtech), and 1% (v/v) 
penicillin/streptomycin mix.  
Complete Growth Media 
for Hs 294T and B16 F10 
DMEM (Dulbecco’s Modified Eagle Medium) (Labtech 
Internationl Ltd, East Sussex, UK) high glucose was 
supplemented with 10 fetal bovine resume heat-inactivated 
(Labtech), 4 mM L-Glutamine (Labtech), and 1% (v/v) 
penicillin/streptomycin mix. 
Complete Growth Media 
for VMM-1 
RPMI-1640 (Labtech Internationl Ltd, East Sussex, UK) high 
glucose was supplemented with 10 fetal bovine resume heat-
inactivated (Labtech), 2 mM L-Glutamine (Labtech), and 1% 
(v/v) penicillin/streptomycin mix. 
Phosphate Buffer Saline 
(PBS) [1X] 
 [NaCl]= 140 mM, [KCl]= 2.7 mM, [Na2HPO4]= 10 mM, 
[KH2PO4]= 1.7 mM, pH 7.4 
Trypsin-EDTA Solution 
[1X] 
Trypsin-EDTA 0.25% in PBS w/o Mg2+, w/o Ca2+ (Labtech) 
Cell Culture plates & 
flasks 
Corning Inc., NY, USA 
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11.1.3 Cells recovery 
 
All cell lines were stored under vapor phase of liquid nitrogen for long term storage in fetal 
bovin serum (FBS) containing 10% (v/v) DMSO. Prior to use, cells were rapidly thawed and 
resuspended in ~5 mL of complete growth media (depending of type of cell line) and 
centrifuged at 2000 rpm for 2 min at RT. The freezing media was aspirated and the cells were 
resuspended in complete growth media. Then the cells suspensions were transferred into a 25 
cm3 cell culture flask. All cell lines were authenticated with the STR method and were also 
tested for mycoplasma contamination. All cell lines were cultured for 15-20 passages before 
new stocks were utilized.  
 
11.1.4  Cells propagation 
 
All cell lines were cultured in flasks containing complete growth media and maintained in 5% 
atmospheric CO2, at 37oC, in a humidified incubator. Cells were subcultured via trypsinization 
2-3 times per week prior to reaching 100% confluence. More specifically, cells were washed 
with ~5 mL PBS after aspirating growth media and were then washed with 1 mL of trypsin-
EDTA (1X). Fresh trypsin-EDTA was added in the flask (1 mL for A375, B16 F10 cells or 2 
mL for HaCaT, A431, VMM-1 and Hs 294T cells) and then cells were placed in the incubator 
until they detached from the flask's surface (5-10 min depending on the cell line). The cells 
were then observed under the microscope to ensure that they had detached and 4-5 mL of 
complete growth media was added into the flask in order to deactivate trypsin-EDTA. Finally, 
cells were resuspended and the wanted number of them was returned in the flask while more 
media was added (10-15 mL).  
11.1.5 Cells plating  
 
After trypsinization and suspension, the cells in complete growth media were transferred into 
a falcon tube and then centrifuged at 2,000 rpm for 2 min at room temperature. Media was 
then aspirated, and cells were thoroughly suspended in fresh media (5-12 mL according to the 
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size of cell pellet) while a 30 μL sample was transferred into a microcentrifuge tube. An equal 
amount of trypan blue solution 0.4% (v/v) (HyClone Inc, South Logan, USA) was added, into 
the tube, and mixed with the sample of cell suspension. For the determination of cell number, 
10 μL of the previously mentioned mix was loaded into a Neubauer counting chamber 
(hemocytometer) and the number of viable cells were counted, under the microscope. The 
concentration of cells (number of cells/ mL) was calculated by using the following formula:  
[𝐂𝐄𝐋𝐋𝐒] =  
𝑵
𝟒
𝐱 𝐃𝐅 𝐱 𝟏𝟎𝟒 
Where N= the number of cells counted in the 4 squares of the counting chamber, DF = 2 (1:1 
dilution with trypan blue solution) and 104 = conversion factor to convert 10-4 mL to 1 mL 
(calculated according to the dimensions of the small square). After estimating the 
concentration of cells in the suspension, the desired number of cells were seeded into 100 mm3, 
cell culture dishes, 96-well plates, etc. (according to the requirements of the various 
experimental protocols). 
11.2 Morphological observation of cells  
A375, A431 and HaCaT cells were seeded in 100 mm dishes and exposed to either complete 
medium only (control) or 100 µM of L-SK-4 for 24, 48 and 72 hr. The density of A375 cells 
was 1.4 × 106, 0.7 × 106 and 0.4 × 106 per dish and the density of A431 and HaCaT cells was 
1.8 x 106, 1.0 x 106 and 0.7 x 106 for 24, 48 and 72 hr, respectively. At the indicated time 
points, the morphology of cells was observed by an inverted phase contrast microscope (ZOE 
fluorescent cell imager, Bio-rad, CA, USA) and images were captured at 20x magnification. 
11.3 Determination of cell viability – Alamar Blue Assay  
11.3.1 Principle of the assay: 
 
The assay is based on the ability of the indicator resazurin (blue dye) (non-fluorescent) to be 
uptaken and reduced by live cells into rezorufin (pink color, fluorescent) by the oxidation of 
the coenzyme NADH/H+. (Figure 111).711  
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Figure 111: Reduction of the non-fluorescent reassuring into highly fluorescence resorufin by 
metabolically active (live) cells. The electrons required for the reduction reaction arise from 
the oxidation of the NADH/H+. 712 
The detection of the levels of oxidation/reduction by means of absorbance or fluorescence 
intensity, indicates the quantitatively measure of cell viability.711 
 
11.3.1.1 Experimental procedure: 
 
The Alamar-blue assay was utilized in this set of experiments. A375, A431, and HaCaT cells 
were seeded in 100 µL/well into 96-well plates and incubated overnight prior to exposure to 
each of the hydroxypyridone compounds (e.g. SK-n compounds). Density of A375 cells was 
8,000, 4,000, 2,000 cells/well and for A431 and HaCaT cells 10,000, 5,000, 2,500 cells/well 
for 24, 48 and 72 hr, respectively. On the following day, cells were exposed to a range of 
concentrations of the SK-n compounds (10-1000 µM). In the case of co-treatments, A375 cells 
have been pretreated for 2 hr with either L-thyroxin (0.1-1 mM), BCH (0.5-10 mM), reduced-
GSH (1.5-3 mM) or Myriocin (0-50 µM) prior to the addition of L-SK-4 (100 µM) over 
different incubation periods. For control conditions, cells were incubated with complete 
medium only. At the indicated time points, resazurin [dissolved in PBS (1mg/ mL final 
concentration)] was added in an amount equal to 1/10 of the volume in each well and incubated 
for 2-4 hr (depending on the type of cancer cell line), at 37oC. The plates were then centrifuged, 
and absorbance was recorded at 570 nm and 600 nm (reference wavelength) using a Spark 
multimode plate reader (Tecan, Switzerland). The levels of cell viability were estimated and 
expressed as percentage of control cells. 
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11.4  Flow Cytometry Methodologies 
The following experiments have been done using FACS Canto II flow cytometer (BD 
Biosciences, San Jose, CA, USA. Details about the reagents that were used can be found on 
Table 27 
 
Table 27: Reagents used in flow cytometry experiments 
Reagent Supplier Item No 
DHR 123 Sigma Aldrich Ltd D1054 
CellEvent Caspase 3/7 ThermoFisher Scientific Ltd C10423 
JC-1 Invitrogen 65-0851-38 
FxCycle PI/RNase ThermoFisher Scientific Ltd F10797 
DAPI Sigma Aldrich Ltd 10236276001 
 
 
 
11.4.1 Determination of ROS kinetics  
 
11.4.1.1 Principle of the assay: 
 
Dihydrorhodamine 123 (DHR 123) is a non-fluorescent compound that reacts rapidly with 
either ROS or RNS and it is converted into rhodamine 123 which exhibits fluorescent intensity 
(Figure 112A).713 In addition to this, 4’,6 – diamidino-2-phenylindole (DAPI) is a fluorescent 
stain that can diffuse though the membranes of the dead cells only. Once it reaches the nucleus 
of the cell, it binds (by intercalation) to adenine-thymine rich regions of the major groove of 
the DNA (Figure 112B).714 The utilization of DAPI aims to exclude the dead cells from the 
analysis, as ROS are generated by live cells.715,716  
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Figure 112: (A) DHR 123 is oxidized as illustrated by alkylperoxyl radicals into the 
fluorescence Rhodamine 123. (B) Structure of DAPI.713,716   
The detection of the levels of rhodamine 123 by means of fluorescent intensity through flow 
cytometry, indicates the quantitatively the presence of ROS, whereas the fluorescent intensity 
of DAPI corresponds to the quantification of the dead cells. 
11.4.1.1.1 Experimental procedure: 
Cells were seeded in 60 mm dishes (0.35 × 106, 0.25 × 106 and 0.15 × 106 per dish for A375), 
(0.45 × 106, 0.35 × 106 and 0.25 × 106 per dish for Hs 294T), (0.3 × 106, 0.2 × 106 and 0.1 × 
106 per dish for B16-F10), (0.8 × 106, 0.6 × 106 and 0.4 × 106 per dish for VMM-1, HaCaT 
and A431) for 24, 48 and 72 hr, respectively and exposed to L-SK-4 (100 µM) with or without 
pretreatment with either reduced GSH (1.5 mM) or myriocin (50 nM). Then, they were 
harvested and washed twice with PBS and a single cell suspension of 106 cells/mL was 
prepared. DHR 123 (10 µM) was added in the suspension and incubated for 5 min at 37 oC. 
Then, DAPI (1 µM) was added to each sample and incubated for 5 min in order to determine 
the percent of dead cells in the suspension. Data acquisition and analysis of 10,000 events, for 
each sample. DAPI-positive cells were excluded from further analysis of the results. 
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11.4.2 Determination of apoptosis  
 
11.4.2.1 Principle of the assay: 
 
CellEvent Caspase 3/7 is a tetrapeptide (DVED) conjugated to a nucleic acid binding dye 
which is non-fluorescence. Upon activation of either caspase 3 or 7, in apoptotic cells, the 
bond between the DVED and the dye is cleaved (by caspase 3 or 7) liberating the dye which 
binds to the DNA and producing a fluorogenic response at 530 nm (Figure 113).717 
 
Figure 113: Activation of caspase 3/7 leads to the dissociation of the non-fluorescent dye from 
the DEVD peptide. Once it dissociated, it can reach the nucleus and upon DNA binding it 
emits fluorescent signal.  
Once again DAPI is used in order to exclude dead (necrotic) cells from the analysis. The 
measured fluorescent intensity (through flow cytometry), indicates the quantitatively 
activation of caspase 3/7, whereas the fluorescent intensity of DAPI corresponds to the 
quantification of the dead (necrotic) cells.716,718  
 
11.4.2.1.1 Experimental procedure: 
 
The CellEvent Caspase 3/7 Green flow cytometry assay kit was utilized for the detection of 
apoptosis according to the manufacturer’s instructions. Cells were seeded and allowed to 
adhere overnight in 60 mm dishes (0.35 × 106, 0.25 × 106 and 0.15 × 106 per dish for A375), 
(0.45 × 106, 0.35 × 106 and 0.25 × 106 per dish for Hs 294T), (0.3 × 106, 0.2 × 106 and 0.1 × 
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106 per dish for B16-F10) (0.8 × 106, 0.6 × 106 and 0.4 × 106 for VMM1) per dish for 24, 48 
and 72 hr, respectively and exposed to L-SK-4 (100 µM) with or without pretreatment with 
either reduced GSH (1.5 mM) or myriocin (50 nM). Next, cells were harvested, washed twice 
with PBS and a single cell suspension of 106 cells/mL was prepared. Then, 0.5 µL of CellEvent 
Caspase 3/7 Green detection reagent was added into 0.5 mL of each cell suspension and 
samples were incubated at 37oC for 30 min. Then, DAPI (1 µM) was added to each sample 
and incubated for 5 min in order to determine the percent of dead cells in the suspension. Data 
acquisition and analysis of 20,000 events, for each sample. Caspase-3/7-positive cells were 
identified as apoptotic whereas DAPI-positive cells as necrotic.  
 
11.4.3 Determination of mitochondria membrane depolarization 
 
11.4.3.1 Principle of the assay:  
 
This principle of this assay is based into the ability of molecules to move across the membranes 
of mitochondria using the potential difference (ΔΨ) between the exterior and the interior of 
the mitochondria.719 Under pathological conditions mitochondrial membranes become 
permeable and the potential inside the membrane is decreased whereas the potential of the 
exterior space is increased.719 Therefore, the high potential outside the membrane has the 
ability to pull 1,1’,3,3’-tetraethyl-5-5’,6,6’ tetrachloroimidacarbocyanine iodide (JC-1) 
(Figure 114) stain insidstain inside mitochondrial forming aggregates with characteristic 
absorption/ emission properties.720 In contrast, healthy mitochondria have higher interior 
potential preventing in that way the entrance of JC-1 into mitochondria. JC-1 that is 
accumulated in the exterior space forms monomers with characteristic absorption/ emission 
properties.720 
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Figure 114: Structure of JC-1 stain.  
11.4.3.1.1 Experimental Procedure:  
 
The JC-1 staining solution was used according to the manufacturer’s instructions. The density 
of A375 cells was 0.35 × 106, 0.25 × 106 and 0.15 × 106 cells per dish (60 mm) for 24, 48 and 
72 hr, respectively. Following exposure to L-SK-4 (100 µM) with or without pretreatment with 
myriocin (50 nM), cells were harvested and washed twice with PBS. Then, 0.3 µL of the stain 
(JC-1: 0.1 mg/mL) was added into 0.3 mL of each cell suspension in PBS and samples were 
incubated at 37oC for 30 min. Afterwards cell suspensions were centrifuged at 1000 rpm for 5 
min and the pellets were re-suspended in fresh PBS. Data acquisition and analysis of 10,000 
events, for each sample. 
 
11.4.4 Determination of cell cycle kinetics 
 
11.4.4.1 Principle of the assay: 
 
Propidium Iodide (PI) (Figure 115) is dye that has the ability to intercalate with the major 
groove of double stranded DNA upon cell death.721 It can only penetrate the membranes of 
dead cells and therefore it can be used as an indicator for dead cells. Due to the fact that 
different quantities of DNA exist in the various stages of the cell cycle, PI can be used for the 
identification and quantification of the DNA that is presented in each phase based on the 
fluorescent intensity that PI arise upon DNA binding.721 
 
Figure 115: Structure of PI.  
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11.4.4.1.1 Experimental procedure:  
 
The FxCycle PI/RNase staining solution was used according to the manufacturer’s 
instructions. Following exposure to 100 µM of L-SK-4, cells were harvested and washed twice 
with PBS. The density of; A375 cells was 1.4 × 106, 0.7 × 106 and 0.4 × 106 cells per dish, 
A431 and HaCaT cells was 1.8 × 106, 1.0 × 106, 0.7 × 106 for 24, 48 and 72 hr, respectively. 
Approximately 0.5 × 106 cells were fixed in cold 70% ethanol, for 1 hr or longer, and kept at 
4 oC until further processing. Cells were then washed twice with PBS to remove ethanol and 
finally suspended in FxCycle PI/RNase staining solution for 30 min at RT in the dark. Data 
acquisition and analysis of 10,000 events, for each sample. 
 
11.4.5 Protein Methodologies  
 
11.4.5.1 Preparation of cell lysates and protein determination 
 
A375 cells were plated in 100 mm dishes and cultured overnight at 37oC at a density of 1.4 × 
106, 0.7 × 106 and 0.4 × 106 cells per dish for 24, 48 and 72 hr respectively. Next day, cells 
were treated with L-SK-4 (100 µM) with or without pretreatment with either reduced GSH 
(1.5 mM) or Myriocin (50 nM) for 24, 48 and 72 hr and then trypsinized, washed twice with 
ice-cold PBS and pellets were collected after centrifugation at 2,000 rpm for 3 min at 4oC. Cell 
pellets were then lysed in lysis buffer (10 mM HEPES at pH 7.9, 10 mM KCl, 0.1 mM EDTA, 
1.5 mM MgCl2, 0.2% NP40) and supplemented with Protease Inhibitor Tablets (Thermo 
Scientific, Waltham, MA, USA). Then, they were left on ice while periodically vortexed over 
a 30 min period and sonicated (three cycles at 10 amplitudes for 20 sec on ice) to disrupt 
cellular membranes. Cell lysates were centrifuged at full speed (15,000 rpm) for 10 min at 4oC 
and supernatants were transferred in new tubes. Protein content was determined by utilizing 
the BCA protein assay kit (Thermo Scientific, Waltham, MA, USA), according to the 
manufacturer’s protocols. To carry out the protein concentration quantification, a standard 
curve using Bovine Serum Albumin (BSA) was used. Briefly, a series of various BSA 
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concentrations (0, 0.2, 0.5, 1, 2 μg/ μL) were added into the wells of a 96-well plate by mixing 
the appropriate volumes of dH2O and BSA stock to a final volume of 20 μL. Samples were 
also added at a 1:10 dilution in duplicates. The appropriate volume of working reagent was 
prepared by mixing 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1), and then 
200 μL was loaded in each well. The plate was covered and incubated at 37oC for 30 min. 
Finally, the plate was centrifuged at 2,000 rpm for 2 min before the absorbance was measured 
at 562nm by using a Spark multimode plate reader (Tecan, Switzerland). The unknown protein 
concentrations of the samples were calculated by generating a standard BSA curve. The 
required volume of samples was transferred to new microcentrifuge tubes and loading buffer 
(5X) was added as 4 parts of sample in 1 part of loading buffer. Then, the samples were either 
immediately used or they were stored at -20oC until future usage. 
 
11.4.5.2 Western immunoblotting  
 
Forty micrograms (40 μg) of cytoplasmic protein extracts were separated by SDS-
polyacrylamide gels in SDS Running Buffer (1X) (Table 28) and transferred 
electrophoretically (120 V, 0.35 mA, 2 hr) onto PVDF membranes (either 0.45 or 0.2μm) using 
mini gel tank sand mini blot modules (Invitrogen, Carlsbad, CA, USA) using Transfer Buffer 
(1X). Then the blots were then blocked in 5% non-fat milk powder in TBST buffer (Table 28) 
for 2 hr at RT. After blocking, membranes were washed three times with TBST and incubated 
overnight at 4oC, under agitation, with the appropriate primary antibody and according to the 
manufacturer’s protocol (Table 29). Next day, membranes were incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody (Table 29) for 1 hr at RT, 
under agitation, after being washed three times with TBST. Membranes were washed three 
times with TBST and labelled protein bands were detected by utilizing the SuperSignal West 
Pico PLUS Chemiluminescent Substrate kit from Thermo Scientific (Waltham, MA, USA) 
according to the manufacturer’s protocol. Protein bands were visualized with the use of the 
G:BOX Chemi XX6/XX9 gel imaging system (Syngene, Cambridge, UK). 
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Table 28: List of Buffers used for Western Immunoblottings. 
Buffer Components  
SDS running buffer 
10X 
[Tris Base] 250 mM, [Glycine]= 1% SDS, pH 8.3-8.5 
SDS running buffer 1X 1:100 dilution of the SDS running buffer 10X 
Transfer Buffer 10X  [Tris Base] 250 mM, [Glycine]= 1% SDS, pH 8.3-8.5 
Transfer Buffer 1X 1:100 dilution of the Transfer Buffer 10X, 0.5% (v/v) [SDS]= 
(10% w/v), 20% MeOH, dH2O to bring buffer to desire volume 
Tris Buffered Saline-
Tween 20 (TBST) 1X 
[Tris]= 20 mM, [NaCl]= 150 mM, 0.1% Tween 20 in dH2O, pH 
7.6 
 
Table 29: List of Antibodies used for Western Immunoblottings.  
Antibody Dilution  Blocking Buffer Isotype Company 
Anti-Caspase-8 1:1000 5% BSA in TBST Mouse Cell Signaling  
Anti-Caspase-9 1:1000 5% dry milk in TBST Rabbit Cell Signaling  
Anti-BID 1:1000 5% dry milk in TBST Rabbit Cell Signaling  
Anti-Apaf-1 1:1000 5% BSA in TBST Rabbit Cell Signaling  
Anti-BAX 1:1000 5% BSA in TBST Rabbit Cell Signaling  
Anti-BAK 1:1000 5% BSA in TBST Rabbit Cell Signaling  
Anti-FADD 1:1000 5% BSA in TBST Rabbit Cell Signaling 
Anti-FAS 1:1000 5% dry milk in TBST Rabbit Cell Signaling 
Anti-Tubulin 1:20000 5% dry milk in TBST Mouse Sigma Aldrich 
Horse Anti-
mouse HRP 
conjugate 2o 
Antibody 
1:2000 5% dry milk in TBST Mouse Cell Signaling 
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Goat Anti-rabbit 
HRP conjugate 
2o Antibody 
1:2000 5% dry milk in TBST Rabbit Cell Signaling 
 
11.4.6 Biochemical Assays 
 
Table 30: Details about the assays that have been used for the biochemical characterization. 
Supplier Assay Item No 
Thibarbituric acid (TBARS ) Cambridge Bioscience Ltd Cambridge, UK 10009055 
Protein Carbonyl 
Colorimetric Assay  
 
Cambridge Bioscience Ltd, Cambridge, UK 10005020  
DNA oxidative Damage Elisa 
Assay  
 
Cambridge Bioscience Ltd, Cambridge, UK 589320 
 
11.4.6.1 TBARS assay 
 
11.4.6.1.1 Principle of the assay:  
 
Malondialdehyde (MDA) is one of the major byproducts of lipid peroxidation, therefore its 
quantification can give insides into the magnitude of this effect.722 MDA can react 
stoichiometricaly under acidic conditions and heat with thiobarbituric acid forming a 
fluorescent addduct with characteristic excitiation/ emission properties (Figure 116).723 
 
Figure 116: Stoichiometric reaction of MDA that produced as byproduct of lipid peroxidation 
with thiobarbituric acid.723 
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11.4.6.1.1.1 Experimental procedure: 
 
For the determination of the concentration of malondialdehyde, A375 cells were plated in 100 
mm dishes and cultured overnight at 37oC at a density of 1.4 × 106, 0.7 × 106 and 0.4 × 106 
cells per dish for 24, 48 and 72 hr respectively Next day, cells were treated with L-SK-4 (100 
µM) and then trypsinised and washed twitched with ice-cold PBS and pellets were collected 
after centrifugation at 2,000 rpm for 3 min at 4oC. The pellets were re-suspended in ice-cold 
PBS, and sonicated (three cycles at 10 amplitudes for 20 sec on ice). Afterwards 100 µL of 
each sample has been mixed with 100 µL of SDS solution and the final solution was mixed by 
swirling. Then, 4 mL of the color reagent was added and the solutions were heated at 95 oC for 
1 hr. The reaction has been quenched by their immediate addition to ice for 10 min. After the 
incubation time, the vials were centrifuged at 1600 g at 4oC and allowed to equilibrate at room 
temperature for 30 min. Eventually, 150 µL was loaded in triplicates into a 96 well plate and 
the absorbance was measured at 530 nm. A standard curved was generated using MDA in a 
range of concentrations (0-50 µM). The results have been expressed as nnmols of MDA/mg 
of protein.  
 
11.4.6.2 Protein Carbonyl Colorimetric Assay  
11.4.6.2.1 Principle of the assay: 
 
The side chains of proteins tends to oxidised into the respective carbonyl compounds under 
oxidative stress conditions.724 The identification and quantification of the protein carbonyl 
content, can give information about the magnitute of oxidative stess that it has been induced. 
In this assay the protein carbonyl content was determined using 2,4-dinitrophenylhydrazine 
(2,4-DNPH). Upon condensation of the carbonyl moeity of the protein with 2,4- DNPH a 
yellow/ orange adduct is formed with characteristic absorption properties (Figure 117).725  
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Figure 117: Reaction of protein carbonyl with 2,4-DNPH.725 
 
11.4.6.2.1.1 Experimental procedure:  
 
For the determination of protein carbonyl content, A375 cells were plated in 100 mm dishes 
and cultured overnight at 37oC at a density of 1.4 × 106, 0.7 × 106 and 0.4 × 106 cells per dish 
for 24, 48 and 72 hr respectively Next day, cells were treated with L-SK-4 (100 µM) and then 
trypsinised and collected by centrifugation at 2000 g for 10 min at 4oC. The pellet was then 
re-suspended in PBS (containing 1 mM EDTA) and sonicated (three cycles at 10 amplitudes 
for 20 sec on ice). Then the cell suspensions were centrifuged at 10000 g for 15 min at 4oC 
and the supernatant was kept for assaying.  A volume of 200 µL of each sample was transferred 
into a 2 mL Eppendorf tubes (one tube was sample tube and the other was the control tube – 
for each of the assaying sample). Then 800 µL of 2.4-DNPH was placed in the sample tube 
and 800 µL of 2.5 M HCl was placed into the control tube. All the tubes were vortexed every 
15 min at room temperature in the dark. Afterwards 1 mL of 20% TCA was added into each 
tube and then the samples were vortexed, incubated on ice for further 5 min and centrifuged 
at 10000 g for 10 min at 4oC. The supernatant was discarded, the pellets were re-suspended in 
1 mL of ice-cold 10% TCA solution and then solutions were incubated on ice for 5 min. The 
tubes were then centrifuged at 10000 g for 10 min at 4oC. The supernatant was discarded and 
the pellet was taken up in ethanol/ ethyl acetate (1:1). The sample tubes were centrifuged at 
10000 g for 10 min at 4oC. After repeating this procedure twice, the protein pellet was re 
suspended in 500 µL of guanidine hydrochloride and the final solutions were centrifuged at 
326 | P a g e  
 
10000 g for 10 min at 4oC to remove and left over debris. Afterwards, 220 µL of the 
supernatant (from the sample tube and control respectively) was loaded in triplicates in a 96 
well plate and the absorbance was measured at 370 nm. The results were expressed as 
nmol/mL/mg protein/mL.  
 
11.4.6.3 DNA oxidative Damage Elisa Assay  
 
11.4.6.3.1 Principle of the assay:  
 
This principle of this assay is based on the competition between oxidised (damage) guanine 
and 8-OHG-acetylcholinesterase congugate tracer for a limited amount of DNA oxidative 
damage monoclonal antibody. The amount of the tracer is held constant in the assay and the 
concentration of the oxidised guanine varies, the amound of the tracer that is capable to bind 
to the monoclonal antibody is inversly proportional to the concentration of the oxidised 
guanine (in the well). The DNA oxidative damage monoclonal antibody binds to the goat anti 
mouse polyclonal IgG which already coats the well (Figure 118).726  
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Figure 118: The principle of the DNA oxidative Damage Elisa assay for the determination 
and quantification of 8-OHdG.727 
 
Then, the addition of  Ellman’s reagent (substrate of AChE) promote the enzymatic reaction 
where a product with distinct yellow colour is liberated and the spectophotmetric 
determination is proportional to the amound of DNA oxidative damage AChE tracer bound to 
the well and inverserly proportional to the amount of free 8-OHdG (Figure 119).727  
 
 
Figure 119: Enzymatic reaction where the tracer (Acetylthiocholine) is hydrolysed into the 
thiocholine which reacts further with 5,5’-dithio-bis-(2-nitrobenzoic acid) in order to produce 
5-thio-2-nitrobenzoic acid which has a strong absorbance at 412 nm.727 
 
11.4.6.3.1.1 Experimental procedure: 
 
For the determination of the concentration of 8-oxo2-deoxy guanosine (8-OHdG), A375 cells 
were plated in 100 mm dishes and cultured overnight at 37oC at a density of 1.4 × 106, 0.7 × 
106 and 0.4 × 106 cells per dish for 24, 48 and 72 hr respectively Next day, cells were treated 
with L-SK-4 (100 µM) and then trypsinised and washed twiced with ice-cold PBS and pellets 
were collected after centrifugation at 2,000 rpm for 3 min at 4oC. Then the dsDNA was 
extracted using the PureLinKTM Genomic DNA Mini Kit (Invitrogen- K1820-01) (Carlsbad, 
CA, USA) according to the manufacture’s protocol, and it was converted into ssDNA by heat 
denaturation (98oC for 10 min, 0 oC for 30 sec) Afterwards, the ssDNA was digested to single 
nucleotides using Nuclease P1 (New England Biolabs) (0.5 µL of Nuclease P1, 5 µL of 
Nuclease P1 Buffer, 37oC for 30 min, and 75oC for 10 min for inactivation) followed by de-
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phosphorylation of the nucleotide by incubating the samples with shrimp alkaline phosphatase 
(New England Biolabs) (1 µL of shrimp alkaline phosphatase, 100 µL shrimp alkaline 
phosphatase, 50 µL dH2O, 37oC for 30 min, and 65oC for 5 min for inactivation). Then the 
plate was constructed according to the manufacture’s recommendation. Then the reconstituted 
antibody was mixed with 60 µL of antiserum dye and added to the wells (in a dilution 1:100) 
except the total activity, non-specific binding as well as the blank wells. The plate was then 
incubated at 4oC for 18 hr under continuous agitation. Next day, the wells were emptied, and 
washed 5 times with 100 µL of Elisa Washing Buffer and then Ellman’s reagent was added to 
each well. The plate was then incubated at room temperature and agitated in an orbital shaker 
for 3 hr. The absorbance was measured at 412 nm. The results were expressed as pg/mL/ng/µL.  
 
11.5 Lipidomics 
 
11.5.1 Lipidomic extraction protocol: 
 
A375 cells were plated in 100 mm dishes and cultured overnight at 37 oC at a density of 1.4 × 
106 for 24 respectively Next day, cells were treated with L-SK-4 (100 µM) and then trypsinised 
and collected by centrifugation at 2000 rpm for 3 min at 4oC.  Approximately 3 x 106 cells 
were washed with ice-cold PBS three times prior to extraction. Then the cell pellet was 
resuspended in 300 µL of the extraction buffer (dichloromethane/methanol (3:1 v/v) chilled to 
4oC) and cell lysis was induced by snap freezing the samples in liquid nitrogen for 1 min and 
thawed over ice. This was repeated 5 times to ensure full cell lysis. Afterwards, cell 
suspensions were then sonicated for 15 min and ultracentrifuged at 15000 rpm for 15 min. The 
entire supernatant was then transfered to 1.5 mL Eppendorf and allowed to evaporate at RT 
overnight under a fume hood.  The dried down extracts were then reconstituted in 300 µL of 
isopropyl alcohol/ acetonitrile/ water (2: 1: 1), sonicated for 15 min and ultracentrifuged at 
15000 rpm for additional 15 min before transferring 100 µL to 1.5ml autosampler vial with 
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200 µL microinsert, caped and subjected to lipidomic characterization.   
 
11.5.2 Sample analysis  
 
LC parameters: The chemical analysis was performed on a ThermoScientific Orbritap classic 
mass spectrometer system hyphenated to Dionex 3000 UHPLC system with the autosamper 
tray been set to 4oC. The separation was performed on a Waters C18 CSH analytical column, 
2 x 100mm with a 1.7 µm particle size. The column was maintained at 55oC with a flow rate 
of 400 µL/min. A binary buffer system was used for the chromatographic separation. Buffer 
A was 60/40 (v/v ACN/MillQ water) and Buffer B (90/10 v/v isopropyl alcohol and ACN) 
with 10 mM ammonium formate in both and 0.1% formic acid.  
11.5.3 LC profile 
 
Starting condition: 00.00 min 45% (B) → 11.00 min 65% (B) → 20.00 min 99% (B) → 24.00 
min 99% (B) → 24.25 min 45% (B) → 28.50 min 45% (B).  
 
11.5.4 Mass spectrometer  
 
The HESI source condition were as follows: Sheath gas flow: 50, Aux Gas flow: 13, Sweep 
gas flow: 3. Spray voltage was set 3.5 kV, Capillary temperature was set to 275oC S-lens RF 
level was set to 50 and the temperature of the HESI was set to 425 oC.  
 
11.5.5 Mass spectral acquisition parameter   
 
Scan range was set from 300 to 2000 m/z at mass resolution of 140K with a scan rate of 1.6 
scans/s with an automatic gain control of 1 x 106 with a maximum injection time of 100 ms. 
MS1 profiling in positive polarity mode.  
 
11.5.6 Peak table generations  
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Compound discoverer V2, the alignment window was set to 0.25 min with mass tolerance of 
5 ppm with (M-H)+ adducts only. Quality control and extraction blanks was imbedded into the 
analysis for stability assessment and background subtractions.      
 
11.5.7 Statistical analysis  
 
Data were expressed as mean values ± standard deviation (SD) and comparisons were made 
between control and treated groups. Statistical analyses were performed by one-way ANOVA 
with Tukey’s test for multiple comparisons after using the SPSS v.22 software. Finally, 
statistical significance was set at p<0.05, p<0.01 and p<0.001 and indicated as *or # or ◊, ** 
or ## or ◊◊ and *** or ### or ◊◊◊ respectively when compared to the respective control and/or 
positive control. 
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12 Appendices  
12.1 Appendix I: derivatization of L-SK-4 
Due to the exceptional results that L-SK-4 has been shown in biological evaluation against 
melanoma cancer and PD an attempt to optimize its structure has been contacted in order to 
increase the therapeutic index. The optimization aimed to increase the lipophilicity of the 
compound in order to improve the BBB penetration.  
Therefore, the synthesis was initiated by using the ethyl maltol (2-ethyl-3-hydroxy-4-
pyranone) rather than maltol. The first synthetic attempt was the same as it was discribed for 
L and D-SK-4. Namely, the synthesis was initiated with the benzyl protection of ethyl maltol 
follow by condensation with N-Boc-L or D- Asn respectively (Scheme 41).  
 
Scheme 41: Reagents and conditions: (i) BnBr, K2CO3, DMF, 80oC, 16 hr (73%); (ii) L or D-
59, EtOH: H2O, various temperatures and times. 
However, the reaction failed to proceed even after changing the temperature and the duration 
of the reaction.  
An alternative approach has been followed according to which, the benzyl protected ethyl 
maltol was converted to the respective pyridone (74) by treatment with ammonium hydroxide 
in methanol in the presence of sodium hydroxide as it was previously reported in the literature 
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(Scheme 42).728 Afterwards, by using the Mitsonobu reaction, using TPP, benzyl alcohol and 
DEAD, in dry THF -78oC underwent dibenzylation (75) in a moderated yield (49%).728  
 
Scheme 42: Reagents and conditions: (i) NH4OH, NaOH, EtOH, reflux, 18 hr, 83%; (ii) 
BnOH, DEAD, TPP, THFdry, -78oC, 3 hr, 49%; (iii) Imidazole, TPP, I2, DCMdry, 0oC -20 oC, 4 
hr 63%; (iv) ACN, various temperatures and times. 
The formed intermediate (75) was then reacted with the iodoserine benzoyl protected 
intermediate (76) which was prepared according to the literature.729 However, the reaction 
failed to proceed.  
Eventually, in the last attempt, the benzyl protected intermediate (73) reacted with 
ethanolamine to give intermediate (77) which was then oxidized into the respective aldehyde 
in the presence of manganese dioxide in chloroform in excellent yield and purity (97%) 
(Scheme 43).730  
 
Scheme 43: Reagents and conditions: (i) Ethanolamine, NaOH, EtOH, reflux, 16 hr, 67%; (ii) 
MnO2, CHCl3, reflux, 2 hr, 97%, (iii) KCN, (NH4)2CO3, MeOH, H2O, RT, 1 week. 
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Afterwards the hydantoin formation has been attempted as an amino acid precursor as it was 
described in (Figure 46) however the reaction failed once again.494 
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